1	The	O
2	results	O
3	of	O
4	these	O
5	analyses	O
6	indicate	O
7	that	O
8	the	O
9	proteinase	O
10	cleaves	O
11	at	O
12	amino	O
13	acid	O
14	residues	O
15	E960	O
16	-	O
17	A961	O
18	,	O
19	E1071	O
20	-	O
21	S1072	O
22	,	O
23	E1345	O
24	-	O
25	T1346	O
26	,	O
27	and	O
28	E1419	O
29	-	O
30	G1420	O
31	;	O
32	however	O
33	,	O
34	the	O
35	cleavage	O
36	efficiency	O
37	is	O
38	varied	O
39	.	O

1	Correlating	O
2	with	O
3	the	O
4	previous	O
5	observation	O
6	that	O
7	CBF	B
8	binding	O
9	to	O
10	the	O
11	78C1	O
12	site	O
13	is	O
14	enhanced	O
15	by	O
16	EGTA	O
17	and	O
18	EDTA	O
19	,	O
20	these	O
21	divalent	O
22	cation	O
23	chelators	O
24	specifically	O
25	stimulate	O
26	78C1	O
27	-	O
28	directed	O
29	transcription	O
30	.	O

1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	O
6	pgp2	B
7	/	O
8	mdr1b	B
9	gene	O
10	has	O
11	a	O
12	GC	O
13	-	O
14	rich	O
15	region	O
16	(	O
17	pgp2GC	B
18	)	O
19	that	O
20	is	O
21	highly	O
22	conserved	O
23	in	O
24	mdr	B
25	genes	I
26	and	O
27	contains	O
28	an	O
29	consensus	O
30	Sp1	B
31	site	I
32	.	O

1	59	O
2	cases	O
3	of	O
4	surgically	O
5	resectable	O
6	cancers	O
7	(	O
8	T1	O
9	,	O
10	T2	O
11	,	O
12	T3	O
13	,	O
14	N0	O
15	,	O
16	N1	O
17	)	O
18	had	O
19	a	O
20	minimum	O
21	followup	O
22	of	O
23	two	O
24	years	O
25	(	O
26	average	O
27	4	O
28	years	O
29	+/-	O
30	3	O
31	months	O
32	).	O

1	Expression	O
2	,	O
3	nucleotide	O
4	sequence	O
5	and	O
6	mutational	O
7	analysis	O
8	of	O
9	two	O
10	open	O
11	reading	O
12	frames	O
13	in	O
14	the	O
15	nif	B
16	gene	I
17	region	I
18	of	I
19	Anabaena	I
20	sp	I
21	.	I
22	strain	I
23	PCC7120	I
24	.	O

1	The	O
2	results	O
3	indicate	O
4	considerable	O
5	flexibility	O
6	in	O
7	the	O
8	spacing	O
9	between	O
10	DH	B
11	regulatory	O
12	sites	O
13	.	O

1	The	O
2	strong	O
3	conservation	O
4	of	O
5	the	O
6	inverted	O
7	terminal	O
8	repeat	O
9	sequence	O
10	may	O
11	reflect	O
12	a	O
13	common	O
14	integration	O
15	mechanism	O
16	for	O
17	VL30	B
18	elements	I
19	and	O
20	MuLV	O
21	proviruses	O
22	.	O

1	Area	O
2	under	O
3	the	O
4	drug	O
5	concentration	O
6	-	O
7	time	O
8	curves	O
9	(	O
10	AUC0	O
11	-	O
12	24	O
13	hr	O
14	)	O
15	for	O
16	MTX	O
17	were	O
18	2379	O
19	and	O
20	3534	O
21	ng	O
22	*	O
23	hr	O
24	/	O
25	ml	O
26	from	O
27	PG	O
28	-	O
29	2	O
30	.	O
31	5	O
32	%	O
33	Azone	O
34	and	O
35	PG	O
36	-	O
37	7	O
38	.	O
39	5	O
40	%	O
41	Azone	O
42	systems	O
43	respectively	O
44	.	O

1	In	O
2	the	O
3	infected	O
4	neonates	O
5	serum	O
6	alpha	B
7	-	I
8	amylase	I
9	value	O
10	,	O
11	as	O
12	determined	O
13	by	O
14	the	O
15	blue	O
16	starch	O
17	method	O
18	,	O
19	was	O
20	only	O
21	40	O
22	%	O
23	that	O
24	of	O
25	healthy	O
26	controls	O
27	;	O
28	the	O
29	mean	O
30	value	O
31	of	O
32	175	O
33	.	O
34	1	O
35	+/-	O
36	64	O
37	.	O
38	9	O
39	IU	O
40	/	O
41	l	O
42	for	O
43	healthy	O
44	neonates	O
45	was	O
46	significantly	O
47	higher	O
48	(	O
49	p	O
50	less	O
51	than	O
52	0	O
53	.	O
54	0010	O
55	)	O
56	than	O
57	the	O
58	value	O
59	of	O
60	82	O
61	.	O
62	8	O
63	+/-	O
64	44	O
65	.	O
66	4	O
67	IU	O
68	/	O
69	l	O
70	for	O
71	the	O
72	infected	O
73	neonates	O
74	.	O

1	These	O
2	responses	O
3	were	O
4	compared	O
5	with	O
6	others	O
7	in	O
8	the	O
9	same	O
10	subjects	O
11	under	O
12	the	O
13	same	O
14	conditions	O
15	and	O
16	it	O
17	was	O
18	concluded	O
19	that	O
20	the	O
21	antihypertensive	O
22	effect	O
23	of	O
24	labetalol	O
25	is	O
26	explained	O
27	by	O
28	concurrent	O
29	blockade	O
30	of	O
31	alpha	B
32	-	I
33	and	I
34	beta	I
35	-	I
36	adrenoceptors	I
37	.	O

1	Lack	O
2	of	O
3	cyclin	B
4	D	I
5	-	O
6	Cdk	B
7	complexes	O
8	in	O
9	Rb	B
10	-	O
11	negative	O
12	cells	O
13	correlates	O
14	with	O
15	high	O
16	levels	O
17	of	O
18	p16INK4	B
19	/	O
20	MTS1	B
21	tumour	O
22	suppressor	O
23	gene	O
24	product	O
25	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	Dbf8p	B
9	plays	O
10	an	O
11	essential	O
12	role	O
13	in	O
14	chromosome	O
15	segregation	O
16	.	O

1	Despite	O
2	resolution	O
3	of	O
4	the	O
5	solid	O
6	portion	O
7	of	O
8	the	O
9	tumor	O
10	,	O
11	serial	O
12	MRI	O
13	showed	O
14	enlargement	O
15	of	O
16	a	O
17	bilobar	O
18	tumor	O
19	cyst	O
20	3	O
21	years	O
22	after	O
23	the	O
24	original	O
25	diagnosis	O
26	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	late	O
6	MYO	O
7	/	O
8	M	O
9	is	O
10	more	O
11	useful	O
12	than	O
13	washout	O
14	rate	O
15	to	O
16	assess	O
17	the	O
18	effect	O
19	of	O
20	treatment	O
21	on	O
22	heart	O
23	failure	O
24	due	O
25	to	O
26	DCM	O
27	.	O

1	Animal	O
2	experimental	O
3	and	O
4	clinical	O
5	applications	O
6	of	O
7	plates	O
8	,	O
9	screws	O
10	and	O
11	spinal	O
12	segmental	O
13	replacement	O
14	implants	O
15	made	O
16	of	O
17	this	O
18	composite	O
19	material	O
20	have	O
21	shown	O
22	good	O
23	results	O
24	so	O
25	far	O
26	.	O

1	Cognitive	O
2	visual	O
3	dysfunction	O
4	in	O
5	a	O
6	child	O
7	with	O
8	cerebral	O
9	damage	O
10	.	O

1	During	O
2	BH	O
3	the	O
4	ventilator	O
5	was	O
6	disconnected	O
7	and	O
8	a	O
9	bias	O
10	flow	O
11	of	O
12	50	O
13	%	O
14	O2	O
15	at	O
16	4	O
17	-	O
18	5	O
19	l	O
20	/	O
21	min	O
22	was	O
23	delivered	O
24	through	O
25	the	O
26	side	O
27	ports	O
28	of	O
29	a	O
30	small	O
31	catheter	O
32	whose	O
33	tip	O
34	was	O
35	positioned	O
36	1	O
37	cm	O
38	cephalad	O
39	of	O
40	the	O
41	carina	O
42	.	O

1	The	O
2	main	O
3	issues	O
4	are	O
5	the	O
6	need	O
7	to	O
8	explain	O
9	a	O
10	number	O
11	of	O
12	still	O
13	unknown	O
14	mechanisms	O
15	,	O
16	to	O
17	determine	O
18	which	O
19	"	O
20	natural	O
21	diet	O
22	"	O
23	carries	O
24	the	O
25	minimum	O
26	coronary	O
27	risk	O
28	and	O
29	whether	O
30	"	O
31	new	O
32	"	O
33	foods	O
34	produced	O
35	by	O
36	modern	O
37	technology	O
38	are	O
39	really	O
40	needed	O
41	to	O
42	contrast	O
43	this	O
44	epidemic	O
45	.	O

1	Solving	O
2	an	O
3	age	O
4	old	O
5	problem	O
6	.	O

1	RNAs	O
2	are	O
3	not	O
4	only	O
5	essential	O
6	components	O
7	of	O
8	both	O
9	ribosomal	O
10	subunits	O
11	but	O
12	also	O
13	transiently	O
14	interacting	O
15	factors	O
16	during	O
17	particle	O
18	formation	O
19	.	O

1	The	O
2	inhibition	O
3	by	O
4	cytosolic	O
5	Ca2	O
6	+	O
7	was	O
8	caused	O
9	by	O
10	a	O
11	decrease	O
12	in	O
13	cooperativity	O
14	and	O
15	by	O
16	a	O
17	shift	O
18	in	O
19	EC50	O
20	toward	O
21	higher	O
22	InsP3	O
23	concentrations	O
24	.	O

1	This	O
2	study	O
3	was	O
4	undertaken	O
5	to	O
6	assess	O
7	the	O
8	effects	O
9	of	O
10	hypothermia	O
11	and	O
12	chemical	O
13	cardioplegia	O
14	on	O
15	the	O
16	functional	O
17	recovery	O
18	of	O
19	hypertrophied	O
20	non	O
21	-	O
22	failing	O
23	rat	O
24	hearts	O
25	subjected	O
26	to	O
27	an	O
28	extended	O
29	period	O
30	of	O
31	global	O
32	ischaemia	O
33	.	O

1	The	O
2	location	O
3	and	O
4	approximate	O
5	length	O
6	of	O
7	the	O
8	intron	O
9	are	O
10	conserved	O
11	in	O
12	both	O
13	the	O
14	tomato	O
15	and	O
16	Arabidopsis	O
17	genes	O
18	,	O
19	with	O
20	the	O
21	intron	O
22	separating	O
23	the	O
24	'	O
25	nose	O
26	'	O
27	region	O
28	(	O
29	encoded	O
30	by	O
31	exon	O
32	1	O
33	)	O
34	from	O
35	the	O
36	central	O
37	globular	O
38	domain	O
39	(	O
40	exon	O
41	2	O
42	).	O

1	The	O
2	analysis	O
3	of	O
4	the	O
5	prevalence	O
6	values	O
7	shows	O
8	clearly	O
9	that	O
10	the	O
11	global	O
12	MS	O
13	-	O
14	frequency	O
15	is	O
16	closer	O
17	related	O
18	to	O
19	the	O
20	geomagnetic	O
21	than	O
22	to	O
23	the	O
24	geographic	O
25	latitude	O
26	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	the	O
6	plasma	B
7	prolactin	I
8	response	O
9	to	O
10	12	O
11	.	O
12	5	O
13	micrograms	O
14	i	O
15	.	O
16	v	O
17	.	O

1	As	O
2	with	O
3	the	O
4	murine	B
5	and	I
6	human	I
7	mb	I
8	-	I
9	1	I
10	genes	I
11	,	O
12	the	O
13	5	O
14	'	O
15	region	O
16	of	O
17	the	O
18	bovine	B
19	mb	I
20	-	I
21	1	I
22	gene	I
23	lacked	O
24	a	O
25	TATA	O
26	box	O
27	.	O

1	Its	O
2	expression	O
3	pattern	O
4	is	O
5	representative	O
6	of	O
7	many	O
8	B	O
9	cell	O
10	-	O
11	specific	O
12	proteins	O
13	,	O
14	which	O
15	are	O
16	essential	O
17	for	O
18	B	O
19	cell	O
20	development	O
21	and	O
22	activation	O
23	but	O
24	are	O
25	down	O
26	-	O
27	regulated	O
28	after	O
29	B	O
30	cells	O
31	become	O
32	terminally	O
33	differentiated	O
34	plasma	O
35	cells	O
36	.	O

1	The	O
2	levels	O
3	of	O
4	galactosyltransferase	B
5	activity	O
6	in	O
7	sera	O
8	from	O
9	normal	O
10	children	O
11	and	O
12	patients	O
13	with	O
14	cystic	O
15	fibrosis	O
16	.	O

1	(	O
2	5	O
3	)	O
4	An	O
5	increase	O
6	in	O
7	leukocyte	O
8	-	O
9	counts	O
10	occurred	O
11	on	O
12	the	O
13	administration	O
14	of	O
15	serum	O
16	obtained	O
17	from	O
18	rabbit	O
19	during	O
20	phase	O
21	-	O
22	2	O
23	.	O

1	Regulation	O
2	of	O
3	HIV	O
4	-	O
5	1	O
6	transcription	O
7	.	O

1	As	O
2	a	O
3	last	O
4	resort	O
5	,	O
6	it	O
7	may	O
8	be	O
9	possible	O
10	to	O
11	maintain	O
12	a	O
13	patient	O
14	on	O
15	dialysis	O
16	in	O
17	reasonable	O
18	health	O
19	with	O
20	a	O
21	DiaTAP	O
22	button	O
23	graft	O
24	complex	O
25	infected	O
26	with	O
27	Staphylococcus	O
28	epidermidis	O
29	and	O
30	intermittent	O
31	positive	O
32	blood	O
33	cultures	O
34	using	O
35	long	O
36	term	O
37	vancomycin	O
38	therapy	O
39	.	O

1	Conclusion	O
2	:	O
3	inlet	O
4	type	O
5	VSD	O
6	and	O
7	perimembranous	O
8	type	O
9	TOF	O
10	have	O
11	anatomic	O
12	features	O
13	in	O
14	which	O
15	the	O
16	proximal	O
17	His	O
18	bundle	O
19	tends	O
20	to	O
21	be	O
22	jeopardized	O
23	by	O
24	suturing	O
25	for	O
26	VSD	O
27	closure	O
28	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	retroplasmid	O
7	reverse	B
8	transcriptase	I
9	is	O
10	uniquely	O
11	adapted	O
12	to	O
13	initiate	O
14	cDNA	O
15	synthesis	O
16	by	O
17	recognizing	O
18	a	O
19	3	O
20	'	O
21	CCA	O
22	sequence	O
23	.	O

1	Early	O
2	-	O
3	onset	O
4	scleral	O
5	necrosis	O
6	after	O
7	iodine	O
8	I	O
9	125	O
10	plaque	O
11	radiotherapy	O
12	for	O
13	ciliochoroidal	O
14	melanoma	O
15	.	O

1	Mutants	O
2	lacking	O
3	the	O
4	3	O
5	'	O
6	stem	O
7	-	O
8	loop	O
9	exhibited	O
10	a	O
11	75	O
12	%	O
13	reduction	O
14	in	O
15	the	O
16	level	O
17	of	O
18	psaB	B
19	mRNA	O
20	.	O

1	Differences	O
2	in	O
3	profiles	O
4	of	O
5	viscosity	O
6	variables	O
7	between	O
8	subgroups	O
9	of	O
10	EAD	O
11	in	O
12	RA	O
13	patients	O
14	were	O
15	observed	O
16	.	O

1	The	O
2	microphthalmia	B
3	-	I
4	TFE	I
5	(	O
6	MiT	B
7	)	O
8	subfamily	O
9	of	O
10	basic	B
11	helix	I
12	-	I
13	loop	I
14	-	I
15	helix	I
16	leucine	I
17	zipper	I
18	(	I
19	bHLH	I
20	-	I
21	ZIP	I
22	)	I
23	transcription	I
24	factors	I
25	,	O
26	including	O
27	TFE3	B
28	,	O
29	TFEB	B
30	,	O
31	TFEC	B
32	,	O
33	and	O
34	Mitf	B
35	,	O
36	has	O
37	been	O
38	implicated	O
39	in	O
40	the	O
41	regulation	O
42	of	O
43	tissue	O
44	-	O
45	specific	O
46	gene	O
47	expression	O
48	in	O
49	several	O
50	cell	O
51	lineages	O
52	.	O

1	Using	O
2	lectin	B
3	-	O
4	affinity	O
5	chromatography	O
6	,	O
7	discordance	O
8	between	O
9	the	O
10	pattern	O
11	of	O
12	O	O
13	-	O
14	glycosylation	O
15	of	O
16	SSBP	B
17	and	O
18	DSBP	B
19	was	O
20	demonstrated	O
21	.	O

1	Trial	O
2	treatment	O
3	of	O
4	schizophrenia	O
5	with	O
6	des	B
7	-	I
8	Tyr	I
9	-	I
10	gamma	I
11	-	I
12	endorphin	I

1	In	O
2	recent	O
3	years	O
4	,	O
5	successful	O
6	physiological	O
7	models	O
8	have	O
9	been	O
10	developed	O
11	for	O
12	a	O
13	variety	O
14	of	O
15	volatile	O
16	and	O
17	nonvolatile	O
18	chemicals	O
19	,	O
20	and	O
21	their	O
22	ability	O
23	to	O
24	perform	O
25	the	O
26	extrapolations	O
27	needed	O
28	in	O
29	risk	O
30	assessment	O
31	has	O
32	been	O
33	demonstrated	O
34	.	O

1	METHODS	O
2	:	O
3	A	O
4	population	O
5	survey	O
6	was	O
7	undertaken	O
8	in	O
9	10	O
10	,	O
11	148	O
12	individuals	O
13	to	O
14	measure	O
15	the	O
16	prevalence	O
17	and	O
18	identify	O
19	the	O
20	causes	O
21	of	O
22	blindness	O
23	in	O
24	Lebanon	O
25	.	O

1	Patients	O
2	had	O
3	to	O
4	have	O
5	adequate	O
6	liver	O
7	,	O
8	renal	O
9	,	O
10	and	O
11	marrow	O
12	functions	O
13	.	O

1	The	O
2	class	B
3	II	I
4	Escherichia	I
5	coli	I
6	alanine	I
7	tRNA	I
8	synthetase	I
9	aminoacylates	I
10	RNA	I
11	miniduplexes	I
12	,	O
13	which	O
14	reconstruct	O
15	the	O
16	acceptor	O
17	end	O
18	of	O
19	alanine	B
20	tRNA	I
21	with	O
22	the	O
23	critical	O
24	G3	O
25	:	O
26	U70	O
27	base	O
28	pair	O
29	.	O

1	Amplification	O
2	and	O
3	overexpression	O
4	of	O
5	the	O
6	c	B
7	-	I
8	erbB	I
9	-	I
10	2	I
11	gene	I
12	in	O
13	21MT	O
14	-	O
15	2	O
16	and	O
17	21MT	O
18	-	O
19	1	O
20	human	O
21	breast	O
22	carcinoma	O
23	cells	O
24	results	O
25	in	O
26	progressively	O
27	elevated	O
28	levels	O
29	of	O
30	constitutively	O
31	tyrosine	B
32	-	I
33	phosphorylated	I
34	p185erbB	I
35	-	I
36	2	I
37	and	O
38	is	O
39	associated	O
40	with	O
41	progressive	O
42	insulin	B
43	-	I
44	like	I
45	growth	I
46	factor	I
47	(	O
48	IGF	B
49	)	O
50	and	O
51	combined	O
52	IGF	B
53	/	O
54	epidermal	B
55	growth	I
56	factor	I
57	(	O
58	EGF	B
59	)	O
60	independence	O
61	in	O
62	culture	O
63	.	O

1	Thus	O
2	,	O
3	IRF	B
4	-	I
5	7	I
6	exhibits	O
7	functional	O
8	similarity	O
9	to	O
10	IRF	B
11	-	I
12	3	I
13	;	O
14	however	O
15	,	O
16	the	O
17	preferential	O
18	expression	O
19	of	O
20	IRF	B
21	-	I
22	7	I
23	in	O
24	lymphoid	O
25	cells	O
26	(	O
27	the	O
28	cell	O
29	type	O
30	that	O
31	expresses	O
32	IFNA	B
33	)	O
34	suggests	O
35	that	O
36	IRF	B
37	-	I
38	7	I
39	may	O
40	play	O
41	a	O
42	critical	O
43	role	O
44	in	O
45	regulating	O
46	the	O
47	IFNA	B
48	gene	I
49	expression	O
50	.	O

1	However	O
2	,	O
3	it	O
4	is	O
5	only	O
6	one	O
7	-	O
8	half	O
9	and	O
10	one	O
11	-	O
12	third	O
13	the	O
14	size	O
15	of	O
16	the	O
17	proteolipids	O
18	from	O
19	M	O
20	.	O
21	thermoautotrophicum	O
22	and	O
23	M	O
24	.	O
25	jannaschii	O
26	,	O
27	respectively	O
28	.	O
29	ahaK	B
30	is	O
31	expressed	O
32	in	O
33	Escherichia	O
34	coli	O
35	,	O
36	and	O
37	it	O
38	is	O
39	incorporated	O
40	into	O
41	the	O
42	cytoplasmic	O
43	membrane	O
44	despite	O
45	the	O
46	different	O
47	chemical	O
48	natures	O
49	of	O
50	lipids	O
51	from	O
52	archaea	O
53	and	O
54	bacteria	O
55	.	O

1	This	O
2	paper	O
3	describes	O
4	the	O
5	advantages	O
6	and	O
7	limitations	O
8	of	O
9	the	O
10	main	O
11	study	O
12	approaches	O
13	used	O
14	.	O

1	Histamine	O
2	-	O
3	2	O
4	blockade	O
5	in	O
6	psoriasis	O

1	The	O
2	first	O
3	symptoms	O
4	of	O
5	enzootic	O
6	calcinosis	O
7	were	O
8	noted	O
9	in	O
10	March	O
11	1998	O
12	,	O
13	when	O
14	some	O
15	of	O
16	the	O
17	cows	O
18	developed	O
19	locomotor	O
20	abnormalities	O
21	.	O

1	This	O
2	vector	O
3	transfected	O
4	into	O
5	the	O
6	yeast	O
7	Saccharomyces	O
8	cerevisiae	O
9	directs	O
10	expression	O
11	of	O
12	a	O
13	secreted	O
14	mature	O
15	protein	O
16	at	O
17	levels	O
18	up	O
19	to	O
20	200	O
21	mg	O
22	of	O
23	LAPP	O
24	/	O
25	liter	O
26	of	O
27	culture	O
28	medium	O
29	.	O

1	However	O
2	,	O
3	the	O
4	mouse	O
5	has	O
6	previously	O
7	been	O
8	shown	O
9	to	O
10	possess	O
11	only	O
12	three	O
13	forms	O
14	of	O
15	ADH	B
16	.	O

1	We	O
2	found	O
3	that	O
4	T3	O
5	(	O
6	10	O
7	(-	O
8	8	O
9	)	O
10	M	O
11	)	O
12	selectively	O
13	stimulates	O
14	transcription	O
15	from	O
16	rGH	B
17	-	O
18	TRE	O
19	-	O
20	and	O
21	TREpal	O
22	-,	O
23	but	O
24	not	O
25	ME	O
26	-	O
27	TRE	O
28	-	O
29	and	O
30	F2	O
31	-	O
32	TRE	O
33	-,	O
34	containing	O
35	templates	O
36	in	O
37	which	O
38	these	O
39	TREs	O
40	are	O
41	linked	O
42	in	O
43	front	O
44	of	O
45	the	O
46	rGH	B
47	minimal	I
48	promoter	I
49	containing	O
50	only	O
51	the	O
52	TATA	B
53	box	I
54	binding	I
55	protein	I
56	,	O
57	but	O
58	not	O
59	any	O
60	other	O
61	proximal	O
62	binding	O
63	protein	O
64	,	O
65	sequence	O
66	.	O

1	RESULTS	O
2	:	O
3	Transpulmonary	O
4	passage	O
5	of	O
6	contrast	O
7	occurred	O
8	in	O
9	sufficient	O
10	amounts	O
11	to	O
12	enhance	O
13	the	O
14	intensity	O
15	of	O
16	the	O
17	Doppler	O
18	signal	O
19	significantly	O
20	,	O
21	but	O
22	the	O
23	duration	O
24	of	O
25	this	O
26	effect	O
27	was	O
28	short	O
29	.	O

1	The	O
2	primary	O
3	pancreatic	O
4	insult	O
5	seemed	O
6	to	O
7	be	O
8	unaffected	O
9	by	O
10	the	O
11	treatment	O
12	,	O
13	because	O
14	neither	O
15	the	O
16	rise	O
17	in	O
18	plasma	B
19	lipase	I
20	nor	O
21	the	O
22	development	O
23	of	O
24	ascites	O
25	or	O
26	the	O
27	extension	O
28	of	O
29	the	O
30	pancreatic	O
31	necrosis	O
32	were	O
33	diminished	O
34	.	O

1	Comparison	O
2	to	O
3	other	O
4	coxI	B
5	genes	I
6	revealed	O
7	a	O
8	966	O
9	-	O
10	bp	O
11	group	O
12	I	O
13	intron	O
14	,	O
15	which	O
16	,	O
17	based	O
18	on	O
19	homology	O
20	with	O
21	the	O
22	related	O
23	yeast	B
24	coxI	I
25	intron	I
26	aI4	I
27	,	O
28	potentially	O
29	encodes	O
30	a	O
31	279	O
32	-	O
33	amino	O
34	-	O
35	acid	O
36	site	O
37	-	O
38	specific	O
39	DNA	B
40	endonuclease	I
41	.	O

1	Myelomatous	O
2	pleural	O
3	effusion	O
4	as	O
5	presentation	O
6	form	O
7	of	O
8	multiple	O
9	myeloma	O

1	For	O
2	pressure	O
3	greater	O
4	than	O
5	121	O
6	atm	O
7	abs	O
8	,	O
9	an	O
10	increased	O
11	excitability	O
12	of	O
13	the	O
14	tadpoles	O
15	made	O
16	it	O
17	difficult	O
18	to	O
19	distinguish	O
20	the	O
21	righting	O
22	reflex	O
23	from	O
24	involuntary	O
25	movements	O
26	.	O

1	Prostate	B
2	-	I
3	specific	I
4	antigen	I
5	(	O
6	PSA	B
7	)	O
8	promoter	O
9	-	O
10	driven	O
11	androgen	O
12	-	O
13	inducible	O
14	expression	O
15	of	O
16	sodium	B
17	iodide	I
18	symporter	I
19	in	O
20	prostate	O
21	cancer	O
22	cell	O
23	lines	O
24	.	O

1	The	O
2	hydrophobicity	O
3	plot	O
4	of	O
5	NHE	B
6	-	I
7	3	I
8	is	O
9	very	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	NHE	B
15	-	I
16	1	I
17	and	O
18	NHE	B
19	-	I
20	2	I
21	.	O

1	The	O
2	effect	O
3	of	O
4	water	O
5	deprivation	O
6	for	O
7	19	O
8	h	O
9	on	O
10	renal	O
11	Na	O
12	excretion	O
13	of	O
14	conscious	O
15	adrenalectomized	O
16	(	O
17	ADX	O
18	)	O
19	sheep	O
20	maintained	O
21	on	O
22	a	O
23	constant	O
24	intravenous	O
25	infusion	O
26	of	O
27	aldosterone	O
28	and	O
29	cortisol	O
30	(	O
31	ADX	O
32	-	O
33	constant	O
34	steroid	O
35	sheep	O
36	)	O
37	was	O
38	investigated	O
39	.	O

1	These	O
2	results	O
3	provide	O
4	evidence	O
5	of	O
6	a	O
7	bypass	O
8	of	O
9	p53	B
10	-	O
11	induced	O
12	Waf1	B
13	/	O
14	Cip1	B
15	-	O
16	mediated	O
17	cell	O
18	cycle	O
19	regulatory	O
20	pathways	O
21	by	O
22	a	O
23	member	O
24	of	O
25	the	O
26	myb	B
27	oncogene	I
28	family	I
29	.	O

1	Similarity	O
2	of	O
3	DNA	O
4	binding	O
5	and	O
6	transcriptional	O
7	regulation	O
8	by	O
9	Caenorhabditis	B
10	elegans	I
11	MAB	I
12	-	I
13	3	I
14	and	O
15	Drosophila	B
16	melanogaster	I
17	DSX	I
18	suggests	O
19	conservation	O
20	of	O
21	sex	O
22	determining	O
23	mechanisms	O
24	.	O

1	Additionally	O
2	,	O
3	deletion	O
4	analysis	O
5	of	O
6	the	O
7	UCP2	B
8	promoter	O
9	-	O
10	PLAP	B
11	constructs	O
12	indicated	O
13	that	O
14	the	O
15	minimal	O
16	region	O
17	exhibiting	O
18	the	O
19	promoter	O
20	activity	O
21	was	O
22	located	O
23	between	O
24	nt	O
25	-	O
26	33	O
27	and	O
28	+	O
29	100	O
30	,	O
31	and	O
32	that	O
33	a	O
34	strong	O
35	enhancer	O
36	was	O
37	present	O
38	within	O
39	601	O
40	bp	O
41	of	O
42	the	O
43	5	O
44	'-	O
45	promoter	O
46	region	O
47	.	O

1	Combination	O
2	of	O
3	a	O
4	Shwachman	O
5	syndrome	O
6	and	O
7	a	O
8	complex	O
9	granulocyte	O
10	function	O
11	disorder	O
12	in	O
13	a	O
14	girl	O

1	Rinit	O
2	reflects	O
3	the	O
4	Newtonian	O
5	resistances	O
6	and	O
7	Rdiff	O
8	represents	O
9	the	O
10	viscoelastic	O
11	/	O
12	inhomogeneous	O
13	pressure	O
14	dissipations	O
15	in	O
16	the	O
17	system	O
18	.	O

1	Polyclonal	O
2	antiserum	O
3	generated	O
4	to	O
5	the	O
6	fusion	O
7	protein	O
8	was	O
9	capable	O
10	of	O
11	detecting	O
12	42	O
13	-	O
14	and	O
15	46	O
16	-	O
17	kilodalton	O
18	polypeptides	O
19	from	O
20	virus	O
21	particles	O
22	;	O
23	both	O
24	polypeptides	O
25	were	O
26	also	O
27	shown	O
28	to	O
29	contain	O
30	HBsAg	B
31	determinants	I
32	.	O

1	We	O
2	measured	O
3	serum	B
4	hepatocyte	I
5	growth	I
6	factor	I
7	(	O
8	HGF	B
9	)	O
10	in	O
11	patients	O
12	with	O
13	acute	O
14	myocardial	O
15	infarction	O
16	,	O
17	angina	O
18	pectoris	O
19	,	O
20	and	O
21	other	O
22	heart	O
23	diseases	O
24	.	O

1	We	O
2	found	O
3	that	O
4	multiple	O
5	tumor	O
6	suppressor	O
7	genes	O
8	(	O
9	e	O
10	.	O
11	g	O
12	.,	O
13	p53	B
14	,	O
15	DCC	B
16	,	O
17	APC	B
18	,	O
19	MCC	B
20	,	O
21	BRCA1	B
22	,	O
23	and	O
24	WAF1	B
25	/	O
26	CIP1	B
27	)	O
28	were	O
29	inactivated	O
30	at	O
31	different	O
32	frequencies	O
33	via	O
34	various	O
35	mechanisms	O
36	[	O
37	e	O
38	.	O
39	g	O
40	.,	O
41	loss	O
42	of	O
43	heterozygosity	O
44	(	O
45	LOH	O
46	),	O
47	loss	O
48	of	O
49	expression	O
50	(	O
51	LOE	O
52	),	O
53	mutation	O
54	,	O
55	and	O
56	inactivation	O
57	by	O
58	cellular	O
59	binding	O
60	protein	O
61	].	O

1	Furthermore	O
2	it	O
3	was	O
4	suggested	O
5	that	O
6	FK506	O
7	plasma	O
8	levels	O
9	were	O
10	concerned	O
11	with	O
12	the	O
13	appearance	O
14	of	O
15	side	O
16	effect	O
17	.	O

1	We	O
2	studied	O
3	the	O
4	role	O
5	of	O
6	prostaglandins	O
7	in	O
8	acid	O
9	-	O
10	induced	O
11	esophagitis	O
12	and	O
13	the	O
14	associated	O
15	LES	O
16	hypotension	O
17	by	O
18	simultaneous	O
19	treatment	O
20	of	O
21	some	O
22	animals	O
23	with	O
24	indomethacin	O
25	(	O
26	150	O
27	micrograms	O
28	/	O
29	kg	O
30	intravenous	O
31	),	O
32	a	O
33	specific	O
34	inhibitor	O
35	of	O
36	prostaglandin	O
37	synthesis	O
38	,	O
39	either	O
40	during	O
41	production	O
42	of	O
43	esophagitis	O
44	or	O
45	during	O
46	recovery	O
47	.	O

1	A	O
2	significant	O
3	association	O
4	between	O
5	a	O
6	family	O
7	history	O
8	and	O
9	a	O
10	higher	O
11	urinary	O
12	pH	O
13	was	O
14	observed	O
15	among	O
16	the	O
17	female	O
18	calcium	O
19	stone	O
20	patients	O
21	.	O

1	A	O
2	2	O
3	.	O
4	3	O
5	-	O
6	kb	O
7	full	O
8	-	O
9	length	O
10	cDNA	O
11	clone	O
12	of	O
13	an	O
14	Atlantic	B
15	halibut	I
16	Mx	I
17	gene	I
18	was	O
19	isolated	O
20	from	O
21	a	O
22	liver	O
23	cDNA	O
24	library	O
25	.	O

1	A	O
2	study	O
3	of	O
4	chromosomes	O
5	of	O
6	lymphocytes	O
7	from	O
8	patients	O
9	treated	O
10	with	O
11	hycanthone	O
12	.	O

1	The	O
2	term	O
3	osteomesopycnosis	O
4	is	O
5	proposed	O
6	for	O
7	a	O
8	sclerosing	O
9	bone	O
10	disease	O
11	with	O
12	dominant	O
13	inheritance	O
14	that	O
15	has	O
16	been	O
17	discovered	O
18	in	O
19	five	O
20	members	O
21	of	O
22	four	O
23	different	O
24	families	O
25	.	O

1	Doppler	O
2	ultrasound	O
3	studies	O
4	of	O
5	long	O
6	-	O
7	term	O
8	follow	O
9	-	O
10	up	O
11	of	O
12	children	O
13	with	O
14	hemolytic	O
15	-	O
16	uremic	O
17	syndrome	O

1	This	O
2	family	O
3	of	O
4	proteins	O
5	binds	O
6	GC	O
7	-	O
8	rich	O
9	motifs	O
10	widely	O
11	distributed	O
12	in	O
13	gene	O
14	promoters	O
15	,	O
16	resulting	O
17	in	O
18	distinct	O
19	activation	O
20	or	O
21	repression	O
22	of	O
23	transcriptional	O
24	activities	O
25	.	O

1	Cp	B
2	is	O
3	normally	O
4	the	O
5	main	O
6	promoter	O
7	for	O
8	EBNA	B
9	mRNA	I
10	initiation	O
11	,	O
12	so	O
13	it	O
14	appears	O
15	that	O
16	EBNA3C	B
17	contributes	O
18	to	O
19	a	O
20	negative	O
21	autoregulatory	O
22	control	O
23	loop	O
24	.	O

1	Iodine	O
2	deficiency	O
3	disorders	O
4	in	O
5	Bangladesh	O
6	.	O

1	Most	O
2	other	O
3	end	O
4	points	O
5	were	O
6	highly	O
7	significant	O
8	,	O
9	and	O
10	death	O
11	,	O
12	which	O
13	was	O
14	monitored	O
15	across	O
16	the	O
17	U	O
18	.	O
19	S	O
20	.	O
21	program	O
22	,	O
23	was	O
24	different	O
25	with	O
26	p	O
27	<	O
28	0	O
29	.	O
30	0001	O
31	.	O

1	The	O
2	potency	O
3	of	O
4	the	O
5	effect	O
6	of	O
7	Nim	O
8	(	O
9	0	O
10	.	O
11	5	O
12	mg	O
13	.	O
14	kg	O
15	-	O
16	1	O
17	i	O
18	.	O
19	p	O
20	.)	O
21	was	O
22	similar	O
23	to	O
24	that	O
25	of	O
26	NBP	O
27	(	O
28	10	O
29	mg	O
30	.	O
31	kg	O
32	-	O
33	1	O
34	i	O
35	.	O
36	p	O
37	.).	O

1	Evoked	O
2	electromyographic	O
3	response	O
4	to	O
5	indirect	O
6	supramaximal	O
7	stimulation	O
8	at	O
9	1	O
10	Hz	O
11	was	O
12	monitored	O
13	in	O
14	ten	O
15	adult	O
16	goats	O
17	under	O
18	thiopentone	O
19	-	O
20	halothane	O
21	anaesthesia	O
22	.	O

1	As	O
2	extensively	O
3	examined	O
4	with	O
5	the	O
6	myogenin	B
7	promoter	I
8	,	O
9	presence	O
10	of	O
11	one	O
12	or	O
13	multiple	O
14	copies	O
15	of	O
16	Me	B
17	in	O
18	the	O
19	vectors	O
20	elevated	O
21	the	O
22	expression	O
23	activity	O
24	in	O
25	myotubes	O
26	by	O
27	4	O
28	.	O
29	5	O
30	-	O
31	to	O
32	19	O
33	-	O
34	fold	O
35	over	O
36	those	O
37	without	O
38	Me	B
39	,	O
40	but	O
41	not	O
42	significantly	O
43	in	O
44	myoblasts	O
45	.	O

1	Deletion	O
2	of	O
3	a	O
4	53	O
5	-	O
6	bp	O
7	early	O
8	promoter	O
9	region	O
10	containing	O
11	the	O
12	transcription	O
13	start	O
14	site	O
15	and	O
16	a	O
17	putative	O
18	TATA	O
19	box	O
20	completely	O
21	abolishes	O
22	the	O
23	ability	O
24	of	O
25	upstream	O
26	elements	O
27	to	O
28	drive	O
29	transcription	O
30	of	O
31	the	O
32	luciferase	B
33	cDNA	I
34	.	O

1	VII	O
2	.	O

1	Both	O
2	domains	O
3	were	O
4	required	O
5	for	O
6	specific	O
7	DNA	O
8	binding	O
9	to	O
10	the	O
11	beta	B
12	-	I
13	retinoic	I
14	acid	I
15	receptor	I
16	element	I
17	,	O
18	producing	O
19	a	O
20	DNase	B
21	I	I
22	footprint	O
23	covering	O
24	predominantly	O
25	one	O
26	strand	O
27	.	O

1	Some	O
2	studies	O
3	of	O
4	exercise	O
5	have	O
6	associated	O
7	beta	B
8	-	I
9	endorphin	I
10	release	O
11	with	O
12	increased	O
13	exertion	O
14	levels	O
15	,	O
16	but	O
17	other	O
18	evidence	O
19	suggests	O
20	that	O
21	acidosis	O
22	may	O
23	stimulate	O
24	the	O
25	release	O
26	of	O
27	beta	B
28	-	I
29	endorphin	I
30	.	O

1	Furthermore	O
2	,	O
3	competitor	O
4	containing	O
5	the	O
6	YY1	B
7	consensus	I
8	sequence	I
9	competed	O
10	for	O
11	protein	B
12	B	I
13	binding	O
14	,	O
15	whereas	O
16	competitor	O
17	containing	O
18	a	O
19	perfect	O
20	yeast	B
21	ABF	I
22	-	I
23	1	I
24	consensus	I
25	sequence	I
26	did	O
27	not	O
28	.(	O
29	ABSTRACT	O
30	TRUNCATED	O
31	AT	O
32	400	O
33	WORDS	O
34	)	O

1	Various	O
2	treatment	O
3	modalities	O
4	are	O
5	reviewed	O
6	in	O
7	the	O
8	context	O
9	of	O
10	the	O
11	psychology	O
12	as	O
13	well	O
14	as	O
15	the	O
16	physiology	O
17	of	O
18	severe	O
19	intractable	O
20	pain	O
21	.	O

1	CO2	O
2	assimilation	O
3	by	O
4	chloroplasts	O
5	illuminated	O
6	on	O
7	filter	O
8	paper	O
9	.	O

1	The	O
2	IC50	O
3	values	O
4	for	O
5	rat	O
6	and	O
7	dog	O
8	urinary	O
9	bladder	O
10	were	O
11	3	O
12	.	O
13	9	O
14	x	O
15	10	O
16	(-	O
17	6	O
18	)	O
19	M	O
20	and	O
21	3	O
22	.	O
23	8	O
24	x	O
25	10	O
26	(-	O
27	6	O
28	)	O
29	M	O
30	,	O
31	respectively	O
32	.	O

1	The	O
2	11	O
3	;	O
4	22	O
5	chromosomal	O
6	translocation	O
7	specifically	O
8	linked	O
9	to	O
10	Ewing	O
11	sarcoma	O
12	and	O
13	primitive	O
14	neuroectodermal	O
15	tumor	O
16	results	O
17	in	O
18	a	O
19	chimeric	O
20	molecule	O
21	fusing	O
22	the	O
23	amino	O
24	-	O
25	terminal	O
26	-	O
27	encoding	O
28	portion	O
29	of	O
30	the	O
31	EWS	B
32	gene	I
33	to	O
34	the	O
35	carboxyl	O
36	-	O
37	terminal	O
38	DNA	O
39	-	O
40	binding	O
41	domain	O
42	encoded	O
43	by	O
44	the	O
45	FLI1	B
46	gene	I
47	.	O

1	NOT4	B
2	interacts	O
3	with	O
4	NOT1	B
5	and	O
6	NOT3	B
7	in	O
8	the	O
9	two	O
10	-	O
11	hybrid	O
12	assay	O
13	,	O
14	and	O
15	overexpression	O
16	of	O
17	NOT3	B
18	or	O
19	NOT4	B
20	suppresses	O
21	not1	B
22	and	O
23	not2	B
24	mutations	O
25	.	O

1	Copper	O
2	treatments	O
3	were	O
4	assigned	O
5	to	O
6	simulate	O
7	the	O
8	different	O
9	levels	O
10	of	O
11	copper	O
12	intake	O
13	that	O
14	might	O
15	result	O
16	from	O
17	differences	O
18	in	O
19	daily	O
20	feed	O
21	intake	O
22	similar	O
23	to	O
24	the	O
25	practice	O
26	followed	O
27	with	O
28	commercial	O
29	industry	O
30	.	O

1	Hydroxypropyl	O
2	methacrylate	O
3	,	O
4	a	O
5	new	O
6	water	O
7	-	O
8	miscible	O
9	embedding	O
10	medium	O
11	for	O
12	electron	O
13	microscopy	O
14	.	O

1	The	O
2	identity	O
3	between	O
4	hnRNPs	B
5	H	I
6	and	O
7	H	B
8	'	I
9	is	O
10	96	O
11	%,	O
12	between	O
13	H	B
14	and	O
15	F	B
16	78	O
17	%,	O
18	and	O
19	between	O
20	H	B
21	'	I
22	and	O
23	F	B
24	75	O
25	%,	O
26	respectively	O
27	.	O

1	Cloning	O
2	and	O
3	primary	O
4	structure	O
5	of	O
6	neurocan	O
7	,	O
8	a	O
9	developmentally	O
10	regulated	O
11	,	O
12	aggregating	O
13	chondroitin	O
14	sulfate	O
15	proteoglycan	O
16	of	O
17	brain	O
18	.	O

1	The	O
2	structural	O
3	changes	O
4	in	O
5	intra	O
6	-	O
7	acinar	O
8	artery	O
9	manifested	O
10	mainly	O
11	by	O
12	an	O
13	increase	O
14	in	O
15	number	O
16	of	O
17	muscular	O
18	artery	O
19	resulting	O
20	from	O
21	muscularization	O
22	of	O
23	precursor	O
24	cells	O
25	(	O
26	pericytes	O
27	and	O
28	intermediate	O
29	cells	O
30	)	O
31	located	O
32	within	O
33	partially	O
34	muscular	O
35	and	O
36	nonmuscular	O
37	arterial	O
38	wall	O
39	to	O
40	smooth	O
41	muscle	O
42	cell	O
43	,	O
44	and	O
45	by	O
46	the	O
47	medial	O
48	wall	O
49	thickened	O
50	due	O
51	to	O
52	hypertrophy	O
53	and	O
54	hyperplasia	O
55	of	O
56	smooth	O
57	muscle	O
58	cells	O
59	as	O
60	well	O
61	as	O
62	accumulation	O
63	of	O
64	a	O
65	large	O
66	amount	O
67	of	O
68	collagen	B
69	,	O
70	especially	O
71	the	O
72	type	B
73	1	I
74	collagen	I
75	.	O

1	INTERVENTIONS	O
2	:	O
3	Study	O
4	patients	O
5	were	O
6	randomly	O
7	divided	O
8	into	O
9	four	O
10	parallel	O
11	groups	O
12	to	O
13	receive	O
14	either	O
15	terbinafine	O
16	250	O
17	mg	O
18	a	O
19	day	O
20	for	O
21	12	O
22	or	O
23	16	O
24	weeks	O
25	(	O
26	groups	O
27	T12	O
28	and	O
29	T16	O
30	)	O
31	or	O
32	itraconazole	O
33	400	O
34	mg	O
35	a	O
36	day	O
37	for	O
38	1	O
39	week	O
40	in	O
41	every	O
42	4	O
43	weeks	O
44	for	O
45	12	O
46	or	O
47	16	O
48	weeks	O
49	(	O
50	groups	O
51	I3	O
52	and	O
53	I4	O
54	).	O

1	The	O
2	average	O
3	values	O
4	were	O
5	199	O
6	and	O
7	424	O
8	revertants	O
9	/	O
10	g	O
11	for	O
12	the	O
13	hamburgers	O
14	and	O
15	hot	O
16	dogs	O
17	,	O
18	respectively	O
19	.	O

1	Characterization	O
2	of	O
3	the	O
4	5	O
5	'-	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	human	B
11	multidrug	I
12	resistance	I
13	protein	I
14	2	I
15	(	O
16	MRP2	B
17	)	O
18	gene	O
19	and	O
20	its	O
21	regulation	O
22	in	O
23	comparison	O
24	withthe	O
25	multidrug	B
26	resistance	I
27	protein	I
28	3	I
29	(	O
30	MRP3	B
31	)	O
32	gene	O
33	.	O

1	Identification	O
2	of	O
3	Ste4	B
4	as	O
5	a	O
6	potential	O
7	regulator	O
8	of	O
9	Byr2	B
10	in	O
11	the	O
12	sexual	O
13	response	O
14	pathway	O
15	of	O
16	Schizosaccharomyces	O
17	pombe	O
18	.	O

1	We	O
2	linked	O
3	hypersensitivity	O
4	site	O
5	2	O
6	(	O
7	HS2	O
8	)	O
9	from	O
10	the	O
11	locus	O
12	control	O
13	region	O
14	(	O
15	LCR	O
16	)	O
17	to	O
18	a	O
19	A	B
20	gamma	I
21	-	I
22	globin	I
23	gene	O
24	(	O
25	A	O
26	gamma	O
27	*)	O
28	mutationally	O
29	marked	O
30	to	O
31	allow	O
32	its	O
33	transcript	O
34	to	O
35	be	O
36	distinguished	O
37	from	O
38	endogenous	O
39	gamma	B
40	-	I
41	globin	I
42	mRNA	O
43	.	O

1	Hybridization	O
2	data	O
3	indicate	O
4	that	O
5	6F6	B
6	.	I
7	2	I
8	corresponds	O
9	to	O
10	the	O
11	previously	O
12	characterized	O
13	m6F6	B
14	cDNA	I
15	clone	I
16	and	O
17	that	O
18	6F6	B
19	.	I
20	1	I
21	and	O
22	6F6	B
23	.	I
24	3	I
25	,	O
26	but	O
27	not	O
28	6F6	B
29	.	I
30	2	I
31	,	O
32	are	O
33	adjacent	O
34	to	O
35	alpha	B
36	-	I
37	type	I
38	genes	I
39	.	O

1	The	O
2	lysozyme	B
3	FEF	I
4	site	O
5	is	O
6	immediately	O
7	5	O
8	'	O
9	to	O
10	a	O
11	PU	B
12	.	O

1	The	O
2	cellular	O
3	sequences	O
4	5	O
5	'	O
6	to	O
7	the	O
8	viral	O
9	integration	O
10	site	O
11	exhibited	O
12	85	O
13	to	O
14	97	O
15	%	O
16	identity	O
17	to	O
18	several	O
19	sequences	O
20	belonging	O
21	to	O
22	the	O
23	mouse	B
24	L1	I
25	family	I
26	of	O
27	long	O
28	interspersed	O
29	repetitive	O
30	sequences	O
31	.	O

1	FDA	O
2	regulations	O
3	for	O
4	growth	O
5	factors	O
6	and	O
7	related	O
8	products	O
9	.	O

1	We	O
2	previously	O
3	showed	O
4	that	O
5	the	O
6	upstream	O
7	promoter	O
8	element	O
9	of	O
10	the	O
11	yeast	B
12	RP39A	I
13	gene	I
14	consists	O
15	of	O
16	these	O
17	identical	O
18	sequence	O
19	motifs	O
20	.	O

1	Variation	O
2	in	O
3	the	O
4	temporal	O
5	-	O
6	spatial	O
7	distribution	O
8	of	O
9	228Ra	O
10	and	O
11	224Ra	O
12	in	O
13	the	O
14	RES	O
15	and	O
16	marrow	O
17	-	O
18	free	O
19	skeleton	O
20	after	O
21	incorporation	O
22	of	O
23	colloidal	O
24	ThO2	O

1	The	O
2	heterogeneity	O
3	of	O
4	bovine	B
5	IgG2	I
6	--	I
7	VIII	I
8	.	O

1	COGLAB	O
2	includes	O
3	measures	O
4	of	O
5	preattentional	O
6	,	O
7	attentional	O
8	,	O
9	conceptual	O
10	,	O
11	and	O
12	psychomotor	O
13	performance	O
14	.	O

1	Autoimmune	O
2	neutropenia	O
3	(	O
4	AIN	O
5	)	O
6	is	O
7	a	O
8	frequent	O
9	cause	O
10	of	O
11	chronic	O
12	neutropenia	O
13	especially	O
14	in	O
15	youngest	O
16	children	O
17	.	O

1	Sequence	O
2	analysis	O
3	and	O
4	identification	O
5	of	O
6	two	O
7	hyp	B
8	regulatory	I
9	mutants	I
10	.	O

1	The	O
2	Cdk2	B
3	-	O
4	cyclin	B
5	-	I
6	D1	I
7	complex	O
8	did	O
9	not	O
10	phosphorylate	O
11	any	O
12	tested	O
13	substrates	O
14	,	O
15	such	O
16	as	O
17	H1	B
18	histone	I
19	,	O
20	pRB	B
21	,	O
22	SV40	B
23	large	I
24	T	I
25	antigen	I
26	,	O
27	p53	B
28	,	O
29	E2F	B
30	-	I
31	1	I
32	or	O
33	a	O
34	preparation	O
35	of	O
36	nuclear	O
37	proteins	O
38	from	O
39	HeLa	O
40	cells	O
41	;	O
42	in	O
43	contrast	O
44	,	O
45	Cdk2	B
46	-	O
47	cyclin	B
48	-	I
49	E	I
50	and	O
51	Cdk2	B
52	-	O
53	cyclin	B
54	-	I
55	A	I
56	phosphorylated	O
57	these	O
58	proteins	O
59	.	O

1	These	O
2	rearrangements	O
3	result	O
4	in	O
5	the	O
6	formation	O
7	of	O
8	chimeric	O
9	genes	O
10	showing	O
11	the	O
12	tyrosine	B
13	kinase	I
14	domain	I
15	of	O
16	ret	B
17	fused	O
18	with	O
19	the	O
20	5	O
21	'	O
22	end	O
23	sequences	O
24	of	O
25	different	O
26	genes	O
27	.	O

1	PCR	O
2	-	O
3	derived	O
4	fragments	O
5	were	O
6	used	O
7	as	O
8	probes	O
9	for	O
10	the	O
11	isolation	O
12	of	O
13	the	O
14	U3	B
15	snRNA	I
16	genes	I
17	from	O
18	a	O
19	genomic	O
20	library	O
21	of	O
22	Arabidopsis	O
23	.	O

1	Thus	O
2	,	O
3	YMIP	B
4	is	O
5	a	O
6	functional	O
7	homolog	O
8	of	O
9	RMIP	B
10	and	O
11	represents	O
12	a	O
13	new	O
14	component	O
15	of	O
16	the	O
17	yeast	O
18	mitochondrial	O
19	import	O
20	machinery	O
21	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	cis	O
7	-	O
8	regulatory	O
9	elements	O
10	required	O
11	for	O
12	developmental	O
13	control	O
14	of	O
15	the	O
16	HaG3	B
17	-	I
18	A	I
19	helianthinin	I
20	gene	I
21	are	O
22	located	O
23	in	O
24	a	O
25	2	O
26	.	O
27	4	O
28	kb	O
29	upstream	O
30	region	O
31	of	O
32	this	O
33	gene	O
34	.	O

1	After	O
2	screening	O
3	the	O
4	Berkeley	O
5	Drosophila	O
6	Genome	O
7	Project	O
8	database	O
9	with	O
10	sequences	O
11	from	O
12	a	O
13	recently	O
14	characterized	O
15	Leu	B
16	-	I
17	rich	I
18	repeats	I
19	-	I
20	containing	I
21	G	I
22	protein	I
23	-	I
24	coupled	I
25	receptor	I
26	(	O
27	LGR	B
28	)	O
29	from	O
30	Drosophila	O
31	(	O
32	DLGR	B
33	-	I
34	1	I
35	),	O
36	we	O
37	identified	O
38	a	O
39	second	O
40	gene	O
41	for	O
42	a	O
43	different	O
44	LGR	B
45	(	O
46	DLGR	B
47	-	I
48	2	I
49	)	O
50	and	O
51	cloned	O
52	its	O
53	cDNA	O
54	.	O

1	Thus	O
2	,	O
3	Sir	B
4	proteins	I
5	from	O
6	K	O
7	.	O
8	lactis	O
9	have	O
10	roles	O
11	in	O
12	both	O
13	silencing	O
14	and	O
15	telomere	O
16	length	O
17	maintenance	O
18	,	O
19	reflecting	O
20	conserved	O
21	functional	O
22	themes	O
23	.	O

1	At	O
2	an	O
3	ambient	O
4	temperature	O
5	of	O
6	25	O
7	degrees	O
8	C	O
9	,	O
10	the	O
11	responses	O
12	to	O
13	spinal	O
14	cooling	O
15	are	O
16	reduced	O
17	during	O
18	the	O
19	dark	O
20	phase	O
21	.	O

1	Genomic	O
2	DNA	O
3	hybridization	O
4	suggests	O
5	that	O
6	SpSHR2	B
7	is	O
8	a	O
9	single	O
10	-	O
11	copy	O
12	gene	O
13	in	O
14	the	O
15	S	O
16	.	O
17	purpuratus	O
18	genome	O
19	.	O

1	The	O
2	identification	O
3	of	O
4	viable	O
5	myocardium	O
6	with	O
7	both	O
8	99mTc	O
9	-	O
10	tetrofosmin	O
11	and	O
12	201Tl	O
13	can	O
14	be	O
15	greatly	O
16	enhanced	O
17	to	O
18	a	O
19	similar	O
20	degree	O
21	if	O
22	the	O
23	severity	O
24	of	O
25	reduction	O
26	in	O
27	activity	O
28	within	O
29	nonreversible	O
30	defects	O
31	is	O
32	considered	O
33	.	O

1	Laser	O
2	ablation	O
3	has	O
4	been	O
5	employed	O
6	as	O
7	a	O
8	therapeutic	O
9	measure	O
10	for	O
11	chronic	O
12	pulmonary	O
13	emphysema	O
14	.	O

1	A	O
2	leucine	O
3	zipper	O
4	domain	O
5	of	O
6	the	O
7	suppressor	B
8	of	I
9	Hairy	I
10	-	I
11	wing	I
12	protein	I
13	mediates	O
14	its	O
15	repressive	O
16	effect	O
17	on	O
18	enhancer	O
19	function	O
20	.	O

1	Two	O
2	mammalian	O
3	enzymes	O
4	,	O
5	the	O
6	haem	B
7	-	I
8	controlled	I
9	repressor	I
10	(	O
11	HCR	B
12	)	O
13	and	O
14	the	O
15	double	B
16	-	I
17	stranded	I
18	RNA	I
19	-	I
20	activated	I
21	inhibitor	I
22	(	O
23	dsI	B
24	),	O
25	phosphorylate	O
26	Ser	O
27	-	O
28	51	O
29	of	O
30	the	O
31	alpha	O
32	subunit	O
33	,	O
34	thereby	O
35	inhibiting	O
36	the	O
37	exchange	O
38	of	O
39	bound	O
40	nucleotides	O
41	on	O
42	,	O
43	and	O
44	thus	O
45	the	O
46	recycling	O
47	of	O
48	,	O
49	eIF	B
50	-	I
51	2	I
52	.	O

1	These	O
2	data	O
3	will	O
4	help	O
5	us	O
6	to	O
7	better	O
8	detail	O
9	the	O
10	CXCR4	B
11	structural	O
12	requirements	O
13	exhibited	O
14	by	O
15	different	O
16	HIV	O
17	-	O
18	1	O
19	strains	O
20	and	O
21	will	O
22	direct	O
23	further	O
24	mutagenesis	O
25	efforts	O
26	aimed	O
27	at	O
28	better	O
29	defining	O
30	the	O
31	domains	O
32	in	O
33	CXCR4	B
34	involved	O
35	in	O
36	the	O
37	HIV	O
38	-	O
39	1	O
40	Env	B
41	-	O
42	mediated	O
43	fusion	O
44	process	O
45	.	O

1	It	O
2	encodes	O
3	a	O
4	protein	O
5	with	O
6	three	O
7	zinc	O
8	fingers	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	transcription	B
15	factor	I
16	Sp1	I
17	.	O

1	A	O
2	point	O
3	mutation	O
4	in	O
5	Galphao	B
6	and	O
7	Galphai1	B
8	blocks	O
9	interaction	O
10	with	O
11	regulator	O
12	of	O
13	G	B
14	protein	I
15	signaling	O
16	proteins	O
17	.	O

1	The	O
2	detection	O
3	ratio	O
4	peaked	O
5	at	O
6	ages	O
7	30	O
8	to	O
9	34	O
10	and	O
11	decreased	O
12	heavily	O
13	during	O
14	the	O
15	next	O
16	15	O
17	years	O
18	of	O
19	age	O
20	.	O

1	FASEB	O
2	Federal	O
3	Funding	O
4	Consensus	O
5	Conference	O
6	FY	O
7	2000	O
8	.	O

1	The	O
2	eukaryotic	O
3	cell	O
4	cycle	O
5	is	O
6	governed	O
7	in	O
8	part	O
9	by	O
10	the	O
11	periodic	O
12	transcription	O
13	of	O
14	cyclin	B
15	genes	I
16	,	O
17	whose	O
18	protein	O
19	products	O
20	associate	O
21	with	O
22	and	O
23	positively	O
24	regulate	O
25	the	O
26	cyclin	B
27	-	I
28	dependent	I
29	kinases	I
30	.	O

1	Serotonin	B
2	5	I
3	-	I
4	HT2	I
5	receptor	I
6	binding	O
7	on	O
8	blood	O
9	platelets	O
10	as	O
11	a	O
12	state	O
13	dependent	O
14	marker	O
15	in	O
16	major	O
17	affective	O
18	disorder	O
19	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	small	O
6	segment	O
7	of	O
8	yeast	B
9	TAF145	I
10	(	O
11	yTAF145	B
12	)	O
13	binds	O
14	to	O
15	TBP	B
16	and	O
17	thereby	O
18	inhibits	O
19	TBP	B
20	function	O
21	.	O

1	Oseltamivir	O
2	(	O
3	GS4104	O
4	),	O
5	which	O
6	can	O
7	be	O
8	administered	O
9	orally	O
10	,	O
11	is	O
12	the	O
13	prodrug	O
14	of	O
15	GS4071	O
16	,	O
17	a	O
18	potent	O
19	and	O
20	selective	O
21	inhibitor	O
22	of	O
23	influenzavirus	B
24	neuraminidases	I
25	.	O

1	Cortical	O
2	afferents	O
3	to	O
4	the	O
5	entorhinal	O
6	cortex	O
7	of	O
8	the	O
9	Rhesus	O
10	monkey	O
11	.	O

1	BACKGROUND	O
2	:	O
3	Chronic	O
4	alcohol	O
5	consumption	O
6	has	O
7	been	O
8	demonstrated	O
9	to	O
10	be	O
11	deleterious	O
12	to	O
13	bone	O
14	health	O
15	.	O

1	During	O
2	conventional	O
3	hemofiltration	O
4	using	O
5	substitution	O
6	fluid	O
7	with	O
8	a	O
9	Na	O
10	+	O
11	concentration	O
12	of	O
13	140	O
14	mEq	O
15	/	O
16	L	O
17	,	O
18	a	O
19	decrease	O
20	in	O
21	extracellular	O
22	fluid	O
23	volume	O
24	was	O
25	noted	O
26	whereas	O
27	the	O
28	intracellular	O
29	fluid	O
30	volume	O
31	was	O
32	unaltered	O
33	.	O

1	Pseudomonas	O
2	aeruginosa	O
3	strains	O
4	infecting	O
5	patients	O
6	with	O
7	cystic	O
8	fibrosis	O
9	(	O
10	CF	O
11	)	O
12	acquire	O
13	a	O
14	mucoid	O
15	phenotype	O
16	due	O
17	to	O
18	overproduction	O
19	of	O
20	alginate	O
21	.	O

1	Measurements	O
2	of	O
3	activity	O
4	with	O
5	the	O
6	radioprotective	O
7	chamber	O
8	VA	O
9	-	O
10	K	O
11	-	O
12	254	O
13	of	O
14	the	O
15	osimeter	O
16	VA	O
17	-	O
18	J18	O

1	We	O
2	also	O
3	discovered	O
4	a	O
5	V	B
6	lambda	I
7	pseudogene	I
8	,	O
9	called	O
10	psi	B
11	V	I
12	lambda	I
13	1	I
14	,	O
15	3	O
16	kb	O
17	upstream	O
18	of	O
19	the	O
20	U266	B
21	lambda	I
22	gene	I
23	.	O

1	We	O
2	have	O
3	previously	O
4	identified	O
5	mouse	B
6	and	I
7	human	I
8	cDNAs	I
9	encoding	I
10	UNC	I
11	-	I
12	51	I
13	-	I
14	like	I
15	kinase	I
16	(	O
17	ULK1	B
18	).	O

1	Positive	O
2	correlations	O
3	were	O
4	seen	O
5	between	O
6	the	O
7	measurements	O
8	for	O
9	protein	O
10	intake	O
11	(	O
12	r	O
13	=.	O
14	58	O
15	,	O
16	P	O
17	=.	O
18	0026	O
19	)	O
20	energy	O
21	intake	O
22	(	O
23	r	O
24	=.	O
25	78	O
26	,	O
27	P	O
28	<.	O
29	00001	O
30	),	O
31	with	O
32	mean	O
33	differences	O
34	of	O
35	.	O
36	066	O
37	g	O
38	/	O
39	kg	O
40	/	O
41	d	O
42	(	O
43	SD	O
44	.	O
45	38	O
46	)	O
47	2	O
48	.	O
49	04	O
50	kcal	O
51	/	O
52	kg	O
53	/	O
54	day	O
55	(	O
56	SD	O
57	6	O
58	.	O
59	67	O
60	),	O
61	respectively	O
62	.	O

1	A	O
2	73	O
3	bp	O
4	fragment	O
5	(	O
6	X1	O
7	region	O
8	)	O
9	of	O
10	the	O
11	PRB	B
12	-	I
13	1b	I
14	promoter	I
15	,	O
16	located	O
17	between	O
18	positions	O
19	-	O
20	213	O
21	and	O
22	-	O
23	141	O
24	,	O
25	was	O
26	sufficient	O
27	to	O
28	confer	O
29	ethylene	O
30	responsiveness	O
31	to	O
32	the	O
33	reporter	O
34	gene	O
35	.	O

1	C	O
2	.	O

1	When	O
2	transfected	O
3	into	O
4	Drosophila	O
5	SL	O
6	-	O
7	2	O
8	cells	O
9	,	O
10	pCAT	O
11	plasmid	O
12	containing	O
13	2	O
14	,	O
15	090	O
16	bp	O
17	of	O
18	5	O
19	'-	O
20	flanking	O
21	region	O
22	shows	O
23	a	O
24	3	O
25	.	O
26	0	O
27	-	O
28	to	O
29	3	O
30	.	O
31	5	O
32	-	O
33	fold	O
34	increase	O
35	in	O
36	chloramphenicol	B
37	acetyltransferase	I
38	activity	O
39	after	O
40	induction	O
41	with	O
42	retinoic	O
43	acid	O
44	and	O
45	/	O
46	or	O
47	8	O
48	-	O
49	bromo	O
50	-	O
51	cAMP	O
52	.	O

1	This	O
2	protein	O
3	-	O
4	protein	O
5	interaction	O
6	does	O
7	not	O
8	require	O
9	the	O
10	simultaneous	O
11	binding	O
12	of	O
13	Oct	B
14	proteins	I
15	to	O
16	DNA	O
17	,	O
18	and	O
19	high	O
20	resolution	O
21	footprinting	O
22	of	O
23	the	O
24	Oct	B
25	-	I
26	DNA	I
27	interaction	O
28	reveals	O
29	that	O
30	binding	O
31	of	O
32	BOB	B
33	.	I
34	1	I
35	/	O
36	OBF	B
37	.	I
38	1	I
39	to	O
40	Oct1	B
41	or	O
42	Oct2	B
43	does	O
44	not	O
45	alter	O
46	the	O
47	interaction	O
48	with	O
49	DNA	O
50	.	O

1	Reactive	O
2	lymphoid	O
3	hyperplasia	O
4	was	O
5	found	O
6	in	O
7	15	O
8	cases	O
9	,	O
10	2	O
11	cases	O
12	had	O
13	angiofollicular	O
14	lymphoid	O
15	hyperplasia	O
16	or	O
17	Castleman	O
18	'	O
19	s	O
20	disease	O
21	,	O
22	atypical	O
23	lymphoid	O
24	hyperplasia	O
25	suggestive	O
26	of	O
27	malignant	O
28	lymphoma	O
29	was	O
30	observed	O
31	in	O
32	3	O
33	cases	O
34	,	O
35	and	O
36	malignant	O
37	lymphoma	O
38	was	O
39	diagnosed	O
40	in	O
41	the	O
42	remaining	O
43	4	O
44	cases	O
45	.	O

1	Despite	O
2	this	O
3	DNA	O
4	binding	O
5	activity	O
6	,	O
7	AP	B
8	-	I
9	1	I
10	reporter	I
11	activity	O
12	was	O
13	suppressed	O
14	in	O
15	these	O
16	cells	O
17	.	O

1	CONCLUSION	O
2	:	O
3	Treatment	O
4	of	O
5	sepsis	O
6	with	O
7	the	O
8	platelet	B
9	-	I
10	activating	I
11	factor	I
12	antagonist	O
13	BB	O
14	-	O
15	882	O
16	offers	O
17	no	O
18	advantage	O
19	over	O
20	placebo	O
21	on	O
22	survival	O
23	,	O
24	hemodynamic	O
25	status	O
26	,	O
27	respiratory	O
28	function	O
29	,	O
30	or	O
31	organ	O
32	failure	O
33	scores	O
34	.	O

1	Hyperactivation	O
2	of	O
3	Cdc2	B
4	in	O
5	fission	O
6	yeast	O
7	causes	O
8	cells	O
9	to	O
10	undergo	O
11	a	O
12	lethal	O
13	premature	O
14	mitosis	O
15	called	O
16	mitotic	O
17	catastrophe	O
18	.	O

1	Lysozyme	B
2	activity	O
3	was	O
4	evidently	O
5	increased	O
6	as	O
7	well	O
8	in	O
9	undiluted	O
10	as	O
11	in	O
12	diluted	O
13	sera	O
14	in	O
15	all	O
16	our	O
17	tested	O
18	patients	O
19	.	O

1	A	O
2	second	O
3	study	O
4	group	O
5	,	O
6	with	O
7	intact	O
8	cardiac	O
9	innervation	O
10	,	O
11	consisted	O
12	of	O
13	19	O
14	patients	O
15	with	O
16	stable	O
17	angina	O
18	pectoris	O
19	class	O
20	I	O
21	to	O
22	III	O
23	.	O

1	This	O
2	study	O
3	provides	O
4	a	O
5	direct	O
6	demonstration	O
7	of	O
8	a	O
9	role	O
10	for	O
11	G	B
12	betagamma	I
13	in	O
14	mediating	O
15	the	O
16	agonist	O
17	-	O
18	stimulated	O
19	translocation	O
20	of	O
21	GRK2	B
22	and	O
23	GRK3	B
24	in	O
25	an	O
26	intact	O
27	cellular	O
28	system	O
29	and	O
30	demonstrates	O
31	isoform	O
32	specificity	O
33	in	O
34	the	O
35	interaction	O
36	of	O
37	these	O
38	components	O
39	.	O

1	Among	O
2	the	O
3	patients	O
4	grades	O
5	1	O
6	-	O
7	2	O
8	-	O
9	3	O
10	,	O
11	81	O
12	%	O
13	had	O
14	a	O
15	good	O
16	out	O
17	come	O
18	without	O
19	any	O
20	neurological	O
21	abnormality	O
22	,	O
23	among	O
24	the	O
25	patients	O
26	graded	O
27	4	O
28	-	O
29	5	O
30	,	O
31	only	O
32	27	O
33	%	O
34	had	O
35	a	O
36	fair	O
37	out	O
38	come	O
39	.	O

1	In	O
2	10	O
3	control	O
4	sheep	O
5	mean	O
6	plasma	O
7	TXB2	O
8	concentration	O
9	increased	O
10	from	O
11	0	O
12	.	O
13	39	O
14	ng	O
15	/	O
16	ml	O
17	prebypass	O
18	to	O
19	about	O
20	1	O
21	.	O
22	1	O
23	ng	O
24	/	O
25	ml	O
26	at	O
27	8	O
28	and	O
29	16	O
30	min	O
31	of	O
32	bypass	O
33	.	O

1	Psychological	O
2	examinations	O
3	in	O
4	patients	O
5	with	O
6	chronic	O
7	kidney	O
8	insufficiency	O

1	According	O
2	to	O
3	their	O
4	staining	O
5	affinity	O
6	for	O
7	anti	B
8	-	I
9	T	I
10	antibodies	I
11	,	O
12	the	O
13	glandular	O
14	tissue	O
15	cells	O
16	were	O
17	classified	O
18	as	O
19	T	B
20	-,	O
21	T	B
22	+,	O
23	T	B
24	++,	O
25	and	O
26	T	B
27	and	O
28	the	O
29	annual	O
30	changes	O
31	in	O
32	the	O
33	numbers	O
34	of	O
35	these	O
36	cell	O
37	populations	O
38	,	O
39	as	O
40	well	O
41	as	O
42	in	O
43	the	O
44	volume	O
45	occupied	O
46	by	O
47	the	O
48	glandular	O
49	tissue	O
50	,	O
51	were	O
52	calculated	O
53	.	O

1	In	O
2	11	O
3	eyes	O
4	that	O
5	had	O
6	been	O
7	selected	O
8	at	O
9	random	O
10	10	O
11	micrograms	O
12	of	O
13	recombinant	B
14	tissue	I
15	plasminogen	I
16	activator	I
17	were	O
18	injected	O
19	midvitreally	O
20	24	O
21	hrs	O
22	later	O
23	.	O

1	Parodoxical	O
2	rise	O
3	in	O
4	urinary	B
5	albumin	I
6	levels	O
7	after	O
8	treatment	O
9	of	O
10	essential	O
11	hypertension	O
12	.	O

1	SETTING	O
2	:	O
3	A	O
4	division	O
5	of	O
6	a	O
7	large	O
8	tea	O
9	plantation	O
10	in	O
11	Kandy	O
12	.	O

1	Habituation	O
2	of	O
3	completely	O
4	isolated	O
5	neurons	O
6	of	O
7	the	O
8	edible	O
9	snail	O
10	to	O
11	electrical	O
12	stimulation	O
13	.	O

1	Host	O
2	lipids	O
3	in	O
4	tuberculous	O
5	infection	O
6	.	O

1	Cheung	O
2	and	O
3	S	O
4	.	O

1	Other	O
2	assays	O
3	also	O
4	distinguished	O
5	the	O
6	processive	O
7	replication	O
8	of	O
9	pNeo	O
10	.	O
11	Myc	O
12	-	O
13	2	O
14	.	O
15	4	O
16	from	O
17	the	O
18	dispersive	O
19	labeling	O
20	of	O
21	control	O
22	plasmids	O
23	.	O

1	Deletion	O
2	mapping	O
3	studies	O
4	revealed	O
5	that	O
6	the	O
7	upstream	O
8	DNA	O
9	sequences	O
10	up	O
11	to	O
12	-	O
13	86	O
14	were	O
15	sufficient	O
16	for	O
17	the	O
18	optimal	O
19	basal	O
20	level	O
21	transcription	O
22	in	O
23	HeLa	O
24	cells	O
25	and	O
26	also	O
27	for	O
28	the	O
29	EIA	B
30	-	O
31	induced	O
32	transcription	O
33	.	O

1	Two	O
2	hundred	O
3	forty	O
4	-	O
5	three	O
6	patients	O
7	have	O
8	received	O
9	WR	O
10	-	O
11	2721	O
12	in	O
13	Phase	O
14	I	O
15	-	O
16	II	O
17	studies	O
18	.	O

1	The	O
2	cpc	B
3	-	I
4	1	I
5	-	I
6	encoded	I
7	transcript	I
8	contains	O
9	three	O
10	open	O
11	reading	O
12	frames	O
13	,	O
14	two	O
15	of	O
16	which	O
17	are	O
18	located	O
19	in	O
20	the	O
21	720	O
22	-	O
23	nucleotide	O
24	leader	O
25	segment	O
26	preceding	O
27	the	O
28	cpc	B
29	-	I
30	1	I
31	coding	I
32	region	I
33	.	O

1	RegA	B
2	is	O
3	a	O
4	positive	O
5	yet	O
6	nonessential	O
7	regulator	O
8	of	O
9	tol	B
10	-	O
11	oprL	B
12	expression	O
13	.	O

1	With	O
2	aging	O
3	,	O
4	many	O
5	aspects	O
6	of	O
7	immune	O
8	function	O
9	change	O
10	.	O

1	A	O
2	human	O
3	cytoplasmic	O
4	signaling	O
5	protein	O
6	has	O
7	been	O
8	cloned	O
9	that	O
10	possesses	O
11	the	O
12	same	O
13	structural	O
14	arrangement	O
15	of	O
16	SH3	B
17	-	O
18	SH2	B
19	-	O
20	SH3	B
21	domains	O
22	as	O
23	Grb2	B
24	.	O

1	Adrenergic	O
2	system	O
3	activation	O
4	,	O
5	indicated	O
6	by	O
7	metanephrine	O
8	/	O
9	epinephrine	O
10	ratio	O
11	,	O
12	increased	O
13	with	O
14	time	O
15	in	O
16	losing	O
17	males	O
18	,	O
19	except	O
20	that	O
21	after	O
22	one	O
23	month	O
24	of	O
25	cohabitation	O
26	,	O
27	turnover	O
28	returned	O
29	to	O
30	levels	O
31	that	O
32	equaled	O
33	those	O
34	of	O
35	control	O
36	animals	O
37	.	O

1	A	O
2	new	O
3	bioencapsulation	O
4	technology	O
5	for	O
6	microbial	O
7	inoculants	O
8	.	O

1	R	O
2	.	O

1	Copyright	O
2	1998	O
3	Elsevier	O
4	Science	O
5	B	O
6	.	O
7	V	O
8	.	O

1	Transient	O
2	overexpression	O
3	of	O
4	mutant	B
5	EphB1	I
6	receptors	I
7	(	O
8	Y594F	O
9	)	O
10	blocked	O
11	Nck	B
12	recruitment	O
13	to	O
14	EphB1	B
15	,	O
16	attenuated	O
17	downstream	O
18	JNK	B
19	activation	O
20	,	O
21	and	O
22	blocked	O
23	cell	O
24	attachment	O
25	responses	O
26	.	O

1	Following	O
2	the	O
3	satisfactory	O
4	results	O
5	and	O
6	taking	O
7	into	O
8	account	O
9	that	O
10	the	O
11	complications	O
12	had	O
13	reduced	O
14	to	O
15	a	O
16	very	O
17	low	O
18	rate	O
19	(	O
20	in	O
21	2	O
22	cases	O
23	lead	O
24	tip	O
25	displacement	O
26	and	O
27	pouch	O
28	haematoma	O
29	occurred	O
30	respectively	O
31	),	O
32	the	O
33	Authors	O
34	consider	O
35	the	O
36	adopted	O
37	method	O
38	an	O
39	useful	O
40	approach	O
41	for	O
42	PMK	O
43	implantation	O
44	particularly	O
45	when	O
46	the	O
47	use	O
48	of	O
49	the	O
50	vena	O
51	cephalica	O
52	is	O
53	deemed	O
54	impossible	O
55	.	O

1	Three	O
2	experiments	O
3	contrasted	O
4	the	O
5	effects	O
6	of	O
7	6	O
8	-	O
9	hydroxydopamine	O
10	-	O
11	induced	O
12	lesions	O
13	of	O
14	the	O
15	ventral	O
16	noradrenergic	O
17	and	O
18	dorsal	O
19	noradrenergic	O
20	projections	O
21	,	O
22	predominantly	O
23	to	O
24	hypothalamus	O
25	and	O
26	cortex	O
27	,	O
28	respectively	O
29	,	O
30	upon	O
31	body	O
32	weight	O
33	changes	O
34	and	O
35	food	O
36	-	O
37	related	O
38	behaviour	O
39	in	O
40	the	O
41	rat	O
42	.	O

1	After	O
2	determining	O
3	isoflurane	O
4	MAC	O
5	in	O
6	triplicate	O
7	,	O
8	birds	O
9	were	O
10	given	O
11	a	O
12	mu	O
13	-	O
14	opioid	O
15	agonist	O
16	(	O
17	morphine	O
18	,	O
19	n	O
20	=	O
21	9	O
22	)	O
23	or	O
24	a	O
25	kappa	O
26	-	O
27	opioid	O
28	agonist	O
29	(	O
30	U50488H	O
31	,	O
32	n	O
33	=	O
34	9	O
35	).	O

1	The	O
2	major	O
3	transcription	O
4	factors	O
5	controlling	O
6	arginine	O
7	metabolism	O
8	in	O
9	Escherichia	O
10	coli	O
11	and	O
12	Bacillus	O
13	subtilis	O
14	,	O
15	ArgR	B
16	and	O
17	AhrC	B
18	,	O
19	respectively	O
20	,	O
21	are	O
22	homologous	O
23	multimeric	O
24	proteins	O
25	that	O
26	form	O
27	l	O
28	-	O
29	arginine	O
30	-	O
31	dependent	O
32	DNA	O
33	-	O
34	binding	O
35	complexes	O
36	capable	O
37	of	O
38	repressing	O
39	transcription	O
40	of	O
41	the	O
42	biosynthetic	O
43	genes	O
44	(	O
45	both	O
46	),	O
47	activating	O
48	transcription	O
49	of	O
50	catabolic	O
51	genes	O
52	(	O
53	AhrC	B
54	only	O
55	)	O
56	or	O
57	facilitating	O
58	plasmid	O
59	dimer	O
60	resolution	O
61	(	O
62	both	O
63	).	O

1	CONCLUSIONS	O
2	:	O
3	Congenital	O
4	horizontal	O
5	tarsal	O
6	kink	O
7	is	O
8	rare	O
9	and	O
10	its	O
11	cause	O
12	is	O
13	unknown	O
14	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	describe	O
7	a	O
8	mammalian	O
9	cell	O
10	-	O
11	free	O
12	transcription	O
13	system	O
14	reconstituted	O
15	with	O
16	only	O
17	recombinant	O
18	proteins	O
19	and	O
20	epitope	O
21	-	O
22	tagged	O
23	multiprotein	O
24	complexes	O
25	.	O

1	Effect	O
2	of	O
3	time	O
4	and	O
5	dose	O
6	on	O
7	alterations	O
8	following	O
9	inhalation	O
10	of	O
11	plutonium	O
12	-	O
13	239	O
14	dioxide	O
15	aerosol	O
16	in	O
17	rat	O
18	.	O

1	The	O
2	human	O
3	pathogenic	O
4	bacterium	O
5	group	O
6	A	O
7	Streptococcus	O
8	produces	O
9	an	O
10	extracellular	O
11	cysteine	B
12	protease	I
13	[	O
14	streptococcal	B
15	pyrogenic	I
16	exotoxin	I
17	B	I
18	(	O
19	SpeB	B
20	)]	O
21	that	O
22	is	O
23	a	O
24	critical	O
25	virulence	O
26	factor	O
27	for	O
28	invasive	O
29	disease	O
30	episodes	O
31	.	O

1	INTERVENTIONS	O
2	:	O
3	Patients	O
4	received	O
5	rt	B
6	-	I
7	PA	I
8	,	O
9	heparin	O
10	,	O
11	and	O
12	aspirin	O
13	.	O

1	In	O
2	the	O
3	multivariate	O
4	analysis	O
5	,	O
6	six	O
7	variables	O
8	were	O
9	independently	O
10	correlated	O
11	with	O
12	survival	O
13	:	O
14	blood	O
15	urea	O
16	nitrogen	O
17	level	O
18	,	O
19	serum	B
20	aspartate	I
21	aminotransferase	I
22	level	O
23	,	O
24	community	O
25	-	O
26	acquired	O
27	vs	O
28	.	O
29	hospital	O
30	-	O
31	acquired	O
32	peritonitis	O
33	,	O
34	age	O
35	,	O
36	Child	O
37	-	O
38	Pugh	O
39	score	O
40	and	O
41	ileus	O
42	.	O

1	The	O
2	mustard	B
3	chloroplast	I
4	gene	I
5	rps16	I
6	is	O
7	split	O
8	by	O
9	an	O
10	887	O
11	bp	O
12	group	O
13	II	O
14	(	O
15	or	O
16	III	O
17	)	O
18	intron	O
19	.	O

1	Nipponbare	O
2	as	O
3	well	O
4	as	O
5	O	O
6	.	O
7	australiensis	O
8	.	O

1	Biochemical	O
2	analysis	O
3	shows	O
4	that	O
5	Ssm1p	B
6	is	O
7	a	O
8	structural	O
9	protein	O
10	that	O
11	forms	O
12	part	O
13	of	O
14	the	O
15	largest	O
16	60S	B
17	ribosomal	I
18	subunit	I
19	,	O
20	which	O
21	does	O
22	not	O
23	exist	O
24	in	O
25	a	O
26	pool	O
27	of	O
28	free	O
29	proteins	O
30	.	O

1	Plasma	B
2	leptin	I
3	concentrations	O
4	were	O
5	higher	O
6	in	O
7	women	O
8	than	O
9	men	O
10	,	O
11	even	O
12	after	O
13	the	O
14	adjustment	O
15	for	O
16	differences	O
17	in	O
18	fat	O
19	mass	O
20	(	O
21	28	O
22	+/-	O
23	3	O
24	ng	O
25	/	O
26	ml	O
27	for	O
28	women	O
29	vs	O
30	.	O

1	With	O
2	the	O
3	human	B
4	Rhotekin	I
5	cDNA	I
6	as	O
7	a	O
8	probe	O
9	,	O
10	Northern	O
11	hybridization	O
12	revealed	O
13	that	O
14	a	O
15	4	O
16	.	O
17	0	O
18	-	O
19	kb	O
20	transcript	O
21	was	O
22	expressed	O
23	at	O
24	a	O
25	high	O
26	level	O
27	in	O
28	prostate	O
29	and	O
30	at	O
31	a	O
32	middle	O
33	level	O
34	in	O
35	13	O
36	of	O
37	16	O
38	tissues	O
39	examined	O
40	,	O
41	but	O
42	it	O
43	cannot	O
44	be	O
45	detected	O
46	in	O
47	liver	O
48	and	O
49	lung	O
50	tissues	O
51	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	in	O
6	AIDS	O
7	patients	O
8	with	O
9	cryptococcosis	O
10	,	O
11	tolerance	O
12	to	O
13	ILd	O
14	-	O
15	AmB	O
16	was	O
17	acceptable	O
18	when	O
19	the	O
20	daily	O
21	dosage	O
22	did	O
23	not	O
24	exceed	O
25	1	O
26	mg	O
27	/	O
28	kg	O
29	,	O
30	but	O
31	the	O
32	higher	O
33	1	O
34	.	O
35	5	O
36	mg	O
37	/	O
38	kg	O
39	daily	O
40	dosage	O
41	was	O
42	associated	O
43	with	O
44	an	O
45	unacceptable	O
46	rate	O
47	of	O
48	nephrotoxicity	O
49	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	of	O
5	a	O
6	3213	O
7	bp	O
8	BamHI	B
9	-	O
10	ClaI	B
11	fragment	O
12	revealed	O
13	that	O
14	three	O
15	open	O
16	reading	O
17	frames	O
18	(	O
19	ORFs	O
20	)	O
21	were	O
22	encoded	O
23	in	O
24	the	O
25	same	O
26	orientation	O
27	.	O

1	Band	O
2	-	O
3	shift	O
4	assays	O
5	were	O
6	performed	O
7	using	O
8	the	O
9	LPS	B
10	-	I
11	and	I
12	IL	I
13	-	I
14	1	I
15	-	I
16	responsive	I
17	element	I
18	(	O
19	LILRE	B
20	)	O
21	oligonucleotide	O
22	,	O
23	a	O
24	gamma	B
25	interferon	I
26	activation	I
27	site	I
28	-	I
29	like	I
30	site	I
31	that	O
32	is	O
33	present	O
34	in	O
35	the	O
36	human	B
37	IL	I
38	-	I
39	1beta	I
40	promoter	I
41	.	O

1	Twelve	O
2	patients	O
3	had	O
4	stage	O
5	IBG3	O
6	,	O
7	14	O
8	had	O
9	ICG1	O
10	,	O
11	9	O
12	had	O
13	ICG2	O
14	,	O
15	and	O
16	3	O
17	had	O
18	ICG3	O
19	disease	O
20	.	O

1	Large	B
2	T	I
3	antigen	I
4	was	O
5	coimmunoprecipitated	O
6	by	O
7	antibodies	O
8	to	O
9	epitope	O
10	-	O
11	tagged	O
12	TBP	B
13	,	O
14	endogenous	O
15	TBP	B
16	,	O
17	hTAF	B
18	(	I
19	II	I
20	)	I
21	100	I
22	,	O
23	hTAF	B
24	(	I
25	II	I
26	)	I
27	130	I
28	,	O
29	and	O
30	hTAF	B
31	(	I
32	II	I
33	)	I
34	250	I
35	,	O
36	under	O
37	conditions	O
38	where	O
39	holo	B
40	-	I
41	TFIID	I
42	would	O
43	be	O
44	precipitated	O
45	.	O

1	Additionally	O
2	,	O
3	I	B
4	kappa	I
5	B	I
6	beta	I
7	,	O
8	but	O
9	not	O
10	I	B
11	kappa	I
12	B	I
13	alpha	I
14	,	O
15	also	O
16	prevented	O
17	the	O
18	binding	O
19	of	O
20	Rel	B
21	to	O
22	the	O
23	kappa	B
24	B	I
25	site	I
26	.	O

1	A	O
2	385	O
3	bp	O
4	Glucocorticoid	O
5	Response	O
6	Unit	O
7	(	O
8	GRU	O
9	)	O
10	was	O
11	identified	O
12	whose	O
13	glucocorticoid	O
14	induction	O
15	was	O
16	enhanced	O
17	by	O
18	dibutyryl	O
19	-	O
20	cAMP	O
21	and	O
22	reduced	O
23	by	O
24	phorbol	O
25	esters	O
26	.	O

1	Restriction	O
2	enzyme	O
3	and	O
4	heteroduplex	O
5	analyses	O
6	confirmed	O
7	that	O
8	sequences	O
9	unique	O
10	to	O
11	FeSV	O
12	(	O
13	src	B
14	sequences	I
15	)	O
16	are	O
17	located	O
18	at	O
19	the	O
20	center	O
21	of	O
22	the	O
23	FeSV	O
24	genome	O
25	and	O
26	are	O
27	approximately	O
28	1	O
29	.	O
30	5	O
31	kilobase	O
32	pairs	O
33	in	O
34	length	O
35	.	O

1	However	O
2	,	O
3	the	O
4	favored	O
5	,	O
6	parallel	O
7	beta	O
8	helix	O
9	model	O
10	is	O
11	a	O
12	compact	O
13	coil	O
14	of	O
15	ten	O
16	helically	O
17	arranged	O
18	beta	O
19	strands	O
20	forming	O
21	two	O
22	parallel	O
23	beta	O
24	sheet	O
25	faces	O
26	.	O

1	Heterogeneity	O
2	of	O
3	human	B
4	serum	I
5	albumin	I
6	.	O

1	The	O
2	clinical	O
3	efficacy	O
4	rates	O
5	evaluated	O
6	in	O
7	151	O
8	cases	O
9	(	O
10	KS	O
11	-	O
12	R1	O
13	group	O
14	in	O
15	77	O
16	cases	O
17	,	O
18	oral	O
19	group	O
20	in	O
21	74	O
22	cases	O
23	)	O
24	on	O
25	standard	O
26	criteria	O
27	of	O
28	committee	O
29	members	O
30	were	O
31	88	O
32	.	O
33	3	O
34	%	O
35	for	O
36	the	O
37	KS	O
38	-	O
39	R1	O
40	group	O
41	and	O
42	86	O
43	.	O
44	5	O
45	%	O
46	for	O
47	the	O
48	oral	O
49	group	O
50	,	O
51	respectively	O
52	.	O

1	Resolution	O
2	of	O
3	thermographic	O
4	asymmetry	O
5	and	O
6	/	O
7	or	O
8	decrease	O
9	in	O
10	Delta	O
11	T	O
12	was	O
13	demonstrated	O
14	in	O
15	approximately	O
16	81	O
17	%	O
18	of	O
19	the	O
20	post	O
21	-	O
22	treatment	O
23	population	O
24	.	O

1	After	O
2	infection	O
3	of	O
4	293	O
5	cells	O
6	(	O
7	which	O
8	provide	O
9	complementary	O
10	E1a	B
11	-	O
12	E1b	B
13	functions	O
14	),	O
15	both	O
16	viruses	O
17	directed	O
18	equal	O
19	amounts	O
20	of	O
21	P	B
22	/	I
23	C	I
24	-	I
25	specific	I
26	mRNA	I
27	transcription	O
28	.	O

1	Interestingly	O
2	,	O
3	the	O
4	activated	O
5	PDGF	B
6	beta	I
7	-	I
8	receptor	I
9	was	O
10	found	O
11	not	O
12	to	O
13	bind	O
14	Crk	B
15	proteins	I
16	.	O

1	One	O
2	hundred	O
3	fifty	O
4	patients	O
5	were	O
6	reviewed	O
7	at	O
8	1	O
9	year	O
10	after	O
11	arthroplasty	O
12	.	O

1	No	O
2	symptomatic	O
3	abnormality	O
4	has	O
5	been	O
6	noted	O
7	in	O
8	the	O
9	neonatal	O
10	period	O
11	except	O
12	periventricular	O
13	calcifications	O
14	.	O

1	The	O
2	Babcock	O
3	Surgical	O
4	Clinic	O
5	.	O

1	Nucleotide	O
2	sequences	O
3	of	O
4	the	O
5	clones	O
6	revealed	O
7	that	O
8	one	O
9	clone	O
10	,	O
11	cap3	B
12	,	O
13	contained	O
14	an	O
15	open	O
16	reading	O
17	frame	O
18	(	O
19	ORF	O
20	)	O
21	that	O
22	would	O
23	code	O
24	for	O
25	a	O
26	26	O
27	-	O
28	amino	O
29	acid	O
30	,	O
31	cysteine	O
32	-	O
33	rich	O
34	peptide	O
35	with	O
36	significant	O
37	homology	O
38	to	O
39	Neurospora	B
40	crassa	I
41	copper	I
42	metallothionein	I
43	.	O

1	Respiratory	O
2	chain	O
3	enzyme	O
4	activity	O
5	was	O
6	normal	O
7	.	O

1	Furthermore	O
2	,	O
3	although	O
4	the	O
5	regional	O
6	distribution	O
7	of	O
8	lean	O
9	tissue	O
10	mass	O
11	in	O
12	the	O
13	trunk	O
14	and	O
15	legs	O
16	remained	O
17	fairly	O
18	constant	O
19	at	O
20	different	O
21	pubertal	O
22	stages	O
23	,	O
24	the	O
25	regional	O
26	distribution	O
27	of	O
28	fat	O
29	was	O
30	altered	O
31	significantly	O
32	,	O
33	becoming	O
34	more	O
35	central	O
36	and	O
37	less	O
38	peripheral	O
39	.	O

1	In	O
2	addition	O
3	,	O
4	an	O
5	mck1	B
6	mds1	I
7	mrk1	I
8	triple	O
9	disruptant	O
10	was	O
11	viable	O
12	.	O

1	Commutative	O
2	saccadic	O
3	generator	O
4	is	O
5	sufficient	O
6	to	O
7	control	O
8	a	O
9	3	O
10	-	O
11	D	O
12	ocular	O
13	plant	O
14	with	O
15	pulleys	O
16	.	O

1	In	O
2	human	O
3	proliferative	O
4	cells	O
5	,	O
6	the	O
7	NADP	O
8	-	O
9	dependent	O
10	ME	B
11	activity	O
12	is	O
13	poorly	O
14	expressed	O
15	and	O
16	barely	O
17	inducible	O
18	by	O
19	thyroid	O
20	hormones	O
21	.	O

1	The	O
2	human	B
3	T	I
4	cell	I
5	leukemia	I
6	/	I
7	lymphotropic	I
8	virus	I
9	type	I
10	1	I
11	Tax	I
12	protein	I
13	represses	O
14	MyoD	B
15	-	O
16	dependent	O
17	transcription	O
18	by	O
19	inhibiting	O
20	MyoD	B
21	-	O
22	binding	O
23	to	O
24	the	O
25	KIX	B
26	domain	I
27	of	O
28	p300	B
29	.	O

1	Exposure	O
2	to	O
3	higher	O
4	TPA	O
5	concentrations	O
6	decreased	O
7	the	O
8	content	O
9	of	O
10	these	O
11	transcripts	O
12	.	O

1	We	O
2	also	O
3	demonstrate	O
4	that	O
5	preformed	O
6	triplexes	O
7	are	O
8	quite	O
9	stable	O
10	when	O
11	precipitated	O
12	with	O
13	ethanol	O
14	and	O
15	resuspended	O
16	in	O
17	water	O
18	.	O

1	Demonstration	O
2	of	O
3	the	O
4	agent	O
5	was	O
6	performed	O
7	from	O
8	the	O
9	6th	O
10	to	O
11	the	O
12	11th	O
13	day	O
14	p	O
15	.	O
16	i	O
17	.	O
18	by	O
19	direct	O
20	microscopic	O
21	methods	O
22	(	O
23	Stamp	O
24	and	O
25	auramine	O
26	staining	O
27	,	O
28	fluorescent	O
29	antibody	O
30	technique	O
31	);	O
32	the	O
33	Coxiella	O
34	content	O
35	was	O
36	determined	O
37	by	O
38	titration	O
39	in	O
40	embryonated	O
41	hen	O
42	'	O
43	s	O
44	eggs	O
45	.	O

1	They	O
2	include	O
3	genes	O
4	encoding	O
5	three	O
6	subunits	O
7	of	O
8	the	O
9	cytochrome	B
10	oxidase	I
11	(	O
12	cox1	B
13	to	I
14	3	I
15	),	O
16	apocytochrome	B
17	b	I
18	(	O
19	cob	B
20	),	O
21	seven	O
22	subunits	O
23	of	O
24	the	O
25	NADH	B
26	dehydrogenase	I
27	complex	I
28	(	O
29	nad1	B
30	to	I
31	6	I
32	,	O
33	nad4L	B
34	),	O
35	two	O
36	ATPase	B
37	subunits	O
38	(	O
39	atp6	B
40	and	O
41	atp9	B
42	),	O
43	three	O
44	ribosomal	O
45	RNAs	O
46	(	O
47	rrn5	B
48	,	O
49	srn	B
50	and	O
51	lrn	B
52	),	O
53	23	O
54	tRNAs	O
55	and	O
56	four	O
57	ribosomal	O
58	proteins	O
59	(	O
60	rps3	B
61	,	O
62	rps11	B
63	,	O
64	rps12	B
65	and	O
66	rpl16	B
67	).	O

1	Co	O
2	-	O
3	transfection	O
4	of	O
5	the	O
6	Sp1	B
7	expression	O
8	plasmid	O
9	and	O
10	the	O
11	-	O
12	58	O
13	promoter	O
14	construct	O
15	into	O
16	Drosophila	O
17	Schneider	O
18	cells	O
19	revealed	O
20	that	O
21	Sp1	B
22	contributed	O
23	to	O
24	the	O
25	kinase	O
26	basal	O
27	promoter	O
28	activity	O
29	by	O
30	binding	O
31	to	O
32	the	O
33	non	O
34	-	O
35	consensus	O
36	site	O
37	in	O
38	the	O
39	-	O
40	58	O
41	region	O
42	.	O

1	The	O
2	method	O
3	was	O
4	adapted	O
5	for	O
6	the	O
7	determination	O
8	of	O
9	nadolol	O
10	racemate	O
11	A	O
12	by	O
13	a	O
14	change	O
15	in	O
16	mobile	O
17	phase	O
18	composition	O
19	.	O

1	The	O
2	PDH	B
3	complex	I
4	-	I
5	encoding	I
6	genes	I
7	were	O
8	identified	O
9	by	O
10	hybridization	O
11	experiments	O
12	and	O
13	sequence	O
14	analysis	O
15	in	O
16	two	O
17	separate	O
18	gene	O
19	regions	O
20	in	O
21	the	O
22	genome	O
23	of	O
24	Z	O
25	.	O
26	mobilis	O
27	.	O

1	Addition	O
2	of	O
3	sucralfate	O
4	or	O
5	De	O
6	-	O
7	Nol	O
8	resulted	O
9	in	O
10	increments	O
11	of	O
12	gastric	O
13	HCO3	O
14	secretion	O
15	,	O
16	reaching	O
17	about	O
18	45	O
19	%	O
20	and	O
21	59	O
22	%,	O
23	respectively	O
24	,	O
25	of	O
26	the	O
27	maximal	O
28	HCO3	O
29	response	O
30	to	O
31	16	O
32	,	O
33	16	O
34	-	O
35	dimethyl	O
36	PGE2	O
37	(	O
38	dmPGE2	O
39	).	O

1	Clinicopathologic	O
2	studies	O
3	in	O
4	feminizing	O
5	tumors	O
6	of	O
7	the	O
8	ovary	O
9	.	O

1	Reduced	O
2	NK	O
3	activity	O
4	correlates	O
5	with	O
6	active	O
7	disease	O
8	in	O
9	HIV	O
10	-	O
11	patients	O
12	with	O
13	multidrug	O
14	-	O
15	resistant	O
16	pulmonary	O
17	tuberculosis	O
18	.	O

1	The	O
2	structural	O
3	gene	O
4	encoding	O
5	the	O
6	novel	O
7	lantibiotic	O
8	epilancin	B
9	K7	I
10	from	O
11	Staphylococcus	O
12	epidermidis	O
13	K7	O
14	was	O
15	cloned	O
16	and	O
17	its	O
18	nucleotide	O
19	sequence	O
20	was	O
21	determined	O
22	.	O

1	The	O
2	normal	O
3	cell	O
4	cycle	O
5	is	O
6	regulated	O
7	by	O
8	several	O
9	molecules	O
10	,	O
11	such	O
12	as	O
13	the	O
14	tumor	B
15	-	I
16	suppressor	I
17	protein	I
18	pRb	I
19	,	O
20	the	O
21	G1	B
22	cyclins	I
23	,	O
24	the	O
25	cyclin	B
26	-	I
27	dependent	I
28	kinases	I
29	,	O
30	and	O
31	their	O
32	inhibitors	O
33	.	O

1	A	O
2	surgical	O
3	technique	O
4	for	O
5	correcting	O
6	this	O
7	problem	O
8	is	O
9	described	O
10	.	O

1	To	O
2	gain	O
3	further	O
4	insight	O
5	into	O
6	the	O
7	pathogenesis	O
8	of	O
9	the	O
10	adult	O
11	respiratory	O
12	distress	O
13	syndrome	O
14	(	O
15	ARDS	O
16	),	O
17	the	O
18	authors	O
19	studied	O
20	possible	O
21	relationships	O
22	among	O
23	the	O
24	activation	O
25	status	O
26	of	O
27	circulating	O
28	polymorphonuclear	O
29	neutrophils	O
30	(	O
31	PMN	O
32	),	O
33	cytokine	O
34	levels	O
35	,	O
36	and	O
37	the	O
38	severity	O
39	of	O
40	lung	O
41	injury	O
42	in	O
43	31	O
44	patients	O
45	:	O
46	15	O
47	with	O
48	ARDS	O
49	,	O
50	9	O
51	with	O
52	severe	O
53	pneumonia	O
54	uncomplicated	O
55	by	O
56	ARDS	O
57	,	O
58	and	O
59	7	O
60	mechanically	O
61	ventilated	O
62	patients	O
63	with	O
64	neither	O
65	ARDS	O
66	nor	O
67	pneumonia	O
68	.	O

1	We	O
2	isolated	O
3	a	O
4	ribosomal	B
5	protein	I
6	L18	I
7	by	O
8	interaction	O
9	with	O
10	PKR	B
11	.	O

1	Compensative	O
2	justice	O
3	and	O
4	moral	O
5	investment	O
6	among	O
7	Japanese	O
8	,	O
9	Chinese	O
10	,	O
11	and	O
12	Koreans	O
13	.	O

1	Effect	O
2	of	O
3	bromazepam	O
4	on	O
5	growth	B
6	hormone	I
7	and	O
8	prolactin	B
9	secretion	O
10	in	O
11	normal	O
12	subjects	O
13	.	O

1	Both	O
2	in	O
3	vitro	O
4	-	O
5	synthesized	O
6	S2	B
7	protein	I
8	and	O
9	synthetic	O
10	peptides	O
11	corresponding	O
12	to	O
13	S2	B
14	are	O
15	shown	O
16	to	O
17	react	O
18	positively	O
19	with	O
20	sera	O
21	obtained	O
22	from	O
23	EIAV	O
24	-	O
25	infected	O
26	horses	O
27	,	O
28	providing	O
29	the	O
30	first	O
31	direct	O
32	evidence	O
33	of	O
34	expression	O
35	of	O
36	this	O
37	protein	O
38	in	O
39	infected	O
40	animals	O
41	.	O

1	NSCL	B
2	-	I
3	1	I
4	is	O
5	expressed	O
6	in	O
7	a	O
8	larger	O
9	number	O
10	of	O
11	these	O
12	cell	O
13	lines	O
14	.	O

1	A	O
2	bovine	O
3	abomasum	O
4	lambda	O
5	gt11	O
6	cDNA	O
7	library	O
8	was	O
9	screened	O
10	with	O
11	a	O
12	monoclonal	O
13	antibody	O
14	raised	O
15	against	O
16	the	O
17	rabbit	B
18	H	I
19	,	I
20	K	I
21	-	I
22	ATPase	I
23	beta	I
24	subunit	I
25	.	O

1	Sample	O
2	treatment	O
3	was	O
4	optimized	O
5	in	O
6	order	O
7	to	O
8	achieve	O
9	a	O
10	complete	O
11	extraction	O
12	of	O
13	labetalol	O
14	diastereoisomers	O
15	and	O
16	to	O
17	avoid	O
18	racemization	O
19	during	O
20	extraction	O
21	.	O

1	Advances	O
2	in	O
3	hemophilia	O
4	treatment	O
5	:	O
6	a	O
7	hepatitis	O
8	-	O
9	safe	O
10	factor	B
11	VIII	I
12	concentrate	O

1	Furthermore	O
2	,	O
3	our	O
4	novel	O
5	observation	O
6	that	O
7	expression	O
8	of	O
9	a	O
10	highly	O
11	activated	O
12	FGFR3	B
13	kinase	I
14	domain	I
15	is	O
16	able	O
17	to	O
18	morphologically	O
19	transform	O
20	fibroblasts	O
21	suggests	O
22	that	O
23	dysregulation	O
24	of	O
25	FGFR3	B
26	has	O
27	the	O
28	potential	O
29	to	O
30	play	O
31	a	O
32	role	O
33	in	O
34	human	O
35	neoplasia	O
36	.	O

1	However	O
2	,	O
3	a	O
4	clear	O
5	difference	O
6	exists	O
7	between	O
8	myoblasts	O
9	and	O
10	10T1	O
11	/	O
12	2	O
13	cells	O
14	(	O
15	and	O
16	other	O
17	non	O
18	-	O
19	muscle	O
20	cell	O
21	types	O
22	)	O
23	in	O
24	the	O
25	chromatin	O
26	structure	O
27	of	O
28	the	O
29	chromosomal	O
30	myoD	B
31	core	I
32	enhancer	I
33	,	O
34	suggesting	O
35	that	O
36	the	O
37	myoD	B
38	enhancer	I
39	is	O
40	repressed	O
41	by	O
42	epigenetic	O
43	mechanisms	O
44	in	O
45	10T1	O
46	/	O
47	2	O
48	cells	O
49	.	O

1	Using	O
2	a	O
3	high	O
4	-	O
5	copy	O
6	suppression	O
7	strategy	O
8	,	O
9	we	O
10	have	O
11	identified	O
12	a	O
13	yeast	O
14	gene	O
15	(	O
16	UBS1	B
17	)	O
18	whose	O
19	elevated	O
20	expression	O
21	suppresses	O
22	the	O
23	conditional	O
24	cell	O
25	cycle	O
26	defects	O
27	associated	O
28	with	O
29	cdc34	B
30	mutations	O
31	.	O

1	Unfortunately	O
2	,	O
3	these	O
4	preservatives	O
5	may	O
6	also	O
7	interfere	O
8	with	O
9	microbiological	O
10	assays	O
11	used	O
12	to	O
13	determine	O
14	product	O
15	sterility	O
16	or	O
17	bioburden	O
18	levels	O
19	.	O

1	The	O
2	eluting	O
3	solvent	O
4	was	O
5	methanol	O
6	-	O
7	chloroform	O
8	(	O
9	10	O
10	+	O
11	90	O
12	)	O
13	at	O
14	a	O
15	flow	O
16	rate	O
17	of	O
18	2	O
19	.	O
20	0	O
21	ml	O
22	/	O
23	min	O
24	.	O

1	Serotonin	O
2	levels	O
3	in	O
4	infant	O
5	hypothyroidism	O
6	.	O

1	Similar	O
2	clinical	O
3	evaluation	O
4	of	O
5	an	O
6	obligate	O
7	carrier	O
8	revealed	O
9	no	O
10	ocular	O
11	abnormalities	O
12	.	O

1	In	O
2	simpler	O
3	organisms	O
4	,	O
5	the	O
6	ATP	B
7	sulfurylase	I
8	and	O
9	APS	B
10	kinase	I
11	reactions	O
12	are	O
13	catalyzed	O
14	by	O
15	separate	O
16	enzymes	O
17	encoded	O
18	by	O
19	two	O
20	or	O
21	three	O
22	genes	O
23	,	O
24	suggesting	O
25	that	O
26	a	O
27	fusion	O
28	of	O
29	separate	O
30	genes	O
31	during	O
32	the	O
33	course	O
34	of	O
35	evolution	O
36	generated	O
37	the	O
38	bifunctional	O
39	enzyme	O
40	.	O

1	An	O
2	unusual	O
3	feature	O
4	of	O
5	these	O
6	replicative	O
7	genes	O
8	is	O
9	that	O
10	the	O
11	smaller	O
12	mRNA	O
13	begins	O
14	within	O
15	a	O
16	long	O
17	open	O
18	reading	O
19	frame	O
20	of	O
21	the	O
22	larger	O
23	mRNA	O
24	.	O

1	A	O
2	cDNA	O
3	clone	O
4	pCZ1	O
5	,	O
6	with	O
7	a	O
8	1	O
9	.	O
10	1	O
11	kb	O
12	insert	O
13	,	O
14	was	O
15	isolated	O
16	from	O
17	a	O
18	NaCl	O
19	-	O
20	adapted	O
21	tobacco	O
22	cell	O
23	cDNA	O
24	library	O
25	that	O
26	encodes	O
27	an	O
28	apparently	O
29	full	O
30	-	O
31	length	O
32	29	O
33	kDa	O
34	protein	O
35	(	O
36	251	O
37	amino	O
38	acids	O
39	)	O
40	with	O
41	a	O
42	calculated	O
43	pI	O
44	of	O
45	5	O
46	.	O
47	7	O
48	.	O

1	The	O
2	two	O
3	ParA	B
4	proteins	I
5	that	O
6	are	O
7	produced	O
8	as	O
9	a	O
10	result	O
11	of	O
12	independent	O
13	translation	O
14	initiation	O
15	at	O
16	two	O
17	different	O
18	start	O
19	codons	O
20	within	O
21	the	O
22	same	O
23	open	O
24	reading	O
25	frame	O
26	were	O
27	overexpressed	O
28	in	O
29	Escherichia	O
30	coli	O
31	and	O
32	partially	O
33	purified	O
34	.	O

1	Except	O
2	for	O
3	nonperfusion	O
4	of	O
5	neurosensory	O
6	retinal	O
7	vessels	O
8	at	O
9	a	O
10	light	O
11	dose	O
12	of	O
13	150	O
14	J	O
15	/	O
16	cm2	O
17	,	O
18	no	O
19	other	O
20	adverse	O
21	events	O
22	were	O
23	of	O
24	concern	O
25	.	O

1	Biological	O
2	action	O
3	and	O
4	kinetics	O
5	of	O
6	the	O
7	elimination	O
8	of	O
9	tritium	O
10	oxide	O
11	in	O
12	dogs	O

1	In	O
2	most	O
3	subjects	O
4	,	O
5	markers	O
6	of	O
7	bone	O
8	formation	O
9	and	O
10	resorption	O
11	were	O
12	normal	O
13	.	O

1	SRF	B
2	-	O
3	deficient	O
4	embryos	O
5	(	O
6	Srf	B
7	-/-)	O
8	have	O
9	a	O
10	severe	O
11	gastrulation	O
12	defect	O
13	and	O
14	do	O
15	not	O
16	develop	O
17	to	O
18	term	O
19	.	O

1	The	O
2	yeast	O
3	silent	B
4	information	I
5	regulator	I
6	Sir4p	I
7	anchors	O
8	and	O
9	partitions	O
10	plasmids	O
11	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	EKLF	B
6	provides	O
7	a	O
8	crucial	O
9	transactivation	O
10	function	O
11	for	O
12	globin	B
13	expression	O
14	and	O
15	further	O
16	reinforce	O
17	the	O
18	idea	O
19	that	O
20	EKLF	B
21	is	O
22	an	O
23	important	O
24	regulator	O
25	of	O
26	CACCC	O
27	element	O
28	-	O
29	directed	O
30	transcription	O
31	in	O
32	erythroid	O
33	cells	O
34	.	O

1	At	O
2	pH	O
3	6	O
4	.	O
5	9	O
6	,	O
7	the	O
8	same	O
9	lidocaine	O
10	concentrations	O
11	significantly	O
12	reduced	O
13	resting	O
14	potential	O
15	(	O
16	3	O
17	-	O
18	10	O
19	%),	O
20	action	O
21	potential	O
22	amplitude	O
23	(	O
24	3	O
25	-	O
26	8	O
27	%)	O
28	and	O
29	Vmax	O
30	(	O
31	14	O
32	-	O
33	22	O
34	%).	O

1	Mild	O
2	orbital	O
3	discomfort	O
4	occurred	O
5	in	O
6	some	O
7	patients	O
8	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	conservation	O
6	of	O
7	nucleotides	O
8	154	O
9	to	O
10	156	O
11	is	O
12	likely	O
13	to	O
14	be	O
15	a	O
16	consequence	O
17	of	O
18	their	O
19	role	O
20	as	O
21	a	O
22	sequence	O
23	-	O
24	specific	O
25	recognition	O
26	element	O
27	for	O
28	the	O
29	SRP54	B
30	protein	I
31	.	O

1	Homozygous	O
2	null	O
3	embryos	O
4	also	O
5	displayed	O
6	abnormalities	O
7	in	O
8	heart	O
9	development	O
10	,	O
11	consistent	O
12	with	O
13	the	O
14	conclusion	O
15	that	O
16	Tek	B
17	is	O
18	necessary	O
19	for	O
20	endocardial	O
21	/	O
22	myocardial	O
23	interactions	O
24	during	O
25	development	O
26	.	O

1	High	O
2	levels	O
3	of	O
4	IC	O
5	coincided	O
6	with	O
7	relative	O
8	hypocomplementemia	O
9	.	O

1	MEF	B
2	and	O
3	AML1B	B
4	synergistically	O
5	transactivated	O
6	an	O
7	interleukin	B
8	3	I
9	promoter	I
10	reporter	I
11	gene	I
12	construct	I
13	,	O
14	yet	O
15	the	O
16	activating	O
17	activity	O
18	of	O
19	MEF	B
20	was	O
21	abolished	O
22	when	O
23	MEF	B
24	was	O
25	coexpressed	O
26	with	O
27	AML1	B
28	/	O
29	ETO	B
30	.	O

1	In	O
2	this	O
3	report	O
4	we	O
5	describe	O
6	the	O
7	isolation	O
8	of	O
9	a	O
10	Fab	B
11	fragment	I
12	(	O
13	Fab	B
14	A8	I
15	)	O
16	showing	O
17	a	O
18	high	O
19	relative	O
20	affinity	O
21	for	O
22	the	O
23	receptor	O
24	(	O
25	0	O
26	.	O
27	5	O
28	nM	O
29	).	O

1	Patients	O
2	with	O
3	lesions	O
4	affecting	O
5	the	O
6	PRC	O
7	but	O
8	sparing	O
9	the	O
10	PHC	O
11	,	O
12	and	O
13	patients	O
14	with	O
15	lesions	O
16	affecting	O
17	both	O
18	PRC	O
19	and	O
20	PHC	O
21	,	O
22	performed	O
23	an	O
24	oculomotor	O
25	delayed	O
26	response	O
27	task	O
28	with	O
29	unpredictably	O
30	varied	O
31	memory	O
32	delays	O
33	of	O
34	up	O
35	to	O
36	30	O
37	s	O
38	.	O

1	Problems	O
2	in	O
3	the	O
4	determination	O
5	of	O
6	the	O
7	antigenic	O
8	content	O
9	of	O
10	influenza	O
11	vaccines	O
12	.	O

1	Chloroplast	B
2	mutator	I
3	(	O
4	chm	B
5	)	O
6	of	O
7	Arabidopsis	O
8	is	O
9	a	O
10	recessive	O
11	nuclear	O
12	mutation	O
13	that	O
14	causes	O
15	green	O
16	and	O
17	white	O
18	variegation	O
19	in	O
20	leaves	O
21	and	O
22	is	O
23	inherited	O
24	in	O
25	a	O
26	non	O
27	-	O
28	Mendelian	O
29	fashion	O
30	.	O

1	The	O
2	Ishasha	O
3	samples	O
4	show	O
5	a	O
6	range	O
7	encompassing	O
8	three	O
9	trophic	O
10	levels	O
11	.	O

1	Furthermore	O
2	,	O
3	p150	B
4	suppresses	O
5	actin	B
6	gelation	O
7	,	O
8	which	O
9	is	O
10	induced	O
11	by	O
12	smooth	B
13	muscle	I
14	alpha	I
15	-	I
16	actinin	I
17	.	O

1	The	O
2	effects	O
3	of	O
4	glutaraldehyde	O
5	on	O
6	dimensions	O
7	and	O
8	ultrastructure	O
9	of	O
10	microvascular	O
11	beds	O
12	in	O
13	rat	O
14	mesentery	O
15	were	O
16	studied	O
17	in	O
18	two	O
19	kinds	O
20	of	O
21	experiment	O
22	,	O
23	administering	O
24	the	O
25	fixative	O
26	by	O
27	intra	O
28	-	O
29	arterial	O
30	perfusion	O
31	at	O
32	a	O
33	pressure	O
34	of	O
35	80	O
36	mm	O
37	Hg	O
38	and	O
39	by	O
40	superfusion	O
41	of	O
42	the	O
43	exteriorized	O
44	mesenteric	O
45	membrane	O
46	.	O

1	The	O
2	sequence	O
3	analysis	O
4	of	O
5	both	O
6	products	O
7	of	O
8	individual	O
9	phi	O
10	80	O
11	site	O
12	-	O
13	specific	O
14	recombination	O
15	events	O
16	in	O
17	vivo	O
18	shows	O
19	that	O
20	recombination	O
21	with	O
22	a	O
23	secondary	O
24	attachment	O
25	(	O
26	att	O
27	)	O
28	site	O
29	generates	O
30	several	O
31	different	O
32	novel	O
33	joints	O
34	at	O
35	the	O
36	mismatched	O
37	position	O
38	:	O
39	one	O
40	recombination	O
41	event	O
42	resulted	O
43	in	O
44	a	O
45	single	O
46	base	O
47	-	O
48	pair	O
49	deletion	O
50	and	O
51	two	O
52	other	O
53	recombination	O
54	events	O
55	resulted	O
56	in	O
57	two	O
58	different	O
59	single	O
60	base	O
61	-	O
62	pair	O
63	substitutions	O
64	.	O

1	We	O
2	have	O
3	partially	O
4	sequenced	O
5	the	O
6	RAP74	B
7	protein	I
8	from	O
9	purified	O
10	HeLa	O
11	cells	O
12	,	O
13	cloned	O
14	its	O
15	complementary	O
16	DNA	O
17	and	O
18	shown	O
19	that	O
20	its	O
21	translation	O
22	product	O
23	can	O
24	interact	O
25	with	O
26	RAP30	B
27	in	O
28	vitro	O
29	as	O
30	well	O
31	as	O
32	in	O
33	vivo	O
34	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	characterized	O
8	cis	O
9	-	O
10	elements	O
11	of	O
12	the	O
13	human	B
14	PCI	I
15	gene	I
16	required	O
17	for	O
18	expression	O
19	in	O
20	the	O
21	hepatoma	O
22	-	O
23	derived	O
24	cell	O
25	line	O
26	,	O
27	HepG2	O
28	cells	O
29	,	O
30	and	O
31	also	O
32	evaluated	O
33	rat	B
34	PCI	I
35	mRNA	I
36	expression	O
37	,	O
38	particularly	O
39	on	O
40	the	O
41	effect	O
42	of	O
43	androgen	O
44	in	O
45	rat	O
46	reproductive	O
47	tissues	O
48	.	O

1	Bertioga	O
2	(	O
3	Guama	O
4	group	O
5	)	O
6	and	O
7	Anhembi	O
8	(	O
9	Bunyamwera	O
10	group	O
11	),	O
12	two	O
13	new	O
14	arboviruses	O
15	isolated	O
16	in	O
17	Sao	O
18	Paulo	O
19	,	O
20	Brazil	O
21	.	O

1	The	O
2	molecular	O
3	weight	O
4	of	O
5	in	O
6	vivo	O
7	-	O
8	labeled	O
9	proteins	O
10	was	O
11	increased	O
12	relative	O
13	to	O
14	that	O
15	of	O
16	in	O
17	vitro	O
18	-	O
19	translated	O
20	proteins	O
21	,	O
22	indicating	O
23	that	O
24	a	O
25	posttranslational	O
26	modification	O
27	had	O
28	occurred	O
29	.	O

1	We	O
2	present	O
3	evidence	O
4	that	O
5	the	O
6	upstream	O
7	open	O
8	reading	O
9	frame	O
10	(	O
11	uORF	O
12	)	O
13	represses	O
14	the	O
15	translation	O
16	of	O
17	the	O
18	downstream	O
19	major	O
20	open	O
21	reading	O
22	frame	O
23	(	O
24	mORF	O
25	).	O

1	The	O
2	activation	O
3	of	O
4	the	O
5	HIV	O
6	promoter	O
7	required	O
8	the	O
9	nuclear	O
10	localization	O
11	of	O
12	c	B
13	-	I
14	Abl	I
15	and	O
16	could	O
17	be	O
18	correlated	O
19	with	O
20	increased	O
21	tyrosine	O
22	phosphorylation	O
23	of	O
24	RNA	B
25	polymerase	I
26	II	I
27	.	O

1	The	O
2	greatest	O
3	difference	O
4	between	O
5	the	O
6	Ad7	B
7	and	I
8	Ad5	I
9	DBPs	I
10	is	O
11	the	O
12	absence	O
13	,	O
14	in	O
15	the	O
16	Ad7	O
17	protein	O
18	,	O
19	of	O
20	12	O
21	amino	O
22	acids	O
23	located	O
24	between	O
25	the	O
26	two	O
27	functional	O
28	domains	O
29	in	O
30	the	O
31	Ad5	O
32	protein	O
33	(	O
34	amino	O
35	acids	O
36	151	O
37	-	O
38	162	O
39	).	O

1	The	O
2	RFLP	O
3	patterns	O
4	of	O
5	the	O
6	isolates	O
7	from	O
8	six	O
9	of	O
10	these	O
11	patients	O
12	remained	O
13	essentially	O
14	unchanged	O
15	(	O
16	two	O
17	strains	O
18	showed	O
19	one	O
20	additional	O
21	band	O
22	)	O
23	despite	O
24	the	O
25	development	O
26	of	O
27	drug	O
28	resistance	O
29	.	O

1	Diltiazem	O
2	decreased	O
3	the	O
4	total	O
5	body	O
6	clearance	O
7	from	O
8	34	O
9	.	O
10	0	O
11	+/-	O
12	8	O
13	.	O
14	0	O
15	to	O
16	28	O
17	.	O
18	6	O
19	+/-	O
20	6	O
21	.	O
22	1	O
23	mL	O
24	/	O
25	min	O
26	(	O
27	P	O
28	less	O
29	than	O
30	.	O
31	01	O
32	),	O
33	and	O
34	prolonged	O
35	the	O
36	elimination	O
37	half	O
38	-	O
39	life	O
40	from	O
41	12	O
42	.	O
43	6	O
44	+/-	O
45	3	O
46	.	O
47	0	O
48	to	O
49	14	O
50	.	O
51	3	O
52	+/-	O
53	2	O
54	.	O
55	5	O
56	hours	O
57	(	O
58	P	O
59	less	O
60	than	O
61	.	O
62	01	O
63	)	O
64	of	O
65	antipyrine	O
66	without	O
67	any	O
68	changes	O
69	in	O
70	volume	O
71	of	O
72	distribution	O
73	.	O

1	Dissociative	O
2	anesthetics	O
3	2	O
4	-(	O
5	o	O
6	-	O
7	chlorophenyl	O
8	)-	O
9	2	O
10	-	O
11	methyl	O
12	-	O
13	amino	O
14	cyclohexane	O
15	HCL	O
16	(	O
17	CI	O
18	-	O
19	581	O
20	)	O

1	BACKGROUND	O
2	:	O
3	Checkpoint	O
4	pathways	O
5	prevent	O
6	cell	O
7	-	O
8	cycle	O
9	progression	O
10	in	O
11	the	O
12	event	O
13	of	O
14	DNA	O
15	lesions	O
16	.	O

1	The	O
2	cleavage	O
3	of	O
4	Fak	B
5	by	O
6	caspases	B
7	may	O
8	thus	O
9	play	O
10	an	O
11	important	O
12	role	O
13	in	O
14	the	O
15	execution	O
16	of	O
17	the	O
18	suicide	O
19	program	O
20	by	O
21	disabling	O
22	the	O
23	anti	O
24	-	O
25	apoptotic	O
26	function	O
27	of	O
28	Fak	B
29	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	revealed	O
5	that	O
6	these	O
7	clones	O
8	encode	O
9	two	O
10	distinct	O
11	forms	O
12	of	O
13	translocase	B
14	.	O

1	The	O
2	patient	O
3	was	O
4	treated	O
5	with	O
6	benzathine	O
7	penicillin	O
8	,	O
9	2	O
10	,	O
11	400	O
12	,	O
13	000	O
14	U	O
15	weekly	O
16	for	O
17	three	O
18	weeks	O
19	.	O

1	Counter	O
2	-	O
3	current	O
4	heat	O
5	exchange	O
6	in	O
7	the	O
8	respiratory	O
9	passages	O
10	:	O
11	effect	O
12	on	O
13	water	O
14	and	O
15	heat	O
16	balance	O
17	.	O

1	G	B
2	-	I
3	CSF	I
4	(	O
5	480	O
6	micrograms	O
7	subcutaneously	O
8	(	O
9	s	O
10	.	O
11	c	O
12	.))	O
13	were	O
14	used	O
15	in	O
16	55	O
17	and	O
18	GM	B
19	-	I
20	CSF	I
21	(	O
22	400	O
23	micrograms	O
24	s	O
25	.	O
26	c	O
27	.)	O
28	in	O
29	28	O
30	chemotherapeutic	O
31	cycles	O
32	.	O

1	Thus	O
2	,	O
3	ZNF74	B
4	sublocalization	O
5	in	O
6	nuclear	O
7	domains	O
8	enriched	O
9	in	O
10	pre	O
11	-	O
12	mRNA	O
13	maturating	O
14	factors	O
15	,	O
16	its	O
17	RNA	O
18	binding	O
19	activity	O
20	,	O
21	and	O
22	its	O
23	direct	O
24	phosphodependent	O
25	interaction	O
26	with	O
27	the	O
28	pol	B
29	IIo	I
30	,	O
31	a	O
32	form	O
33	of	O
34	the	O
35	RNA	B
36	polymerase	I
37	functionally	O
38	associated	O
39	with	O
40	pre	O
41	-	O
42	mRNA	O
43	processing	O
44	,	O
45	suggest	O
46	a	O
47	role	O
48	for	O
49	this	O
50	member	O
51	of	O
52	the	O
53	KRAB	B
54	multifinger	I
55	protein	I
56	family	I
57	in	O
58	RNA	O
59	processing	O
60	.	O

1	Analyses	O
2	of	O
3	hGMR	B
4	beta	I
5	subunit	I
6	mutants	I
7	revealed	O
8	two	O
9	cytoplasmic	O
10	regions	O
11	involved	O
12	in	O
13	activation	O
14	of	O
15	the	O
16	c	B
17	-	I
18	myc	I
19	promoter	I
20	,	O
21	one	O
22	is	O
23	essential	O
24	and	O
25	the	O
26	other	O
27	is	O
28	dispensable	O
29	but	O
30	enhances	O
31	the	O
32	activity	O
33	.	O

1	Closure	O
2	of	O
3	the	O
4	patent	O
5	ductus	O
6	arteriosus	O
7	with	O
8	a	O
9	Ligaclip	O
10	through	O
11	a	O
12	minithoracotomy	O
13	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	direct	O
6	cDNA	O
7	mapping	O
8	using	O
9	fluorescence	O
10	in	O
11	situ	O
12	hybridization	O
13	provides	O
14	an	O
15	accurate	O
16	and	O
17	rapid	O
18	approach	O
19	to	O
20	the	O
21	definition	O
22	of	O
23	a	O
24	transcribed	O
25	map	O
26	of	O
27	the	O
28	human	O
29	genome	O
30	.	O

1	Ficat	O
2	and	O
3	Bizou	O
4	'	O
5	s	O
6	condylar	O
7	depth	O
8	index	O
9	and	O
10	the	O
11	condylar	O
12	-	O
13	joint	O
14	surface	O
15	angle	O
16	of	O
17	Brattstrom	O
18	are	O
19	recommended	O
20	as	O
21	especially	O
22	suitable	O
23	methods	O
24	of	O
25	measurement	O
26	.	O

1	During	O
2	early	O
3	neurogenesis	O
4	,	O
5	Vnd	B
6	protein	I
7	is	O
8	restricted	O
9	to	O
10	ventral	O
11	column	O
12	neuroectoderm	O
13	and	O
14	neuroblasts	O
15	;	O
16	later	O
17	it	O
18	is	O
19	detected	O
20	in	O
21	a	O
22	complex	O
23	pattern	O
24	of	O
25	neurons	O
26	.	O

1	The	O
2	above	O
3	results	O
4	mean	O
5	that	O
6	the	O
7	increase	O
8	in	O
9	alpha	B
10	-	I
11	adrenergic	I
12	receptors	I
13	makes	O
14	the	O
15	prostate	O
16	,	O
17	which	O
18	has	O
19	been	O
20	already	O
21	hypertrophied	O
22	,	O
23	less	O
24	elastic	O
25	,	O
26	inhibiting	O
27	external	O
28	urinary	O
29	sphincter	O
30	function	O
31	.	O

1	The	O
2	AL	O
3	-	O
4	R8	O
5	SI	O
6	:	O
7	the	O
8	next	O
9	generation	O
10	staging	O
11	container	O
12	for	O
13	plutonium	O
14	pits	O
15	at	O
16	the	O
17	USDOE	O
18	Pantex	O
19	Plant	O
20	.	O

1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	demonstrated	O
7	that	O
8	HSV	O
9	infection	O
10	caused	O
11	enhanced	O
12	binding	O
13	of	O
14	protein	O
15	factors	O
16	,	O
17	including	O
18	the	O
19	64	B
20	-	I
21	kDa	I
22	component	I
23	of	I
24	cleavage	I
25	stimulation	I
26	factor	I
27	(	O
28	CstF	B
29	),	O
30	to	O
31	poly	O
32	(	O
33	A	O
34	)	O
35	site	O
36	RNAs	O
37	from	O
38	virus	O
39	genes	O
40	of	O
41	all	O
42	temporal	O
43	classes	O
44	and	O
45	that	O
46	this	O
47	enhanced	O
48	binding	O
49	required	O
50	expression	O
51	of	O
52	IE63	B
53	.	O

1	Therapy	O
2	with	O
3	dietary	O
4	modification	O
5	and	O
6	triglyceride	O
7	lowering	O
8	drugs	O
9	resulted	O
10	in	O
11	resolution	O
12	of	O
13	symptoms	O
14	and	O
15	parotid	O
16	swelling	O
17	in	O
18	one	O
19	patient	O
20	.	O

1	Chernoff	O
2	,	O
3	submitted	O
4	for	O
5	publication	O
6	).	O

1	The	O
2	humanized	B
3	LL2	I
4	(	O
5	hLL2	B
6	),	O
7	lacking	O
8	light	B
9	chain	I
10	variable	I
11	region	I
12	glycosylation	O
13	,	O
14	exhibited	O
15	immunoreactivities	O
16	that	O
17	were	O
18	comparable	O
19	to	O
20	that	O
21	of	O
22	chimeric	B
23	LL2	I
24	(	O
25	cLL2	B
26	),	O
27	which	O
28	was	O
29	shown	O
30	previously	O
31	to	O
32	have	O
33	antigen	O
34	-	O
35	binding	O
36	properties	O
37	similar	O
38	to	O
39	its	O
40	murine	O
41	counterpart	O
42	,	O
43	suggesting	O
44	that	O
45	the	O
46	VK	O
47	-	O
48	appended	O
49	oligosaccharides	O
50	found	O
51	in	O
52	mLL2	B
53	are	O
54	not	O
55	necessary	O
56	for	O
57	antigen	O
58	binding	O
59	.	O

1	One	O
2	of	O
3	these	O
4	elements	O
5	,	O
6	the	O
7	homeodomain	B
8	-	I
9	binding	I
10	element	I
11	,	O
12	was	O
13	identified	O
14	to	O
15	mediate	O
16	negative	O
17	regulation	O
18	.	O

1	Ultrasound	O
2	effect	O
3	on	O
4	the	O
5	cytochrome	B
6	oxidase	I
7	activity	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	influence	O
6	of	O
7	NaFe3	O
8	+	O
9	EDTA	O
10	,	O
11	and	O
12	of	O
13	increasing	O
14	dietary	O
15	levels	O
16	of	O
17	Na2EDTA	O
18	,	O
19	on	O
20	Zn	O
21	,	O
22	Cu	O
23	and	O
24	Ca	O
25	metabolism	O
26	in	O
27	rats	O
28	fed	O
29	on	O
30	Zn	O
31	-	O
32	sufficient	O
33	and	O
34	Zn	O
35	-	O
36	deficient	O
37	soya	O
38	-	O
39	bean	O
40	-	O
41	isolate	O
42	-	O
43	based	O
44	diets	O
45	.	O

1	The	O
2	aim	O
3	of	O
4	our	O
5	study	O
6	was	O
7	to	O
8	evaluate	O
9	the	O
10	level	O
11	of	O
12	oxidative	O
13	stress	O
14	in	O
15	healthy	O
16	controls	O
17	(	O
18	CTL	O
19	)	O
20	compared	O
21	with	O
22	CRF	O
23	and	O
24	HD	O
25	patients	O
26	before	O
27	(	O
28	pre	O
29	-	O
30	HD	O
31	)	O
32	and	O
33	after	O
34	(	O
35	post	O
36	-	O
37	HD	O
38	)	O
39	the	O
40	dialysis	O
41	session	O
42	,	O
43	carried	O
44	out	O
45	on	O
46	a	O
47	high	O
48	biocompatible	O
49	polyacrylonitrile	O
50	membrane	O
51	AN69	O
52	.	O

1	I	O
2	.	O

1	Fas	B
2	has	O
3	been	O
4	shown	O
5	to	O
6	require	O
7	ICE	B
8	(	O
9	interleukin	B
10	-	I
11	1	I
12	beta	I
13	-	I
14	converting	I
15	enzyme	I
16	)	O
17	family	O
18	proteases	O
19	to	O
20	induce	O
21	apoptosis	O
22	from	O
23	studies	O
24	utilizing	O
25	the	O
26	cowpox	O
27	ICE	B
28	inhibitor	I
29	protein	I
30	CrmA	I
31	,	O
32	the	O
33	synthetic	O
34	tetrapeptide	O
35	ICE	B
36	inhibitor	O
37	YVAD	B
38	-	I
39	CMK	I
40	,	O
41	and	O
42	the	O
43	tripeptide	O
44	pan	O
45	-	O
46	ICE	B
47	inhibitor	O
48	Z	B
49	-	I
50	VAD	I
51	-	I
52	FMK	I
53	.	O

1	[	O
2	18F	O
3	](+)-	O
4	4	O
5	-	O
6	fluorobenzyltrozamicol	O
7	(	O
8	FBT	O
9	),	O
10	which	O
11	selectively	O
12	binds	O
13	to	O
14	the	O
15	vesicular	O
16	acetylcholine	B
17	transporter	I
18	in	O
19	the	O
20	presynaptic	O
21	cholinergic	O
22	neuron	O
23	,	O
24	has	O
25	previously	O
26	been	O
27	shown	O
28	to	O
29	be	O
30	a	O
31	useful	O
32	ligand	O
33	for	O
34	the	O
35	study	O
36	of	O
37	cholinergic	O
38	terminal	O
39	density	O
40	in	O
41	the	O
42	basal	O
43	ganglia	O
44	with	O
45	PET	O
46	.	O

1	Ischemia	O
2	and	O
3	reperfusion	O
4	markedly	O
5	increased	O
6	the	O
7	release	O
8	of	O
9	6	O
10	-	O
11	keto	O
12	-	O
13	PGF1	O
14	alpha	O
15	and	O
16	TXB2	O
17	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	CT	O
6	should	O
7	be	O
8	routinely	O
9	employed	O
10	in	O
11	patients	O
12	with	O
13	N1	O
14	-	O
15	N3	O
16	neck	O
17	disease	O
18	to	O
19	determine	O
20	the	O
21	proper	O
22	electron	O
23	-	O
24	energy	O
25	prescription	O
26	.	O

1	Lars	O
2	has	O
3	AIDS	O
4	--	O
5	a	O
6	more	O
7	dignified	O
8	life	O
9	with	O
10	care	O
11	at	O
12	home	O
13	.	O

1	However	O
2	,	O
3	when	O
4	combined	O
5	with	O
6	mitomycin	O
7	C	O
8	given	O
9	with	O
10	1	O
11	to	O
12	5	O
13	-	O
14	days	O
15	interval	O
16	,	O
17	the	O
18	concurrent	O
19	administration	O
20	of	O
21	SPG	O
22	prolonged	O
23	significantly	O
24	the	O
25	life	O
26	-	O
27	span	O
28	of	O
29	the	O
30	tumor	O
31	-	O
32	bearing	O
33	mice	O
34	.	O

1	The	O
2	accumulated	O
3	products	O
4	of	O
5	ancient	O
6	duplication	O
7	events	O
8	can	O
9	be	O
10	readily	O
11	observed	O
12	among	O
13	the	O
14	genes	O
15	encoding	O
16	voltage	O
17	-	O
18	dependent	O
19	Ca	O
20	(	O
21	2	O
22	+)	O
23	ion	O
24	channels	O
25	.	O

1	Following	O
2	seizure	O
3	induction	O
4	,	O
5	MABP	O
6	increased	O
7	to	O
8	105	O
9	mm	O
10	Hg	O
11	and	O
12	brain	O
13	pHi	O
14	fell	O
15	to	O
16	6	O
17	.	O
18	79	O
19	+/-	O
20	0	O
21	.	O
22	03	O
23	within	O
24	15	O
25	min	O
26	and	O
27	remained	O
28	at	O
29	this	O
30	level	O
31	for	O
32	1	O
33	h	O
34	(	O
35	P	O
36	<	O
37	0	O
38	.	O
39	001	O
40	).	O

1	Site	O
2	S	O
3	-	O
4	II	O
5	also	O
6	spans	O
7	a	O
8	23	O
9	bp	O
10	sequence	O
11	containing	O
12	two	O
13	tandem	O
14	consensus	O
15	binding	O
16	sites	O
17	with	O
18	three	O
19	base	O
20	pair	O
21	mismatches	O
22	in	O
23	each	O
24	and	O
25	a	O
26	one	O
27	base	O
28	pair	O
29	deletion	O
30	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	demonstrate	O
8	that	O
9	expression	O
10	of	O
11	TD	B
12	-	I
13	IkappaBalpha	I
14	blocked	O
15	phorbol	O
16	myristate	O
17	acetate	B
18	-	I
19	phytohemagglutinin	I
20	or	O
21	tumor	B
22	necrosis	I
23	factor	I
24	alpha	I
25	-	O
26	induced	O
27	IkappaBalpha	B
28	gene	I
29	transcription	O
30	and	O
31	abolished	O
32	NF	B
33	-	I
34	kappaB	I
35	DNA	O
36	binding	O
37	activity	O
38	,	O
39	due	O
40	to	O
41	the	O
42	continued	O
43	cytoplasmic	O
44	sequestration	O
45	of	O
46	RelA	B
47	(	O
48	p65	B
49	)	O
50	by	O
51	TD	B
52	-	I
53	IkappaBalpha	I
54	.	O

1	The	O
2	relatively	O
3	high	O
4	level	O
5	transcription	O
6	from	O
7	this	O
8	gene	O
9	shows	O
10	that	O
11	the	O
12	polymorphic	O
13	chromosome	O
14	ends	O
15	of	O
16	P	O
17	.	O
18	falciparum	O
19	,	O
20	which	O
21	have	O
22	been	O
23	proposed	O
24	to	O
25	be	O
26	transcriptionally	O
27	silent	O
28	,	O
29	can	O
30	be	O
31	active	O
32	expression	O
33	sites	O
34	for	O
35	var	B
36	genes	I
37	.	O

1	Sequence	O
2	comparison	O
3	indicates	O
4	that	O
5	exons	O
6	5	O
7	'/	O
8	L	O
9	and	O
10	L	O
11	/	O
12	N	O
13	in	O
14	PSG12	B
15	and	O
16	PSG12	B
17	psi	I
18	are	O
19	99	O
20	%	O
21	identical	O
22	,	O
23	except	O
24	that	O
25	the	O
26	L	O
27	/	O
28	N	O
29	exon	O
30	in	O
31	the	O
32	PSG12	B
33	psi	I
34	gene	I
35	contains	O
36	a	O
37	stop	O
38	codon	O
39	.	O

1	Renin	B
2	secretion	O
3	in	O
4	essential	O
5	and	O
6	accelerated	O
7	hypertension	O
8	.	O

1	Monotherapy	O
2	with	O
3	ceftazidime	O
4	was	O
5	clinically	O
6	and	O
7	bacteriologically	O
8	as	O
9	effective	O
10	as	O
11	a	O
12	combination	O
13	therapy	O
14	with	O
15	cefazolin	O
16	and	O
17	tobramycin	O
18	.	O

1	The	O
2	viral	B
3	LTR	I
4	was	O
5	used	O
6	as	O
7	the	O
8	promoter	O
9	.	O

1	GAL4	B
2	-	O
3	VP16	B
4	-	O
5	mediated	O
6	antirepression	O
7	required	O
8	an	O
9	auxiliary	O
10	factor	O
11	,	O
12	denoted	O
13	as	O
14	a	O
15	co	O
16	-	O
17	antirepressor	O
18	,	O
19	which	O
20	was	O
21	partially	O
22	purified	O
23	from	O
24	Drosophila	O
25	embryos	O
26	.	O

1	Cell	O
2	49	O
3	,	O
4	753	O
5	-	O
6	761	O
7	].	O

1	We	O
2	recently	O
3	reported	O
4	a	O
5	placenta	O
6	-	O
7	specific	O
8	enhancer	O
9	in	O
10	the	O
11	human	B
12	leukemia	I
13	inhibitory	I
14	factor	I
15	receptor	I
16	(	O
17	LIFR	B
18	)	O
19	gene	O
20	and	O
21	now	O
22	show	O
23	detailed	O
24	characterization	O
25	of	O
26	the	O
27	226	O
28	-	O
29	base	O
30	pair	O
31	enhancer	O
32	(-	O
33	4625	O
34	/-	O
35	4400	O
36	nucleotides	O
37	).	O

1	The	O
2	IE0	B
3	gene	I
4	product	O
5	also	O
6	transactivated	O
7	the	O
8	IE1	B
9	promoter	I
10	but	O
11	did	O
12	not	O
13	affect	O
14	expression	O
15	from	O
16	its	O
17	own	O
18	promoter	O
19	.	O

1	The	O
2	level	O
3	of	O
4	carboxyl	B
5	-	I
6	terminal	I
7	parathyroid	I
8	hormone	I
9	in	O
10	the	O
11	patients	O
12	with	O
13	thyroid	O
14	carcinoma	O
15	was	O
16	higher	O
17	than	O
18	that	O
19	in	O
20	the	O
21	patients	O
22	without	O
23	thyroid	O
24	carcinoma	O
25	(	O
26	P	O
27	less	O
28	than	O
29	0	O
30	.	O
31	05	O
32	).	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	further	O
7	investigated	O
8	the	O
9	regulation	O
10	of	O
11	the	O
12	synthesis	O
13	of	O
14	the	O
15	c	B
16	-	I
17	mos	I
18	oncogene	I
19	product	I
20	,	O
21	which	O
22	is	O
23	necessary	O
24	for	O
25	the	O
26	activation	O
27	of	O
28	Cdc2	B
29	.	O

1	Takahashi	O
2	,	O
3	H	O
4	.	O

1	Cell	O
2	lines	O
3	are	O
4	checked	O
5	to	O
6	find	O
7	out	O
8	whether	O
9	they	O
10	develop	O
11	tumors	O
12	in	O
13	nude	O
14	mice	O
15	followed	O
16	by	O
17	an	O
18	analysis	O
19	of	O
20	the	O
21	karyotype	O
22	.	O

1	The	O
2	recommendation	O
3	is	O
4	made	O
5	that	O
6	specific	O
7	sub	O
8	-	O
9	groups	O
10	of	O
11	attempters	O
12	need	O
13	to	O
14	be	O
15	identified	O
16	and	O
17	may	O
18	warrant	O
19	specialized	O
20	intervention	O
21	strategies	O
22	.	O

1	Alternatively	O
2	,	O
3	loss	O
4	-	O
5	of	O
6	-	O
7	function	O
8	alleles	O
9	of	O
10	genes	O
11	that	O
12	inhibit	O
13	cAPK	B
14	lead	O
15	to	O
16	the	O
17	inability	O
18	to	O
19	undergo	O
20	sexual	O
21	differentiation	O
22	.	O

1	The	O
2	role	O
3	of	O
4	neuroplasticity	O
5	in	O
6	the	O
7	response	O
8	to	O
9	drugs	O
10	.	O

1	Chromatin	O
2	repression	O
3	of	O
4	these	O
5	replacement	O
6	genes	O
7	would	O
8	be	O
9	avoided	O
10	,	O
11	consistent	O
12	with	O
13	the	O
14	high	O
15	,	O
16	constitutive	O
17	expression	O
18	of	O
19	replacement	O
20	H3	B
21	histone	I
22	genes	I
23	in	O
24	plants	O
25	.	O

1	However	O
2	,	O
3	Southern	O
4	blot	O
5	and	O
6	karyotype	O
7	analyses	O
8	did	O
9	not	O
10	reveal	O
11	any	O
12	significant	O
13	changes	O
14	in	O
15	copy	O
16	number	O
17	or	O
18	gross	O
19	rearrangements	O
20	of	O
21	the	O
22	p53	B
23	gene	I
24	in	O
25	any	O
26	of	O
27	the	O
28	p53	B
29	-	I
30	cell	O
31	lines	O
32	.	O

1	Cluster	O
2	formation	O
3	of	O
4	E	B
5	-	I
6	cadherin	I
7	on	O
8	the	O
9	cell	O
10	surface	O
11	is	O
12	believed	O
13	to	O
14	be	O
15	of	O
16	major	O
17	importance	O
18	for	O
19	cell	O
20	-	O
21	cell	O
22	adhesion	O
23	.	O

1	Depending	O
2	on	O
3	treatment	O
4	exposures	O
5	,	O
6	this	O
7	at	O
8	-	O
9	risk	O
10	population	O
11	may	O
12	experience	O
13	life	O
14	-	O
15	threatening	O
16	late	O
17	effects	O
18	,	O
19	such	O
20	as	O
21	cirrhosis	O
22	secondary	O
23	to	O
24	hepatitis	O
25	C	O
26	or	O
27	late	O
28	-	O
29	onset	O
30	anthracycline	O
31	-	O
32	induced	O
33	cardiomyopathy	O
34	,	O
35	or	O
36	life	O
37	-	O
38	changing	O
39	late	O
40	effects	O
41	,	O
42	such	O
43	as	O
44	cognitive	O
45	dysfunction	O
46	.	O

1	Prevention	O
2	of	O
3	maternal	O
4	Rh	O
5	sensitization	O
6	:	O
7	anti	B
8	-	I
9	Rh	I
10	immune	I
11	globulin	I
12	.	O

1	Similar	O
2	observations	O
3	were	O
4	made	O
5	with	O
6	unilateral	O
7	pneumothorax	O
8	of	O
9	15	O
10	cmH2O	O
11	for	O
12	30	O
13	min	O
14	.	O

1	Strikingly	O
2	,	O
3	these	O
4	cells	O
5	contain	O
6	a	O
7	missense	O
8	mutation	O
9	of	O
10	the	O
11	p53	B
12	gene	I
13	at	O
14	codon	O
15	242	O
16	(	O
17	p53	B
18	(	O
19	242	O
20	)),	O
21	which	O
22	substitutes	O
23	alanine	O
24	for	O
25	glycine	O
26	.	O

1	Overexpression	O
2	of	O
3	MDR1	B
4	has	O
5	been	O
6	demonstrated	O
7	in	O
8	many	O
9	cancers	O
10	,	O
11	both	O
12	in	O
13	patient	O
14	tumors	O
15	and	O
16	in	O
17	cell	O
18	lines	O
19	selected	O
20	with	O
21	a	O
22	variety	O
23	of	O
24	chemotherapeutic	O
25	agents	O
26	.	O

1	According	O
2	to	O
3	the	O
4	investigation	O
5	,	O
6	the	O
7	recent	O
8	burst	O
9	of	O
10	pseudoterranovosis	O
11	in	O
12	this	O
13	area	O
14	can	O
15	be	O
16	attributed	O
17	to	O
18	the	O
19	increased	O
20	presence	O
21	of	O
22	sea	O
23	lions	O
24	,	O
25	which	O
26	proliferate	O
27	in	O
28	the	O
29	Arctic	O
30	region	O
31	,	O
32	then	O
33	migrate	O
34	to	O
35	the	O
36	northern	O
37	Japan	O
38	Sea	O
39	and	O
40	eat	O
41	the	O
42	intermediate	O
43	host	O
44	fish	O
45	.	O

1	The	O
2	lytic	O
3	cycle	O
4	of	O
5	KSHV	O
6	,	O
7	probably	O
8	under	O
9	the	O
10	initial	O
11	control	O
12	of	O
13	the	O
14	KSHV	B
15	/	I
16	Rta	I
17	gene	I
18	,	O
19	may	O
20	directly	O
21	contribute	O
22	to	O
23	tumor	O
24	pathogenesis	O
25	.	O

1	Using	O
2	a	O
3	battery	O
4	of	O
5	I	B
6	kappa	I
7	B	I
8	alpha	I
9	mutants	I
10	,	O
11	we	O
12	show	O
13	that	O
14	(	O
15	i	O
16	)	O
17	a	O
18	dimer	O
19	binds	O
20	a	O
21	single	O
22	I	B
23	kappa	I
24	B	I
25	alpha	I
26	molecule	I
27	,	O
28	(	O
29	ii	O
30	)	O
31	the	O
32	acidic	O
33	C	O
34	-	O
35	terminal	O
36	region	O
37	of	O
38	I	B
39	kappa	I
40	B	I
41	alpha	I
42	is	O
43	not	O
44	required	O
45	for	O
46	protein	O
47	-	O
48	protein	O
49	binding	O
50	and	O
51	does	O
52	not	O
53	mask	O
54	the	O
55	nuclear	O
56	localization	O
57	signal	O
58	of	O
59	the	O
60	dimer	O
61	,	O
62	(	O
63	iii	O
64	)	O
65	the	O
66	same	O
67	C	O
68	-	O
69	terminal	O
70	region	O
71	is	O
72	required	O
73	for	O
74	inhibition	O
75	of	O
76	DNA	O
77	binding	O
78	,	O
79	and	O
80	(	O
81	iv	O
82	)	O
83	this	O
84	inhibition	O
85	may	O
86	be	O
87	accomplished	O
88	by	O
89	direct	O
90	interaction	O
91	between	O
92	the	O
93	PEST	O
94	-	O
95	like	O
96	region	O
97	and	O
98	the	O
99	DNA	O
100	-	O
101	binding	O
102	region	O
103	of	O
104	one	O
105	of	O
106	the	O
107	subunits	O
108	of	O
109	the	O
110	dimer	O
111	.	O

1	A	O
2	13	O
3	base	O
4	-	O
5	pair	O
6	oligonucleotide	O
7	spanning	O
8	nucleotides	O
9	+	O
10	80	O
11	to	O
12	+	O
13	92	O
14	of	O
15	the	O
16	5	B
17	S	I
18	RNA	I
19	gene	I
20	retained	O
21	specific	O
22	and	O
23	high	O
24	-	O
25	affinity	O
26	binding	O
27	,	O
28	although	O
29	the	O
30	latter	O
31	was	O
32	reduced	O
33	sixfold	O
34	relative	O
35	to	O
36	longer	O
37	DNA	O
38	fragments	O
39	.	O

1	Recombination	O
2	between	O
3	feline	O
4	leukemia	O
5	virus	O
6	subgroup	O
7	B	O
8	or	O
9	C	O
10	and	O
11	endogenous	O
12	env	B
13	elements	O
14	alters	O
15	the	O
16	in	O
17	vitro	O
18	biological	O
19	activities	O
20	of	O
21	the	O
22	viruses	O
23	.	O

1	However	O
2	,	O
3	limited	O
4	comparisons	O
5	reveal	O
6	domains	O
7	in	O
8	the	O
9	NH2	O
10	and	O
11	COOH	O
12	termini	O
13	that	O
14	have	O
15	a	O
16	high	O
17	degree	O
18	of	O
19	similarity	O
20	suggesting	O
21	functional	O
22	conservation	O
23	.	O

1	The	O
2	2	O
3	kb	O
4	of	O
5	5	O
6	'-	O
7	flanking	O
8	region	O
9	and	O
10	the	O
11	1	O
12	.	O
13	1	O
14	kb	O
15	of	O
16	the	O
17	entire	O
18	sGTH	B
19	alpha	I
20	subunit	I
21	coding	O
22	region	O
23	were	O
24	sequenced	O
25	from	O
26	the	O
27	genomic	O
28	clone	O
29	,	O
30	sGTH	B
31	alpha	I
32	-	I
33	G1	I
34	.	O

1	A	O
2	variety	O
3	of	O
4	nuclear	O
5	ribonucleoproteins	O
6	are	O
7	believed	O
8	to	O
9	associate	O
10	directly	O
11	with	O
12	nascent	O
13	RNA	B
14	polymerase	I
15	II	I
16	transcripts	I
17	and	O
18	remain	O
19	associated	O
20	during	O
21	subsequent	O
22	nuclear	O
23	RNA	O
24	processing	O
25	reactions	O
26	,	O
27	including	O
28	pre	O
29	-	O
30	mRNA	O
31	polyadenylation	O
32	and	O
33	splicing	O
34	as	O
35	well	O
36	as	O
37	nucleocytoplasmic	O
38	mRNA	O
39	transport	O
40	.	O

1	Expression	O
2	from	O
3	this	O
4	element	O
5	is	O
6	regulated	O
7	by	O
8	a	O
9	heteromeric	O
10	protein	O
11	complex	O
12	containing	O
13	ubiquitous	O
14	(	O
15	i	O
16	.	O
17	e	O
18	.	O
19	the	O
20	E2A	B
21	-	O
22	and	O
23	HEB	B
24	-	I
25	encoded	I
26	proteins	I
27	)	O
28	and	O
29	islet	O
30	-	O
31	enriched	O
32	members	O
33	of	O
34	the	O
35	bHLH	B
36	family	I
37	.	O

1	Escherichia	O
2	of	O
3	a	O
4	single	O
5	sero	O
6	-	O
7	anzymatic	O
8	type	O
9	(	O
10	06a6b	O
11	:	O
12	K13	O
13	:	O
14	H1	O
15	)	O
16	were	O
17	isolated	O
18	in	O
19	a	O
20	group	O
21	affection	O
22	.	O

1	Sternocleidomastoid	O
2	,	O
3	neck	O
4	or	O
5	facial	O
6	muscles	O
7	wasting	O
8	were	O
9	also	O
10	found	O
11	in	O
12	three	O
13	cases	O
14	.	O

1	The	O
2	factor	O
3	which	O
4	binds	O
5	to	O
6	the	O
7	TR	B
8	promoter	I
9	co	O
10	-	O
11	sedimented	O
12	with	O
13	SV40	O
14	chromosomes	O
15	extracted	O
16	late	O
17	in	O
18	infection	O
19	.	O

1	The	O
2	characterization	O
3	of	O
4	the	O
5	promoter	O
6	region	O
7	indicated	O
8	that	O
9	three	O
10	distinct	O
11	regulatory	O
12	elements	O
13	corresponding	O
14	to	O
15	an	O
16	AP	B
17	-	I
18	1	I
19	binding	I
20	site	I
21	(	O
22	or	O
23	TRE	O
24	),	O
25	a	O
26	PRDII	B
27	/	O
28	kappaB	B
29	domain	O
30	,	O
31	and	O
32	a	O
33	CAAT	O
34	box	O
35	are	O
36	involved	O
37	in	O
38	the	O
39	activation	O
40	by	O
41	pp60	B
42	(	I
43	v	I
44	-)	I
45	src	I
46	.	O

1	Individuals	O
2	attending	O
3	the	O
4	GUM	O
5	Department	O
6	in	O
7	the	O
8	Royal	O
9	Infirmary	O
10	of	O
11	Edinburgh	O
12	between	O
13	1990	O
14	and	O
15	1994	O
16	with	O
17	the	O
18	diagnosis	O
19	of	O
20	HIV	O
21	infection	O
22	,	O
23	genital	O
24	warts	O
25	,	O
26	genital	O
27	herpes	O
28	,	O
29	non	O
30	-	O
31	specific	O
32	genital	O
33	infection	O
34	(	O
35	NSGI	O
36	),	O
37	gonorrhoea	O
38	and	O
39	syphilis	O
40	were	O
41	included	O
42	in	O
43	the	O
44	study	O
45	.	O

1	Indium	O
2	-	O
3	111	O
4	leukocyte	O
5	imaging	O
6	in	O
7	patients	O
8	with	O
9	rheumatoid	O
10	arthritis	O
11	.	O

1	Roentgenographically	O
2	,	O
3	the	O
4	lesion	O
5	was	O
6	usually	O
7	a	O
8	well	O
9	-	O
10	defined	O
11	and	O
12	benign	O
13	appearing	O
14	one	O
15	,	O
16	either	O
17	purely	O
18	lytic	O
19	(	O
20	3	O
21	cases	O
22	)	O
23	or	O
24	with	O
25	central	O
26	radiodensity	O
27	(	O
28	2	O
29	cases	O
30	).	O

1	RESULTS	O
2	:	O
3	Plasma	B
4	AVP	I
5	responses	O
6	to	O
7	osmotic	O
8	stimulation	O
9	,	O
10	and	O
11	non	O
12	-	O
13	osmotic	O
14	inhibition	O
15	by	O
16	drinking	O
17	,	O
18	were	O
19	normal	O
20	in	O
21	patients	O
22	with	O
23	compulsive	O
24	water	O
25	drinking	O
26	.	O

1	Sequence	O
2	comparison	O
3	of	O
4	cytochromes	B
5	bd	I
6	and	O
7	their	O
8	homologs	O
9	from	O
10	various	O
11	organisms	O
12	demonstrates	O
13	that	O
14	the	O
15	proteins	O
16	can	O
17	be	O
18	classified	O
19	into	O
20	two	O
21	subfamilies	O
22	,	O
23	a	O
24	proteobacterial	O
25	type	O
26	including	O
27	E	B
28	.	I
29	coli	I
30	bd	I
31	and	O
32	a	O
33	more	O
34	widely	O
35	distributed	O
36	type	O
37	including	O
38	the	O
39	B	O
40	.	O
41	stearothermophilus	O
42	enzyme	O
43	,	O
44	suggesting	O
45	that	O
46	the	O
47	latter	O
48	type	O
49	is	O
50	evolutionarily	O
51	older	O
52	.	O

1	Decreased	O
2	cardiac	O
3	glycogen	O
4	following	O
5	phenformin	O
6	injection	O
7	in	O
8	hyperglycemic	O
9	,	O
10	hyperinsulinemic	O
11	anaesthetized	O
12	rats	O
13	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	no	O
6	-	O
7	adverse	O
8	-	O
9	effect	O
10	-	O
11	level	O
12	for	O
13	this	O
14	study	O
15	was	O
16	determined	O
17	to	O
18	be	O
19	1000	O
20	ppm	O
21	,	O
22	based	O
23	on	O
24	decreased	O
25	weight	O
26	gain	O
27	in	O
28	female	O
29	rats	O
30	,	O
31	and	O
32	on	O
33	slight	O
34	organ	O
35	weight	O
36	changes	O
37	in	O
38	both	O
39	sexes	O
40	at	O
41	3000	O
42	ppm	O
43	.	O

1	The	O
2	increase	O
3	in	O
4	amplitudes	O
5	of	O
6	the	O
7	b	O
8	-	O
9	wave	O
10	during	O
11	the	O
12	adaptation	O
13	period	O
14	was	O
15	more	O
16	prominent	O
17	in	O
18	lead	O
19	-	O
20	exposed	O
21	subjects	O
22	than	O
23	in	O
24	controls	O
25	.	O

1	Measurement	O
2	of	O
3	open	O
4	-	O
5	loop	O
6	responses	O
7	to	O
8	electrical	O
9	stimulation	O
10	in	O
11	olfactory	O
12	bulb	O
13	of	O
14	cat	O
15	.	O

1	Glycogen	O
2	utilization	O
3	was	O
4	increased	O
5	,	O
6	but	O
7	tissue	O
8	levels	O
9	of	O
10	creatine	O
11	phosphate	O
12	,	O
13	ATP	O
14	,	O
15	and	O
16	lactate	O
17	were	O
18	similar	O
19	to	O
20	those	O
21	in	O
22	hearts	O
23	receiving	O
24	normal	O
25	flow	O
26	.	O

1	Max	B
2	:	O
3	functional	O
4	domains	O
5	and	O
6	interaction	O
7	with	O
8	c	B
9	-	I
10	Myc	I
11	.	O

1	They	O
2	are	O
3	subdivided	O
4	into	O
5	two	O
6	types	O
7	that	O
8	activate	O
9	transduction	O
10	pathways	O
11	via	O
12	different	O
13	cell	O
14	surface	O
15	receptors	O
16	.	O

1	When	O
2	considered	O
3	with	O
4	the	O
5	known	O
6	neurotoxic	O
7	effects	O
8	on	O
9	children	O
10	of	O
11	"	O
12	low	O
13	levels	O
14	"	O
15	of	O
16	exposure	O
17	to	O
18	lead	O
19	,	O
20	these	O
21	results	O
22	also	O
23	suggest	O
24	that	O
25	either	O
26	an	O
27	excessively	O
28	narrow	O
29	margin	O
30	of	O
31	safety	O
32	or	O
33	insufficient	O
34	safety	O
35	is	O
36	provided	O
37	by	O
38	present	O
39	U	O
40	.	O
41	S	O
42	.	O
43	guidelines	O
44	,	O
45	which	O
46	classify	O
47	an	O
48	elevated	O
49	blood	O
50	lead	O
51	concentration	O
52	as	O
53	25	O
54	micrograms	O
55	/	O
56	dl	O
57	or	O
58	greater	O
59	.	O

1	With	O
2	steady	O
3	illumination	O
4	,	O
5	outer	O
6	retinal	O
7	(	O
8	photoreceptor	O
9	)	O
10	QO2	O
11	decreased	O
12	to	O
13	1	O
14	.	O
15	4	O
16	+/-	O
17	0	O
18	.	O
19	9	O
20	ml	O
21	O2	O
22	/(	O
23	100	O
24	g	O
25	.	O
26	min	O
27	),	O
28	but	O
29	inner	O
30	retinal	O
31	QO2	O
32	remained	O
33	unchanged	O
34	at	O
35	3	O
36	.	O
37	7	O
38	+/-	O
39	1	O
40	.	O
41	5	O
42	ml	O
43	O2	O
44	/(	O
45	100	O
46	g	O
47	.	O
48	min	O
49	)	O
50	(	O
51	5	O
52	cats	O
53	).	O

1	The	O
2	models	O
3	accurately	O
4	localized	O
5	the	O
6	common	O
7	boundaries	O
8	between	O
9	the	O
10	PBB	O
11	and	O
12	CN	O
13	.	O

1	The	O
2	influence	O
3	of	O
4	p53	B
5	on	O
6	cytokine	O
7	-	O
8	triggered	O
9	Janus	B
10	kinase	I
11	-	O
12	STAT	B
13	signaling	O
14	was	O
15	investigated	O
16	in	O
17	human	O
18	hepatoma	O
19	Hep3B	O
20	cell	O
21	lines	O
22	engineered	O
23	to	O
24	constitutively	O
25	express	O
26	the	O
27	temperature	O
28	-	O
29	sensitive	O
30	Val135	B
31	mutant	I
32	of	I
33	p53	I
34	.	O

1	Creatine	B
2	kinase	I
3	release	O
4	after	O
5	hepatic	O
6	artery	O
7	embolization	O
8	in	O
9	patients	O
10	with	O
11	carcinoid	O
12	tumors	O
13	.	O

1	A	O
2	quantitative	O
3	analysis	O
4	of	O
5	the	O
6	diffraction	O
7	intensity	O
8	as	O
9	function	O
10	of	O
11	the	O
12	accumulated	O
13	electron	O
14	dose	O
15	suggests	O
16	the	O
17	possibility	O
18	of	O
19	recording	O
20	up	O
21	to	O
22	250	O
23	diffraction	O
24	patterns	O
25	with	O
26	3	O
27	.	O
28	5	O
29	A	O
30	resolution	O
31	from	O
32	a	O
33	single	O
34	crotoxin	O
35	complex	O
36	crystal	O
37	128	O
38	A	O
39	thick	O
40	.	O

1	Routine	O
2	psychometric	O
3	screening	O
4	of	O
5	IHD	O
6	patients	O
7	may	O
8	provide	O
9	a	O
10	cost	O
11	-	O
12	effective	O
13	means	O
14	of	O
15	alerting	O
16	cardiologists	O
17	and	O
18	internists	O
19	to	O
20	the	O
21	relatively	O
22	high	O
23	levels	O
24	of	O
25	distress	O
26	among	O
27	their	O
28	patients	O
29	.	O

1	SPECT	O
2	is	O
3	an	O
4	important	O
5	aid	O
6	in	O
7	the	O
8	diagnosis	O
9	of	O
10	AIDS	O
11	dementia	O
12	complex	O
13	and	O
14	contributes	O
15	to	O
16	the	O
17	understanding	O
18	of	O
19	the	O
20	pathophysiological	O
21	mechanisms	O
22	of	O
23	this	O
24	disorder	O
25	.	O

1	Northern	O
2	analysis	O
3	of	O
4	RNA	O
5	samples	O
6	isolated	O
7	from	O
8	ammonium	O
9	-	O
10	grown	O
11	cultures	O
12	of	O
13	the	O
14	ntcA	B
15	mutant	I
16	showed	O
17	reduced	O
18	amounts	O
19	of	O
20	glnA	B
21	message	I
22	and	O
23	the	O
24	absence	O
25	of	O
26	a	O
27	1	O
28	.	O
29	7	O
30	-	O
31	kb	O
32	transcript	O
33	.	O

1	The	O
2	results	O
3	of	O
4	the	O
5	ISIS	O
6	-	O
7	2	O
8	trial	O
9	and	O
10	the	O
11	data	O
12	from	O
13	the	O
14	Antiplatelet	O
15	Trialists	O
16	'	O
17	Collaboration	O
18	indicated	O
19	that	O
20	aspirin	O
21	is	O
22	mandatory	O
23	in	O
24	patients	O
25	with	O
26	acute	O
27	myocardial	O
28	infarction	O
29	and	O
30	for	O
31	secondary	O
32	prevention	O
33	.	O

1	Magnetic	O
2	resonance	O
3	imaging	O
4	in	O
5	coccidioidal	O
6	arthritis	O
7	.	O

1	A	O
2	previous	O
3	report	O
4	described	O
5	that	O
6	a	O
7	548	O
8	-	O
9	bp	O
10	BglII	B
11	-	O
12	SmaI	B
13	fragment	O
14	has	O
15	an	O
16	SSO	O
17	activity	O
18	(	O
19	ori2	O
20	;	O
21	Kataoka	O
22	et	O
23	al	O
24	.,	O
25	Mol	O
26	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	observe	O
6	that	O
7	the	O
8	hUBF	B
9	-	I
10	promoter	I
11	interaction	O
12	is	O
13	highly	O
14	sensitive	O
15	to	O
16	the	O
17	antagonistic	O
18	effects	O
19	of	O
20	cisplatin	O
21	-	O
22	DNA	O
23	adducts	O
24	.	O

1	Restoration	O
2	of	O
3	opponens	O
4	function	O
5	with	O
6	transplantation	O
7	of	O
8	free	O
9	composites	O
10	dorsal	O
11	pedal	O
12	skin	O
13	flap	O
14	containing	O
15	m	O
16	.	O
17	extensor	O
18	hallucis	O
19	brevis	O

1	Activation	O
2	was	O
3	biphasic	O
4	;	O
5	peaking	O
6	at	O
7	5	O
8	-	O
9	10	O
10	min	O
11	and	O
12	24	O
13	h	O
14	after	O
15	treatment	O
16	.	O

1	This	O
2	suggests	O
3	roles	O
4	for	O
5	both	O
6	the	O
7	CE1	O
8	and	O
9	CE2	O
10	elements	O
11	in	O
12	regulating	O
13	Hoxb1	B
14	gene	I
15	expression	O
16	during	O
17	development	O
18	.	O

1	The	O
2	use	O
3	of	O
4	an	O
5	appropriate	O
6	solution	O
7	of	O
8	methylene	O
9	blue	O
10	(	O
11	0	O
12	.	O
13	2	O
14	%	O
15	in	O
16	0	O
17	.	O
18	9	O
19	M	O
20	NaCl	O
21	for	O
22	15	O
23	min	O
24	)	O
25	permits	O
26	the	O
27	staining	O
28	of	O
29	premalignant	O
30	areas	O
31	and	O
32	CIS	O
33	,	O
34	and	O
35	their	O
36	early	O
37	diagnosis	O
38	.	O

1	Detection	O
2	of	O
3	congenital	O
4	hypothyroidism	O
5	in	O
6	26	O
7	,	O
8	282	O
9	newborn	O
10	infants	O

1	With	O
2	the	O
3	help	O
4	of	O
5	a	O
6	nomogram	O
7	one	O
8	can	O
9	read	O
10	off	O
11	the	O
12	refraction	O
13	,	O
14	when	O
15	axis	O
16	length	O
17	and	O
18	corneal	O
19	curvature	O
20	are	O
21	known	O
22	.	O

1	The	O
2	distal	O
3	portion	O
4	of	O
5	the	O
6	rat	B
7	insulin	I
8	I	I
9	gene	I
10	5	I
11	'-	I
12	flanking	I
13	DNA	I
14	contains	O
15	two	O
16	sequence	O
17	elements	O
18	,	O
19	the	O
20	Far	O
21	and	O
22	FLAT	O
23	elements	O
24	,	O
25	that	O
26	can	O
27	function	O
28	in	O
29	combination	O
30	,	O
31	but	O
32	not	O
33	separately	O
34	,	O
35	as	O
36	a	O
37	beta	O
38	-	O
39	cell	O
40	-	O
41	specific	O
42	transcriptional	O
43	enhancer	O
44	.	O

1	For	O
2	various	O
3	dog	O
4	vessels	O
5	in	O
6	vivo	O
7	,	O
8	Q	O
9	/	O
10	Dk	O
11	ranged	O
12	from	O
13	0	O
14	.	O
15	15	O
16	to	O
17	47	O
18	X	O
19	10	O
20	(	O
21	5	O
22	)	O
23	Torr	O
24	/	O
25	cm2	O
26	.	O

1	The	O
2	trk	B
3	-	I
4	2h	I
5	oncogene	I
6	,	O
7	isolated	O
8	from	O
9	the	O
10	human	O
11	breast	O
12	carcinoma	O
13	cell	O
14	line	O
15	MDA	O
16	-	O
17	MB	O
18	231	O
19	by	O
20	genomic	O
21	DNA	O
22	-	O
23	transfection	O
24	into	O
25	NIH3T3	O
26	cells	O
27	,	O
28	consists	O
29	of	O
30	the	O
31	trk	B
32	proto	I
33	-	I
34	oncogene	I
35	receptor	I
36	kinase	I
37	domain	I
38	fused	O
39	to	O
40	a	O
41	N	O
42	-	O
43	terminal	O
44	41	O
45	amino	O
46	acid	O
47	activating	O
48	sequence	O
49	(	O
50	Kozma	O
51	,	O
52	S	O
53	.	O
54	C	O
55	.,	O
56	Redmond	O
57	,	O
58	S	O
59	.	O
60	M	O
61	.	O
62	S	O
63	.,	O
64	Xiao	O
65	-	O
66	Chang	O
67	,	O
68	F	O
69	.,	O
70	Saurer	O
71	,	O
72	S	O
73	.	O
74	M	O
75	.,	O
76	Groner	O
77	,	O
78	B	O
79	.	O
80	and	O
81	Hynes	O
82	,	O
83	N	O
84	.	O
85	E	O
86	.	O

1	Anti	B
2	-	I
3	HBc	I
4	production	O
5	of	O
6	PBMC	O
7	was	O
8	enhanced	O
9	remarkably	O
10	in	O
11	this	O
12	case	O
13	.	O

1	Thus	O
2	,	O
3	the	O
4	characterization	O
5	of	O
6	the	O
7	promoter	O
8	region	O
9	should	O
10	help	O
11	to	O
12	define	O
13	regulatory	O
14	elements	O
15	that	O
16	control	O
17	neuron	O
18	-	O
19	specific	O
20	and	O
21	developmental	O
22	expression	O
23	of	O
24	the	O
25	MAP1B	B
26	gene	I
27	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	mouse	O
6	ortholog	O
7	(	O
8	Mharp	B
9	/	O
10	Smarcal1	B
11	)	O
12	was	O
13	cloned	O
14	,	O
15	and	O
16	the	O
17	Caenorhabditis	O
18	elegans	O
19	ortholog	O
20	(	O
21	CEHARP	B
22	)	O
23	was	O
24	identified	O
25	in	O
26	the	O
27	GenBank	O
28	database	O
29	.	O

1	In	O
2	part	O
3	as	O
4	a	O
5	result	O
6	of	O
7	its	O
8	inability	O
9	to	O
10	sustain	O
11	radiative	O
12	loses	O
13	,	O
14	the	O
15	BB	O
16	resonator	O
17	has	O
18	extremely	O
19	low	O
20	RF	O
21	power	O
22	requirements	O
23	.	O

1	This	O
2	proposed	O
3	method	O
4	is	O
5	similar	O
6	in	O
7	principle	O
8	to	O
9	the	O
10	sets	O
11	technique	O
12	but	O
13	is	O
14	shown	O
15	to	O
16	have	O
17	much	O
18	better	O
19	expected	O
20	time	O
21	to	O
22	alarm	O
23	properties	O
24	.	O

1	The	O
2	mean	O
3	percentage	O
4	of	O
5	linoleic	O
6	acid	O
7	in	O
8	the	O
9	triglycerides	O
10	of	O
11	the	O
12	subcutaneous	O
13	adipose	O
14	tissue	O
15	(	O
16	PLASAT	O
17	)	O
18	of	O
19	these	O
20	subjects	O
21	was	O
22	substantially	O
23	higher	O
24	than	O
25	that	O
26	in	O
27	a	O
28	similar	O
29	group	O
30	examined	O
31	in	O
32	1975	O
33	-	O
34	1976	O
35	.	O

1	However	O
2	,	O
3	2	O
4	minimum	O
5	alveolar	O
6	concentration	O
7	anesthesia	O
8	did	O
9	significantly	O
10	decrease	O
11	the	O
12	calculated	O
13	VE	O
14	at	O
15	a	O
16	PCO2	O
17	of	O
18	60	O
19	mmHg	O
20	(	O
21	from	O
22	7	O
23	.	O
24	4	O
25	+/-	O
26	1	O
27	.	O
28	2	O
29	to	O
30	4	O
31	.	O
32	0	O
33	+/-	O
34	0	O
35	.	O
36	6	O
37	l	O
38	.	O
39	min	O
40	-	O
41	1	O
42	),	O
43	indicating	O
44	a	O
45	rightward	O
46	shift	O
47	in	O
48	the	O
49	response	O
50	relationship	O
51	.	O

1	In	O
2	the	O
3	case	O
4	of	O
5	congenital	O
6	protein	B
7	C	I
8	deficiency	O
9	,	O
10	vitamin	O
11	K	O
12	antagonists	O
13	must	O
14	be	O
15	started	O
16	cautiously	O
17	due	O
18	to	O
19	the	O
20	risk	O
21	of	O
22	skin	O
23	necrosis	O
24	.	O

1	We	O
2	show	O
3	that	O
4	IL	B
5	-	I
6	6	I
7	activates	O
8	JRE	B
9	-	I
10	IL6	I
11	through	O
12	an	O
13	H7	O
14	-	O
15	sensitive	O
16	pathway	O
17	that	O
18	does	O
19	not	O
20	involve	O
21	protein	B
22	kinase	I
23	C	I
24	,	O
25	cyclic	B
26	AMP	I
27	-	I
28	dependent	I
29	kinase	I
30	,	O
31	Ca	B
32	(	I
33	2	I
34	+)-	I
35	or	I
36	calmodulin	I
37	-	I
38	dependent	I
39	kinases	I
40	,	O
41	Ras	B
42	,	O
43	Raf	B
44	-	I
45	1	I
46	,	O
47	or	O
48	NF	B
49	-	I
50	IL6	I
51	(	O
52	C	B
53	/	I
54	EBP	I
55	beta	I
56	).	O

1	Ca2	O
2	+	O
3	decreased	O
4	Zn2	O
5	+	O
6	binding	O
7	in	O
8	S100	B
9	beta	I
10	but	O
11	it	O
12	did	O
13	not	O
14	influence	O
15	binding	O
16	to	O
17	MRP14	B
18	,	O
19	suggesting	O
20	that	O
21	the	O
22	Zn2	O
23	+	O
24	binding	O
25	site	O
26	was	O
27	distinct	O
28	from	O
29	and	O
30	independent	O
31	of	O
32	the	O
33	two	O
34	Ca2	O
35	+	O
36	binding	O
37	domains	O
38	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	have	O
8	isolated	O
9	and	O
10	sequenced	O
11	several	O
12	p15E	B
13	cDNA	I
14	gene	I
15	fragments	I
16	amplified	O
17	by	O
18	means	O
19	of	O
20	polymerase	O
21	chain	O
22	reaction	O
23	(	O
24	PCR	O
25	)	O
26	from	O
27	parental	O
28	(	O
29	P815	O
30	)	O
31	and	O
32	xenogenized	O
33	(	O
34	P815	O
35	/	O
36	DTIC	O
37	)	O
38	tumour	O
39	cells	O
40	.	O

1	U73	B
2	contains	O
3	C	O
4	,	O
5	D	O
6	and	O
7	D	O
8	'	O
9	boxes	O
10	and	O
11	a	O
12	12	O
13	-	O
14	nucleotide	O
15	antisense	O
16	complementarity	O
17	to	O
18	the	O
19	28S	B
20	ribosomal	I
21	RNA	I
22	.	O

1	The	O
2	mei4	B
3	+	I
4	gene	I
5	of	O
6	the	O
7	fission	O
8	yeast	O
9	Schizosaccharomyces	O
10	pombe	O
11	was	O
12	cloned	O
13	by	O
14	functional	O
15	complementation	O
16	.	O

1	On	O
2	the	O
3	third	O
4	occasion	O
5	water	O
6	(	O
7	W	O
8	)	O
9	was	O
10	ingested	O
11	throughout	O
12	the	O
13	run	O
14	.	O

1	Slowed	O
2	lysosomal	B
3	enzyme	I
4	release	O
5	and	O
6	its	O
7	normalization	O
8	by	O
9	drugs	O
10	in	O
11	adjuvant	O
12	-	O
13	induced	O
14	polyarthritis	O
15	.	O

1	The	O
2	relative	O
3	importance	O
4	of	O
5	these	O
6	two	O
7	mechanisms	O
8	differed	O
9	in	O
10	a	O
11	response	O
12	element	O
13	-	O
14	specific	O
15	manner	O
16	.	O

1	Assays	O
2	of	O
3	total	O
4	cholesterol	O
5	as	O
6	well	O
7	as	O
8	the	O
9	HDL	B
10	,	O
11	HDL2	B
12	,	O
13	LDL	B
14	,	O
15	triglycerides	O
16	,	O
17	endothelin	B
18	-	I
19	1	I
20	,	O
21	lipoprotein	O
22	(	O
23	a	O
24	),	O
25	estradiol	O
26	and	O
27	FSH	B
28	were	O
29	also	O
30	obtained	O
31	at	O
32	baseline	O
33	before	O
34	receiving	O
35	ERT	O
36	and	O
37	after	O
38	3	O
39	months	O
40	of	O
41	ERT	O
42	.	O

1	These	O
2	probable	O
3	border	O
4	sequences	O
5	are	O
6	closely	O
7	related	O
8	to	O
9	those	O
10	of	O
11	other	O
12	known	O
13	T	O
14	-	O
15	regions	O
16	and	O
17	define	O
18	a	O
19	second	O
20	T	O
21	-	O
22	region	O
23	of	O
24	pTiChry5	O
25	,	O
26	called	O
27	T	O
28	-	O
29	right	O
30	(	O
31	TR	O
32	),	O
33	that	O
34	confers	O
35	production	O
36	of	O
37	the	O
38	Amadoriopines	O
39	.	O

1	V	O
2	.	O

1	The	O
2	residue	O
3	functions	O
4	,	O
5	R	O
6	(	O
7	t	O
8	),	O
9	for	O
10	C	O
11	-	O
12	11	O
13	CPZ	O
14	and	O
15	In	O
16	-	O
17	113m	O
18	transferrin	B
19	were	O
20	plotted	O
21	against	O
22	time	O
23	for	O
24	selected	O
25	areas	O
26	of	O
27	interest	O
28	,	O
29	and	O
30	the	O
31	CPZ	O
32	area	O
33	-	O
34	weighted	O
35	extraction	O
36	,	O
37	E	O
38	(	O
39	t	O
40	),	O
41	was	O
42	computed	O
43	for	O
44	the	O
45	same	O
46	areas	O
47	every	O
48	250	O
49	msec	O
50	using	O
51	the	O
52	formula	O
53	:	O
54	E	O
55	(	O
56	t	O
57	)	O
58	=	O
59	[	O
60	RT	O
61	(	O
62	t	O
63	)	O
64	-	O
65	RR	O
66	(	O
67	t	O
68	)]/[	O
69	1	O
70	-	O
71	RR	O
72	(	O
73	t	O
74	)],	O
75	where	O
76	RT	O
77	and	O
78	RR	O
79	are	O
80	the	O
81	normalized	O
82	residue	O
83	functions	O
84	for	O
85	CPZ	O
86	and	O
87	transferrin	B
88	,	O
89	respectively	O
90	.	O

1	Methyllevamisole	O
2	was	O
3	used	O
4	as	O
5	the	O
6	internal	O
7	standard	O
8	.	O

1	Since	O
2	1948	O
3	,	O
4	the	O
5	use	O
6	of	O
7	saline	O
8	-	O
9	washed	O
10	red	O
11	cells	O
12	(	O
13	WRBCs	O
14	)	O
15	has	O
16	been	O
17	advocated	O
18	to	O
19	minimize	O
20	hemolysis	O
21	after	O
22	transfusion	O
23	to	O
24	patients	O
25	with	O
26	PNH	O
27	.	O

1	In	O
2	throttling	O
3	valves	O
4	,	O
5	the	O
6	aim	O
7	is	O
8	to	O
9	correlate	O
10	the	O
11	effect	O
12	of	O
13	shear	O
14	to	O
15	a	O
16	parameter	O
17	related	O
18	to	O
19	the	O
20	inner	O
21	geometry	O
22	of	O
23	the	O
24	valve	O
25	and	O
26	to	O
27	operating	O
28	conditions	O
29	.	O

1	We	O
2	used	O
3	the	O
4	Toshiba	O
5	IIDR	O
6	system	O
7	,	O
8	which	O
9	is	O
10	composed	O
11	of	O
12	an	O
13	X	O
14	-	O
15	ray	O
16	TV	O
17	system	O
18	and	O
19	a	O
20	digital	O
21	image	O
22	managing	O
23	circuit	O
24	.	O

1	The	O
2	5	O
3	'-	O
4	flanking	O
5	region	O
6	,	O
7	from	O
8	nucleotide	O
9	-	O
10	837	O
11	to	O
12	-	O
13	336	O
14	,	O
15	contains	O
16	TATA	O
17	and	O
18	inverted	O
19	CAAT	O
20	boxes	O
21	as	O
22	well	O
23	as	O
24	GATA	B
25	-	I
26	1	I
27	/	O
28	SP1	B
29	erythroid	O
30	-	O
31	specific	O
32	cis	O
33	-	O
34	acting	O
35	regulatory	O
36	elements	O
37	.	O

1	The	O
2	poly	O
3	(	O
4	A	O
5	)	O
6	segment	O
7	of	O
8	the	O
9	RNA	O
10	was	O
11	selectively	O
12	cross	O
13	-	O
14	linked	O
15	to	O
16	the	O
17	72	O
18	,	O
19	000	O
20	-	O
21	molecular	O
22	-	O
23	weight	O
24	protein	O
25	(	O
26	72K	O
27	protein	O
28	).	O

1	A	O
2	second	O
3	,	O
4	novel	O
5	C	O
6	subunit	O
7	(	O
8	CeCAT	O
9	alpha	O
10	',	O
11	374	O
12	residues	O
13	)	O
14	has	O
15	a	O
16	unique	O
17	56	O
18	-	O
19	residue	O
20	carboxyl	O
21	-	O
22	terminal	O
23	region	O
24	that	O
25	is	O
26	generated	O
27	by	O
28	the	O
29	alternative	O
30	splicing	O
31	of	O
32	the	O
33	C	B
34	pre	I
35	-	I
36	mRNA	I
37	.	O

1	Clinical	O
2	and	O
3	biological	O
4	correlates	O
5	of	O
6	panic	O
7	states	O
8	.	O

1	As	O
2	demonstrated	O
3	by	O
4	gel	O
5	mobility	O
6	shift	O
7	analysis	O
8	and	O
9	supershift	O
10	experiments	O
11	,	O
12	FIRE1	B
13	,	O
14	located	O
15	between	O
16	-	O
17	516	O
18	and	O
19	-	O
20	498	O
21	,	O
22	is	O
23	responsible	O
24	for	O
25	binding	O
26	NF	B
27	-	I
28	Y	I
29	.	O

1	Oligonucleotide	O
2	-	O
3	directed	O
4	mutagenesis	O
5	was	O
6	used	O
7	to	O
8	create	O
9	an	O
10	NdeI	B
11	restriction	I
12	site	I
13	at	O
14	the	O
15	natural	O
16	ATG	O
17	of	O
18	the	O
19	yeast	O
20	R	O
21	.	O

1	39	O
2	-	O
3	47	O
4	.	O

1	The	O
2	variable	O
3	HMG	B
4	dosage	O
5	regimen	O
6	was	O
7	found	O
8	to	O
9	offer	O
10	no	O
11	advantages	O
12	when	O
13	compared	O
14	with	O
15	our	O
16	standard	O
17	daily	O
18	dosage	O
19	regimen	O
20	.	O

1	It	O
2	was	O
3	concluded	O
4	that	O
5	Scotchbond	O
6	2	O
7	and	O
8	Prisma	O
9	Universal	O
10	Bond	O
11	2	O
12	are	O
13	effective	O
14	and	O
15	are	O
16	the	O
17	dentine	O
18	bonding	O
19	agents	O
20	of	O
21	choice	O
22	.	O

1	MEASUREMENTS	O
2	AND	O
3	MAIN	O
4	RESULTS	O
5	:	O
6	Lung	O
7	elastance	O
8	(	O
9	EL	O
10	)	O
11	and	O
12	resistance	O
13	(	O
14	RL	O
15	)	O
16	were	O
17	calculated	O
18	from	O
19	measurements	O
20	of	O
21	airway	O
22	pressure	O
23	,	O
24	esophageal	O
25	pressure	O
26	,	O
27	and	O
28	airway	O
29	flow	O
30	in	O
31	five	O
32	anesthetized	O
33	,	O
34	paralyzed	O
35	dogs	O
36	during	O
37	sinusoidal	O
38	forcing	O
39	at	O
40	a	O
41	constant	O
42	mean	O
43	airway	O
44	pressure	O
45	of	O
46	10	O
47	cmH2O	O
48	in	O
49	a	O
50	wide	O
51	range	O
52	of	O
53	breathing	O
54	frequencies	O
55	(	O
56	0	O
57	.	O
58	2	O
59	to	O
60	1	O
61	.	O
62	0	O
63	Hz	O
64	in	O
65	intervals	O
66	of	O
67	0	O
68	.	O
69	2	O
70	)	O
71	and	O
72	tidal	O
73	volumes	O
74	(	O
75	50	O
76	,	O
77	100	O
78	,	O
79	200	O
80	,	O
81	and	O
82	to	O
83	300	O
84	mL	O
85	).	O

1	Study	O
2	on	O
3	the	O
4	evagination	O
5	of	O
6	Cysticercus	O
7	pisiformis	O
8	.	O

1	Salivary	O
2	estradiol	O
3	17	O
4	beta	O
5	(	O
6	E2	O
7	-	O
8	17	O
9	beta	O
10	)	O
11	and	O
12	progesterone	O
13	(	O
14	P	O
15	)	O
16	were	O
17	determined	O
18	by	O
19	using	O
20	radioimmunoassay	O
21	techniques	O
22	in	O
23	30	O
24	pregnant	O
25	females	O
26	in	O
27	the	O
28	first	O
29	,	O
30	second	O
31	and	O
32	third	O
33	trimesters	O
34	as	O
35	well	O
36	as	O
37	in	O
38	10	O
39	non	O
40	-	O
41	pregnant	O
42	controls	O
43	during	O
44	the	O
45	luteal	O
46	phase	O
47	of	O
48	the	O
49	menstrual	O
50	cycle	O
51	.	O

1	Ketanserin	O
2	,	O
3	a	O
4	hypotensive	O
5	drug	O
6	with	O
7	5	B
8	-	I
9	HT2	I
10	receptor	I
11	antagonism	O
12	,	O
13	when	O
14	administered	O
15	by	O
16	topical	O
17	infusion	O
18	of	O
19	a	O
20	0	O
21	.	O
22	25	O
23	%	O
24	w	O
25	/	O
26	v	O
27	solution	O
28	by	O
29	corneal	O
30	and	O
31	scleral	O
32	applications	O
33	,	O
34	was	O
35	found	O
36	to	O
37	lower	O
38	intraocular	O
39	pressure	O
40	with	O
41	four	O
42	times	O
43	more	O
44	activity	O
45	than	O
46	its	O
47	metabolite	O
48	,	O
49	ketanserinol	O
50	.	O

1	The	O
2	Mig1	B
3	repressor	I
4	is	O
5	a	O
6	zinc	B
7	finger	I
8	protein	I
9	that	O
10	mediates	O
11	glucose	O
12	repression	O
13	in	O
14	yeast	O
15	.	O

1	Editorial	O
2	:	O
3	Low	O
4	-	O
5	dose	O
6	heparin	O
7	and	O
8	the	O
9	prevention	O
10	of	O
11	venous	O
12	thromboembolic	O
13	disease	O
14	.	O

1	Homology	O
2	with	O
3	the	O
4	human	O
5	protein	O
6	is	O
7	only	O
8	34	O
9	%	O
10	in	O
11	the	O
12	tandem	O
13	repeat	O
14	domain	O
15	,	O
16	mainly	O
17	showing	O
18	conservation	O
19	of	O
20	serines	O
21	and	O
22	threonines	O
23	,	O
24	presumed	O
25	sites	O
26	of	O
27	O	O
28	-	O
29	linked	O
30	carbohydrate	O
31	attachment	O
32	.	O

1	A	O
2	prospectively	O
3	gated	O
4	2D	O
5	axial	O
6	sequence	O
7	with	O
8	velocity	O
9	encoding	O
10	in	O
11	the	O
12	craniocaudal	O
13	direction	O
14	in	O
15	the	O
16	cervical	O
17	region	O
18	was	O
19	set	O
20	at	O
21	a	O
22	velocity	O
23	of	O
24	+/-	O
25	10	O
26	cm	O
27	/	O
28	s	O
29	.	O

1	The	O
2	clinico	O
3	-	O
4	pathological	O
5	data	O
6	from	O
7	a	O
8	patient	O
9	with	O
10	irreversible	O
11	post	O
12	-	O
13	partum	O
14	renal	O
15	failure	O
16	(	O
17	IPRF	O
18	)	O
19	are	O
20	presented	O
21	.	O

1	GTPase	B
2	activating	O
3	specificity	O
4	of	O
5	RGS12	B
6	and	O
7	binding	O
8	specificity	O
9	of	O
10	an	O
11	alternatively	O
12	spliced	O
13	PDZ	B
14	(	O
15	PSD	B
16	-	I
17	95	I
18	/	O
19	Dlg	B
20	/	O
21	ZO	B
22	-	I
23	1	I
24	)	O
25	domain	O
26	.	O

1	Autotransplantation	O
2	of	O
3	a	O
4	vein	O
5	segment	O
6	with	O
7	valve	O
8	in	O
9	the	O
10	treatment	O
11	of	O
12	deep	O
13	vein	O
14	valvular	O
15	insufficiency	O
16	of	O
17	the	O
18	lower	O
19	extremity	O

1	Double	O
2	-	O
3	staining	O
4	confirmed	O
5	that	O
6	there	O
7	were	O
8	separate	O
9	populations	O
10	of	O
11	CD68	B
12	-	O
13	positive	O
14	macrophages	O
15	and	O
16	XIIIa	B
17	-	O
18	positive	O
19	dendrocytes	O
20	.	O

1	At	O
2	the	O
3	end	O
4	of	O
5	the	O
6	experiment	O
7	the	O
8	urinary	O
9	porphyrin	O
10	excretion	O
11	and	O
12	the	O
13	porphyrin	O
14	content	O
15	in	O
16	lijver	O
17	and	O
18	skin	O
19	were	O
20	diminished	O
21	in	O
22	HCB	O
23	-	O
24	CQ	O
25	-	O
26	treated	O
27	animals	O
28	by	O
29	about	O
30	50	O
31	%	O
32	compared	O
33	to	O
34	the	O
35	HCB	O
36	controls	O
37	.	O

1	A	O
2	miracle	O
3	cure	O
4	and	O
5	its	O
6	solution	O

1	Pigs	O
2	were	O
3	switched	O
4	from	O
5	the	O
6	growing	O
7	to	O
8	the	O
9	finishing	O
10	diet	O
11	at	O
12	57	O
13	and	O
14	61	O
15	kg	O
16	in	O
17	Exp	O
18	.	O

1	The	O
2	ARX2	O
3	procedure	O
4	models	O
5	the	O
6	recorded	O
7	signal	O
8	as	O
9	the	O
10	sum	O
11	of	O
12	three	O
13	signals	O
14	:	O
15	(	O
16	a	O
17	)	O
18	the	O
19	background	O
20	EEG	O
21	activity	O
22	,	O
23	modelled	O
24	as	O
25	an	O
26	autoregressive	O
27	process	O
28	driven	O
29	by	O
30	a	O
31	white	O
32	noise	O
33	;	O
34	(	O
35	b	O
36	)	O
37	a	O
38	filtered	O
39	version	O
40	of	O
41	a	O
42	reference	O
43	signal	O
44	carrying	O
45	the	O
46	average	O
47	information	O
48	contained	O
49	in	O
50	each	O
51	sweep	O
52	;	O
53	(	O
54	c	O
55	)	O
56	a	O
57	signal	O
58	due	O
59	to	O
60	the	O
61	ocular	O
62	artefact	O
63	propagation	O
64	.	O

1	With	O
2	this	O
3	bisected	O
4	diastolic	O
5	driving	O
6	,	O
7	the	O
8	abnormal	O
9	echo	O
10	disappeared	O
11	completely	O
12	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	both	O
6	in	O
7	atrial	O
8	myocytes	O
9	and	O
10	in	O
11	Xenopus	O
12	oocytes	O
13	,	O
14	beta	O
15	-	O
16	adrenergic	O
17	stimulation	O
18	potentiates	O
19	the	O
20	ACh	O
21	-	O
22	evoked	O
23	GIRK	B
24	channels	I
25	via	O
26	a	O
27	pathway	O
28	that	O
29	involves	O
30	PKA	B
31	-	O
32	catalyzed	O
33	phosphorylation	O
34	downstream	O
35	from	O
36	beta	B
37	(	I
38	2	I
39	)	I
40	AR	I
41	.	O

1	Histological	O
2	slides	O
3	of	O
4	one	O
5	biopsy	O
6	of	O
7	each	O
8	patient	O
9	(	O
10	formalin	O
11	-	O
12	fixed	O
13	and	O
14	paraffin	O
15	-	O
16	embedded	O
17	)	O
18	were	O
19	stained	O
20	with	O
21	a	O
22	Modified	O
23	Giemsa	O
24	(	O
25	MG	O
26	),	O
27	the	O
28	Warthin	O
29	-	O
30	Starry	O
31	(	O
32	WS	O
33	),	O
34	and	O
35	an	O
36	immunohistochemical	O
37	method	O
38	(	O
39	IMM	O
40	)	O
41	using	O
42	purified	O
43	polyclonal	O
44	H	O
45	.	O
46	pylori	O
47	antiserum	O
48	(	O
49	DAKO	O
50	B471	O
51	).	O

1	Primers	O
2	for	O
3	subsequent	O
4	rounds	O
5	of	O
6	RACE	O
7	were	O
8	designed	O
9	from	O
10	the	O
11	5	O
12	'-	O
13	ends	O
14	of	O
15	amplified	O
16	RACE	O
17	products	O
18	.	O

1	The	O
2	infection	O
3	rate	O
4	was	O
5	five	O
6	times	O
7	greater	O
8	in	O
9	patients	O
10	with	O
11	Hickman	O
12	catheters	O
13	than	O
14	in	O
15	those	O
16	with	O
17	Broviac	O
18	catheters	O
19	(	O
20	p	O
21	=	O
22	0	O
23	.	O
24	01	O
25	).	O

1	The	O
2	decline	O
3	in	O
4	the	O
5	activity	O
6	of	O
7	cytochrome	B
8	oxidase	I
9	,	O
10	peroxidase	B
11	and	O
12	in	O
13	the	O
14	lipid	O
15	content	O
16	of	O
17	peripheral	O
18	neutrophils	O
19	was	O
20	followed	O
21	by	O
22	a	O
23	decrease	O
24	in	O
25	the	O
26	phagocytic	O
27	activity	O
28	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	results	O
5	of	O
6	several	O
7	experiments	O
8	suggest	O
9	that	O
10	the	O
11	TSF	B
12	genes	I
13	encode	O
14	global	O
15	regulatory	O
16	factors	O
17	.	O
18	tsf1	B
19	to	O
20	tsf6	B
21	mutations	O
22	derepressed	O
23	expression	O
24	from	O
25	yeast	O
26	CYC	B
27	-	O
28	GAL	B
29	hybrid	O
30	promoters	O
31	(	O
32	fused	O
33	to	O
34	lacZ	B
35	)	O
36	that	O
37	harbor	O
38	a	O
39	variety	O
40	of	O
41	operator	O
42	sequences	O
43	,	O
44	and	O
45	caused	O
46	pleiotropic	O
47	defects	O
48	in	O
49	cell	O
50	growth	O
51	,	O
52	mating	O
53	,	O
54	and	O
55	sporulation	O
56	.	O

1	Roles	O
2	of	O
3	the	O
4	Candida	B
5	albicans	I
6	mitogen	I
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	homolog	I
12	,	O
13	Cek1p	B
14	,	O
15	in	O
16	hyphal	O
17	development	O
18	and	O
19	systemic	O
20	candidiasis	O
21	.	O

1	In	O
2	several	O
3	studies	O
4	the	O
5	RDFS	O
6	has	O
7	shown	O
8	evidence	O
9	of	O
10	reliability	O
11	and	O
12	validity	O
13	.	O

1	An	O
2	ion	O
3	chromatographic	O
4	method	O
5	was	O
6	used	O
7	to	O
8	determine	O
9	Br	O
10	ion	O
11	in	O
12	the	O
13	urine	O
14	of	O
15	Greyhounds	O
16	.	O

1	A	O
2	neuropsychological	O
3	test	O
4	battery	O
5	was	O
6	used	O
7	that	O
8	contained	O
9	the	O
10	Wisconsin	O
11	card	O
12	sorting	O
13	test	O
14	,	O
15	Street	O
16	completion	O
17	test	O
18	,	O
19	Stroop	O
20	test	O
21	,	O
22	a	O
23	dichotic	O
24	memory	O
25	listening	O
26	test	O
27	,	O
28	and	O
29	a	O
30	facial	O
31	recognition	O
32	test	O
33	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	axillo	O
6	-	O
7	axillary	O
8	by	O
9	-	O
10	pass	O
11	is	O
12	a	O
13	simple	O
14	solution	O
15	for	O
16	a	O
17	complex	O
18	haemodynamic	O
19	,	O
20	clinical	O
21	and	O
22	therapeutic	O
23	problem	O
24	.	O

1	This	O
2	apparently	O
3	anomalous	O
4	structure	O
5	/	O
6	activity	O
7	relationship	O
8	raises	O
9	important	O
10	issues	O
11	for	O
12	understanding	O
13	the	O
14	evolution	O
15	of	O
16	regulatory	O
17	peptides	O
18	and	O
19	the	O
20	mechanisms	O
21	that	O
22	control	O
23	their	O
24	expression	O
25	.	O

1	The	O
2	dying	O
3	tTG	B
4	-	O
5	transfected	O
6	cells	O
7	exhibit	O
8	both	O
9	cytoplasmic	O
10	and	O
11	nuclear	O
12	changes	O
13	characteristic	O
14	of	O
15	cells	O
16	undergoing	O
17	apoptosis	O
18	.	O

1	The	O
2	first	O
3	exon	O
4	encodes	O
5	66	O
6	bp	O
7	of	O
8	the	O
9	5	O
10	'-	O
11	untranslated	O
12	sequence	O
13	,	O
14	while	O
15	exon	O
16	2	O
17	encodes	O
18	the	O
19	coding	O
20	and	O
21	3	O
22	'-	O
23	untranslated	O
24	sequences	O
25	.	O

1	Antithrombin	B
2	III	I
3	(	O
4	AT	B
5	III	I
6	)	O
7	is	O
8	a	O
9	plasma	O
10	protein	O
11	which	O
12	acts	O
13	as	O
14	the	O
15	principal	O
16	inhibitor	O
17	of	O
18	thrombin	B
19	and	O
20	is	O
21	a	O
22	major	O
23	modulator	O
24	of	O
25	intravascular	O
26	coagulation	O
27	.	O

1	This	O
2	finding	O
3	suggested	O
4	that	O
5	the	O
6	PI3K	B
7	-	O
8	Akt	B
9	activation	O
10	pathway	O
11	plays	O
12	some	O
13	role	O
14	in	O
15	the	O
16	antiapoptotic	O
17	effect	O
18	of	O
19	EPO	B
20	.	O

1	Effect	O
2	of	O
3	castration	O
4	on	O
5	pituitary	B
6	and	I
7	serum	I
8	LH	I
9	and	O
10	FSH	B
11	in	O
12	testosterone	O
13	-	O
14	sterilized	O
15	rats	O
16	.	O

1	PCR	O
2	/	O
3	Southern	O
4	blot	O
5	analysis	O
6	of	O
7	human	O
8	kidney	O
9	cDNA	O
10	using	O
11	primers	O
12	flanking	O
13	the	O
14	hKID	B
15	coding	I
16	sequence	I
17	revealed	O
18	expression	O
19	of	O
20	a	O
21	full	O
22	-	O
23	length	O
24	mRNA	O
25	and	O
26	short	O
27	transcripts	O
28	with	O
29	partial	O
30	exon	O
31	1	O
32	and	O
33	partial	O
34	exon	O
35	4	O
36	deletions	O
37	.	O

1	These	O
2	features	O
3	were	O
4	considered	O
5	consistent	O
6	with	O
7	a	O
8	diagnosis	O
9	of	O
10	Rothmund	O
11	-	O
12	Thomson	O
13	syndrome	O
14	.	O

1	The	O
2	murine	B
3	facilitative	I
4	glucose	I
5	transporter	I
6	isoform	I
7	3	I
8	(	O
9	Glut	B
10	3	I
11	)	O
12	is	O
13	developmentally	O
14	regulated	O
15	and	O
16	is	O
17	predominantly	O
18	expressed	O
19	in	O
20	neurons	O
21	and	O
22	trophoblasts	O
23	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	full	O
6	mu	O
7	-	O
8	opioid	O
9	agonists	O
10	fentanyl	O
11	,	O
12	morphine	O
13	,	O
14	I	O
15	-	O
16	methadone	O
17	and	O
18	levorphanol	O
19	produced	O
20	50	O
21	%	O
22	fentanyl	O
23	-	O
24	appropriate	O
25	responding	O
26	at	O
27	doses	O
28	only	O
29	1	O
30	.	O
31	3	O
32	to	O
33	10	O
34	.	O
35	9	O
36	times	O
37	smaller	O
38	than	O
39	those	O
40	required	O
41	to	O
42	decrease	O
43	response	O
44	rates	O
45	by	O
46	50	O
47	%.	O

1	Finally	O
2	,	O
3	Cas	B
4	existed	O
5	mainly	O
6	in	O
7	cytosol	O
8	and	O
9	membrane	O
10	cytoskeleton	O
11	fractions	O
12	in	O
13	the	O
14	resting	O
15	state	O
16	,	O
17	and	O
18	remained	O
19	unchanged	O
20	during	O
21	platelet	O
22	aggregation	O
23	,	O
24	when	O
25	FAK	B
26	translocated	O
27	to	O
28	the	O
29	cytoskeletal	O
30	fraction	O
31	.	O

1	The	O
2	effects	O
3	of	O
4	intracisternal	O
5	injection	O
6	(	O
7	i	O
8	.	O
9	c	O
10	.	O
11	i	O
12	.)	O
13	of	O
14	clonidine	O
15	(	O
16	1	O
17	microgram	O
18	kg	O
19	-	O
20	1	O
21	)	O
22	on	O
23	blood	O
24	pressure	O
25	and	O
26	heart	O
27	rate	O
28	were	O
29	studied	O
30	in	O
31	conscious	O
32	rabbits	O
33	with	O
34	an	O
35	implanted	O
36	catheter	O
37	in	O
38	the	O
39	cisterna	O
40	magna	O
41	.	O

1	Chem	O
2	.	O

1	Elimination	O
2	of	O
3	ETH1	B
4	in	O
5	apn1	B
6	strains	O
7	also	O
8	increased	O
9	spontaneous	O
10	mutation	O
11	rates	O
12	9	O
13	-	O
14	or	O
15	31	O
16	-	O
17	fold	O
18	compared	O
19	to	O
20	the	O
21	wild	O
22	type	O
23	as	O
24	determined	O
25	by	O
26	reversion	O
27	to	O
28	adenine	O
29	or	O
30	lysine	O
31	prototrophy	O
32	,	O
33	respectively	O
34	.	O

1	The	O
2	median	O
3	age	O
4	was	O
5	33	O
6	years	O
7	(	O
8	range	O
9	17	O
10	-	O
11	56	O
12	years	O
13	).	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	binding	O
7	of	O
8	CBF	B
9	/	O
10	NF	B
11	-	I
12	Y	I
13	to	O
14	the	O
15	inverted	O
16	CCAAT	O
17	box	O
18	is	O
19	responsible	O
20	for	O
21	transcriptional	O
22	activation	O
23	of	O
24	the	O
25	nTPH	B
26	gene	I
27	.	O

1	There	O
2	was	O
3	no	O
4	evident	O
5	inciting	O
6	agent	O
7	of	O
8	the	O
9	disease	O
10	.	O

1	The	O
2	alpha	O
3	-	O
4	subunit	O
5	by	O
6	itself	O
7	binds	O
8	to	O
9	telomeric	O
10	DNA	O
11	.	O

1	Improvement	O
2	of	O
3	the	O
4	CRT	O
5	display	O
6	of	O
7	an	O
8	averager	O
9	.	O

1	Anatomy	O
2	of	O
3	the	O
4	uterine	O
5	artery	O
6	.	O

1	Both	O
2	promoters	O
3	lack	O
4	a	O
5	TATA	O
6	box	O
7	,	O
8	and	O
9	Pint	B
10	belongs	O
11	to	O
12	the	O
13	MED	B
14	-	I
15	1	I
16	class	O
17	of	O
18	promoters	O
19	,	O
20	which	O
21	initiate	O
22	transcription	O
23	at	O
24	multiple	O
25	sites	O
26	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	Cktsf1b1	B
9	,	O
10	a	O
11	gene	O
12	associated	O
13	with	O
14	early	O
15	development	O
16	and	O
17	cell	O
18	transformation	O
19	,	O
20	is	O
21	sensitive	O
22	to	O
23	MKK	B
24	levels	O
25	and	O
26	may	O
27	be	O
28	regulated	O
29	via	O
30	multiple	O
31	transcription	O
32	factor	O
33	complexes	O
34	.	O

1	The	O
2	original	O
3	technique	O
4	was	O
5	developed	O
6	in	O
7	the	O
8	1960	O
9	'	O
10	s	O
11	to	O
12	analyze	O
13	the	O
14	inner	O
15	ear	O
16	fluid	O
17	as	O
18	a	O
19	diagnostic	O
20	procedure	O
21	(	O
22	i	O
23	.	O
24	e	O
25	.,	O
26	diagnostic	O
27	labyrinthotomy	O
28	)	O
29	in	O
30	acoustic	O
31	neuroma	O
32	suspects	O
33	.	O

1	Materials	O
2	science	O
3	studies	O
4	on	O
5	the	O
6	soldering	O
7	of	O
8	different	O
9	orthodontic	O
10	wires	O

1	Intriguingly	O
2	,	O
3	three	O
4	hypomorphic	O
5	Scm	B
6	mutations	O
7	,	O
8	which	O
9	map	O
10	within	O
11	an	O
12	mbt	B
13	repeat	I
14	,	O
15	interact	O
16	with	O
17	PcG	B
18	mutations	I
19	more	O
20	strongly	O
21	than	O
22	do	O
23	Scm	B
24	null	O
25	alleles	O
26	.	O

1	Survival	O
2	rates	O
3	for	O
4	the	O
5	original	O
6	treatment	O
7	group	O
8	were	O
9	84	O
10	.	O
11	5	O
12	%	O
13	and	O
14	57	O
15	.	O
16	6	O
17	%	O
18	at	O
19	12	O
20	and	O
21	21	O
22	months	O
23	,	O
24	respectively	O
25	;	O
26	for	O
27	the	O
28	delayed	O
29	treatment	O
30	group	O
31	,	O
32	78	O
33	.	O
34	8	O
35	%	O
36	and	O
37	64	O
38	.	O
39	6	O
40	%	O
41	at	O
42	12	O
43	and	O
44	21	O
45	months	O
46	,	O
47	respectively	O
48	,	O
49	and	O
50	78	O
51	.	O
52	8	O
53	%	O
54	and	O
55	47	O
56	.	O
57	5	O
58	%	O
59	at	O
60	12	O
61	and	O
62	21	O
63	months	O
64	,	O
65	respectively	O
66	,	O
67	for	O
68	77	O
69	subjects	O
70	with	O
71	AIDS	O
72	and	O
73	93	O
74	.	O
75	0	O
76	%	O
77	and	O
78	71	O
79	.	O
80	8	O
81	%,	O
82	respectively	O
83	,	O
84	for	O
85	50	O
86	subjects	O
87	with	O
88	AIDS	O
89	-	O
90	related	O
91	complex	O
92	in	O
93	the	O
94	original	O
95	treatment	O
96	group	O
97	.	O

1	During	O
2	the	O
3	first	O
4	3	O
5	min	O
6	of	O
7	recovery	O
8	,	O
9	plasma	O
10	potassium	O
11	fell	O
12	rapidly	O
13	in	O
14	spite	O
15	of	O
16	nearly	O
17	unchanged	O
18	blood	O
19	acidosis	O
20	and	O
21	significantly	O
22	decreasing	O
23	bicarbonate	O
24	concentration	O
25	.	O

1	The	O
2	interaction	O
3	between	O
4	U	O
5	(	O
6	L	O
7	)	O
8	3	O
9	.	O

1	Analysis	O
2	of	O
3	viral	O
4	mutants	O
5	in	O
6	vivo	O
7	demonstrated	O
8	that	O
9	the	O
10	NFIII	B
11	/	O
12	OCT	B
13	-	I
14	1	I
15	binding	O
16	site	O
17	and	O
18	a	O
19	conserved	O
20	ATF	B
21	motif	I
22	were	O
23	important	O
24	for	O
25	efficient	O
26	viral	O
27	growth	O
28	.	O

1	Regulation	O
2	of	O
3	the	O
4	alpha	B
5	inhibin	I
6	gene	I
7	by	O
8	cyclic	O
9	adenosine	O
10	3	O
11	',	O
12	5	O
13	'-	O
14	monophosphate	O
15	after	O
16	transfection	O
17	into	O
18	rat	O
19	granulosa	O
20	cells	O
21	.	O

1	Radiolabeled	O
2	recombinant	B
3	TARC	I
4	specifically	O
5	bound	O
6	to	O
7	T	O
8	cell	O
9	lines	O
10	and	O
11	peripheral	O
12	T	O
13	cells	O
14	but	O
15	not	O
16	to	O
17	monocytes	O
18	or	O
19	granulocytes	O
20	.	O

1	The	O
2	role	O
3	of	O
4	transport	O
5	by	O
6	sea	O
7	ice	O
8	from	O
9	the	O
10	Kara	O
11	Sea	O
12	into	O
13	the	O
14	Arctic	O
15	Ocean	O
16	was	O
17	assessed	O
18	by	O
19	a	O
20	small	O
21	subgroup	O
22	at	O
23	GEOMAR	O
24	.	O

1	We	O
2	now	O
3	provide	O
4	evidence	O
5	for	O
6	physical	O
7	and	O
8	functional	O
9	interaction	O
10	between	O
11	Doa4	B
12	and	O
13	the	O
14	proteasome	O
15	.	O

1	We	O
2	suggest	O
3	that	O
4	this	O
5	gene	O
6	cluster	O
7	codes	O
8	for	O
9	(	O
10	parts	O
11	of	O
12	)	O
13	a	O
14	multisubunit	B
15	cytochrome	I
16	c	I
17	haem	I
18	lyase	I
19	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	there	O
6	may	O
7	be	O
8	a	O
9	relationship	O
10	between	O
11	the	O
12	pathogenesis	O
13	of	O
14	MAL	O
15	,	O
16	narcolepsy	O
17	,	O
18	and	O
19	OSA	O
20	.	O

1	Genetic	O
2	experiments	O
3	using	O
4	mutants	O
5	defective	O
6	in	O
7	apontic	B
8	and	O
9	bruno	B
10	reveal	O
11	a	O
12	functional	O
13	interaction	O
14	between	O
15	these	O
16	genes	O
17	.	O

1	A	O
2	36	O
3	year	O
4	-	O
5	old	O
6	woman	O
7	was	O
8	given	O
9	Ergotamine	O
10	Tartrate	O
11	4	O
12	.	O
13	5	O
14	mg	O
15	p	O
16	.	O
17	d	O
18	.	O
19	during	O
20	seven	O
21	days	O
22	,	O
23	after	O
24	an	O
25	abortion	O
26	(	O
27	a	O
28	still	O
29	birth	O
30	).	O

1	The	O
2	result	O
3	suggests	O
4	that	O
5	this	O
6	non	O
7	-	O
8	invasive	O
9	TTD	O
10	method	O
11	is	O
12	easily	O
13	available	O
14	and	O
15	useful	O
16	in	O
17	monitoring	O
18	the	O
19	intraoperative	O
20	cardiac	O
21	output	O
22	.	O

1	J	O
2	.	O

1	This	O
2	conclusion	O
3	was	O
4	confirmed	O
5	by	O
6	Northern	O
7	blotting	O
8	analysis	O
9	of	O
10	the	O
11	5	O
12	'-	O
13	flanking	O
14	region	O
15	of	O
16	CAD	B
17	gene	I
18	.	O

1	The	O
2	location	O
3	of	O
4	the	O
5	IBS	O
6	within	O
7	the	O
8	catB	B
9	structural	I
10	gene	I
11	,	O
12	the	O
13	cooperativity	O
14	observed	O
15	in	O
16	footprinting	O
17	studies	O
18	and	O
19	phasing	O
20	studies	O
21	suggest	O
22	that	O
23	the	O
24	IBS	O
25	participates	O
26	in	O
27	the	O
28	interaction	O
29	of	O
30	CatR	B
31	with	O
32	the	O
33	upstream	O
34	binding	O
35	sites	O
36	by	O
37	looping	O
38	out	O
39	the	O
40	intervening	O
41	DNA	O
42	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	expression	O
6	of	O
7	the	O
8	protein	O
9	was	O
10	maximum	O
11	in	O
12	mitosis	O
13	and	O
14	minimum	O
15	in	O
16	G1	O
17	,	O
18	which	O
19	correlated	O
20	with	O
21	the	O
22	expression	O
23	of	O
24	its	O
25	messenger	O
26	RNA	O
27	.	O

1	Consciousness	O
2	is	O
3	connected	O
4	with	O
5	attention	O
6	,	O
7	working	O
8	memory	O
9	and	O
10	perception	O
11	.	O

1	Regression	O
2	analyses	O
3	identified	O
4	7	O
5	risk	O
6	and	O
7	7	O
8	protective	O
9	factors	O
10	with	O
11	minimal	O
12	overlap	O
13	.	O

1	To	O
2	avoid	O
3	complications	O
4	,	O
5	accurate	O
6	quantitative	O
7	analysis	O
8	of	O
9	NO	O
10	and	O
11	NO2	O
12	is	O
13	necessary	O
14	during	O
15	this	O
16	therapy	O
17	.	O

1	Constitutive	O
2	phosphorylation	O
3	of	O
4	the	O
5	CD30v	B
6	protein	I
7	was	O
8	demonstrated	O
9	by	O
10	in	O
11	vitro	O
12	labeling	O
13	with	O
14	[	O
15	32P	O
16	].	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	study	O
5	was	O
6	conducted	O
7	to	O
8	assess	O
9	the	O
10	relative	O
11	roles	O
12	of	O
13	99mTc	O
14	-	O
15	sestamibi	O
16	scintimammography	O
17	and	O
18	sonography	O
19	in	O
20	the	O
21	evaluation	O
22	of	O
23	breast	O
24	lesions	O
25	that	O
26	are	O
27	indeterminate	O
28	or	O
29	suspicious	O
30	on	O
31	mammography	O
32	or	O
33	clinical	O
34	examination	O
35	.	O

1	The	O
2	Clb5	B
3	kinase	I
4	,	O
5	which	O
6	promotes	O
7	S	O
8	phase	O
9	,	O
10	remains	O
11	active	O
12	during	O
13	the	O
14	G2	O
15	-	O
16	phase	O
17	arrest	O
18	of	O
19	cells	O
20	of	O
21	the	O
22	parental	O
23	strain	O
24	,	O
25	but	O
26	its	O
27	activity	O
28	declines	O
29	rapidly	O
30	in	O
31	sim	B
32	mutants	I
33	.	O

1	METHODS	O
2	:	O
3	Rats	O
4	received	O
5	continuous	O
6	intragastric	O
7	infusion	O
8	of	O
9	elemental	O
10	diet	O
11	or	O
12	with	O
13	supplementation	O
14	of	O
15	oatbase	O
16	,	O
17	Lactobacillus	O
18	reuteri	O
19	R2LC	O
20	,	O
21	and	O
22	Lactobacillus	O
23	plantarum	O
24	DSM	O
25	9843	O
26	,	O
27	with	O
28	and	O
29	without	O
30	fermentation	O
31	,	O
32	from	O
33	the	O
34	beginning	O
35	of	O
36	the	O
37	study	O
38	.	O

1	Renal	O
2	excretion	O
3	of	O
4	sulphadimidine	O
5	in	O
6	normal	O
7	and	O
8	uraemic	O
9	subjects	O
10	.	O

1	Kidney	O
2	length	O
3	did	O
4	not	O
5	significantly	O
6	differ	O
7	between	O
8	right	O
9	and	O
10	left	O
11	,	O
12	however	O
13	,	O
14	kidney	O
15	width	O
16	,	O
17	cortical	O
18	thickness	O
19	and	O
20	size	O
21	did	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	).	O

1	Therefore	O
2	,	O
3	we	O
4	propose	O
5	that	O
6	p27	B
7	represents	O
8	a	O
9	crucial	O
10	molecule	O
11	in	O
12	HMBA	O
13	signaling	O
14	that	O
15	cannot	O
16	be	O
17	replaced	O
18	by	O
19	p21	B
20	.	O

1	It	O
2	is	O
3	possible	O
4	that	O
5	cyclic	O
6	variations	O
7	in	O
8	heme	O
9	turnover	O
10	are	O
11	related	O
12	to	O
13	changes	O
14	in	O
15	erythrocyte	O
16	characteristics	O
17	during	O
18	the	O
19	progesterone	O
20	phase	O
21	.	O

1	They	O
2	also	O
3	indicate	O
4	that	O
5	direct	O
6	interactions	O
7	between	O
8	C	B
9	/	I
10	EBPs	I
11	and	O
12	specific	O
13	Ets	B
14	family	O
15	members	O
16	,	O
17	together	O
18	with	O
19	GATA	B
20	-	I
21	1	I
22	,	O
23	are	O
24	important	O
25	for	O
26	eosinophil	O
27	lineage	O
28	determination	O
29	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	identification	O
6	of	O
7	HSF	B
8	in	O
9	the	O
10	fission	O
11	yeast	O
12	Schizosaccharomyces	O
13	pombe	O
14	.	O

1	These	O
2	cells	O
3	were	O
4	able	O
5	to	O
6	present	O
7	influenza	O
8	virus	O
9	particles	O
10	to	O
11	HLA	B
12	-	I
13	DR1	I
14	-	O
15	restricted	O
16	T	O
17	cell	O
18	clones	O
19	.	O

1	The	O
2	discussion	O
3	focuses	O
4	primarily	O
5	on	O
6	the	O
7	newer	O
8	drugs	O
9	like	O
10	angiotensin	B
11	converting	I
12	enzyme	I
13	inhibitors	O
14	,	O
15	alpha	B
16	-	I
17	adrenergic	I
18	receptor	I
19	blockers	O
20	,	O
21	and	O
22	calcium	O
23	antagonists	O
24	.	O

1	CONCLUSION	O
2	:	O
3	Chronic	O
4	administration	O
5	of	O
6	misoprostol	O
7	may	O
8	have	O
9	caused	O
10	a	O
11	negative	O
12	natriuretic	O
13	effect	O
14	in	O
15	cirrhotic	O
16	patients	O
17	with	O
18	ascites	O
19	.	O

1	Liquid	O
2	chromatography	O
3	with	O
4	amperometric	O
5	detection	O
6	(	O
7	LC	O
8	/	O
9	AD	O
10	)	O
11	is	O
12	used	O
13	to	O
14	determine	O
15	fluazifop	O
16	acid	O
17	produced	O
18	from	O
19	the	O
20	metabolism	O
21	or	O
22	base	O
23	hydrolysis	O
24	of	O
25	fluazifop	O
26	-	O
27	butyl	O
28	in	O
29	soybeans	O
30	and	O
31	soybean	O
32	oil	O
33	.	O

1	The	O
2	records	O
3	from	O
4	1948	O
5	through	O
6	1967	O
7	of	O
8	344	O
9	previously	O
10	untreated	O
11	patients	O
12	with	O
13	squamous	O
14	cell	O
15	carcinoma	O
16	of	O
17	the	O
18	oral	O
19	cavity	O
20	,	O
21	oropharynx	O
22	,	O
23	supraglottic	O
24	larynx	O
25	and	O
26	hypopharynx	O
27	who	O
28	had	O
29	clinically	O
30	positive	O
31	cervical	O
32	lymph	O
33	node	O
34	metastases	O
35	staged	O
36	N1	O
37	,	O
38	N2A	O
39	,	O
40	or	O
41	N2B	O
42	,	O
43	and	O
44	whose	O
45	initial	O
46	neck	O
47	treatment	O
48	consisted	O
49	of	O
50	external	O
51	radiation	O
52	therapy	O
53	alone	O
54	were	O
55	reviewed	O
56	.	O

1	We	O
2	conclude	O
3	that	O
4	(	O
5	i	O
6	)	O
7	we	O
8	have	O
9	identified	O
10	several	O
11	candidate	O
12	latency	O
13	genes	O
14	of	O
15	murine	O
16	gammaHV68	O
17	,	O
18	(	O
19	ii	O
20	)	O
21	expression	O
22	of	O
23	genes	O
24	during	O
25	latency	O
26	may	O
27	be	O
28	different	O
29	in	O
30	different	O
31	organs	O
32	,	O
33	consistent	O
34	with	O
35	multiple	O
36	latency	O
37	programs	O
38	and	O
39	/	O
40	or	O
41	multiple	O
42	cellular	O
43	sites	O
44	of	O
45	latency	O
46	,	O
47	and	O
48	(	O
49	iii	O
50	)	O
51	regions	O
52	of	O
53	the	O
54	viral	O
55	genome	O
56	(	O
57	v	B
58	-	I
59	bcl	I
60	-	I
61	2	I
62	gene	I
63	,	O
64	v	B
65	-	I
66	GCR	I
67	gene	I
68	,	O
69	and	O
70	gene	B
71	73	I
72	)	O
73	are	O
74	transcribed	O
75	during	O
76	latency	O
77	with	O
78	both	O
79	gammaHV68	O
80	and	O
81	primate	O
82	gammaherpesviruses	O
83	.	O

1	Although	O
2	the	O
3	expression	O
4	of	O
5	the	O
6	4E	B
7	-	I
8	BP1	I
9	gene	I
10	alone	O
11	has	O
12	not	O
13	yet	O
14	been	O
15	accomplished	O
16	,	O
17	the	O
18	gene	O
19	was	O
20	expressed	O
21	in	O
22	Escherichia	O
23	coli	O
24	[	O
25	BL21	O
26	(	O
27	DE3	O
28	)]	O
29	as	O
30	a	O
31	fusion	O
32	gene	O
33	with	O
34	the	O
35	glutathione	B
36	-	I
37	S	I
38	-	I
39	transferase	I
40	(	O
41	GST	B
42	)	O
43	gene	O
44	using	O
45	a	O
46	prokaryotic	O
47	gene	O
48	fusion	O
49	vector	O
50	(	O
51	pGEX	O
52	-	O
53	4T	O
54	-	O
55	2	O
56	),	O
57	which	O
58	contains	O
59	a	O
60	gene	O
61	sequence	O
62	coding	O
63	the	O
64	cleavage	O
65	site	O
66	for	O
67	a	O
68	specific	O
69	protease	O
70	,	O
71	alpha	B
72	-	I
73	thrombin	I
74	.	O

1	Displacement	O
2	thresholds	O
3	of	O
4	peripheral	O
5	sites	O
6	in	O
7	monocular	O
8	human	O
9	vision	O
10	were	O
11	obtained	O
12	.	O

1	A	O
2	chromosome	B
3	transmission	I
4	fidelity	I
5	(	O
6	ctf	B
7	)	O
8	mutant	O
9	,	O
10	s138	O
11	,	O
12	of	O
13	Saccharomyces	O
14	cerevisiae	O
15	was	O
16	identified	O
17	by	O
18	its	O
19	centromere	O
20	(	O
21	CEN	O
22	)	O
23	transcriptional	O
24	readthrough	O
25	phenotype	O
26	,	O
27	suggesting	O
28	perturbed	O
29	kinetochore	O
30	integrity	O
31	in	O
32	vivo	O
33	.	O

1	PKC	B
2	-	I
3	gamma	I
4	,	O
5	which	O
6	is	O
7	not	O
8	present	O
9	in	O
10	keratinocytes	O
11	,	O
12	also	O
13	induces	O
14	involucrin	B
15	gene	I
16	expression	O
17	in	O
18	a	O
19	TPA	O
20	-	O
21	independent	O
22	manner	O
23	,	O
24	when	O
25	introduced	O
26	into	O
27	SVHK	O
28	cells	O
29	.	O

1	The	O
2	beta	O
3	subunit	O
4	of	O
5	the	O
6	heterotrimeric	B
7	G	I
8	proteins	I
9	that	O
10	transduce	O
11	signals	O
12	across	O
13	the	O
14	plasma	O
15	membrane	O
16	is	O
17	made	O
18	up	O
19	of	O
20	an	O
21	amino	O
22	-	O
23	terminal	O
24	alpha	O
25	-	O
26	helical	O
27	segment	O
28	followed	O
29	by	O
30	seven	O
31	repeating	O
32	units	O
33	called	O
34	WD	O
35	(	O
36	Trp	O
37	-	O
38	Asp	O
39	)	O
40	repeats	O
41	that	O
42	occur	O
43	in	O
44	about	O
45	140	O
46	different	O
47	proteins	O
48	.	O

1	Approximately	O
2	20	O
3	%	O
4	of	O
5	ALCLs	O
6	that	O
7	express	O
8	ALK	B
9	do	O
10	not	O
11	contain	O
12	the	O
13	t	O
14	(	O
15	2	O
16	;	O
17	5	O
18	),	O
19	suggesting	O
20	that	O
21	other	O
22	genetic	O
23	abnormalities	O
24	can	O
25	result	O
26	in	O
27	aberrant	O
28	ALK	B
29	expression	O
30	.	O

1	In	O
2	addition	O
3	,	O
4	computer	O
5	analysis	O
6	suggests	O
7	that	O
8	sequences	O
9	similar	O
10	to	O
11	the	O
12	A	O
13	stem	O
14	element	O
15	are	O
16	present	O
17	within	O
18	the	O
19	three	O
20	AAV	B
21	promoter	I
22	regions	O
23	.	O

1	Krox	B
2	-	I
3	20	I
4	,	O
5	a	O
6	zinc	B
7	finger	I
8	gene	I
9	,	O
10	has	O
11	a	O
12	highly	O
13	conserved	O
14	pattern	O
15	of	O
16	expression	O
17	in	O
18	r3	O
19	and	O
20	r5	O
21	and	O
22	is	O
23	functionally	O
24	required	O
25	for	O
26	their	O
27	maintenance	O
28	in	O
29	mouse	O
30	embryos	O
31	.	O

1	With	O
2	current	O
3	methodology	O
4	beta	B
5	-	I
6	2	I
7	transferrin	I
8	does	O
9	not	O
10	appear	O
11	to	O
12	be	O
13	a	O
14	reliable	O
15	clinical	O
16	marker	O
17	for	O
18	perilymph	O
19	in	O
20	the	O
21	operative	O
22	setting	O
23	.	O

1	These	O
2	mutant	O
3	proteins	O
4	retained	O
5	the	O
6	ability	O
7	to	O
8	competitively	O
9	inhibit	O
10	kappa	B
11	B	I
12	-	O
13	mediated	O
14	transcriptional	O
15	activation	O
16	of	O
17	the	O
18	human	B
19	immunodeficiency	I
20	virus	I
21	long	I
22	terminal	I
23	repeat	I
24	but	O
25	failed	O
26	to	O
27	efficiently	O
28	transform	O
29	chicken	O
30	lymphoid	O
31	cells	O
32	both	O
33	in	O
34	vitro	O
35	and	O
36	in	O
37	vivo	O
38	.	O

1	The	O
2	zona	O
3	pellucida	O
4	(	O
5	ZP	O
6	),	O
7	the	O
8	extracellular	O
9	glycocalyx	O
10	that	O
11	surrounds	O
12	the	O
13	oocyte	O
14	,	O
15	is	O
16	well	O
17	known	O
18	to	O
19	mediate	O
20	homologous	O
21	gamete	O
22	interaction	O
23	.	O

1	Within	O
2	their	O
3	polypeptide	O
4	chain	O
5	,	O
6	they	O
7	all	O
8	contain	O
9	those	O
10	conserved	O
11	features	O
12	that	O
13	define	O
14	a	O
15	plant	O
16	CDPK	B
17	;	O
18	kinase	O
19	catalytic	O
20	sequences	O
21	are	O
22	linked	O
23	to	O
24	a	O
25	calmodulin	B
26	-	I
27	like	I
28	regulatory	I
29	domain	I
30	through	O
31	a	O
32	junction	O
33	region	O
34	.	O

1	Comparison	O
2	of	O
3	cDNA	O
4	and	O
5	genomic	O
6	sequences	O
7	shows	O
8	that	O
9	the	O
10	ZNF189	B
11	gene	I
12	spans	O
13	approximately	O
14	11	O
15	kb	O
16	and	O
17	is	O
18	organized	O
19	into	O
20	at	O
21	least	O
22	four	O
23	exons	O
24	,	O
25	the	O
26	large	O
27	3	O
28	'-	O
29	end	O
30	exon	O
31	coding	O
32	for	O
33	the	O
34	complete	O
35	zinc	O
36	finger	O
37	domain	O
38	and	O
39	the	O
40	3	O
41	'	O
42	untranslated	O
43	region	O
44	.	O

1	Of	O
2	7	O
3	patients	O
4	treated	O
5	with	O
6	cyclophosphamide	O
7	,	O
8	hexamethylmelamine	O
9	,	O
10	adriamycin	O
11	and	O
12	cisplatin	O
13	(	O
14	CHAP	O
15	-	O
16	5	O
17	),	O
18	6	O
19	had	O
20	measurable	O
21	disease	O
22	,	O
23	of	O
24	whom	O
25	5	O
26	yielded	O
27	a	O
28	response	O
29	(	O
30	2	O
31	complete	O
32	responses	O
33	for	O
34	19	O
35	+	O
36	and	O
37	40	O
38	months	O
39	and	O
40	3	O
41	partial	O
42	responses	O
43	for	O
44	4	O
45	,	O
46	7	O
47	and	O
48	8	O
49	months	O
50	).	O

1	Genomic	O
2	Southern	O
3	blot	O
4	analysis	O
5	of	O
6	rat	B
7	EFIA	I
8	(	O
9	gene	O
10	encoding	O
11	enhancer	B
12	factor	I
13	I	I
14	subunit	I
15	A	I
16	)	O
17	reveals	O
18	a	O
19	complex	O
20	band	O
21	pattern	O
22	when	O
23	cDNA	O
24	subfragment	O
25	probes	O
26	are	O
27	used	O
28	.	O

1	Switching	O
2	FDC	O
3	-	O
4	P1	O
5	/	O
6	MAC	O
7	cells	O
8	from	O
9	growth	O
10	in	O
11	M	B
12	-	I
13	CSF	I
14	to	O
15	GM	B
16	-	I
17	CSF	I
18	caused	O
19	the	O
20	selective	O
21	degradation	O
22	of	O
23	c	B
24	-	I
25	fms	I
26	mRNA	I
27	within	O
28	6	O
29	h	O
30	after	O
31	factor	O
32	switching	O
33	.	O

1	Here	O
2	,	O
3	we	O
4	report	O
5	that	O
6	swa5	B
7	-	I
8	1	I
9	is	O
10	a	O
11	new	O
12	temperature	O
13	-	O
14	sensitive	O
15	allele	O
16	of	O
17	the	O
18	clathrin	B
19	heavy	I
20	chain	I
21	gene	I
22	(	O
23	chc1	B
24	-	I
25	5	I
26	),	O
27	which	O
28	carries	O
29	a	O
30	frameshift	O
31	mutation	O
32	near	O
33	the	O
34	3	O
35	'	O
36	end	O
37	of	O
38	the	O
39	CHC1	B
40	open	O
41	reading	O
42	frame	O
43	.	O

1	Adverse	O
2	reaction	O
3	of	O
4	the	O
5	apparently	O
6	healthy	O
7	partner	O
8	in	O
9	response	O
10	to	O
11	improvement	O
12	in	O
13	the	O
14	overtly	O
15	dysfunctional	O
16	partner	O
17	.	O

1	It	O
2	has	O
3	been	O
4	proposed	O
5	that	O
6	the	O
7	parCBA	B
8	operon	I
9	encodes	O
10	a	O
11	plasmid	O
12	partitioning	O
13	system	O
14	(	O
15	M	O
16	.	O

1	One	O
2	of	O
3	these	O
4	,	O
5	the	O
6	origin	O
7	core	O
8	,	O
9	is	O
10	required	O
11	only	O
12	for	O
13	DNA	O
14	replication	O
15	.	O

1	Using	O
2	varying	O
3	conditions	O
4	,	O
5	three	O
6	distinct	O
7	complexes	O
8	were	O
9	shown	O
10	to	O
11	interact	O
12	specifically	O
13	with	O
14	the	O
15	NIP	B
16	region	I
17	,	O
18	although	O
19	only	O
20	one	O
21	correlates	O
22	with	O
23	repressor	O
24	activity	O
25	.	O

1	This	O
2	suggested	O
3	that	O
4	baboon	B
5	liver	I
6	class	I
7	I	I
8	ADH	I
9	is	O
10	of	O
11	the	O
12	same	O
13	ancestral	O
14	lineage	O
15	as	O
16	the	O
17	human	B
18	ADH	I
19	-	I
20	beta	I
21	.	O

1	Among	O
2	these	O
3	are	O
4	:	O
5	(	O
6	1	O
7	)	O
8	Is	O
9	there	O
10	sufficient	O
11	understanding	O
12	of	O
13	family	O
14	pathophysiology	O
15	,	O
16	of	O
17	the	O
18	sensitivity	O
19	and	O
20	specificity	O
21	of	O
22	diagnostic	O
23	techniques	O
24	and	O
25	of	O
26	the	O
27	safety	O
28	and	O
29	efficacy	O
30	of	O
31	therapeutic	O
32	modalities	O
33	to	O
34	make	O
35	true	O
36	family	O
37	health	O
38	care	O
39	possible	O
40	?	O
41	(	O
42	2	O
43	)	O
44	If	O
45	this	O
46	type	O
47	of	O
48	care	O
49	is	O
50	possible	O
51	,	O
52	how	O
53	are	O
54	the	O
55	needs	O
56	of	O
57	the	O
58	family	O
59	and	O
60	its	O
61	individual	O
62	members	O
63	met	O
64	,	O
65	or	O
66	value	O
67	judgements	O
68	made	O
69	about	O
70	their	O
71	relative	O
72	importance	O
73	?	O
74	and	O
75	(	O
76	3	O
77	)	O
78	What	O
79	are	O
80	the	O
81	consequences	O
82	for	O
83	the	O
84	health	O
85	care	O
86	delivery	O
87	system	O
88	of	O
89	this	O
90	type	O
91	of	O
92	care	O
93	?	O
94	An	O
95	extensive	O
96	literature	O
97	review	O
98	is	O
99	used	O
100	in	O
101	an	O
102	attempt	O
103	to	O
104	answer	O
105	these	O
106	queries	O
107	,	O
108	from	O
109	which	O
110	questions	O
111	for	O
112	further	O
113	study	O
114	are	O
115	posed	O
116	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	relationship	O
7	between	O
8	comprehension	O
9	and	O
10	production	O
11	is	O
12	different	O
13	at	O
14	different	O
15	stages	O
16	in	O
17	development	O
18	.	O

1	Processivity	O
2	of	O
3	DNA	O
4	synthesis	O
5	by	O
6	the	O
7	mutant	O
8	holoenzyme	O
9	containing	O
10	pcna	B
11	-	I
12	79	I
13	was	O
14	unaffected	O
15	on	O
16	poly	O
17	(	O
18	dA	O
19	)	O
20	x	O
21	oligo	O
22	(	O
23	dT	O
24	)	O
25	but	O
26	was	O
27	dramatically	O
28	reduced	O
29	on	O
30	a	O
31	natural	O
32	template	O
33	with	O
34	secondary	O
35	structure	O
36	.	O

1	The	O
2	intensity	O
3	of	O
4	myocardial	O
5	uptake	O
6	of	O
7	Tc	O
8	-	O
9	99m	O
10	-	O
11	PYP	O
12	in	O
13	patients	O
14	with	O
15	echocardiographic	O
16	left	O
17	ventricular	O
18	hypertrophy	O
19	and	O
20	/	O
21	or	O
22	highly	O
23	refractile	O
24	myocardial	O
25	echoes	O
26	,	O
27	so	O
28	-	O
29	called	O
30	granular	O
31	sparkling	O
32	appearance	O
33	(	O
34	GS	O
35	)	O
36	was	O
37	slightly	O
38	greater	O
39	than	O
40	that	O
41	in	O
42	patients	O
43	with	O
44	neither	O
45	myocardial	O
46	hypertrophy	O
47	nor	O
48	GS	O
49	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	exhibited	O
7	98	O
8	%	O
9	identity	O
10	to	O
11	the	O
12	human	O
13	cellular	O
14	transglutaminase	O
15	sequence	O
16	.	O

1	A	O
2	brief	O
3	account	O
4	of	O
5	the	O
6	1988	O
7	seminar	O
8	in	O
9	Shanghai	O
10	on	O
11	viral	O
12	hepatitis	O
13	A	O

1	In	O
2	conclusion	O
3	,	O
4	our	O
5	data	O
6	do	O
7	not	O
8	support	O
9	a	O
10	role	O
11	for	O
12	IVIg	B
13	in	O
14	the	O
15	remyelination	O
16	of	O
17	stable	O
18	multiple	O
19	sclerosis	O
20	lesions	O
21	as	O
22	measured	O
23	by	O
24	central	O
25	conduction	O
26	time	O
27	.	O

1	Recent	O
2	investigations	O
3	have	O
4	shown	O
5	that	O
6	Grenz	O
7	rays	O
8	can	O
9	suppress	O
10	the	O
11	allergic	O
12	contact	O
13	dermatitis	O
14	reaction	O
15	completely	O
16	and	O
17	that	O
18	Langerhans	O
19	cells	O
20	,	O
21	identified	O
22	by	O
23	OKT6	B
24	antibodies	I
25	and	O
26	electron	O
27	microscopy	O
28	,	O
29	disappear	O
30	from	O
31	the	O
32	epidermis	O
33	at	O
34	the	O
35	same	O
36	time	O
37	.	O

1	Preparation	O
2	of	O
3	a	O
4	stable	O
5	phospholipid	O
6	reagent	O
7	for	O
8	coagulation	O
9	assays	O
10	.	O

1	The	O
2	RanQ69L	B
3	preincubation	O
4	leads	O
5	to	O
6	accumulation	O
7	of	O
8	CRM1	B
9	at	O
10	the	O
11	cytoplasmic	O
12	periphery	O
13	of	O
14	the	O
15	nuclear	O
16	pore	O
17	complex	O
18	(	O
19	NPC	O
20	)	O
21	in	O
22	association	O
23	with	O
24	the	O
25	p62	B
26	complex	I
27	and	O
28	Can	B
29	/	O
30	Nup214	B
31	.	O

1	10	O
2	long	O
3	-	O
4	term	O
5	hemodialysis	O
6	patients	O
7	had	O
8	immediate	O
9	and	O
10	redistribution	O
11	thallium	O
12	-	O
13	201	O
14	myocardial	O
15	imaging	O
16	performed	O
17	after	O
18	a	O
19	course	O
20	of	O
21	hemodialysis	O
22	.	O

1	It	O
2	was	O
3	subsequently	O
4	shown	O
5	that	O
6	Tip60	B
7	had	O
8	histone	B
9	acetyltransferase	I
10	(	O
11	HAT	B
12	)	O
13	activity	O
14	.	O

1	MAIN	O
2	OUTCOME	O
3	MEASURES	O
4	:	O
5	Percentage	O
6	change	O
7	in	O
8	the	O
9	apnea	O
10	-	O
11	hypopnea	O
12	index	O
13	(	O
14	AHI	O
15	;	O
16	apnea	O
17	events	O
18	+	O
19	hypopnea	O
20	events	O
21	per	O
22	hour	O
23	of	O
24	sleep	O
25	)	O
26	and	O
27	odds	O
28	of	O
29	developing	O
30	moderate	O
31	-	O
32	to	O
33	-	O
34	severe	O
35	SDB	O
36	(	O
37	defined	O
38	by	O
39	an	O
40	AHI	O
41	>	O
42	or	O
43	=	O
44	15	O
45	events	O
46	per	O
47	hour	O
48	of	O
49	sleep	O
50	),	O
51	with	O
52	respect	O
53	to	O
54	change	O
55	in	O
56	weight	O
57	.	O

1	A	O
2	comparative	O
3	study	O
4	of	O
5	the	O
6	cortical	O
7	end	O
8	of	O
9	the	O
10	auditory	O
11	analyzer	O
12	during	O
13	postnatal	O
14	ontogenesis	O
15	in	O
16	lower	O
17	monkeys	O
18	and	O
19	man	O

1	Thus	O
2	,	O
3	despite	O
4	the	O
5	potential	O
6	for	O
7	common	O
8	regulatory	O
9	mechanisms	O
10	,	O
11	the	O
12	available	O
13	evidence	O
14	indicates	O
15	that	O
16	the	O
17	Mtx	B
18	minimal	I
19	promoter	I
20	does	O
21	not	O
22	significantly	O
23	affect	O
24	Thbs3	B
25	gene	I
26	expression	O
27	.	O

1	Our	O
2	study	O
3	also	O
4	demonstrated	O
5	significant	O
6	increases	O
7	in	O
8	the	O
9	number	O
10	of	O
11	larger	O
12	myelinated	O
13	fibers	O
14	crossing	O
15	the	O
16	repair	O
17	site	O
18	in	O
19	comparison	O
20	with	O
21	the	O
22	neonatal	O
23	and	O
24	adult	O
25	groups	O
26	(	O
27	p	O
28	<	O
29	0	O
30	.	O
31	04	O
32	).	O

1	FZD4	B
2	is	O
3	homologous	O
4	to	O
5	FZD9	B
6	and	O
7	FZD10	B
8	,	O
9	and	O
10	overall	O
11	amino	O
12	acid	O
13	identity	O
14	is	O
15	as	O
16	follows	O
17	:	O
18	FZD4	B
19	vs	O
20	FZD9	B
21	,	O
22	51	O
23	.	O
24	6	O
25	%;	O
26	FZD4	B
27	vs	O
28	FZD10	B
29	,	O
30	51	O
31	.	O
32	2	O
33	%;	O
34	FZD9	B
35	vs	O
36	FZD10	B
37	,	O
38	65	O
39	.	O
40	7	O
41	%.	O

1	The	O
2	detection	O
3	success	O
4	rate	O
5	was	O
6	determined	O
7	for	O
8	different	O
9	markers	O
10	using	O
11	this	O
12	MEK	B
13	.	O

1	Reproducing	O
2	populations	O
3	of	O
4	this	O
5	aphid	O
6	were	O
7	first	O
8	detected	O
9	in	O
10	Puerto	O
11	Rico	O
12	in	O
13	April	O
14	1992	O
15	.	O

1	Absorption	O
2	was	O
3	rapid	O
4	,	O
5	with	O
6	a	O
7	mean	O
8	time	O
9	to	O
10	peak	O
11	of	O
12	39	O
13	min	O
14	.	O

1	T	B
2	-	I
3	cell	I
4	receptor	I
5	beta	I
6	(	O
7	TCR	B
8	beta	I
9	)	O
10	gene	O
11	rearrangements	O
12	occur	O
13	in	O
14	a	O
15	third	O
16	of	O
17	early	O
18	B	O
19	-	O
20	cell	O
21	acute	O
22	lymphoblastic	O
23	leukemias	O
24	(	O
25	ALLs	O
26	).	O

1	Two	O
2	rare	O
3	novel	O
4	mutations	O
5	,	O
6	D811N	O
7	in	O
8	exon	O
9	20	O
10	and	O
11	R835C	O
12	in	O
13	exon	O
14	21	O
15	,	O
16	were	O
17	identified	O
18	in	O
19	the	O
20	first	O
21	nucleotide	O
22	-	O
23	binding	O
24	fold	O
25	(	O
26	NBF	O
27	),	O
28	a	O
29	functionally	O
30	important	O
31	region	O
32	of	O
33	SUR1	B
34	,	O
35	in	O
36	one	O
37	patient	O
38	each	O
39	,	O
40	both	O
41	heterozygotes	O
42	.	O

1	Disruption	O
2	mutations	O
3	have	O
4	been	O
5	constructed	O
6	in	O
7	the	O
8	SLK1	B
9	gene	I
10	.	O
11	slk1	B
12	null	I
13	mutants	I
14	cannot	O
15	grow	O
16	at	O
17	37	O
18	degrees	O
19	C	O
20	,	O
21	but	O
22	many	O
23	cells	O
24	can	O
25	grow	O
26	at	O
27	30	O
28	,	O
29	24	O
30	,	O
31	and	O
32	17	O
33	degrees	O
34	C	O
35	.	O

1	Atherosclerosis	O

1	When	O
2	this	O
3	DNA	O
4	fragment	O
5	was	O
6	placed	O
7	upstream	O
8	of	O
9	the	O
10	chloramphenicol	B
11	acetyltransferase	I
12	(	O
13	CAT	B
14	)	O
15	reporter	O
16	gene	O
17	and	O
18	transfected	O
19	into	O
20	a	O
21	carp	O
22	CF	O
23	cell	O
24	line	O
25	,	O
26	it	O
27	could	O
28	drive	O
29	the	O
30	synthesis	O
31	of	O
32	CAT	B
33	enzyme	I
34	16	O
35	times	O
36	more	O
37	efficiently	O
38	than	O
39	the	O
40	promoterless	O
41	pCAT	B
42	-	I
43	Basic	I
44	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	that	O
6	the	O
7	STORP	B
8	gene	I
9	has	O
10	a	O
11	ubiquitous	O
12	pattern	O
13	of	O
14	expression	O
15	similar	O
16	to	O
17	that	O
18	of	O
19	the	O
20	PML	B
21	gene	I
22	.	O

1	Those	O
2	dosages	O
3	that	O
4	inhibited	O
5	mean	O
6	NTE	B
7	activity	O
8	in	O
9	spinal	O
10	cord	O
11	greater	O
12	than	O
13	or	O
14	equal	O
15	to	O
16	72	O
17	%	O
18	and	O
19	brain	O
20	greater	O
21	than	O
22	or	O
23	equal	O
24	to	O
25	66	O
26	%	O
27	of	O
28	control	O
29	values	O
30	within	O
31	44	O
32	hr	O
33	postexposure	O
34	produced	O
35	marked	O
36	spinal	O
37	cord	O
38	pathology	O
39	14	O
40	days	O
41	postexposure	O
42	in	O
43	greater	O
44	than	O
45	or	O
46	equal	O
47	to	O
48	90	O
49	%	O
50	of	O
51	similarly	O
52	dosed	O
53	animals	O
54	.	O

1	Mortality	O
2	on	O
3	the	O
4	last	O
5	ranch	O
6	was	O
7	particularly	O
8	severe	O
9	among	O
10	certain	O
11	segregated	O
12	groups	O
13	of	O
14	turkeys	O
15	that	O
16	included	O
17	toms	O
18	,	O
19	heavier	O
20	birds	O
21	,	O
22	and	O
23	birds	O
24	undergoing	O
25	a	O
26	stressful	O
27	event	O
28	such	O
29	as	O
30	artificial	O
31	insemination	O
32	.	O

1	High	O
2	expression	O
3	of	O
4	the	O
5	peroxisome	B
6	proliferator	I
7	-	I
8	activated	I
9	receptor	I
10	alpha	I
11	(	O
12	PPARalpha	B
13	)	O
14	differentiates	O
15	brown	O
16	fat	O
17	from	O
18	white	O
19	,	O
20	and	O
21	is	O
22	related	O
23	to	O
24	its	O
25	high	O
26	capacity	O
27	of	O
28	lipid	O
29	oxidation	O
30	.	O

1	We	O
2	and	O
3	others	O
4	have	O
5	demonstrated	O
6	that	O
7	the	O
8	c	B
9	-	I
10	cbl	I
11	proto	I
12	-	I
13	oncogene	I
14	product	I
15	is	O
16	one	O
17	of	O
18	the	O
19	earliest	O
20	targets	O
21	of	O
22	tyrosine	O
23	phosphorylation	O
24	upon	O
25	T	B
26	cell	I
27	receptor	I
28	stimulation	O
29	.	O

1	RNase	B
2	protection	O
3	experiments	O
4	confirmed	O
5	the	O
6	presence	O
7	of	O
8	the	O
9	GHR1	B
10	-	I
11	279	I
12	variant	I
13	in	O
14	IM	O
15	-	O
16	9	O
17	cells	O
18	and	O
19	human	O
20	liver	O
21	.	O

1	Additionally	O
2	,	O
3	the	O
4	enzyme	O
5	shows	O
6	activity	O
7	towards	O
8	triglycerides	O
9	such	O
10	as	O
11	olive	O
12	oil	O
13	and	O
14	tributyrin	O
15	and	O
16	towards	O
17	egg	O
18	-	O
19	yolk	O
20	emulsions	O
21	.	O

1	This	O
2	brief	O
3	review	O
4	analyses	O
5	these	O
6	interactions	O
7	and	O
8	defines	O
9	clinical	O
10	settings	O
11	where	O
12	antibiotic	O
13	-	O
14	induced	O
15	endotoxin	O
16	release	O
17	may	O
18	prove	O
19	to	O
20	be	O
21	clinically	O
22	relevant	O
23	.	O

1	In	O
2	vitro	O
3	binding	O
4	studies	O
5	using	O
6	GST	B
7	fusion	O
8	proteins	O
9	and	O
10	yeast	O
11	extracts	O
12	defined	O
13	distinct	O
14	binding	O
15	sites	O
16	on	O
17	yAP180A	B
18	for	O
19	Pan1p	B
20	and	O
21	clathrin	B
22	.	O
23	yAP180	B
24	proteins	I
25	and	O
26	Pan1p	B
27	,	O
28	like	O
29	actin	B
30	,	O
31	localize	O
32	to	O
33	peripheral	O
34	patches	O
35	along	O
36	the	O
37	plasma	O
38	membrane	O
39	.	O

1	We	O
2	thus	O
3	conclude	O
4	that	O
5	the	O
6	NFAT	B
7	RIR	I
8	plays	O
9	an	O
10	essential	O
11	dual	O
12	role	O
13	in	O
14	DNA	O
15	recognition	O
16	and	O
17	cooperative	O
18	binding	O
19	to	O
20	AP	B
21	-	I
22	1	I
23	family	I
24	transcription	I
25	factors	I
26	.	O

1	Polysorbate	O
2	80	O
3	did	O
4	not	O
5	have	O
6	a	O
7	direct	O
8	stimulant	O
9	or	O
10	relaxant	O
11	effect	O
12	on	O
13	either	O
14	guinea	O
15	pig	O
16	ileum	O
17	or	O
18	rat	O
19	uterus	O
20	,	O
21	however	O
22	,	O
23	it	O
24	antagonised	O
25	the	O
26	contractions	O
27	induced	O
28	by	O
29	acetylcholine	O
30	,	O
31	histamine	O
32	,	O
33	barium	O
34	,	O
35	5	O
36	-	O
37	hydroxytryptamine	O
38	and	O
39	carbachol	O
40	in	O
41	a	O
42	dose	O
43	-	O
44	dependent	O
45	manner	O
46	.	O

1	The	O
2	high	O
3	conservation	O
4	of	O
5	the	O
6	3	O
7	'	O
8	terminus	O
9	suggests	O
10	that	O
11	this	O
12	region	O
13	directs	O
14	the	O
15	assembly	O
16	of	O
17	proteins	O
18	required	O
19	for	O
20	the	O
21	initiation	O
22	of	O
23	RNA	O
24	replication	O
25	.	O

1	Drosophila	B
2	orthodenticle	I
3	(	O
4	otd	B
5	)	O
6	and	O
7	murine	B
8	Otx	I
9	genes	I
10	exemplify	O
11	this	O
12	,	O
13	both	O
14	in	O
15	terms	O
16	of	O
17	expression	O
18	patterns	O
19	and	O
20	mutant	O
21	phenotypes	O
22	.	O

1	They	O
2	were	O
3	almost	O
4	regularly	O
5	excited	O
6	by	O
7	pressure	O
8	to	O
9	the	O
10	ipsilateral	O
11	cornea	O
12	or	O
13	to	O
14	both	O
15	corneas	O
16	at	O
17	a	O
18	strength	O
19	well	O
20	above	O
21	the	O
22	human	O
23	corneal	O
24	pain	O
25	threshold	O
26	.	O

1	ORF	O
2	2	O
3	potentially	O
4	encoded	O
5	a	O
6	hydrophobic	O
7	protein	O
8	of	O
9	29	O
10	,	O
11	705	O
12	Da	O
13	with	O
14	six	O
15	potential	O
16	membrane	O
17	-	O
18	spanning	O
19	regions	O
20	.	O

1	Reproductive	O
2	period	O
3	affects	O
4	water	O
5	intake	O
6	in	O
7	heat	O
8	-	O
9	stressed	O
10	dehydrated	O
11	goats	O
12	.	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	I
4	(	O
5	GGTP	B
6	)	O
7	activity	O
8	in	O
9	the	O
10	seminal	O
11	fluid	O

1	Similarly	O
2	,	O
3	we	O
4	observed	O
5	synthetic	O
6	phenotypes	O
7	between	O
8	mutations	O
9	in	O
10	MIF2	B
11	and	O
12	trans	O
13	-	O
14	acting	O
15	mutations	O
16	in	O
17	three	O
18	known	O
19	yeast	O
20	centromere	O
21	protein	O
22	genes	O
23	-	O
24	CEP1	B
25	/	O
26	CBF1	B
27	/	O
28	CPF1	B
29	,	O
30	NDC10	B
31	/	O
32	CBF2	B
33	,	O
34	and	O
35	CEP3	B
36	/	O
37	CBF3B	B
38	.	O

1	The	O
2	antigen	B
3	-	I
4	specific	I
5	IgG4	I
6	antibody	I
7	seems	O
8	to	O
9	be	O
10	an	O
11	index	O
12	in	O
13	evaluating	O
14	immunotherapy	O
15	objectively	O
16	.	O

1	A	O
2	canonical	O
3	TATA	O
4	box	O
5	was	O
6	not	O
7	detected	O
8	.	O

1	The	O
2	article	O
3	deals	O
4	with	O
5	the	O
6	diagnosing	O
7	and	O
8	correction	O
9	of	O
10	reversible	O
11	ischemia	O
12	of	O
13	the	O
14	intestine	O
15	.	O

1	The	O
2	biology	O
3	of	O
4	Hyostrongylus	O
5	ruidus	O
6	.	O

1	In	O
2	the	O
3	eight	O
4	patients	O
5	with	O
6	persistent	O
7	generalized	O
8	lymph	O
9	-	O
10	adenopathy	O
11	(	O
12	PGL	O
13	)	O
14	and	O
15	nontender	O
16	,	O
17	nonenlarging	O
18	nodes	O
19	,	O
20	pathologic	O
21	analysis	O
22	revealed	O
23	lymphoid	O
24	hyperplasia	O
25	.	O

1	The	O
2	effect	O
3	of	O
4	ethanol	O
5	on	O
6	human	O
7	sensorimotor	O
8	reactivity	O
9	was	O
10	assessed	O
11	by	O
12	examining	O
13	the	O
14	acoustic	O
15	startle	O
16	response	O
17	.	O

1	All	O
2	patients	O
3	then	O
4	received	O
5	suxamethonium	O
6	1	O
7	.	O
8	5	O
9	mg	O
10	kg	O
11	-	O
12	1	O
13	i	O
14	.	O
15	v	O
16	.	O

1	The	O
2	Nur77	B
3	protein	I
4	can	O
5	act	O
6	as	O
7	a	O
8	potent	O
9	transcription	O
10	activator	O
11	and	O
12	may	O
13	function	O
14	to	O
15	regulate	O
16	the	O
17	expression	O
18	of	O
19	downstream	O
20	genes	O
21	in	O
22	response	O
23	to	O
24	extracellular	O
25	stimuli	O
26	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	Anabaena	O
6	strain	O
7	7120	O
8	leuA	B
9	gene	O
10	did	O
11	not	O
12	complement	O
13	the	O
14	nifV	B
15	mutation	I
16	of	O
17	R229I	O
18	efficiently	O
19	.	O

1	Recombinant	O
2	plasmid	O
3	pFV100	O
4	was	O
5	subsequently	O
6	isolated	O
7	by	O
8	its	O
9	ability	O
10	to	O
11	complement	O
12	B	O
13	-	O
14	band	O
15	expression	O
16	in	O
17	ge6	B
18	.	O

1	The	O
2	gene	O
3	(	O
4	ApxII	B
5	)	O
6	encoding	O
7	both	O
8	chloroplastic	B
9	ascorbate	I
10	peroxidase	I
11	isoenzymes	I
12	was	O
13	isolated	O
14	and	O
15	the	O
16	organization	O
17	of	O
18	the	O
19	gene	O
20	was	O
21	determined	O
22	.	O

1	Leukocyte	O
2	enzyme	O
3	activity	O
4	and	O
5	blood	O
6	lymphocyte	O
7	blast	O
8	transformation	O
9	in	O
10	chronic	O
11	bronchitis	O

1	In	O
2	gel	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	we	O
8	found	O
9	no	O
10	evidence	O
11	for	O
12	VDR	B
13	-	O
14	TR	B
15	heterodimer	O
16	interaction	O
17	with	O
18	any	O
19	tested	O
20	element	O
21	.	O

1	Seventy	O
2	-	O
3	one	O
4	supplementary	O
5	doses	O
6	of	O
7	vecuronium	O
8	were	O
9	used	O
10	for	O
11	muscle	O
12	relaxation	O
13	during	O
14	a	O
15	22	O
16	-	O
17	h	O
18	-	O
19	long	O
20	NLA	O
21	II	O
22	anaesthesia	O
23	.	O

1	However	O
2	,	O
3	Cbf5p	B
4	was	O
5	found	O
6	to	O
7	be	O
8	nucleolar	O
9	and	O
10	is	O
11	highly	O
12	homologous	O
13	to	O
14	the	O
15	rat	B
16	nucleolar	I
17	protein	I
18	NAP57	I
19	,	O
20	which	O
21	coimmunoprecipitates	O
22	with	O
23	Nopp140	B
24	and	O
25	which	O
26	is	O
27	postulated	O
28	to	O
29	be	O
30	involved	O
31	in	O
32	nucleolar	O
33	-	O
34	cytoplasmic	O
35	shuttling	O
36	(	O
37	U	O
38	.	O

1	Here	O
2	the	O
3	conventional	O
4	tests	O
5	clearly	O
6	pointed	O
7	to	O
8	the	O
9	presence	O
10	of	O
11	retrocochlear	O
12	disease	O
13	.	O

1	Effect	O
2	of	O
3	nitrous	O
4	oxide	O
5	(	O
6	N2O	O
7	)	O
8	on	O
9	the	O
10	somatosympathetic	O
11	A	O
12	-	O
13	and	O
14	C	O
15	-	O
16	reflexes	O
17	was	O
18	investigated	O
19	using	O
20	artificially	O
21	ventilated	O
22	rats	O
23	anesthetized	O
24	with	O
25	alpha	O
26	-	O
27	chloralose	O
28	and	O
29	urethane	O
30	.	O

1	"	O
2	In	O
3	vitro	O
4	"	O
5	study	O
6	of	O
7	dentin	O
8	adhesion	O
9	to	O
10	adhesives	O
11	made	O
12	from	O
13	urethane	O
14	molecules	O
15	with	O
16	free	O
17	groups	O
18	of	O
19	isocyanate	O

1	This	O
2	paper	O
3	gives	O
4	an	O
5	overview	O
6	of	O
7	the	O
8	global	O
9	pattern	O
10	of	O
11	casualties	O
12	in	O
13	earthquakes	O
14	which	O
15	occurred	O
16	during	O
17	the	O
18	30	O
19	-	O
20	month	O
21	period	O
22	from	O
23	1	O
24	September	O
25	1993	O
26	to	O
27	29	O
28	February	O
29	1996	O
30	.	O

1	Extracellular	B
2	-	I
3	regulated	I
4	kinase	I
5	(	O
6	ERK	B
7	)	O
8	activation	O
9	and	O
10	molecular	O
11	coupling	O
12	of	O
13	the	O
14	adaptor	O
15	proteins	O
16	p130	B
17	Crk	I
18	-	I
19	associated	I
20	substrate	I
21	(	O
22	CAS	B
23	)	O
24	and	O
25	c	B
26	-	I
27	CrkII	I
28	(	O
29	Crk	B
30	)	O
31	represent	O
32	two	O
33	distinct	O
34	pathways	O
35	that	O
36	induce	O
37	cell	O
38	invasion	O
39	and	O
40	protect	O
41	cells	O
42	from	O
43	apoptosis	O
44	in	O
45	a	O
46	three	O
47	-	O
48	dimensional	O
49	collagen	B
50	matrix	O
51	.	O

1	A	O
2	rapid	O
3	staining	O
4	technique	O
5	for	O
6	Leishmania	O
7	parasites	O
8	in	O
9	splenic	O
10	aspirate	O
11	smears	O
12	.	O

1	Our	O
2	findings	O
3	also	O
4	provide	O
5	the	O
6	basis	O
7	for	O
8	the	O
9	development	O
10	of	O
11	assays	O
12	to	O
13	screen	O
14	for	O
15	the	O
16	ligands	O
17	to	O
18	testis	B
19	receptor	I
20	2	I
21	and	O
22	hERR1	B
23	.	O

1	Northern	O
2	blotting	O
3	analysis	O
4	indicates	O
5	that	O
6	expression	O
7	of	O
8	the	O
9	genes	O
10	corresponding	O
11	to	O
12	these	O
13	clones	O
14	is	O
15	confined	O
16	to	O
17	pollen	O
18	tissue	O
19	.	O

1	Analysis	O
2	of	O
3	cell	O
4	cycle	O
5	proteins	O
6	showed	O
7	that	O
8	24	O
9	h	O
10	of	O
11	lovastatin	O
12	treatment	O
13	in	O
14	the	O
15	control	O
16	cells	O
17	caused	O
18	an	O
19	elevation	O
20	in	O
21	the	O
22	levels	O
23	of	O
24	the	O
25	cyclin	B
26	-	I
27	dependent	I
28	kinase	I
29	inhibitor	O
30	p27	B
31	(	O
32	kip1	B
33	),	O
34	inhibition	O
35	of	O
36	both	O
37	cyclin	B
38	E	I
39	-	I
40	and	I
41	cyclin	I
42	A	I
43	-	I
44	dependent	I
45	kinase	I
46	activity	O
47	,	O
48	and	O
49	decreased	O
50	levels	O
51	of	O
52	hyperphosphorylated	O
53	retinoblastoma	B
54	protein	I
55	(	O
56	pRb	B
57	).	O

1	Evaluation	O
2	of	O
3	the	O
4	new	O
5	Gravigard	O
6	IUCD	O
7	inserter	O
8	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	PPSF	O
6	+	O
7	DBP	O
8	side	O
9	showed	O
10	large	O
11	amounts	O
12	of	O
13	bone	O
14	formation	O
15	,	O
16	and	O
17	bone	O
18	almost	O
19	covered	O
20	the	O
21	implant	O
22	.	O

1	Serine	O
2	528	O
3	is	O
4	phosphorylated	O
5	in	O
6	vivo	O
7	in	O
8	several	O
9	cell	O
10	lines	O
11	,	O
12	and	O
13	substitution	O
14	of	O
15	serine	O
16	528	O
17	to	O
18	alanine	O
19	(	O
20	S528A	O
21	)	O
22	resulted	O
23	in	O
24	an	O
25	increased	O
26	ability	O
27	of	O
28	Myb	B
29	to	O
30	transactivate	O
31	a	O
32	synthetic	O
33	promoter	O
34	containing	O
35	five	O
36	copies	O
37	of	O
38	the	O
39	mim	B
40	-	I
41	1A	I
42	Myb	I
43	-	O
44	responsive	O
45	element	O
46	and	O
47	a	O
48	minimal	O
49	herpes	B
50	tk	I
51	promoter	I
52	.	O

1	The	O
2	need	O
3	for	O
4	including	O
5	forensic	O
6	medical	O
7	expertise	O
8	in	O
9	the	O
10	list	O
11	of	O
12	urgent	O
13	criminal	O
14	investigative	O
15	actions	O

1	These	O
2	results	O
3	show	O
4	that	O
5	targeting	O
6	of	O
7	Ras	B
8	-	O
9	GAP	B
10	could	O
11	represent	O
12	a	O
13	novel	O
14	anticancer	O
15	approach	O
16	.	O

1	We	O
2	propose	O
3	that	O
4	CTS1	B
5	and	I
6	CTS2	I
7	of	I
8	Ci	I
9	are	O
10	members	O
11	of	O
12	two	O
13	distinct	O
14	classes	O
15	of	O
16	fungal	B
17	chitinases	I
18	,	O
19	an	O
20	observation	O
21	not	O
22	previously	O
23	reported	O
24	for	O
25	a	O
26	single	O
27	fungus	O
28	.	O

1	Pyrrolidine	O
2	dithiocarbamate	O
3	,	O
4	a	O
5	potent	O
6	transcriptional	O
7	inhibitor	O
8	of	O
9	the	O
10	viral	B
11	LTR	I
12	,	O
13	abrogated	O
14	the	O
15	cytokine	O
16	responses	O
17	in	O
18	both	O
19	U1	O
20	and	O
21	ACH	O
22	-	O
23	2	O
24	cells	O
25	,	O
26	suggesting	O
27	a	O
28	common	O
29	TNF	B
30	-	I
31	alpha	I
32	-	O
33	mediated	O
34	transcriptional	O
35	mechanism	O
36	in	O
37	these	O
38	cell	O
39	types	O
40	despite	O
41	their	O
42	different	O
43	modes	O
44	of	O
45	provirus	O
46	latency	O
47	.	O

1	However	O
2	,	O
3	subcutaneously	O
4	administered	O
5	pneumococci	O
6	gave	O
7	a	O
8	lower	O
9	mortality	O
10	than	O
11	pneumococci	O
12	given	O
13	intravenously	O
14	or	O
15	intraperitoneally	O
16	.	O

1	A	O
2	genomic	O
3	clone	O
4	was	O
5	isolated	O
6	that	O
7	contained	O
8	12	O
9	.	O
10	5	O
11	kb	O
12	of	O
13	the	O
14	5	O
15	'-	O
16	flanking	O
17	region	O
18	and	O
19	the	O
20	first	O
21	exon	O
22	of	O
23	the	O
24	p69	B
25	/	I
26	71	I
27	2	I
28	-	I
29	5A	I
30	synthetase	I
31	gene	I
32	.	O

1	Therefore	O
2	,	O
3	it	O
4	is	O
5	important	O
6	to	O
7	control	O
8	hypertension	O
9	and	O
10	keep	O
11	appropriate	O
12	renal	O
13	blood	O
14	flow	O
15	during	O
16	living	O
17	renal	O
18	transplantation	O
19	surgery	O
20	.	O

1	Unexpectedly	O
2	,	O
3	ALK7	B
4	signaling	O
5	produced	O
6	a	O
7	remarkable	O
8	change	O
9	in	O
10	cell	O
11	morphology	O
12	characterized	O
13	by	O
14	cell	O
15	flattening	O
16	and	O
17	elaboration	O
18	of	O
19	blunt	O
20	,	O
21	short	O
22	cell	O
23	processes	O
24	.	O

1	Sex	O
2	ratio	O
3	at	O
4	birth	O
5	.	O

1	Identification	O
2	of	O
3	a	O
4	consensus	O
5	cyclin	B
6	-	I
7	dependent	I
8	kinase	I
9	phosphorylation	I
10	site	I
11	unique	O
12	to	O
13	the	O
14	nuclear	O
15	form	O
16	of	O
17	human	B
18	deoxyuridine	I
19	triphosphate	I
20	nucleotidohydrolase	I
21	.	O

1	Jerseys	O
2	had	O
3	higher	O
4	hepatic	O
5	Cu	O
6	concentrations	O
7	than	O
8	did	O
9	Holsteins	O
10	on	O
11	d	O
12	60	O
13	(	O
14	346	O
15	vs	O
16	.	O

1	The	O
2	yeast	O
3	gene	O
4	that	O
5	encodes	O
6	eIF	B
7	-	I
8	5	I
9	,	O
10	designated	O
11	TIF5	B
12	,	O
13	has	O
14	been	O
15	isolated	O
16	and	O
17	expressed	O
18	in	O
19	Escherichia	O
20	coli	O
21	to	O
22	yield	O
23	a	O
24	catalytically	O
25	active	O
26	eIF	B
27	-	I
28	5	I
29	protein	I
30	.	O

1	A	O
2	promising	O
3	new	O
4	cement	O
5	,	O
6	4	O
7	-	O
8	META	O
9	/	O
10	MMA	O
11	-	O
12	TBB	O
13	opaque	O
14	resin	O
15	,	O
16	has	O
17	shown	O
18	remarkable	O
19	adhesive	O
20	properties	O
21	as	O
22	a	O
23	bone	O
24	cement	O
25	in	O
26	vivo	O
27	.	O

1	Concomitantly	O
2	,	O
3	the	O
4	total	O
5	cellular	O
6	level	O
7	of	O
8	p21	B
9	increased	O
10	severalfold	O
11	via	O
12	a	O
13	posttranscriptional	O
14	mechanism	O
15	.	O

1	This	O
2	in	O
3	turn	O
4	will	O
5	further	O
6	enhance	O
7	the	O
8	role	O
9	of	O
10	meta	O
11	-	O
12	analysis	O
13	in	O
14	helping	O
15	clinicians	O
16	and	O
17	policy	O
18	makers	O
19	answer	O
20	clinical	O
21	questions	O
22	.	O

1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	AGA	O
6	group	O
7	,	O
8	both	O
9	fetal	O
10	and	O
11	maternal	O
12	serum	O
13	prolactin	B
14	concentration	O
15	increased	O
16	significantly	O
17	with	O
18	gestation	O
19	(	O
20	P	O
21	<	O
22	0	O
23	.	O
24	001	O
25	and	O
26	P	O
27	<	O
28	0	O
29	.	O
30	01	O
31	,	O
32	respectively	O
33	).	O

1	Three	O
2	of	O
3	these	O
4	subunits	O
5	are	O
6	also	O
7	homologous	O
8	to	O
9	the	O
10	dimeric	O
11	POR	B
12	from	O
13	a	O
14	mesophilic	O
15	archaeon	O
16	,	O
17	Halobacterium	O
18	halobium	O
19	(	O
20	21	O
21	%	O
22	identity	O
23	).	O

1	Using	O
2	purified	O
3	recombinant	B
4	HMG	I
5	I	I
6	,	O
7	we	O
8	have	O
9	identified	O
10	several	O
11	high	O
12	-	O
13	affinity	O
14	binding	O
15	sites	O
16	which	O
17	overlap	O
18	important	O
19	transcription	O
20	factor	O
21	binding	O
22	sites	O
23	.	O

1	At	O
2	the	O
3	very	O
4	high	O
5	dose	O
6	levels	O
7	used	O
8	,	O
9	sodium	O
10	saccharin	O
11	and	O
12	sodium	O
13	cyclamate	O
14	were	O
15	weak	O
16	solitary	O
17	carcinogens	O
18	producing	O
19	4	O
20	/	O
21	253	O
22	and	O
23	3	O
24	/	O
25	228	O
26	bladder	O
27	tumours	O
28	respectively	O
29	,	O
30	and	O
31	the	O
32	first	O
33	of	O
34	these	O
35	tumours	O
36	did	O
37	not	O
38	appear	O
39	for	O
40	more	O
41	than	O
42	80	O
43	weeks	O
44	.	O

1	Different	O
2	sequence	O
3	elements	O
4	of	O
5	both	O
6	the	O
7	retroviral	O
8	vectors	O
9	and	O
10	the	O
11	c	B
12	-	I
13	myc	I
14	gene	I
15	recombined	O
16	during	O
17	genesis	O
18	of	O
19	highly	O
20	oncogenic	O
21	retroviruses	O
22	CMII	O
23	,	O
24	MC29	O
25	,	O
26	or	O
27	MH2	O
28	.	O

1	These	O
2	six	O
3	amino	O
4	acids	O
5	are	O
6	part	O
7	of	O
8	an	O
9	amphipathic	O
10	helix	O
11	that	O
12	is	O
13	highly	O
14	conserved	O
15	among	O
16	nuclear	B
17	hormone	I
18	receptors	I
19	and	O
20	contains	O
21	the	O
22	core	O
23	domain	O
24	of	O
25	the	O
26	ligand	O
27	-	O
28	dependent	O
29	transactivation	O
30	function	O
31	,	O
32	AF	O
33	-	O
34	2	O
35	.	O

1	Using	O
2	appropriate	O
3	synthetic	O
4	HSE	O
5	oligonucleotides	O
6	,	O
7	three	O
8	types	O
9	of	O
10	clones	O
11	with	O
12	potential	O
13	HSE	O
14	binding	O
15	domains	O
16	were	O
17	isolated	O
18	from	O
19	a	O
20	tomato	O
21	lambda	O
22	gt11	O
23	expression	O
24	library	O
25	by	O
26	DNA	O
27	-	O
28	ligand	O
29	screening	O
30	.	O

1	Furthermore	O
2	,	O
3	this	O
4	study	O
5	demonstrates	O
6	that	O
7	reduced	O
8	inotropy	O
9	with	O
10	timolol	O
11	helped	O
12	uniform	O
13	local	O
14	contraction	O
15	as	O
16	estimated	O
17	by	O
18	the	O
19	increased	O
20	LONG	O
21	/	O
22	CIRC	O
23	ratio	O
24	,	O
25	a	O
26	transition	O
27	that	O
28	could	O
29	improve	O
30	contraction	O
31	efficacy	O
32	.	O

1	Despite	O
2	the	O
3	existence	O
4	of	O
5	30	O
6	cysteine	O
7	residues	O
8	,	O
9	carboxymethylation	O
10	prevented	O
11	the	O
12	formation	O
13	of	O
14	most	O
15	if	O
16	not	O
17	all	O
18	disulfide	O
19	bonds	O
20	that	O
21	otherwise	O
22	occurred	O
23	when	O
24	the	O
25	cells	O
26	were	O
27	sonicated	O
28	.	O

1	BACKGROUND	O
2	:	O
3	Left	O
4	ventricular	O
5	hypertrophy	O
6	is	O
7	a	O
8	heterogeneous	O
9	disorder	O
10	with	O
11	distinct	O
12	morphologies	O
13	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	data	O
6	indicate	O
7	that	O
8	the	O
9	VirD2	B
10	omega	I
11	domain	I
12	is	O
13	important	O
14	for	O
15	efficient	O
16	T	O
17	-	O
18	DNA	O
19	integration	O
20	.	O

1	The	O
2	thrombolytic	O
3	effects	O
4	of	O
5	native	O
6	tissue	B
7	-	I
8	type	I
9	plasminogen	I
10	activator	I
11	(	O
12	AK	B
13	-	I
14	124	I
15	)	O
16	on	O
17	experimental	O
18	canine	O
19	coronary	O
20	thrombosis	O
21	.	O

1	Effect	O
2	of	O
3	corticosteroid	O
4	-	O
5	containing	O
6	antirheumatic	O
7	combination	O
8	drugs	O
9	on	O
10	endogenous	O
11	ACTH	B
12	and	O
13	cortisol	O
14	production	O
15	.	O

1	Activation	O
2	of	O
3	nuclear	B
4	factor	I
5	(	I
6	NF	I
7	)-	I
8	kappaB	I
9	and	O
10	subsequent	O
11	proinflammatory	O
12	gene	O
13	expression	O
14	in	O
15	human	O
16	airway	O
17	epithelial	O
18	cells	O
19	can	O
20	be	O
21	evoked	O
22	by	O
23	oxidative	O
24	stress	O
25	.	O

1	No	O
2	UOxase	B
3	mRNA	I
4	was	O
5	detected	O
6	in	O
7	11	O
8	nonhepatic	O
9	tissues	O
10	of	O
11	rat	O
12	,	O
13	suggesting	O
14	tissue	O
15	specificity	O
16	of	O
17	expression	O
18	of	O
19	this	O
20	UOxase	B
21	gene	I
22	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	new	O
6	human	B
7	RING	I
8	-	I
9	finger	I
10	gene	I
11	(	O
12	RNF4	B
13	)	O
14	that	O
15	encodes	O
16	a	O
17	190	O
18	-	O
19	amino	O
20	-	O
21	acid	O
22	protein	O
23	.	O

1	Clones	O
2	that	O
3	expressed	O
4	DBD	O
5	exhibited	O
6	a	O
7	dominant	O
8	negative	O
9	phenotype	O
10	and	O
11	did	O
12	not	O
13	elicit	O
14	antiviral	O
15	activity	O
16	against	O
17	vesicular	O
18	stomatitis	O
19	virus	O
20	(	O
21	VSV	O
22	)	O
23	infection	O
24	upon	O
25	IFN	B
26	treatment	O
27	.	O

1	Eleven	O
2	biopsy	O
3	specimens	O
4	(	O
5	five	O
6	papules	O
7	and	O
8	six	O
9	dusky	O
10	or	O
11	crusted	O
12	lesions	O
13	)	O
14	from	O
15	four	O
16	patients	O
17	with	O
18	pityriasis	O
19	lichenoides	O
20	et	O
21	varioliformis	O
22	acuta	O
23	(	O
24	PLEVA	O
25	)	O
26	were	O
27	studied	O
28	by	O
29	direct	O
30	immunofluorescence	O
31	and	O
32	immunoperoxidase	B
33	technics	O
34	.	O

1	Transient	O
2	co	O
3	-	O
4	transfection	O
5	assays	O
6	involving	O
7	NFKB2	B
8	expression	O
9	vectors	O
10	and	O
11	kappa	B
12	B	I
13	-	O
14	driven	O
15	reporter	O
16	plasmids	O
17	indicate	O
18	that	O
19	NFKB2	B
20	p85	I
21	has	O
22	lost	O
23	the	O
24	transcriptional	O
25	repressor	O
26	functions	O
27	typical	O
28	of	O
29	normal	O
30	NFKB2	B
31	p52	I
32	.	O

1	Drugs	O
2	suppressed	O
3	>	O
4	or	O
5	=	O
6	75	O
7	%	O
8	of	O
9	the	O
10	total	O
11	premature	O
12	ventricular	O
13	contractions	O
14	in	O
15	all	O
16	patients	O
17	who	O
18	had	O
19	both	O
20	use	O
21	-	O
22	dependent	O
23	QRS	O
24	prolongation	O
25	and	O
26	reverse	O
27	use	O
28	-	O
29	dependent	O
30	QT	O
31	prolongation	O
32	,	O
33	in	O
34	79	O
35	%	O
36	of	O
37	patients	O
38	with	O
39	use	O
40	-	O
41	dependent	O
42	QRS	O
43	prolongation	O
44	alone	O
45	,	O
46	in	O
47	70	O
48	%	O
49	with	O
50	reverse	O
51	use	O
52	-	O
53	dependent	O
54	QT	O
55	prolongation	O
56	alone	O
57	,	O
58	and	O
59	in	O
60	11	O
61	%	O
62	with	O
63	neither	O
64	use	O
65	-	O
66	dependent	O
67	QRS	O
68	prolongation	O
69	nor	O
70	reverse	O
71	use	O
72	-	O
73	dependent	O
74	QT	O
75	prolongation	O
76	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'-	O
7	flanking	O
8	region	O
9	of	O
10	the	O
11	CD69	B
12	gene	I
13	revealed	O
14	the	O
15	presence	O
16	of	O
17	a	O
18	potential	O
19	TATA	O
20	element	O
21	30	O
22	base	O
23	pairs	O
24	upstream	O
25	of	O
26	the	O
27	major	O
28	transcription	O
29	initiation	O
30	site	O
31	and	O
32	several	O
33	putative	O
34	binding	O
35	sequences	O
36	for	O
37	inducible	O
38	transcription	O
39	factors	O
40	(	O
41	NF	B
42	-	I
43	kappa	I
44	B	I
45	,	O
46	Egr	B
47	-	I
48	1	I
49	,	O
50	AP	B
51	-	I
52	1	I
53	),	O
54	which	O
55	might	O
56	mediate	O
57	the	O
58	inducible	O
59	expression	O
60	of	O
61	this	O
62	gene	O
63	.	O

1	A	O
2	DNA	O
3	fragment	O
4	carrying	O
5	1	O
6	,	O
7	100	O
8	nucleotides	O
9	derived	O
10	from	O
11	the	O
12	5	O
13	'-	O
14	flanking	O
15	region	O
16	of	O
17	the	O
18	UGT1A1	B
19	gene	I
20	was	O
21	enough	O
22	for	O
23	MC	O
24	induction	O
25	.	O

1	One	O
2	patient	O
3	only	O
4	had	O
5	any	O
6	test	O
7	abnormalities	O
8	.	O

1	The	O
2	possibility	O
3	of	O
4	selective	O
5	chemotherapy	O
6	of	O
7	progressive	O
8	recurring	O
9	ovarian	O
10	carcinoma	O
11	with	O
12	the	O
13	aid	O
14	of	O
15	cytodiagnosis	O
16	and	O
17	incorporation	O
18	of	O
19	tagged	O
20	idoxuridine	O

1	CONCLUSION	O
2	:	O
3	Our	O
4	results	O
5	suggest	O
6	that	O
7	AIF	O
8	peak	O
9	saturation	O
10	leads	O
11	to	O
12	a	O
13	significant	O
14	systematic	O
15	error	O
16	in	O
17	the	O
18	determination	O
19	of	O
20	CBV	O
21	and	O
22	CBF	O
23	values	O
24	and	O
25	has	O
26	necessarily	O
27	to	O
28	be	O
29	taken	O
30	into	O
31	account	O
32	for	O
33	dynamic	O
34	contrast	O
35	-	O
36	enhanced	O
37	MR	O
38	perfusion	O
39	studies	O
40	.	O

1	Studies	O
2	carried	O
3	out	O
4	with	O
5	the	O
6	Glossina	O
7	morsitans	O
8	colony	O
9	of	O
10	Lisbon	O
11	.	O

1	We	O
2	have	O
3	performed	O
4	toeprinting	O
5	analyses	O
6	on	O
7	repA	B
8	mRNA	I
9	of	O
10	plasmid	O
11	R1	O
12	,	O
13	both	O
14	free	O
15	and	O
16	in	O
17	duplex	O
18	with	O
19	the	O
20	antisense	O
21	RNA	O
22	,	O
23	CopA	B
24	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	mutants	O
6	were	O
7	strongly	O
8	dominant	O
9	over	O
10	TraR	B
11	,	O
12	suggesting	O
13	that	O
14	they	O
15	can	O
16	form	O
17	heteromultimers	O
18	with	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	activator	O
24	.	O

1	They	O
2	also	O
3	occur	O
4	in	O
5	similar	O
6	locations	O
7	in	O
8	the	O
9	promoters	O
10	of	O
11	several	O
12	other	O
13	ribosomal	B
14	protein	I
15	genes	I
16	.	O

1	Double	O
2	mutant	O
3	analysis	O
4	suggests	O
5	that	O
6	Rad54p	B
7	and	O
8	Mus81p	B
9	act	O
10	in	O
11	one	O
12	pathway	O
13	for	O
14	the	O
15	repair	O
16	of	O
17	,	O
18	or	O
19	tolerance	O
20	to	O
21	,	O
22	UV	O
23	-	O
24	induced	O
25	DNA	O
26	damage	O
27	.	O

1	Urease	B
2	activity	O
3	,	O
4	judged	O
5	as	O
6	the	O
7	amount	O
8	of	O
9	ammonia	O
10	production	O
11	from	O
12	urea	O
13	,	O
14	could	O
15	be	O
16	measured	O
17	at	O
18	25	O
19	ng	O
20	per	O
21	tube	O
22	(	O
23	S	O
24	/	O
25	N	O
26	=	O
27	1	O
28	.	O
29	5	O
30	)	O
31	with	O
32	Jack	B
33	bean	I
34	meal	I
35	urease	I
36	.	O

1	We	O
2	remain	O
3	convinced	O
4	that	O
5	antilymphocyte	B
6	globulin	I
7	(	O
8	ALG	B
9	)	O
10	is	O
11	a	O
12	potent	O
13	immunosuppressive	O
14	agent	O
15	in	O
16	humans	O
17	.	O

1	Drugs	O
2	that	O
3	are	O
4	transformed	O
5	via	O
6	phase	O
7	II	O
8	reactions	O
9	usually	O
10	do	O
11	not	O
12	require	O
13	dosage	O
14	adjustment	O
15	.	O

1	A	O
2	concentration	O
3	of	O
4	12	O
5	.	O
6	5	O
7	ppm	O
8	SO2	O
9	induced	O
10	a	O
11	decrease	O
12	from	O
13	baseline	O
14	values	O
15	of	O
16	approximately	O
17	80	O
18	%	O
19	in	O
20	mean	O
21	MCA	O
22	and	O
23	of	O
24	roughly	O
25	70	O
26	%	O
27	in	O
28	mean	O
29	CBF	O
30	.	O

1	They	O
2	also	O
3	negatively	O
4	modulate	O
5	the	O
6	PI	B
7	3	I
8	-	I
9	kinase	I
10	catalytic	O
11	activity	O
12	but	O
13	to	O
14	different	O
15	extents	O
16	,	O
17	dependent	O
18	on	O
19	the	O
20	unique	O
21	N	O
22	-	O
23	terminal	O
24	structure	O
25	of	O
26	each	O
27	isoform	O
28	.	O

1	A	O
2	particularly	O
3	striking	O
4	HpaII	B
5	tiny	O
6	fragment	O
7	island	O
8	,	O
9	extending	O
10	over	O
11	nearly	O
12	2	O
13	,	O
14	000	O
15	base	O
16	pairs	O
17	,	O
18	surrounds	O
19	the	O
20	USF2	B
21	translation	I
22	initiation	I
23	site	I
24	.	O

1	We	O
2	examined	O
3	the	O
4	effects	O
5	of	O
6	long	O
7	-	O
8	term	O
9	perfusion	O
10	with	O
11	pyridoxalated	O
12	hemoglobin	B
13	polyoxyethylene	O
14	conjugate	O
15	(	O
16	PHP	O
17	)	O
18	solution	O
19	on	O
20	cardiac	O
21	function	O
22	of	O
23	isolated	O
24	rat	O
25	hearts	O
26	.	O

1	A	O
2	crucial	O
3	transcription	O
4	factor	O
5	in	O
6	this	O
7	process	O
8	is	O
9	STAT6	B
10	,	O
11	which	O
12	binds	O
13	to	O
14	a	O
15	specific	O
16	DNA	O
17	element	O
18	upon	O
19	cytokine	O
20	activation	O
21	.	O

1	These	O
2	data	O
3	show	O
4	that	O
5	PTH	B
6	and	O
7	cAMP	O
8	can	O
9	repress	O
10	collagen	B
11	promoter	I
12	activity	O
13	in	O
14	calvariae	O
15	from	O
16	transgenic	O
17	mice	O
18	,	O
19	suggesting	O
20	that	O
21	the	O
22	alpha	B
23	1	I
24	(	I
25	I	I
26	)	I
27	collagen	I
28	promoter	I
29	may	O
30	contain	O
31	cis	O
32	elements	O
33	down	O
34	-	O
35	stream	O
36	of	O
37	-	O
38	2	O
39	.	O
40	3	O
41	kilobases	O
42	that	O
43	mediate	O
44	PTH	B
45	and	O
46	cAMP	O
47	repression	O
48	of	O
49	collagen	B
50	gene	I
51	expression	O
52	in	O
53	bone	O
54	.	O

1	Chronic	O
2	hypophosphatemia	O
3	is	O
4	the	O
5	most	O
6	common	O
7	type	O
8	of	O
9	"	O
10	resistant	O
11	"	O
12	rickets	O
13	.	O

1	The	O
2	two	O
3	larger	O
4	peptides	O
5	,	O
6	one	O
7	containing	O
8	amino	O
9	acids	O
10	1	O
11	-	O
12	228	O
13	and	O
14	the	O
15	other	O
16	containing	O
17	amino	O
18	acids	O
19	85	O
20	-	O
21	228	O
22	,	O
23	formed	O
24	dimers	O
25	in	O
26	solution	O
27	and	O
28	bound	O
29	DNA	O
30	specifically	O
31	as	O
32	a	O
33	dimer	O
34	.	O

1	Active	O
2	lambda	B
3	and	I
4	kappa	I
5	antibody	I
6	gene	I
7	rearrangement	O
8	in	O
9	Abelson	O
10	murine	O
11	leukemia	O
12	virus	O
13	-	O
14	transformed	O
15	pre	O
16	-	O
17	B	O
18	cell	O
19	lines	O
20	.	O

1	The	O
2	median	O
3	durations	O
4	for	O
5	response	O
6	and	O
7	survival	O
8	time	O
9	in	O
10	the	O
11	late	O
12	phase	O
13	II	O
14	trial	O
15	were	O
16	2	O
17	.	O
18	3	O
19	months	O
20	and	O
21	5	O
22	.	O
23	8	O
24	months	O
25	,	O
26	respectively	O
27	.	O

1	Orthop	O
2	.	O

1	Pilot	O
2	study	O
3	of	O
4	blood	O
5	coagulation	O
6	in	O
7	gout	O
8	patients	O
9	.	O

1	It	O
2	is	O
3	,	O
4	however	O
5	,	O
6	extremely	O
7	homologous	O
8	to	O
9	a	O
10	third	O
11	'	O
12	non	O
13	-	O
14	classical	O
15	'	O
16	gene	O
17	,	O
18	HLA	B
19	-	I
20	5	I
21	.	I
22	4	I
23	,	O
24	and	O
25	to	O
26	the	O
27	chimpanzee	O
28	gene	O
29	,	O
30	Ch28	B
31	.	O

1	An	O
2	in	O
3	vitro	O
4	binding	O
5	site	O
6	selection	O
7	procedure	O
8	was	O
9	used	O
10	to	O
11	determine	O
12	DNA	O
13	sequences	O
14	preferentially	O
15	bound	O
16	by	O
17	wild	B
18	-	I
19	type	I
20	HLF	I
21	and	O
22	chimeric	O
23	E2A	B
24	-	O
25	HLF	B
26	proteins	O
27	isolated	O
28	from	O
29	various	O
30	t	O
31	(	O
32	17	O
33	;	O
34	19	O
35	)-	O
36	bearing	O
37	leukemias	O
38	.	O

1	All	O
2	problems	O
3	were	O
4	associated	O
5	with	O
6	fractured	O
7	or	O
8	lost	O
9	screws	O
10	.	O

1	The	O
2	experiment	O
3	results	O
4	showed	O
5	:	O
6	(	O
7	i	O
8	)	O
9	not	O
10	only	O
11	1O2	O
12	,	O
13	but	O
14	also	O
15	free	O
16	radicals	O
17	(	O
18	O2	O
19	-.	O
20	.	O
21	OH	O
22	and	O
23	YHPD	O
24	-.)	O
25	can	O
26	be	O
27	formed	O
28	by	O
29	the	O
30	aid	O
31	of	O
32	YHPD	O
33	;	O
34	and	O
35	(	O
36	ii	O
37	)	O
38	as	O
39	to	O
40	the	O
41	ability	O
42	of	O
43	producing	O
44	1O2	O
45	,	O
46	YHPD	O
47	less	O
48	than	O
49	BHPD	O
50	,	O
51	while	O
52	for	O
53	generating	O
54	O2	O
55	-.	O
56	and	O
57	.	O
58	OH	O
59	,	O
60	YHPD	O
61	greater	O
62	than	O
63	BHPD	O
64	.	O

1	Polypeptide	O
2	growth	O
3	factors	O
4	and	O
5	cytokines	O
6	mediate	O
7	their	O
8	biochemical	O
9	functions	O
10	through	O
11	their	O
12	responsive	O
13	receptors	O
14	.	O

1	However	O
2	,	O
3	we	O
4	identified	O
5	a	O
6	gene	O
7	between	O
8	the	O
9	MDV2	B
10	UL54	I
11	and	O
12	UL55	B
13	genes	I
14	with	O
15	homology	O
16	to	O
17	the	O
18	first	B
19	ORF	I
20	(	I
21	ORF	I
22	-	I
23	1	I
24	)	I
25	of	I
26	equine	I
27	herpesvirus	I
28	type	I
29	1	I
30	and	O
31	corresponding	O
32	gene	O
33	identified	O
34	in	O
35	pseudorabies	O
36	virus	O
37	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	investigate	O
9	the	O
10	spontaneous	O
11	reports	O
12	of	O
13	suspected	O
14	adverse	O
15	drug	O
16	reactions	O
17	,	O
18	observed	O
19	in	O
20	elderly	O
21	patients	O
22	(	O
23	over	O
24	65	O
25	years	O
26	of	O
27	age	O
28	)	O
29	in	O
30	Sicily	O
31	(	O
32	Italy	O
33	)	O
34	during	O
35	the	O
36	period	O
37	from	O
38	1	O
39	January	O
40	1995	O
41	to	O
42	31	O
43	December	O
44	1997	O
45	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	MAZE	O
5	-	O
6	III	O
7	is	O
8	the	O
9	surgical	O
10	treatment	O
11	of	O
12	choice	O
13	for	O
14	medically	O
15	refractory	O
16	atrial	O
17	fibrillation	O
18	.	O

1	Of	O
2	49	O
3	receptors	O
4	which	O
5	fired	O
6	in	O
7	phase	O
8	with	O
9	ventilation	O
10	,	O
11	13	O
12	behaved	O
13	like	O
14	mammalian	O
15	rapidly	O
16	adapting	O
17	pulmonary	O
18	stretch	O
19	receptors	O
20	,	O
21	19	O
22	like	O
23	mammalian	O
24	slowly	O
25	adapting	O
26	pulmonary	O
27	stretch	O
28	receptors	O
29	(	O
30	PSR	O
31	),	O
32	and	O
33	17	O
34	like	O
35	avian	O
36	intrapulmonary	O
37	CO2	O
38	-	O
39	sensitive	O
40	chemoreceptors	O
41	(	O
42	IPC	O
43	).	O

1	The	O
2	present	O
3	studies	O
4	compare	O
5	the	O
6	biochemical	O
7	characteristics	O
8	,	O
9	Kanagawa	O
10	hemolysin	B
11	reactions	O
12	,	O
13	and	O
14	plasmid	O
15	profiles	O
16	of	O
17	13	O
18	patient	O
19	and	O
20	221	O
21	environmental	O
22	isolates	O
23	of	O
24	the	O
25	organism	O
26	.	O

1	We	O
2	have	O
3	isolated	O
4	three	O
5	mutant	O
6	alleles	O
7	of	O
8	CDC4	B
9	(	O
10	cdc4	B
11	-	I
12	10	I
13	,	O
14	cdc4	B
15	-	I
16	11	I
17	,	O
18	and	O
19	cdc4	B
20	-	I
21	16	I
22	)	O
23	which	O
24	suppress	O
25	the	O
26	nuclear	O
27	division	O
28	defect	O
29	of	O
30	cdc20	B
31	-	I
32	1	I
33	cells	O
34	.	O

1	The	O
2	most	O
3	common	O
4	types	O
5	of	O
6	malformations	O
7	were	O
8	eye	O
9	defects	O
10	and	O
11	open	O
12	coeloms	O
13	.	O

1	Crohn	O
2	'	O
3	s	O
4	disease	O
5	in	O
6	prolonged	O
7	remission	O
8	:	O
9	should	O
10	one	O
11	augment	O
12	protein	O
13	-	O
14	calorie	O
15	intake	O
16	as	O
17	compared	O
18	to	O
19	healthy	O
20	subjects	O
21	?]	O
22	The	O
23	aim	O
24	of	O
25	our	O
26	two	O
27	year	O
28	prospective	O
29	study	O
30	was	O
31	to	O
32	evaluate	O
33	whether	O
34	adult	O
35	Crohn	O
36	'	O
37	s	O
38	disease	O
39	patients	O
40	in	O
41	prolonged	O
42	remission	O
43	(	O
44	CDAI	O
45	<	O
46	150	O
47	),	O
48	in	O
49	order	O
50	to	O
51	maintain	O
52	their	O
53	body	O
54	weight	O
55	as	O
56	close	O
57	as	O
58	possible	O
59	to	O
60	the	O
61	ideal	O
62	one	O
63	,	O
64	need	O
65	a	O
66	protein	O
67	-	O
68	calorie	O
69	intake	O
70	higher	O
71	than	O
72	the	O
73	predicted	O
74	one	O
75	and	O
76	that	O
77	of	O
78	healthy	O
79	controls	O
80	.	O

1	The	O
2	effect	O
3	of	O
4	sodium	O
5	18	O
6	beta	O
7	-	O
8	glycyrrhetate	O
9	(	O
10	SGA	O
11	)	O
12	on	O
13	experimental	O
14	arrhythmia	O
15	was	O
16	investigated	O
17	.	O

1	A	O
2	pre	O
3	-	O
4	boutonniere	O
5	deformity	O
6	was	O
7	simulated	O
8	by	O
9	dividing	O
10	the	O
11	central	O
12	slip	O
13	.	O

1	This	O
2	suggests	O
3	that	O
4	cardiovascular	O
5	magnetic	O
6	resonance	O
7	is	O
8	the	O
9	preferred	O
10	technique	O
11	for	O
12	volume	O
13	and	O
14	ejection	O
15	fraction	O
16	estimation	O
17	in	O
18	heart	O
19	failure	O
20	patients	O
21	,	O
22	because	O
23	of	O
24	its	O
25	3D	O
26	approach	O
27	for	O
28	non	O
29	-	O
30	symmetric	O
31	ventricles	O
32	and	O
33	superior	O
34	image	O
35	quality	O
36	.	O

1	TcPO2	O
2	measurement	O
3	appears	O
4	to	O
5	be	O
6	a	O
7	reliable	O
8	technique	O
9	that	O
10	can	O
11	influence	O
12	ischaemic	O
13	ulcer	O
14	management	O
15	.	O

1	Hybrid	O
2	female	O
3	mice	O
4	(	O
5	C57BL	O
6	x	O
7	CBA	O
8	)	O
9	were	O
10	paired	O
11	with	O
12	breeder	O
13	males	O
14	(	O
15	CD	O
16	-	O
17	1	O
18	)	O
19	and	O
20	LNG	O
21	pellets	O
22	were	O
23	implanted	O
24	on	O
25	day	O
26	0	O
27	,	O
28	the	O
29	day	O
30	on	O
31	which	O
32	copulation	O
33	plugs	O
34	were	O
35	found	O
36	,	O
37	or	O
38	on	O
39	day	O
40	2	O
41	or	O
42	day	O
43	3	O
44	in	O
45	the	O
46	postcoital	O
47	period	O
48	.	O

1	Scanning	O
2	mutations	O
3	throughout	O
4	the	O
5	AC	O
6	element	O
7	interfered	O
8	with	O
9	induction	O
10	but	O
11	allowed	O
12	us	O
13	to	O
14	define	O
15	five	O
16	overlapping	O
17	sites	O
18	for	O
19	regulatory	O
20	factors	O
21	in	O
22	AC	O
23	and	O
24	to	O
25	design	O
26	probes	O
27	binding	O
28	just	O
29	one	O
30	or	O
31	two	O
32	factors	O
33	.	O

1	We	O
2	conclude	O
3	from	O
4	these	O
5	studies	O
6	that	O
7	CKII	B
8	may	O
9	act	O
10	as	O
11	a	O
12	positive	O
13	regulator	O
14	of	O
15	myogenesis	O
16	by	O
17	preventing	O
18	E	B
19	protein	I
20	homodimers	I
21	from	O
22	binding	O
23	to	O
24	muscle	O
25	gene	O
26	regulatory	O
27	elements	O
28	.	O

1	Mapping	O
2	of	O
3	the	O
4	mouse	B
5	ornithine	I
6	decarboxylase	I
7	-	I
8	related	I
9	sequence	I
10	family	I
11	.	O

1	Gel	O
2	route	O
3	preparation	O
4	of	O
5	low	O
6	fusing	O
7	dental	O
8	porcelain	O
9	frit	O
10	.	O

1	Prognosis	O
2	of	O
3	asymptomatic	O
4	multiple	O
5	myeloma	O
6	.	O

1	However	O
2	,	O
3	an	O
4	intrinsic	O
5	DNA	O
6	-	O
7	binding	O
8	subunit	O
9	for	O
10	HiNF	B
11	-	I
12	D	I
13	was	O
14	not	O
15	identified	O
16	.	O

1	PPAR	B
2	gamma	I
3	mRNA	I
4	levels	O
5	were	O
6	reduced	O
7	by	O
8	95	O
9	%	O
10	with	O
11	3	O
12	nM	O
13	TNF	B
14	alpha	I
15	treatment	O
16	for	O
17	24	O
18	h	O
19	.	O

1	Furthermore	O
2	,	O
3	in	O
4	the	O
5	ischemia	O
6	/	O
7	angiotension	B
8	II	I
9	-	O
10	induced	O
11	AHF	O
12	model	O
13	,	O
14	NIC	O
15	decreased	O
16	left	O
17	ventricular	O
18	end	O
19	-	O
20	diastolic	O
21	pressure	O
22	(	O
23	LVEDP	O
24	).	O

1	These	O
2	findings	O
3	indicate	O
4	that	O
5	autophosphorylation	O
6	of	O
7	Thr286	O
8	(	O
9	alpha	O
10	subunit	O
11	)	O
12	and	O
13	Thr287	O
14	(	O
15	beta	O
16	subunit	O
17	)	O
18	is	O
19	responsible	O
20	for	O
21	transition	O
22	of	O
23	CaM	B
24	-	I
25	kinase	I
26	II	I
27	to	O
28	the	O
29	Ca2	O
30	+-	O
31	independent	O
32	form	O
33	.	O

1	We	O
2	found	O
3	that	O
4	lung	O
5	cancer	O
6	tissues	O
7	of	O
8	positive	O
9	67Ga	O
10	scan	O
11	expressed	O
12	TFR	B
13	,	O
14	but	O
15	those	O
16	of	O
17	a	O
18	negative	O
19	scan	O
20	did	O
21	not	O
22	.	O

1	The	O
2	size	O
3	discrepancy	O
4	is	O
5	not	O
6	due	O
7	to	O
8	glycosylation	O
9	or	O
10	phosphorylation	O
11	of	O
12	Ag35	B
13	but	O
14	may	O
15	result	O
16	from	O
17	a	O
18	proline	O
19	-	O
20	rich	O
21	sequence	O
22	which	O
23	occurs	O
24	in	O
25	this	O
26	polypeptide	O
27	.	O

1	Interaction	O
2	was	O
3	apparently	O
4	determined	O
5	by	O
6	the	O
7	N	O
8	-	O
9	terminal	O
10	splice	O
11	region	O
12	of	O
13	RPDE	B
14	-	I
15	6	I
16	,	O
17	as	O
18	the	O
19	PDE4A	B
20	splice	O
21	variant	O
22	RPDE	B
23	-	I
24	39	I
25	,	O
26	which	O
27	differs	O
28	from	O
29	RPDE	B
30	-	I
31	6	I
32	at	O
33	the	O
34	extreme	O
35	N	O
36	-	O
37	terminus	O
38	,	O
39	failed	O
40	to	O
41	associate	O
42	with	O
43	v	B
44	-	I
45	Src	I
46	-	O
47	SH3	B
48	;	O
49	met26RD1	B
50	(	O
51	where	O
52	RD1	B
53	is	O
54	rat	B
55	'	I
56	dunc	I
57	-	I
58	like	I
59	'	I
60	PDE	I
61	),	O
62	which	O
63	has	O
64	the	O
65	N	O
66	-	O
67	terminal	O
68	splice	O
69	region	O
70	deleted	O
71	,	O
72	failed	O
73	to	O
74	associate	O
75	with	O
76	v	B
77	-	I
78	Src	I
79	-	O
80	SH3	B
81	,	O
82	and	O
83	the	O
84	association	O
85	of	O
86	RPDE	B
87	-	I
88	6	I
89	and	O
90	v	B
91	-	I
92	Src	I
93	-	O
94	SH3	B
95	was	O
96	blocked	O
97	by	O
98	a	O
99	fusion	O
100	protein	O
101	formed	O
102	from	O
103	the	O
104	N	O
105	-	O
106	terminal	O
107	splice	O
108	region	O
109	.	O

1	Women	O
2	'	O
3	s	O
4	opportunities	O
5	for	O
6	paid	O
7	work	O
8	outside	O
9	the	O
10	home	O
11	are	O
12	constrained	O
13	by	O
14	their	O
15	role	O
16	as	O
17	primary	O
18	carer	O
19	within	O
20	the	O
21	family	O
22	,	O
23	writes	O
24	Trudy	O
25	Wynne	O
26	.	O

1	Activation	O
2	of	O
3	the	O
4	SH2	B
5	-	I
6	containing	I
7	protein	I
8	tyrosine	I
9	phosphatase	I
10	,	O
11	SH	B
12	-	I
13	PTP2	I
14	,	O
15	by	O
16	phosphotyrosine	O
17	-	O
18	containing	O
19	peptides	O
20	derived	O
21	from	O
22	insulin	B
23	receptor	I
24	substrate	I
25	-	I
26	1	I
27	.	O

1	Only	O
2	seven	O
3	patients	O
4	,	O
5	five	O
6	of	O
7	whom	O
8	have	O
9	metastatic	O
10	disease	O
11	,	O
12	survive	O
13	more	O
14	than	O
15	10	O
16	years	O
17	after	O
18	first	O
19	presentation	O
20	;	O
21	nine	O
22	patients	O
23	,	O
24	one	O
25	of	O
26	whom	O
27	has	O
28	secondaries	O
29	,	O
30	survive	O
31	for	O
32	5	O
33	years	O
34	or	O
35	less	O
36	.	O

1	Ligand	O
2	binding	O
3	to	O
4	the	O
5	receptor	O
6	complex	O
7	leads	O
8	to	O
9	tyrosine	O
10	phosphorylation	O
11	and	O
12	activation	O
13	of	O
14	Janus	B
15	kinases	I
16	(	O
17	Jak	B
18	),	O
19	phosphorylation	O
20	of	O
21	the	O
22	signal	B
23	transducing	I
24	subunit	I
25	gp130	I
26	,	O
27	followed	O
28	by	O
29	recruitment	O
30	and	O
31	phosphorylation	O
32	of	O
33	the	O
34	signal	B
35	transducer	I
36	and	I
37	activator	I
38	of	I
39	transcription	I
40	factors	I
41	STAT3	I
42	and	O
43	STAT1	B
44	and	O
45	the	O
46	src	B
47	homology	I
48	domain	I
49	(	O
50	SH2	B
51	)-	O
52	containing	O
53	protein	B
54	tyrosine	I
55	phosphatase	I
56	(	O
57	SHP2	B
58	).	O

1	The	O
2	FBF	O
3	questionnaire	O
4	did	O
5	not	O
6	highlight	O
7	a	O
8	characteristic	O
9	basic	O
10	symptoms	O
11	profile	O
12	of	O
13	schizoaffective	O
14	disorder	O
15	,	O
16	when	O
17	compared	O
18	with	O
19	bipolar	O
20	affective	O
21	disorder	O
22	and	O
23	schizophrenia	O
24	.	O

1	Our	O
2	study	O
3	differs	O
4	from	O
5	previous	O
6	studies	O
7	in	O
8	that	O
9	it	O
10	is	O
11	limited	O
12	to	O
13	one	O
14	diagnostic	O
15	entity	O
16	,	O
17	yet	O
18	at	O
19	the	O
20	same	O
21	time	O
22	evaluates	O
23	a	O
24	broad	O
25	range	O
26	of	O
27	social	O
28	and	O
29	work	O
30	-	O
31	related	O
32	factors	O
33	in	O
34	disability	O
35	.	O

1	The	O
2	experimentally	O
3	mapped	O
4	regions	O
5	of	O
6	RPB5	B
7	involved	O
8	in	O
9	these	O
10	interactions	O
11	correspond	O
12	to	O
13	distinct	O
14	and	O
15	surface	O
16	-	O
17	exposed	O
18	alpha	O
19	-	O
20	helical	O
21	structures	O
22	.	O

1	UbiA	B
2	is	O
3	also	O
4	unique	O
5	among	O
6	known	O
7	polyubiquitin	B
8	genes	I
9	in	O
10	containing	O
11	four	O
12	cis	O
13	-	O
14	spliced	O
15	introns	O
16	within	O
17	its	O
18	coding	O
19	sequence	O
20	.	O

1	Moreover	O
2	,	O
3	in	O
4	transient	O
5	transfection	O
6	assays	O
7	,	O
8	PU	B
9	.	I
10	1	I
11	alone	O
12	activated	O
13	reporter	O
14	constructs	O
15	containing	O
16	the	O
17	JB	O
18	cis	O
19	-	O
20	element	O
21	,	O
22	and	O
23	the	O
24	activation	O
25	was	O
26	shown	O
27	to	O
28	be	O
29	dependent	O
30	on	O
31	a	O
32	glutamine	O
33	-	O
34	rich	O
35	sequence	O
36	in	O
37	the	O
38	amino	O
39	-	O
40	terminal	O
41	portion	O
42	of	O
43	PU	B
44	.	I
45	1	I
46	.	O

1	The	O
2	priming	O
3	activity	O
4	of	O
5	DNA	O
6	incised	O
7	by	O
8	either	O
9	of	O
10	the	O
11	Drosophila	O
12	enzymes	O
13	can	O
14	be	O
15	enhanced	O
16	,	O
17	however	O
18	,	O
19	by	O
20	an	O
21	additional	O
22	incubation	O
23	with	O
24	E	B
25	.	I
26	coli	I
27	endonuclease	I
28	IV	I
29	,	O
30	which	O
31	is	O
32	known	O
33	to	O
34	cleave	O
35	depurinated	O
36	DNA	O
37	on	O
38	the	O
39	5	O
40	'-	O
41	side	O
42	of	O
43	an	O
44	apurinic	O
45	site	O
46	.	O

1	The	O
2	two	O
3	drugs	O
4	increase	O
5	the	O
6	rate	O
7	of	O
8	early	O
9	diastolic	O
10	filling	O
11	.	O

1	Estimated	O
2	nucleic	O
3	acid	O
4	N	O
5	absorption	O
6	is	O
7	7	O
8	-	O
9	8	O
10	%	O
11	of	O
12	N	O
13	intake	O
14	.	O

1	A	O
2	contiguous	O
3	and	O
4	sequentially	O
5	occupied	O
6	secondary	O
7	Fur	B
8	-	I
9	binding	I
10	site	I
11	in	O
12	entC	B
13	was	O
14	protected	O
15	at	O
16	higher	O
17	Fur	B
18	concentrations	O
19	,	O
20	extending	O
21	the	O
22	protected	O
23	region	O
24	to	O
25	+	O
26	49	O
27	,	O
28	and	O
29	sequestering	O
30	the	O
31	putative	O
32	Shine	O
33	-	O
34	Dalgarno	O
35	sequence	O
36	.	O

1	Thus	O
2	RV	O
3	O2	O
4	demand	O
5	fell	O
6	when	O
7	RC	O
8	O2	O
9	supply	O
10	was	O
11	reduced	O
12	,	O
13	although	O
14	a	O
15	flow	O
16	reserve	O
17	was	O
18	available	O
19	.	O

1	Using	O
2	adenoviral	O
3	transfer	O
4	of	O
5	IkappaBalpha	B
6	(	O
7	IkappaBalpha	B
8	overexpression	O
9	),	O
10	the	O
11	production	O
12	of	O
13	TNF	B
14	-	I
15	alpha	I
16	induced	O
17	by	O
18	whole	O
19	GBS	O
20	was	O
21	inhibited	O
22	by	O
23	only	O
24	20	O
25	%.	O

1	We	O
2	also	O
3	identified	O
4	an	O
5	alternative	O
6	spliced	O
7	form	O
8	of	O
9	Lyp	B
10	RNA	I
11	,	O
12	Lyp2	B
13	.	O

1	In	O
2	the	O
3	whole	O
4	group	O
5	of	O
6	infected	O
7	children	O
8	,	O
9	an	O
10	age	O
11	-	O
12	specific	O
13	z	O
14	score	O
15	<	O
16	-	O
17	2	O
18	for	O
19	weight	O
20	and	O
21	for	O
22	FFM	O
23	was	O
24	significantly	O
25	associated	O
26	with	O
27	an	O
28	increased	O
29	risk	O
30	of	O
31	death	O
32	[	O
33	relative	O
34	risk	O
35	(	O
36	95	O
37	%	O
38	CI	O
39	)	O
40	=	O
41	11	O
42	.	O
43	4	O
44	(	O
45	3	O
46	.	O
47	1	O
48	,	O
49	41	O
50	.	O
51	0	O
52	)	O
53	and	O
54	5	O
55	.	O
56	1	O
57	(	O
58	1	O
59	.	O
60	5	O
61	,	O
62	18	O
63	.	O
64	2	O
65	),	O
66	respectively	O
67	];	O
68	when	O
69	only	O
70	children	O
71	with	O
72	more	O
73	severe	O
74	disease	O
75	were	O
76	considered	O
77	,	O
78	only	O
79	z	O
80	score	O
81	for	O
82	weight	O
83	was	O
84	significantly	O
85	associated	O
86	with	O
87	an	O
88	increased	O
89	risk	O
90	[	O
91	4	O
92	.	O
93	6	O
94	(	O
95	1	O
96	.	O
97	4	O
98	,	O
99	14	O
100	.	O
101	9	O
102	)].	O

1	A	O
2	hydrodynamic	O
3	description	O
4	of	O
5	the	O
6	osmotic	O
7	reflection	O
8	coefficient	O
9	with	O
10	application	O
11	to	O
12	the	O
13	pore	O
14	theory	O
15	of	O
16	transcapillary	O
17	exchange	O
18	.	O

1	Thus	O
2	,	O
3	methylation	O
4	of	O
5	Pph21p	B
6	is	O
7	important	O
8	for	O
9	formation	O
10	of	O
11	PP2A	B
12	trimeric	I
13	and	I
14	dimeric	I
15	complexes	I
16	,	O
17	and	O
18	consequently	O
19	,	O
20	for	O
21	PP2A	B
22	function	O
23	.	O

1	The	O
2	use	O
3	of	O
4	antibodies	O
5	to	O
6	the	O
7	polypyrimidine	B
8	tract	I
9	binding	I
10	protein	I
11	(	O
12	PTB	B
13	)	O
14	to	O
15	analyze	O
16	the	O
17	protein	O
18	components	O
19	that	O
20	assemble	O
21	on	O
22	alternatively	O
23	spliced	O
24	pre	O
25	-	O
26	mRNAs	O
27	that	O
28	use	O
29	distant	O
30	branch	O
31	points	O
32	.	O

1	An	O
2	approximately	O
3	2	B
4	-	I
5	kilobase	I
6	B2	I
7	transcript	I
8	was	O
9	expressed	O
10	in	O
11	all	O
12	alfalfa	O
13	organs	O
14	tested	O
15	.	O

1	After	O
2	an	O
3	initial	O
4	titration	O
5	period	O
6	and	O
7	adjustment	O
8	of	O
9	the	O
10	therapeutic	O
11	dose	O
12	,	O
13	the	O
14	individual	O
15	doses	O
16	were	O
17	from	O
18	21	O
19	to	O
20	500	O
21	micrograms	O
22	/	O
23	24	O
24	hrs	O
25	(	O
26	mean	O
27	160	O
28	micrograms	O
29	/	O
30	24	O
31	hrs	O
32	).	O

1	(	O
2	total	O
3	soluble	O
4	solids	O
5	)	O
6	and	O
7	organoleptic	O
8	characteristics	O
9	under	O
10	the	O
11	influence	O
12	of	O
13	different	O
14	treatments	O
15	.	O

1	Samples	O
2	from	O
3	1415	O
4	neurological	O
5	patients	O
6	were	O
7	used	O
8	to	O
9	study	O
10	the	O
11	diagnostic	O
12	value	O
13	of	O
14	acid	B
15	alpha	I
16	1	I
17	-	I
18	glycoprotein	I
19	in	O
20	the	O
21	lumbar	O
22	cerebrospinal	O
23	fluid	O
24	.	O

1	Sequence	O
2	divergence	O
3	is	O
4	observed	O
5	in	O
6	untranslated	O
7	regions	O
8	which	O
9	allows	O
10	the	O
11	definition	O
12	of	O
13	gene	O
14	-	O
15	specific	O
16	probes	O
17	.	O

1	In	O
2	fus3	B
3	mutants	I
4	,	O
5	the	O
6	levels	O
7	of	O
8	Ty1	B
9	RNA	I
10	,	O
11	protein	O
12	synthesis	O
13	,	O
14	and	O
15	proteolytic	O
16	processing	O
17	were	O
18	not	O
19	altered	O
20	relative	O
21	to	O
22	those	O
23	in	O
24	FUS3	B
25	strains	O
26	but	O
27	steady	O
28	-	O
29	state	O
30	levels	O
31	of	O
32	TyA	B
33	,	O
34	integrase	B
35	,	O
36	and	O
37	reverse	B
38	transcriptase	I
39	proteins	O
40	and	O
41	Ty1	B
42	cDNA	I
43	were	O
44	all	O
45	increased	O
46	.	O

1	Expression	O
2	of	O
3	Bcl	B
4	-	I
5	XL	I
6	inhibited	O
7	the	O
8	association	O
9	of	O
10	Apaf	B
11	-	I
12	1	I
13	with	O
14	caspase	B
15	-	I
16	9	I
17	in	O
18	mammalian	O
19	cells	O
20	.	O

1	Organ	O
2	transplantation	O
3	in	O
4	Denmark	O
5	.	O

1	The	O
2	results	O
3	suggested	O
4	that	O
5	,	O
6	depending	O
7	upon	O
8	the	O
9	cell	O
10	type	O
11	,	O
12	gene	O
13	cotransfer	O
14	using	O
15	aminoglycoside	O
16	resistance	O
17	as	O
18	a	O
19	selectable	O
20	marker	O
21	may	O
22	seriously	O
23	perturb	O
24	important	O
25	cellular	O
26	control	O
27	mechanisms	O
28	such	O
29	as	O
30	the	O
31	PKC	B
32	pathway	O
33	leading	O
34	to	O
35	activation	O
36	of	O
37	gene	O
38	expression	O
39	.	O

1	We	O
2	suggest	O
3	that	O
4	such	O
5	occlusions	O
6	occurred	O
7	at	O
8	the	O
9	time	O
10	of	O
11	the	O
12	infarction	O
13	.	O

1	In	O
2	patients	O
3	with	O
4	type	O
5	IA	O
6	maple	O
7	syrup	O
8	urine	O
9	disease	O
10	,	O
11	the	O
12	E1alpha	B
13	subunit	I
14	is	O
15	affected	O
16	,	O
17	resulting	O
18	in	O
19	the	O
20	loss	O
21	of	O
22	E1	B
23	and	O
24	branched	B
25	-	I
26	chain	I
27	ketoacid	I
28	dehydrogenase	I
29	catalytic	O
30	activities	O
31	.	O

1	CONCLUSION	O
2	:	O
3	Vitrectomy	O
4	for	O
5	vitreous	O
6	hemorrhage	O
7	in	O
8	Terson	O
9	syndrome	O
10	is	O
11	a	O
12	safe	O
13	and	O
14	effective	O
15	procedure	O
16	,	O
17	offering	O
18	a	O
19	rapid	O
20	and	O
21	prolonged	O
22	improvement	O
23	in	O
24	vision	O
25	.	O

1	When	O
2	blood	O
3	samples	O
4	of	O
5	patients	O
6	with	O
7	hyperbilirubinemia	O
8	were	O
9	analyzed	O
10	,	O
11	direct	O
12	measurement	O
13	of	O
14	ZPP	O
15	by	O
16	this	O
17	fluorimeter	O
18	yielded	O
19	significantly	O
20	higher	O
21	levels	O
22	than	O
23	did	O
24	an	O
25	alternate	O
26	extraction	O
27	method	O
28	.	O

1	The	O
2	maximum	O
3	stress	O
4	due	O
5	to	O
6	the	O
7	hygroscopic	O
8	examination	O
9	of	O
10	the	O
11	composite	O
12	was	O
13	0	O
14	.	O
15	74	O
16	kg	O
17	/	O
18	mm2	O
19	at	O
20	equilibrium	O
21	of	O
22	the	O
23	water	O
24	absorbed	O
25	of	O
26	the	O
27	composite	O
28	.	O

1	Most	O
2	patients	O
3	with	O
4	high	O
5	blood	O
6	pressure	O
7	(	O
8	BP	O
9	)	O
10	can	O
11	be	O
12	managed	O
13	by	O
14	using	O
15	one	O
16	of	O
17	4	O
18	classes	O
19	of	O
20	compounds	O
21	:	O
22	a	O
23	diuretic	O
24	,	O
25	beta	O
26	blocker	O
27	,	O
28	converting	O
29	enzyme	O
30	inhibitor	O
31	or	O
32	calcium	O
33	antagonist	O
34	.	O

1	We	O
2	describe	O
3	a	O
4	case	O
5	of	O
6	acetaminophen	O
7	overdose	O
8	that	O
9	was	O
10	treated	O
11	with	O
12	both	O
13	hemodialysis	O
14	(	O
15	HD	O
16	)	O
17	and	O
18	NAC	O
19	due	O
20	to	O
21	severe	O
22	intoxication	O
23	and	O
24	slow	O
25	drug	O
26	clearance	O
27	.	O

1	LHbeta	B
2	is	O
3	expressed	O
4	in	O
5	pituitary	O
6	gonadotrope	O
7	cells	O
8	and	O
9	CGbeta	B
10	is	O
11	expressed	O
12	in	O
13	placental	O
14	trophoblast	O
15	cells	O
16	.	O

1	All	O
2	of	O
3	the	O
4	elements	O
5	exhibited	O
6	a	O
7	uniform	O
8	structure	O
9	.	O

1	Effects	O
2	of	O
3	dioxins	O
4	on	O
5	thyroid	O
6	function	O
7	in	O
8	newborn	O
9	babies	O
10	.	O

1	The	O
2	arginyl	O
3	peptide	O
4	bonds	O
5	that	O
6	are	O
7	cleaved	O
8	in	O
9	the	O
10	conversion	O
11	of	O
12	human	B
13	factor	I
14	IX	I
15	to	O
16	factor	B
17	IXa	I
18	by	O
19	factor	B
20	XIa	I
21	were	O
22	identified	O
23	as	O
24	Arg145	O
25	-	O
26	Ala146	O
27	and	O
28	Arg180	O
29	-	O
30	Val181	O
31	.	O

1	Expression	O
2	of	O
3	thiamin	O
4	biosynthetic	O
5	genes	O
6	(	O
7	thiCOGE	B
8	)	O
9	and	O
10	production	O
11	of	O
12	symbiotic	B
13	terminal	I
14	oxidase	I
15	cbb3	I
16	in	O
17	Rhizobium	O
18	etli	O
19	.	O

1	The	O
2	calculated	O
3	pD2	O
4	values	O
5	were	O
6	8	O
7	.	O
8	8	O
9	for	O
10	E	O
11	,	O
12	8	O
13	.	O
14	6	O
15	for	O
16	DHE	O
17	and	O
18	6	O
19	.	O
20	6	O
21	for	O
22	M	O
23	.	O

1	Induced	O
2	gamma	O
3	-	O
4	ray	O
5	spectroscopy	O

1	Consistent	O
2	with	O
3	ErbB	B
4	-	I
5	2	I
6	being	O
7	a	O
8	shared	O
9	receptor	O
10	subunit	O
11	,	O
12	its	O
13	tyrosine	O
14	phosphorylation	O
15	was	O
16	increased	O
17	by	O
18	both	O
19	heterologous	O
20	ligands	O
21	and	O
22	it	O
23	mediated	O
24	a	O
25	trans	O
26	-	O
27	inhibitory	O
28	effect	O
29	of	O
30	NDF	B
31	on	O
32	EGF	B
33	binding	O
34	.	O

1	Analysis	O
2	of	O
3	cell	O
4	cycle	O
5	regulation	O
6	in	O
7	the	O
8	budding	O
9	yeast	O
10	Saccharomyces	O
11	cerevisiae	O
12	has	O
13	shown	O
14	that	O
15	a	O
16	central	O
17	regulatory	O
18	protein	O
19	kinase	O
20	,	O
21	Cdc28	B
22	,	O
23	undergoes	O
24	changes	O
25	in	O
26	activity	O
27	through	O
28	the	O
29	cell	O
30	cycle	O
31	by	O
32	associating	O
33	with	O
34	distinct	O
35	groups	O
36	of	O
37	cyclins	B
38	that	O
39	accumulate	O
40	at	O
41	different	O
42	times	O
43	.	O

1	TIEG	B
2	expression	O
3	in	O
4	hFOB	O
5	cells	O
6	was	O
7	highly	O
8	induced	O
9	by	O
10	TGF	B
11	-	I
12	beta	I
13	and	O
14	bone	B
15	morphogenetic	I
16	protein	I
17	-	I
18	2	I
19	(	O
20	BMP	B
21	-	I
22	2	I
23	),	O
24	with	O
25	a	O
26	moderate	O
27	induction	O
28	by	O
29	epidermal	B
30	growth	I
31	factor	I
32	(	O
33	EGF	B
34	),	O
35	but	O
36	no	O
37	induction	O
38	by	O
39	other	O
40	growth	O
41	factors	O
42	/	O
43	cytokines	O
44	was	O
45	observed	O
46	.	O

1	The	O
2	colony	B
3	-	I
4	stimulating	I
5	factors	I
6	(	O
7	CSFs	B
8	)	O
9	principally	O
10	involved	O
11	in	O
12	the	O
13	production	O
14	of	O
15	neutrophils	O
16	and	O
17	monocytes	O
18	are	O
19	granulocyte	B
20	CSF	I
21	,	O
22	granulocyte	B
23	-	I
24	macrophage	I
25	CSF	I
26	,	O
27	macrophage	B
28	CSF	I
29	,	O
30	and	O
31	interleukin	B
32	3	I
33	(	O
34	sometimes	O
35	called	O
36	multi	B
37	-	I
38	CSF	I
39	).	O

1	Previous	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	the	O
7	TATA	O
8	element	O
9	is	O
10	critical	O
11	for	O
12	basal	O
13	and	O
14	Tat	B
15	-	O
16	induced	O
17	HIV	O
18	-	O
19	1	O
20	gene	O
21	expression	O
22	.	O

1	The	O
2	SEN1	B
3	gene	I
4	corresponds	O
5	to	O
6	a	O
7	6	O
8	,	O
9	336	O
10	-	O
11	bp	O
12	open	O
13	reading	O
14	frame	O
15	coding	O
16	for	O
17	a	O
18	2	O
19	,	O
20	112	O
21	-	O
22	amino	O
23	-	O
24	acid	O
25	protein	O
26	(	O
27	molecular	O
28	mass	O
29	,	O
30	239	O
31	kDa	O
32	).	O

1	Mapping	O
2	features	O
3	of	O
4	HIV	B
5	-	I
6	1	I
7	integrase	I
8	near	O
9	selected	O
10	sites	O
11	on	O
12	viral	O
13	and	O
14	target	O
15	DNA	O
16	molecules	O
17	in	O
18	an	O
19	active	O
20	enzyme	O
21	-	O
22	DNA	O
23	complex	O
24	by	O
25	photo	O
26	-	O
27	cross	O
28	-	O
29	linking	O
30	.	O

1	We	O
2	demonstrate	O
3	that	O
4	both	O
5	R	B
6	and	O
7	Z	B
8	activate	O
9	the	O
10	cellular	O
11	stress	O
12	mitogen	B
13	-	I
14	activated	I
15	protein	I
16	(	I
17	MAP	I
18	)	I
19	kinases	I
20	,	O
21	p38	B
22	and	O
23	JNK	B
24	,	O
25	resulting	O
26	in	O
27	phosphorylation	O
28	(	O
29	and	O
30	activation	O
31	)	O
32	of	O
33	the	O
34	cellular	B
35	transcription	I
36	factor	I
37	ATF2	I
38	.	O

1	To	O
2	study	O
3	the	O
4	functional	O
5	differences	O
6	between	O
7	cutaneous	O
8	HPV5	O
9	and	O
10	HPV8	O
11	E7s	B
12	and	O
13	genital	B
14	HPV16	I
15	E7	I
16	,	O
17	we	O
18	cloned	O
19	each	O
20	of	O
21	the	O
22	E7	B
23	open	O
24	reading	O
25	frames	O
26	and	O
27	tested	O
28	their	O
29	immortalizing	O
30	and	O
31	transforming	O
32	activities	O
33	,	O
34	the	O
35	binding	O
36	ability	O
37	of	O
38	their	O
39	products	O
40	with	O
41	retinoblastoma	B
42	protein	I
43	(	O
44	RB	B
45	)	O
46	and	O
47	their	O
48	complementation	O
49	activity	O
50	of	O
51	a	O
52	RB	B
53	-	I
54	nonbinding	I
55	adenovirus	I
56	E1A	I
57	mutant	I
58	.	O

1	TNF	B
2	-	I
3	alpha	I
4	exposure	O
5	markedly	O
6	increased	O
7	activity	O
8	of	O
9	several	O
10	RNA	O
11	-	O
12	binding	O
13	proteins	O
14	,	O
15	especially	O
16	a	O
17	novel	O
18	Mr	O
19	50	O
20	,	O
21	000	O
22	-	O
23	55	O
24	,	O
25	000	O
26	RNA	O
27	-	O
28	binding	O
29	protein	O
30	.	O

1	At	O
2	all	O
3	time	O
4	-	O
5	points	O
6	,	O
7	most	O
8	patients	O
9	(>/=	O
10	87	O
11	%)	O
12	were	O
13	receiving	O
14	irbesartan	O
15	/	O
16	HCTZ	O
17	alone	O
18	.	O

1	The	O
2	importin	B
3	alpha	I
4	.	I
5	beta	I
6	heterodimer	I
7	mediates	O
8	nuclear	O
9	import	O
10	of	O
11	proteins	O
12	containing	O
13	classical	O
14	nuclear	O
15	localization	O
16	signals	O
17	.	O

1	The	O
2	recovery	O
3	index	O
4	(	O
5	T25	O
6	-	O
7	T75	O
8	)	O
9	after	O
10	the	O
11	infusion	O
12	stopped	O
13	was	O
14	similar	O
15	in	O
16	patients	O
17	who	O
18	received	O
19	mivacurium	O
20	and	O
21	those	O
22	who	O
23	received	O
24	suxamethonium	O
25	.	O

1	Treatment	O
2	with	O
3	heparin	O
4	,	O
5	plasminogen	B
6	activators	O
7	and	O
8	fibrinogenolytic	O
9	agents	O
10	was	O
11	disappointing	O
12	although	O
13	renal	O
14	function	O
15	has	O
16	stabilized	O
17	in	O
18	one	O
19	patient	O
20	on	O
21	long	O
22	term	O
23	oral	O
24	anticoagulant	O
25	therapy	O
26	.	O

1	All	O
2	control	O
3	persons	O
4	had	O
5	a	O
6	normal	O
7	reaction	O
8	to	O
9	DNFB	O
10	.	O

1	Several	O
2	PTPases	B
3	were	O
4	expressed	O
5	abundantly	O
6	in	O
7	the	O
8	5	O
9	-	O
10	FU	O
11	-	O
12	treated	O
13	bone	O
14	marrow	O
15	stem	O
16	cells	O
17	.	O

1	Similar	O
2	synergistic	O
3	activation	O
4	was	O
5	observed	O
6	in	O
7	the	O
8	IL	B
9	-	I
10	8	I
11	promoter	I
12	,	O
13	which	O
14	also	O
15	contains	O
16	both	O
17	NF	B
18	-	I
19	IL6	I
20	and	O
21	NF	B
22	-	I
23	kappa	I
24	B	I
25	binding	I
26	sites	I
27	.	O

1	All	O
2	lambs	O
3	with	O
4	B	O
5	breeding	O
6	had	O
7	significantly	O
8	higher	O
9	Hb	B
10	levels	O
11	at	O
12	the	O
13	end	O
14	of	O
15	the	O
16	experiment	O
17	than	O
18	did	O
19	NB	O
20	lambs	O
21	.	O
22	b	O
23	and	O
24	S	O
25	x	O
26	B	O
27	lambs	O
28	had	O
29	higher	O
30	(	O
31	P	O
32	<	O
33	.	O
34	05	O
35	)	O
36	Hb	B
37	levels	O
38	than	O
39	the	O
40	D	O
41	x	O
42	B	O
43	lambs	O
44	,	O
45	and	O
46	B	O
47	lambs	O
48	had	O
49	the	O
50	highest	O
51	(	O
52	P	O
53	<	O
54	.	O
55	05	O
56	)	O
57	mean	O
58	corpuscular	O
59	hemoglobin	B
60	concentrations	O
61	.	O

1	Incidences	O
2	of	O
3	nonfatal	O
4	stroke	O
5	,	O
6	myocardial	O
7	infarction	O
8	,	O
9	angina	O
10	pectoris	O
11	und	O
12	left	O
13	ventricular	O
14	hypertrophy	O
15	could	O
16	also	O
17	be	O
18	lowered	O
19	.	O

1	They	O
2	also	O
3	interact	O
4	with	O
5	GTPase	B
6	activating	I
7	proteins	I
8	encoded	O
9	by	O
10	IRA1	B
11	and	O
12	IRA2	B
13	.	O

1	Review	O
2	of	O
3	the	O
4	literature	O
5	and	O
6	report	O
7	of	O
8	a	O
9	case	O
10	of	O
11	a	O
12	dermoid	O
13	cyst	O
14	.	O

1	Chronotherapeutics	O
2	in	O
3	cardiovascular	O
4	disease	O
5	.	O

1	However	O
2	,	O
3	cotransfection	O
4	studies	O
5	indicate	O
6	that	O
7	RVR	B
8	does	O
9	not	O
10	activate	O
11	transcription	O
12	when	O
13	this	O
14	hormone	O
15	response	O
16	element	O
17	is	O
18	linked	O
19	to	O
20	a	O
21	reporter	O
22	gene	O
23	but	O
24	rather	O
25	acts	O
26	as	O
27	a	O
28	potent	O
29	competitive	O
30	repressor	O
31	of	O
32	ROR	B
33	alpha	I
34	function	O
35	.	O

1	RESULTS	O
2	:	O
3	The	O
4	overall	O
5	FNF	O
6	for	O
7	1992	O
8	was	O
9	12	O
10	.	O
11	3	O
12	%	O
13	and	O
14	was	O
15	19	O
16	.	O
17	1	O
18	%,	O
19	22	O
20	.	O
21	2	O
22	%,	O
23	3	O
24	.	O
25	8	O
26	%	O
27	and	O
28	6	O
29	.	O
30	1	O
31	%	O
32	per	O
33	successive	O
34	quarters	O
35	in	O
36	1992	O
37	.	O

1	A	O
2	5	B
3	.	I
4	8S	I
5	-	I
6	like	I
7	structure	I
8	is	O
9	present	O
10	within	O
11	the	O
12	5	O
13	'-	O
14	terminal	O
15	region	O
16	of	O
17	all	O
18	three	O
19	fungal	B
20	mitochondrial	I
21	LSU	I
22	rRNAs	I
23	;	O
24	in	O
25	contrast	O
26	,	O
27	no	O
28	4	B
29	.	I
30	5S	I
31	-	I
32	like	I
33	structure	I
34	is	O
35	evident	O
36	at	O
37	the	O
38	3	O
39	'	O
40	end	O
41	of	O
42	these	O
43	molecules	O
44	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	R	O
6	has	O
7	revealed	O
8	similarities	O
9	to	O
10	the	O
11	R1	O
12	plasmid	O
13	found	O
14	in	O
15	some	O
16	South	O
17	American	O
18	maize	O
19	races	O
20	with	O
21	RU	O
22	cytoplasm	O
23	,	O
24	to	O
25	the	O
26	M1	O
27	plasmid	O
28	found	O
29	in	O
30	one	O
31	source	O
32	of	O
33	Zea	O
34	luxurians	O
35	teosinte	O
36	,	O
37	to	O
38	the	O
39	atp9	B
40	mitochondrial	I
41	gene	I
42	and	O
43	its	O
44	3	O
45	'	O
46	flanking	O
47	sequence	O
48	,	O
49	and	O
50	also	O
51	to	O
52	a	O
53	region	O
54	3	O
55	'	O
56	to	O
57	the	O
58	orf221	B
59	gene	I
60	.	O

1	The	O
2	BAL	O
3	concentrations	O
4	of	O
5	the	O
6	nine	O
7	cytokines	O
8	evaluated	O
9	for	O
10	the	O
11	more	O
12	and	O
13	less	O
14	affected	O
15	lungs	O
16	were	O
17	compared	O
18	:	O
19	interleukin	B
20	-	I
21	6	I
22	(	O
23	IL	B
24	-	I
25	6	I
26	),	O
27	IL	B
28	-	I
29	8	I
30	,	O
31	IL	B
32	-	I
33	12	I
34	,	O
35	tumor	B
36	necrosis	I
37	factor	I
38	-	I
39	alpha	I
40	(	O
41	TNF	B
42	-	I
43	alpha	I
44	),	O
45	and	O
46	interferon	B
47	gamma	I
48	(	O
49	IFN	B
50	-	I
51	gamma	I
52	)	O
53	showed	O
54	significant	O
55	differences	O
56	(	O
57	p	O
58	ranged	O
59	between	O
60	0	O
61	.	O

1	Syndecan	B
2	-	I
3	4	I
4	is	O
5	a	O
6	focal	O
7	adhesion	O
8	component	O
9	,	O
10	and	O
11	this	O
12	interaction	O
13	may	O
14	both	O
15	localize	O
16	PKC	B
17	and	O
18	amplify	O
19	its	O
20	activity	O
21	at	O
22	sites	O
23	of	O
24	forming	O
25	adhesions	O
26	.	O

1	Dystonic	O
2	movement	O
3	of	O
4	the	O
5	left	O
6	upper	O
7	limb	O
8	in	O
9	a	O
10	case	O
11	of	O
12	the	O
13	right	O
14	pontine	O
15	hemorrhage	O

1	DIBA	O
2	was	O
3	more	O
4	sensitive	O
5	and	O
6	had	O
7	a	O
8	better	O
9	negative	O
10	predictive	O
11	value	O
12	and	O
13	a	O
14	lower	O
15	false	O
16	negative	O
17	percentage	O
18	than	O
19	DFAT	O
20	.	O

1	Splice	O
2	variations	O
3	in	O
4	genes	O
5	coding	O
6	for	O
7	the	O
8	transmembrane	B
9	FGF	I
10	receptor	I
11	(	O
12	FGFR	B
13	)	O
14	result	O
15	in	O
16	isoforms	O
17	that	O
18	vary	O
19	in	O
20	the	O
21	ectodomain	O
22	,	O
23	intracellular	O
24	juxtamembrane	O
25	domain	O
26	,	O
27	and	O
28	the	O
29	intracellular	O
30	kinase	O
31	domain	O
32	.	O

1	Voluntary	O
2	wheel	O
3	running	O
4	did	O
5	not	O
6	significantly	O
7	increase	O
8	estimated	O
9	alanine	O
10	or	O
11	pyruvate	O
12	Gneo	O
13	or	O
14	absolute	O
15	glycerol	O
16	Ra	O
17	.	O

1	Relation	O
2	between	O
3	mixing	O
4	ratio	O
5	of	O
6	raw	O
7	materials	O
8	and	O
9	composition	O
10	of	O
11	products	O
12	in	O
13	the	O
14	synthesis	O
15	of	O
16	aluminosilicates	O

1	Insulin	B
2	stimulation	O
3	promoted	O
4	the	O
5	association	O
6	of	O
7	mIRS3	B
8	with	O
9	p85	B
10	,	O
11	SHP2	B
12	,	O
13	Nck	B
14	,	O
15	and	O
16	Shc	B
17	.	O

1	Substitutions	O
2	of	O
3	region	O
4	I	O
5	with	O
6	synthetic	O
7	sequences	O
8	showed	O
9	that	O
10	no	O
11	specific	O
12	sequence	O
13	but	O
14	rather	O
15	repeats	O
16	of	O
17	three	O
18	or	O
19	more	O
20	consecutive	O
21	adenines	O
22	or	O
23	thymines	O
24	,	O
25	without	O
26	interruption	O
27	by	O
28	guanine	O
29	or	O
30	cytosine	O
31	,	O
32	are	O
33	required	O
34	for	O
35	the	O
36	ARS	O
37	activity	O
38	.	O

1	ALT	B
2	levels	O
3	in	O
4	responders	O
5	were	O
6	lowered	O
7	by	O
8	46	O
9	%	O
10	and	O
11	AST	B
12	levels	O
13	were	O
14	lowered	O
15	by	O
16	35	O
17	%	O
18	after	O
19	12	O
20	weeks	O
21	of	O
22	vitamin	O
23	E	O
24	treatment	O
25	.	O

1	In	O
2	metastasis	O
3	-	O
4	free	O
5	patients	O
6	,	O
7	the	O
8	best	O
9	results	O
10	were	O
11	obtained	O
12	with	O
13	tumor	O
14	diameters	O
15	under	O
16	2	O
17	cm	O
18	regardless	O
19	of	O
20	their	O
21	localization	O
22	in	O
23	lung	O
24	tissue	O
25	and	O
26	with	O
27	2	O
28	--	O
29	4	O
30	.	O
31	9	O
32	cm	O
33	tumors	O
34	embedded	O
35	in	O
36	lung	O
37	parenchyma	O
38	.	O

1	Magnetic	O
2	trapping	O
3	of	O
4	spin	O
5	-	O
6	polarized	O
7	atomic	O
8	hydrogen	O
9	.	O

1	Northern	O
2	analysis	O
3	indicated	O
4	differential	O
5	expression	O
6	by	O
7	tissue	O
8	with	O
9	highest	O
10	expression	O
11	in	O
12	the	O
13	heart	O
14	.	O

1	Vestibular	O
2	adaptation	O
3	exercises	O
4	and	O
5	recovery	O
6	:	O
7	acute	O
8	stage	O
9	after	O
10	acoustic	O
11	neuroma	O
12	resection	O
13	.	O

1	We	O
2	recommend	O
3	that	O
4	ovarian	O
5	stimulation	O
6	is	O
7	done	O
8	only	O
9	if	O
10	there	O
11	is	O
12	a	O
13	valid	O
14	indication	O
15	after	O
16	proper	O
17	assessment	O
18	of	O
19	the	O
20	ovaries	O
21	,	O
22	and	O
23	that	O
24	women	O
25	who	O
26	have	O
27	had	O
28	ovarian	O
29	stimulation	O
30	are	O
31	followed	O
32	for	O
33	longer	O
34	than	O
35	at	O
36	present	O
37	.	O

1	Integrin	B
2	adhesion	I
3	receptors	I
4	transduce	O
5	signals	O
6	that	O
7	control	O
8	complex	O
9	cell	O
10	functions	O
11	which	O
12	require	O
13	the	O
14	regulation	O
15	of	O
16	gene	O
17	expression	O
18	,	O
19	such	O
20	as	O
21	proliferation	O
22	,	O
23	differentiation	O
24	and	O
25	survival	O
26	.	O

1	The	O
2	use	O
3	of	O
4	CRF	B
5	-	I
6	41	I
7	in	O
8	the	O
9	differential	O
10	diagnosis	O
11	of	O
12	Cushing	O
13	'	O
14	s	O
15	syndrome	O
16	and	O
17	obesity	O
18	.	O

1	The	O
2	cloned	O
3	genes	O
4	were	O
5	identified	O
6	in	O
7	genetic	O
8	libraries	O
9	by	O
10	hybridization	O
11	screening	O
12	using	O
13	four	O
14	deoxyoligonucleotide	O
15	probes	O
16	which	O
17	corresponded	O
18	to	O
19	the	O
20	partial	O
21	amino	O
22	acid	O
23	sequence	O
24	of	O
25	the	O
26	purified	O
27	enzyme	O
28	.	O

1	We	O
2	show	O
3	that	O
4	these	O
5	three	O
6	gain	O
7	-	O
8	of	O
9	-	O
10	function	O
11	mutants	O
12	differ	O
13	considerably	O
14	in	O
15	their	O
16	ability	O
17	to	O
18	bypass	O
19	the	O
20	sex	O
21	determination	O
22	signal	O
23	,	O
24	with	O
25	SxlM4	B
26	being	O
27	the	O
28	strongest	O
29	and	O
30	SxlM1	B
31	the	O
32	weakest	O
33	.	O

1	Dominant	O
2	negative	O
3	Sos	B
4	did	O
5	not	O
6	affect	O
7	carbachol	O
8	stimulation	O
9	of	O
10	HA	B
11	-	O
12	ERK2	B
13	but	O
14	inhibited	O
15	the	O
16	stimulatory	O
17	effect	O
18	of	O
19	EGF	B
20	by	O
21	60	O
22	%.	O

1	Complementary	O
2	DNAs	O
3	encompassing	O
4	the	O
5	coat	B
6	protein	I
7	coding	O
8	and	O
9	adjacent	O
10	regions	O
11	of	O
12	Agropyron	O
13	mosaic	O
14	virus	O
15	(	O
16	AgMV	O
17	)	O
18	and	O
19	Hordeum	O
20	mosaic	O
21	virus	O
22	(	O
23	HoMV	O
24	)	O
25	were	O
26	cloned	O
27	and	O
28	sequenced	O
29	.	O

1	LY290181	O
2	appears	O
3	to	O
4	inhibit	O
5	uPA	B
6	promoter	I
7	activation	O
8	by	O
9	blocking	O
10	phorbol	O
11	ester	O
12	-	O
13	stimulated	O
14	binding	O
15	of	O
16	nuclear	O
17	proteins	O
18	to	O
19	the	O
20	uPA	B
21	PEA3	I
22	/	O
23	12	O
24	-	O
25	0	O
26	-	O
27	tetradecanoylphorbol	O
28	13	O
29	-	O
30	acetate	O
31	responsive	O
32	element	O
33	(	O
34	TRE	O
35	).	O

1	Our	O
2	analysis	O
3	suggests	O
4	that	O
5	Upf1p	B
6	is	O
7	a	O
8	multifunctional	O
9	protein	O
10	with	O
11	separable	O
12	activities	O
13	that	O
14	can	O
15	affect	O
16	mRNA	O
17	turnover	O
18	and	O
19	nonsense	O
20	suppression	O
21	.	O

1	But	O
2	,	O
3	as	O
4	Theriault	O
5	explains	O
6	,	O
7	improvements	O
8	in	O
9	assessing	O
10	exposure	O
11	have	O
12	not	O
13	yet	O
14	translated	O
15	into	O
16	clear	O
17	and	O
18	consistent	O
19	findings	O
20	.	O

1	2	O
2	cases	O
3	of	O
4	toxic	O
5	lymphomononucleosis	O

1	In	O
2	the	O
3	presence	O
4	of	O
5	the	O
6	in	O
7	vivo	O
8	reducing	O
9	system	O
10	(	O
11	thioredoxin	B
12	,	O
13	thioredoxin	B
14	reductase	I
15	,	O
16	and	O
17	NADPH	O
18	),	O
19	however	O
20	,	O
21	each	O
22	of	O
23	these	O
24	mutants	O
25	catalyzed	O
26	the	O
27	formation	O
28	of	O
29	only	O
30	0	O
31	.	O
32	6	O
33	-	O
34	0	O
35	.	O
36	8	O
37	dCTPs	O
38	per	O
39	mole	O
40	of	O
41	enzyme	O
42	.	O

1	Behavior	O
2	of	O
3	aspartate	B
4	aminotransferase	I
5	(	O
6	EC	B
7	2	I
8	.	I
9	6	I
10	.	I
11	1	I
12	.	I
13	1	I
14	)	O
15	and	O
16	alanine	B
17	aminotransferase	I
18	(	O
19	EC	B
20	2	I
21	.	I
22	6	I
23	.	I
24	1	I
25	.	I
26	2	I
27	)	O
28	in	O
29	rat	O
30	serum	O
31	during	O
32	the	O
33	course	O
34	of	O
35	acute	O
36	radiation	O
37	syndrome	O
38	following	O
39	whole	O
40	body	O
41	X	O
42	-	O
43	irradiation	O

1	The	O
2	ability	O
3	of	O
4	chronic	O
5	UM	O
6	-	O
7	272	O
8	(	O
9	dimethylpropranolol	O
10	)	O
11	treatment	O
12	to	O
13	prevent	O
14	the	O
15	induction	O
16	of	O
17	reentrant	O
18	ventricular	O
19	tachyarrhythmias	O
20	was	O
21	assessed	O
22	in	O
23	the	O
24	conscious	O
25	dog	O
26	subjected	O
27	to	O
28	serial	O
29	programmed	O
30	electrical	O
31	stimulation	O
32	on	O
33	days	O
34	3	O
35	--	O
36	5	O
37	after	O
38	myocardial	O
39	infarction	O
40	.	O

1	Accurate	O
2	evaluation	O
3	of	O
4	the	O
5	treatment	O
6	results	O
7	in	O
8	unresectable	O
9	lung	O
10	cancer	O
11	patients	O
12	must	O
13	take	O
14	the	O
15	strong	O
16	prognostic	O
17	factors	O
18	into	O
19	account	O
20	.	O

1	In	O
2	overdoses	O
3	up	O
4	to	O
5	2	O
6	g	O
7	fluvoxamine	O
8	no	O
9	lasting	O
10	toxic	O
11	effects	O
12	were	O
13	observed	O
14	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	has	O
7	the	O
8	greatest	O
9	homology	O
10	(	O
11	61	O
12	%)	O
13	to	O
14	the	O
15	green	B
16	alga	I
17	Scenedemus	I
18	obliquus	I
19	plastocyanin	I
20	.	O

1	These	O
2	results	O
3	suggest	O
4	KCC3	B
5	is	O
6	a	O
7	new	O
8	member	O
9	of	O
10	the	O
11	KCC	B
12	family	I
13	that	O
14	is	O
15	under	O
16	distinct	O
17	regulation	O
18	from	O
19	KCC1	B
20	.	O

1	This	O
2	mode	O
3	of	O
4	ternary	O
5	complex	O
6	formation	O
7	is	O
8	in	O
9	contrast	O
10	to	O
11	the	O
12	one	O
13	seen	O
14	in	O
15	the	O
16	promoter	O
17	of	O
18	the	O
19	c	B
20	-	I
21	fos	I
22	protooncogene	I
23	,	O
24	where	O
25	formation	O
26	of	O
27	the	O
28	ternary	O
29	complex	O
30	is	O
31	dependent	O
32	on	O
33	the	O
34	prior	O
35	assembly	O
36	of	O
37	the	O
38	serum	B
39	response	I
40	factor	I
41	-	I
42	DNA	I
43	binary	I
44	complex	I
45	.	O

1	Five	O
2	different	O
3	subtypes	O
4	of	O
5	spondyloarthropathy	O
6	(	O
7	SpA	O
8	)	O
9	are	O
10	now	O
11	recognized	O
12	.	O

1	Kidney	O
2	weight	O
3	and	O
4	kidney	O
5	-	O
6	to	O
7	-	O
8	body	O
9	weight	O
10	ratio	O
11	were	O
12	significantly	O
13	elevated	O
14	at	O
15	the	O
16	highest	O
17	dose	O
18	level	O
19	after	O
20	10	O
21	weeks	O
22	and	O
23	at	O
24	the	O
25	two	O
26	higher	O
27	dose	O
28	levels	O
29	after	O
30	15	O
31	weeks	O
32	of	O
33	exposure	O
34	.	O

1	Identification	O
2	and	O
3	estimation	O
4	of	O
5	monosaccharides	O
6	and	O
7	disaccharides	O
8	in	O
9	urine	O
10	by	O
11	gas	O
12	-	O
13	liquid	O
14	chromatography	O
15	.	O

1	Neither	O
2	gene	O
3	possesses	O
4	a	O
5	distinct	O
6	transcriptional	O
7	start	O
8	site	O
9	as	O
10	shown	O
11	by	O
12	nuclease	B
13	S1	I
14	analysis	O
15	.	O

1	Depleted	O
2	and	O
3	enriched	O
4	U3O8	O
5	standard	O
6	reference	O
7	materials	O
8	were	O
9	used	O
10	to	O
11	calibrate	O
12	the	O
13	system	O
14	.	O

1	The	O
2	results	O
3	confirm	O
4	and	O
5	extend	O
6	previous	O
7	work	O
8	by	O
9	other	O
10	researchers	O
11	.	O

1	When	O
2	ligated	O
3	to	O
4	the	O
5	proIL	B
6	-	I
7	1	I
8	beta	I
9	cap	I
10	site	I
11	-	I
12	proximal	I
13	region	I
14	(	O
15	located	O
16	between	O
17	-	O
18	131	O
19	to	O
20	+	O
21	12	O
22	),	O
23	both	O
24	the	O
25	proIL	B
26	-	I
27	1	I
28	beta	I
29	and	O
30	the	O
31	simian	B
32	virus	I
33	40	I
34	enhancer	I
35	elements	I
36	functioned	O
37	more	O
38	efficiently	O
39	in	O
40	monocytes	O
41	than	O
42	in	O
43	HeLa	O
44	cells	O
45	,	O
46	which	O
47	are	O
48	not	O
49	normally	O
50	competent	O
51	for	O
52	IL	B
53	-	I
54	1	I
55	beta	I
56	expression	O
57	.	O

1	Thus	O
2	,	O
3	it	O
4	was	O
5	confirmed	O
6	that	O
7	the	O
8	sodium	O
9	lauryl	O
10	sulfate	O
11	method	O
12	of	O
13	estimating	O
14	hemoglobin	B
15	concentration	O
16	is	O
17	an	O
18	appropriate	O
19	alternative	O
20	to	O
21	the	O
22	cyanmethemoglobin	B
23	method	O
24	and	O
25	avoids	O
26	the	O
27	generation	O
28	of	O
29	toxic	O
30	wastes	O
31	.	O

1	US	O
2	-	O
3	Doppler	O
4	has	O
5	recently	O
6	gained	O
7	attention	O
8	as	O
9	a	O
10	noninvasive	O
11	method	O
12	for	O
13	the	O
14	functional	O
15	evaluation	O
16	of	O
17	arteriovenous	O
18	fistulas	O
19	(	O
20	FAV	O
21	).	O

1	This	O
2	promoter	O
3	could	O
4	direct	O
5	the	O
6	constitutive	O
7	expression	O
8	of	O
9	the	O
10	reporter	O
11	beta	B
12	-	I
13	galactosidase	I
14	at	O
15	high	O
16	frequency	O
17	in	O
18	transfected	O
19	colonies	O
20	of	O
21	transformed	O
22	cells	O
23	that	O
24	express	O
25	L	B
26	-	I
27	plastin	I
28	constitutively	O
29	;	O
30	by	O
31	contrast	O
32	,	O
33	this	O
34	promoter	O
35	was	O
36	virtually	O
37	inactive	O
38	in	O
39	transfected	O
40	colonies	O
41	of	O
42	normal	O
43	fibroblasts	O
44	and	O
45	it	O
46	exhibited	O
47	a	O
48	low	O
49	frequency	O
50	of	O
51	constitutive	O
52	activation	O
53	in	O
54	transfected	O
55	colonies	O
56	of	O
57	in	O
58	vitro	O
59	SV40	O
60	-	O
61	transformed	O
62	fibroblasts	O
63	which	O
64	did	O
65	not	O
66	exhibit	O
67	L	B
68	-	I
69	plastin	I
70	expression	O
71	.	O

1	Myocardial	O
2	interstitial	O
3	edema	O
4	is	O
5	more	O
6	likely	O
7	a	O
8	potential	O
9	mechanism	O
10	of	O
11	diastolic	O
12	dysfunction	O
13	after	O
14	DC	O
15	shocks	O
16	.	O

1	The	O
2	main	O
3	aim	O
4	of	O
5	the	O
6	contribution	O
7	,	O
8	which	O
9	opens	O
10	an	O
11	arena	O
12	for	O
13	discussion	O
14	on	O
15	the	O
16	Rivista	O
17	dell	O
18	'	O
19	Infermiere	O
20	is	O
21	to	O
22	critically	O
23	appraise	O
24	published	O
25	research	O
26	works	O
27	focusing	O
28	both	O
29	on	O
30	strengths	O
31	and	O
32	novelty	O
33	and	O
34	weaknesses	O
35	in	O
36	the	O
37	hypothesis	O
38	formulation	O
39	,	O
40	methods	O
41	and	O
42	instruments	O
43	used	O
44	,	O
45	discussion	O
46	of	O
47	results	O
48	.	O

1	Structural	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'-	O
7	regulatory	O
8	region	O
9	reveals	O
10	that	O
11	the	O
12	c	B
13	-	I
14	met	I
15	promoter	I
16	lacks	O
17	TATA	O
18	or	O
19	CAAT	O
20	elements	O
21	but	O
22	has	O
23	an	O
24	extremely	O
25	high	O
26	G	O
27	-	O
28	C	O
29	content	O
30	and	O
31	multiple	O
32	Sp1	B
33	binding	I
34	sites	I
35	.	O

1	Thus	O
2	,	O
3	the	O
4	absence	O
5	of	O
6	residual	O
7	infarct	O
8	-	O
9	zone	O
10	viability	O
11	discriminates	O
12	patients	O
13	who	O
14	develop	O
15	progressive	O
16	left	O
17	ventricular	O
18	dilation	O
19	after	O
20	reperfused	O
21	AMI	O
22	from	O
23	those	O
24	who	O
25	maintain	O
26	normal	O
27	left	O
28	ventricular	O
29	geometry	O
30	.	O

1	This	O
2	study	O
3	analyzed	O
4	whether	O
5	the	O
6	localization	O
7	of	O
8	an	O
9	accessory	O
10	pathway	O
11	could	O
12	be	O
13	predicted	O
14	by	O
15	using	O
16	the	O
17	polarity	O
18	of	O
19	the	O
20	QRS	O
21	complex	O
22	during	O
23	sinus	O
24	rhythm	O
25	on	O
26	the	O
27	surface	O
28	ECG	O
29	,	O
30	instead	O
31	of	O
32	the	O
33	delta	O
34	wave	O
35	polarity	O
36	as	O
37	used	O
38	in	O
39	many	O
40	reports	O
41	.	O

1	Compared	O
2	to	O
3	those	O
4	with	O
5	normal	O
6	renal	O
7	functions	O
8	,	O
9	these	O
10	patients	O
11	were	O
12	older	O
13	(	O
14	P	O
15	<	O
16	or	O
17	=	O
18	0	O
19	.	O
20	01	O
21	),	O
22	had	O
23	significantly	O
24	elevated	O
25	blood	O
26	pressures	O
27	(	O
28	P	O
29	<	O
30	0	O
31	.	O
32	01	O
33	or	O
34	P	O
35	=	O
36	0	O
37	.	O
38	0001	O
39	),	O
40	and	O
41	in	O
42	the	O
43	case	O
44	of	O
45	Type	O
46	1	O
47	DM	O
48	,	O
49	with	O
50	a	O
51	higher	O
52	body	O
53	mass	O
54	index	O
55	(	O
56	P	O
57	=	O
58	0	O
59	.	O
60	0001	O
61	)	O
62	and	O
63	waist	O
64	-	O
65	hip	O
66	ratio	O
67	(	O
68	P	O
69	<	O
70	0	O
71	.	O
72	01	O
73	).	O

1	All	O
2	patients	O
3	had	O
4	the	O
5	CA	B
6	125	I
7	assay	O
8	performed	O
9	within	O
10	one	O
11	week	O
12	before	O
13	their	O
14	second	O
15	-	O
16	look	O
17	operation	O
18	.	O

1	The	O
2	human	B
3	p100	I
4	protein	I
5	was	O
6	recently	O
7	identified	O
8	as	O
9	a	O
10	coactivator	O
11	of	O
12	the	O
13	Epstein	B
14	-	I
15	Barr	I
16	virus	I
17	nuclear	I
18	antigen	I
19	2	I
20	.	O

1	Composites	O
2	as	O
3	restoration	O
4	materials	O

1	desmethyltrimebutine	O
2	was	O
3	inactive	O
4	.	O

1	The	O
2	RNA	O
3	-	O
4	binding	O
5	and	O
6	RNA	B
7	-	I
8	DNA	I
9	helicase	I
10	activities	O
11	of	O
12	the	O
13	Escherichia	B
14	coli	I
15	transcription	I
16	termination	I
17	factor	I
18	rho	I
19	have	O
20	been	O
21	investigated	O
22	using	O
23	natural	O
24	RNA	O
25	molecules	O
26	that	O
27	are	O
28	255	O
29	and	O
30	391	O
31	nucleotide	O
32	residues	O
33	in	O
34	length	O
35	and	O
36	that	O
37	contain	O
38	the	O
39	trp	B
40	t	I
41	'	I
42	rho	I
43	-	I
44	dependent	I
45	termination	I
46	sequence	I
47	of	O
48	E	O
49	.	O
50	coli	O
51	.	O

1	When	O
2	the	O
3	promoter	O
4	region	O
5	was	O
6	linked	O
7	with	O
8	a	O
9	heterologous	O
10	reporter	O
11	gene	O
12	,	O
13	we	O
14	found	O
15	that	O
16	the	O
17	promoter	O
18	region	O
19	is	O
20	inducible	O
21	by	O
22	both	O
23	interferons	B
24	(	O
25	interferon	B
26	-	I
27	alpha	I
28	and	I
29	-	I
30	gamma	I
31	)	O
32	and	O
33	interferon	B
34	regulatory	I
35	factor	I
36	1	I
37	.	O

1	Analysis	O
2	for	O
3	DNA	O
4	-	O
5	protein	O
6	interactions	O
7	by	O
8	in	O
9	vitro	O
10	DNase	B
11	-	I
12	I	I
13	footprinting	O
14	identified	O
15	a	O
16	broad	O
17	region	O
18	of	O
19	protection	O
20	extending	O
21	from	O
22	nt	O
23	-	O
24	12	O
25	to	O
26	+	O
27	38	O
28	.	O

1	The	O
2	data	O
3	are	O
4	compatible	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	YLL031c	B
10	transfers	O
11	the	O
12	ethanolaminephosphate	O
13	to	O
14	the	O
15	inner	O
16	alpha1	O
17	-	O
18	2	O
19	-	O
20	linked	O
21	mannose	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	the	O
28	group	O
29	that	O
30	links	O
31	the	O
32	GPI	O
33	lipid	O
34	anchor	O
35	to	O
36	proteins	O
37	,	O
38	whereas	O
39	Mcd4p	B
40	and	O
41	Gpi7p	B
42	transfer	O
43	ethanolaminephosphate	O
44	onto	O
45	the	O
46	alpha1	O
47	-	O
48	4	O
49	-	O
50	and	O
51	alpha1	O
52	-	O
53	6	O
54	-	O
55	linked	O
56	mannoses	O
57	of	O
58	the	O
59	GPI	O
60	anchor	O
61	,	O
62	respectively	O
63	.	O

1	PURPOSE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	effects	O
7	of	O
8	hypercholesterolemia	O
9	and	O
10	atherosclerosis	O
11	-	O
12	induced	O
13	chronic	O
14	cavernosal	O
15	arterial	O
16	insufficiency	O
17	on	O
18	cavernosal	O
19	smooth	O
20	muscle	O
21	tone	O
22	,	O
23	nitric	B
24	oxide	I
25	synthase	I
26	(	O
27	NOS	B
28	)	O
29	activity	O
30	and	O
31	cavernosal	O
32	tissue	O
33	synthesis	O
34	of	O
35	constrictor	O
36	eicosanoids	O
37	.	O

1	Replacement	O
2	of	O
3	residues	O
4	in	O
5	positions	O
6	+	O
7	3	O
8	(	O
9	His128Asn	O
10	)	O
11	and	O
12	+	O
13	2	O
14	(	O
15	Gln155Lys	O
16	)	O
17	of	O
18	the	O
19	reading	O
20	helices	O
21	of	O
22	fingers	O
23	2	O
24	and	O
25	3	O
26	,	O
27	respectively	O
28	,	O
29	prevented	O
30	binding	O
31	.	O

1	The	O
2	cglIM	B
3	gene	I
4	is	O
5	organized	O
6	in	O
7	an	O
8	unusual	O
9	operon	O
10	which	O
11	contains	O
12	,	O
13	in	O
14	addition	O
15	,	O
16	two	O
17	genes	O
18	encoding	O
19	stress	O
20	-	O
21	sensitive	O
22	restriction	O
23	enzymes	O
24	.	O

1	The	O
2	present	O
3	study	O
4	examined	O
5	the	O
6	effect	O
7	of	O
8	intensity	O
9	,	O
10	rate	O
11	,	O
12	and	O
13	polarity	O
14	on	O
15	the	O
16	spectral	O
17	content	O
18	of	O
19	ABRs	O
20	of	O
21	15	O
22	normal	O
23	-	O
24	hearing	O
25	subjects	O
26	.	O

1	We	O
2	found	O
3	that	O
4	both	O
5	the	O
6	E26	O
7	virus	O
8	-	O
9	encoded	O
10	v	B
11	-	I
12	ets	I
13	and	O
14	the	O
15	myeloid	B
16	/	I
17	B	I
18	-	I
19	cell	I
20	-	I
21	specific	I
22	factor	I
23	PU	I
24	.	I
25	1	I
26	bind	O
27	efficiently	O
28	to	O
29	this	O
30	site	O
31	in	O
32	vitro	O
33	.	O

1	We	O
2	present	O
3	the	O
4	preliminary	O
5	results	O
6	obtained	O
7	on	O
8	36	O
9	patients	O
10	which	O
11	were	O
12	followed	O
13	for	O
14	a	O
15	mean	O
16	period	O
17	of	O
18	12	O
19	months	O
20	.	O

1	Marinol	O
2	/	O
3	marijuana	O
4	usage	O
5	was	O
6	associated	O
7	with	O
8	depressed	O
9	CD4	B
10	+	I
11	counts	O
12	and	O
13	elevated	O
14	amylase	B
15	levels	O
16	within	O
17	the	O
18	DDI	O
19	subgroup	O
20	.	O

1	Kinetics	O
2	of	O
3	the	O
4	inhibition	O
5	indicated	O
6	that	O
7	this	O
8	polymerase	O
9	domain	O
10	can	O
11	inhibit	O
12	viral	O
13	replication	O
14	only	O
15	during	O
16	the	O
17	preinitiation	O
18	stage	O
19	.	O

1	Sequence	O
2	comparison	O
3	of	O
4	the	O
5	0	O
6	.	O
7	38	O
8	kb	O
9	promoter	O
10	sequence	O
11	with	O
12	the	O
13	promoters	O
14	of	O
15	the	O
16	Sm	B
17	-	I
18	E	I
19	gene	O
20	and	O
21	U1	B
22	snRNA	I
23	genes	I
24	revealed	O
25	several	O
26	homologous	O
27	motifs	O
28	,	O
29	suggesting	O
30	that	O
31	genes	O
32	encoding	O
33	the	O
34	snRNP	O
35	components	O
36	may	O
37	be	O
38	coordinately	O
39	regulated	O
40	.	O

1	The	O
2	selective	O
3	5	B
4	-	I
5	HT3	I
6	receptor	I
7	antagonists	O
8	ramosetron	O
9	(	O
10	YM060	O
11	),	O
12	YM114	O
13	(	O
14	KAE	O
15	-	O
16	393	O
17	),	O
18	granisetron	O
19	and	O
20	ondansetron	O
21	,	O
22	and	O
23	the	O
24	substituted	O
25	benzamides	O
26	(	O
27	5	B
28	-	I
29	HT4	I
30	receptor	I
31	agonist	O
32	/	O
33	5	B
34	-	I
35	HT3	I
36	receptor	I
37	antagonists	O
38	)	O
39	cisapride	O
40	mosapride	O
41	and	O
42	SC	O
43	-	O
44	53116	O
45	dose	O
46	-	O
47	dependently	O
48	enhanced	O
49	gastric	O
50	emptying	O
51	in	O
52	normal	O
53	rats	O
54	.	O

1	To	O
2	gain	O
3	insight	O
4	into	O
5	the	O
6	expression	O
7	of	O
8	the	O
9	AtCP1	B
10	gene	I
11	,	O
12	northern	O
13	blot	O
14	analysis	O
15	was	O
16	carried	O
17	out	O
18	.	O

1	Minor	O
2	differences	O
3	were	O
4	noted	O
5	with	O
6	latamoxef	O
7	producing	O
8	mild	O
9	persistant	O
10	elevation	O
11	of	O
12	prothrombin	B
13	time	O
14	(	O
15	0	O
16	.	O
17	7	O
18	second	O
19	)	O
20	associated	O
21	with	O
22	depression	O
23	of	O
24	factor	B
25	II	I
26	and	O
27	factor	B
28	VII	I
29	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	analyzed	O
6	human	B
7	CTCF	I
8	cDNA	I
9	clones	O
10	and	O
11	show	O
12	here	O
13	that	O
14	the	O
15	ubiquitously	O
16	expressed	O
17	11	B
18	-	I
19	zinc	I
20	-	I
21	finger	I
22	factor	I
23	CTCF	I
24	is	O
25	an	O
26	exceptionally	O
27	highly	O
28	conserved	O
29	protein	O
30	displaying	O
31	93	O
32	%	O
33	identity	O
34	between	O
35	avian	O
36	and	O
37	human	O
38	amino	O
39	acid	O
40	sequences	O
41	.	O

1	Using	O
2	a	O
3	v	B
4	-	I
5	erbA	I
6	probe	O
7	,	O
8	we	O
9	obtained	O
10	a	O
11	cDNA	O
12	which	O
13	encodes	O
14	a	O
15	novel	O
16	445	O
17	-	O
18	amino	O
19	-	O
20	acid	O
21	protein	O
22	,	O
23	RLD	B
24	-	I
25	1	I
26	,	O
27	that	O
28	contains	O
29	the	O
30	characteristic	O
31	domains	O
32	of	O
33	nuclear	O
34	receptors	O
35	.	O

1	Gonadotropin	B
2	levels	O
3	in	O
4	mothers	O
5	who	O
6	have	O
7	had	O
8	two	O
9	sets	O
10	of	O
11	DZ	O
12	twins	O
13	.	O

1	These	O
2	data	O
3	confirm	O
4	the	O
5	existence	O
6	of	O
7	hyperlipemic	O
8	abdominal	O
9	crisis	O
10	as	O
11	a	O
12	distinct	O
13	entity	O
14	and	O
15	testify	O
16	to	O
17	the	O
18	importance	O
19	of	O
20	recognizing	O
21	this	O
22	syndrome	O
23	in	O
24	order	O
25	to	O
26	avoid	O
27	the	O
28	occurrence	O
29	of	O
30	acute	O
31	pancreatitis	O
32	and	O
33	the	O
34	performance	O
35	of	O
36	unnecessary	O
37	and	O
38	potentially	O
39	harmful	O
40	surgery	O
41	.	O

1	The	O
2	mean	O
3	values	O
4	of	O
5	the	O
6	first	O
7	three	O
8	components	O
9	were	O
10	not	O
11	significantly	O
12	different	O
13	in	O
14	ARVD	O
15	patients	O
16	and	O
17	control	O
18	subjects	O
19	.	O

1	Analysis	O
2	with	O
3	additional	O
4	anti	O
5	-	O
6	peptide	O
7	antibodies	O
8	specific	O
9	for	O
10	alpha	B
11	,	I
12	beta	I
13	,	I
14	or	I
15	gamma	I
16	PKC	I
17	indicated	O
18	that	O
19	all	O
20	three	O
21	types	O
22	of	O
23	PKC	B
24	are	O
25	expressed	O
26	in	O
27	JK	O
28	cells	O
29	;	O
30	however	O
31	,	O
32	JKPE	O
33	cells	O
34	lost	O
35	a	O
36	major	O
37	approximately	O
38	82	O
39	kDa	O
40	immunoreactive	O
41	cytosolic	O
42	protein	O
43	detectable	O
44	with	O
45	anti	B
46	-	I
47	PKC	I
48	alpha	I
49	antibody	I
50	.	O

1	Patients	O
2	with	O
3	types	O
4	I	O
5	and	O
6	III	O
7	MPGN	O
8	did	O
9	not	O
10	differ	O
11	in	O
12	age	O
13	at	O
14	apparent	O
15	onset	O
16	,	O
17	age	O
18	at	O
19	diagnosis	O
20	,	O
21	or	O
22	interval	O
23	from	O
24	apparent	O
25	onset	O
26	of	O
27	symptoms	O
28	to	O
29	diagnosis	O
30	(	O
31	biopsy	O
32	).	O

1	220	O
2	,	O
3	263	O
4	-	O
5	273	O
6	).	O

1	First	O
2	,	O
3	two	O
4	MCTs	O
5	using	O
6	a	O
7	long	O
8	electrode	O
9	,	O
10	3	O
11	cm	O
12	in	O
13	size	O
14	,	O
15	were	O
16	performed	O
17	in	O
18	the	O
19	central	O
20	area	O
21	of	O
22	the	O
23	tumor	O
24	,	O
25	and	O
26	eight	O
27	MCTs	O
28	by	O
29	a	O
30	short	O
31	electrode	O
32	,	O
33	2	O
34	cm	O
35	in	O
36	size	O
37	,	O
38	were	O
39	done	O
40	in	O
41	the	O
42	peripheral	O
43	and	O
44	surrounding	O
45	area	O
46	of	O
47	the	O
48	tumor	O
49	.	O

1	Is	O
2	desensitization	O
3	'	O
4	for	O
5	ragweed	O
6	hay	O
7	fever	O
8	immunologically	O
9	specific	O
10	?	O

1	BRCA1	B
2	protein	I
3	contains	O
4	an	O
5	amino	O
6	-	O
7	terminal	O
8	zinc	O
9	finger	O
10	motif	O
11	and	O
12	a	O
13	carboxy	O
14	-	O
15	terminal	O
16	acidic	O
17	region	O
18	.	O

1	Gemfibrozil	O
2	in	O
3	hyperlipidaemic	O
4	patients	O
5	with	O
6	peripheral	O
7	arterial	O
8	disease	O
9	:	O
10	some	O
11	undiscovered	O
12	actions	O
13	.	O

1	F	B
2	-	I
3	box	I
4	proteins	I
5	are	O
6	receptors	O
7	that	O
8	recruit	O
9	phosphorylated	O
10	substrates	O
11	to	O
12	the	O
13	SCF	B
14	ubiquitin	I
15	-	O
16	ligase	B
17	complex	O
18	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	chromosomal	O
5	segment	O
6	64AB	O
7	,	O
8	a	O
9	region	O
10	containing	O
11	the	O
12	glutamic	B
13	acid	I
14	decarboxylase	I
15	gene	I
16	.	O

1	Lck	B
2	has	O
3	been	O
4	postulated	O
5	to	O
6	dimerize	O
7	through	O
8	the	O
9	SH2	B
10	and	O
11	SH3	B
12	domains	I
13	.	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	nucleotide	O
6	(	O
7	nt	O
8	)	O
9	sequence	O
10	of	O
11	the	O
12	7	B
13	.	I
14	5	I
15	-	I
16	kb	I
17	COR	I
18	segment	I
19	that	O
20	encompasses	O
21	a	O
22	cluster	O
23	of	O
24	six	O
25	genes	O
26	(	O
27	CYC1	B
28	,	O
29	UTR1	B
30	,	O
31	UTR3	B
32	,	O
33	OSM1	B
34	,	O
35	tRNA	B
36	(	I
37	Gly	I
38	)	I
39	and	O
40	RAD7	B
41	)	O
42	located	O
43	on	O
44	chromosome	O
45	X	O
46	of	O
47	the	O
48	yeast	O
49	Saccharomyces	O
50	cerevisiae	O
51	.	O

1	No	O
2	TATA	O
3	or	O
4	Inr	O
5	sequence	O
6	was	O
7	found	O
8	.	O

1	The	O
2	effects	O
3	of	O
4	Codonopsis	O
5	pilosula	O
6	oral	O
7	liquor	O
8	(	O
9	CPOL	O
10	)	O
11	on	O
12	tissue	B
13	-	I
14	type	I
15	plasminogen	I
16	activator	I
17	(	O
18	t	B
19	-	I
20	PA	I
21	)	O
22	and	O
23	plasminogen	B
24	activator	I
25	inhibitor	I
26	(	O
27	PAI	B
28	)	O
29	in	O
30	the	O
31	plasma	O
32	of	O
33	25	O
34	patients	O
35	of	O
36	coronary	O
37	heart	O
38	disease	O
39	with	O
40	blood	O
41	stasis	O
42	were	O
43	studied	O
44	.	O

1	BACKGROUND	O
2	:	O
3	We	O
4	conducted	O
5	a	O
6	phase	O
7	I	O
8	study	O
9	with	O
10	MDL	O
11	73	O
12	,	O
13	147EF	O
14	,	O
15	a	O
16	new	O
17	5	B
18	hydroxytryptamine	I
19	3	I
20	(	I
21	5	I
22	-	I
23	HT3	I
24	)	I
25	receptor	I
26	antagonist	O
27	,	O
28	in	O
29	25	O
30	patients	O
31	requiring	O
32	emetogenic	O
33	chemotherapy	O
34	.	O

1	Our	O
2	findings	O
3	provide	O
4	the	O
5	first	O
6	evidence	O
7	that	O
8	the	O
9	function	O
10	of	O
11	WT1	B
12	can	O
13	be	O
14	modulated	O
15	by	O
16	its	O
17	phosphorylation	O
18	in	O
19	vivo	O
20	.	O

1	Based	O
2	on	O
3	these	O
4	data	O
5	,	O
6	we	O
7	conclude	O
8	that	O
9	transcription	O
10	of	O
11	prgX	B
12	is	O
13	initiated	O
14	from	O
15	the	O
16	Qa	B
17	promoter	I
18	in	O
19	prgQ	B
20	,	O
21	and	O
22	PrgX	B
23	autoregulates	O
24	its	O
25	transcription	O
26	either	O
27	by	O
28	mediating	O
29	transcriptional	O
30	readthrough	O
31	or	O
32	increasing	O
33	mRNA	O
34	stability	O
35	.	O

1	Lack	O
2	of	O
3	controlled	O
4	prospective	O
5	studies	O
6	of	O
7	sleep	O
8	electroencephalograms	O
9	(	O
10	EEG	O
11	),	O
12	and	O
13	the	O
14	use	O
15	of	O
16	medication	O
17	,	O
18	in	O
19	children	O
20	with	O
21	developmental	O
22	dysphasia	O
23	,	O
24	may	O
25	deny	O
26	appropriate	O
27	treatment	O
28	strategies	O
29	to	O
30	children	O
31	with	O
32	severe	O
33	developmental	O
34	speech	O
35	and	O
36	language	O
37	disorders	O
38	.	O

1	Immunoprecipitation	O
2	experiments	O
3	using	O
4	DokR	B
5	-	I
6	specific	I
7	antibodies	I
8	revealed	O
9	an	O
10	interaction	O
11	between	O
12	endogenous	B
13	DokR	I
14	and	O
15	a	O
16	150	O
17	-	O
18	kDa	O
19	protein	O
20	that	O
21	is	O
22	tyrosine	O
23	-	O
24	phosphorylated	O
25	in	O
26	EGF	B
27	-	O
28	stimulated	O
29	BaF	O
30	/	O
31	3	O
32	cells	O
33	.	O

1	Biochemical	O
2	studies	O
3	revealed	O
4	the	O
5	expected	O
6	loss	O
7	of	O
8	ChAT	B
9	activity	O
10	in	O
11	the	O
12	dorsal	O
13	and	O
14	ventral	O
15	hippocampi	O
16	of	O
17	lesioned	O
18	animals	O
19	along	O
20	with	O
21	elevated	O
22	levels	O
23	of	O
24	norepinephrine	O
25	(	O
26	NE	O
27	)	O
28	in	O
29	the	O
30	dorsal	O
31	hippocampus	O
32	of	O
33	MS	O
34	/	O
35	HSI	O
36	animals	O
37	.(	O
38	ABSTRACT	O
39	TRUNCATED	O
40	AT	O
41	250	O
42	WORDS	O
43	)	O

1	In	O
2	the	O
3	local	O
4	geomagnetic	O
5	field	O
6	,	O
7	the	O
8	animals	O
9	preferred	O
10	the	O
11	SE	O
12	-	O
13	sector	O
14	.	O

1	Fatal	O
2	encephalitis	O
3	in	O
4	a	O
5	patient	O
6	with	O
7	chronic	O
8	graft	O
9	-	O
10	versus	O
11	-	O
12	host	O
13	disease	O
14	.	O

1	W	O
2	.	O

1	In	O
2	contrast	O
3	,	O
4	gel	O
5	mobility	O
6	shift	O
7	experiments	O
8	have	O
9	failed	O
10	to	O
11	reveal	O
12	that	O
13	HAP2	B
14	or	O
15	HAP3	B
16	binds	O
17	to	O
18	domain	O
19	1	O
20	or	O
21	that	O
22	hap3	B
23	mutations	O
24	affect	O
25	the	O
26	complexes	O
27	bound	O
28	to	O
29	it	O
30	.	O

1	Of	O
2	208	O
3	eligible	O
4	subjects	O
5	,	O
6	82	O
7	received	O
8	supervised	O
9	IPT	O
10	at	O
11	a	O
12	dose	O
13	of	O
14	900	O
15	mg	O
16	twice	O
17	weekly	O
18	for	O
19	6	O
20	mo	O
21	(	O
22	Regimen	O
23	A	O
24	),	O
25	73	O
26	received	O
27	unsupervised	O
28	IPT	O
29	900	O
30	mg	O
31	twice	O
32	weekly	O
33	for	O
34	6	O
35	mo	O
36	(	O
37	Regimen	O
38	B	O
39	),	O
40	and	O
41	53	O
42	received	O
43	unsupervised	O
44	IPT	O
45	300	O
46	mg	O
47	daily	O
48	for	O
49	6	O
50	mo	O
51	(	O
52	Regimen	O
53	C	O
54	).	O

1	Also	O
2	discussed	O
3	is	O
4	the	O
5	possibility	O
6	of	O
7	a	O
8	combined	O
9	genetic	O
10	and	O
11	environmental	O
12	etiology	O
13	.	O

1	Analysis	O
2	of	O
3	lacZ	B
4	transcriptional	I
5	fusions	I
6	shows	O
7	that	O
8	the	O
9	KdgR	B
10	-	I
11	binding	I
12	sites	I
13	negatively	O
14	affect	O
15	the	O
16	expression	O
17	of	O
18	rsmB	B
19	.	O

1	Here	O
2	we	O
3	describe	O
4	a	O
5	mutant	O
6	alpha	O
7	subunit	O
8	designed	O
9	to	O
10	inhibit	O
11	receptor	O
12	-	O
13	mediated	O
14	hormonal	O
15	activation	O
16	of	O
17	Gs	B
18	,	O
19	the	O
20	stimulatory	O
21	regulator	O
22	of	O
23	adenylyl	B
24	cyclase	I
25	.	O

1	METHODS	O
2	:	O
3	IgG	B
4	antibodies	I
5	vs	O
6	HHV	O
7	-	O
8	6	O
9	(	O
10	anti	B
11	-	I
12	HHV	I
13	-	I
14	6	I
15	-	I
16	IgG	I
17	)	O
18	were	O
19	determined	O
20	by	O
21	indirect	O
22	immunofluorescence	O
23	in	O
24	100	O
25	IVDA	O
26	(	O
27	29	O
28	seronegative	O
29	and	O
30	71	O
31	seropositive	O
32	for	O
33	HIV	O
34	-	O
35	1	O
36	of	O
37	which	O
38	45	O
39	were	O
40	in	O
41	stage	O
42	II	O
43	and	O
44	26	O
45	in	O
46	IV	O
47	-	O
48	C1	O
49	of	O
50	CDC	O
51	)	O
52	as	O
53	well	O
54	as	O
55	in	O
56	100	O
57	healthy	O
58	subjects	O
59	of	O
60	a	O
61	similar	O
62	age	O
63	(	O
64	control	O
65	group	O
66	).	O

1	A	O
2	rabbit	O
3	antiserum	O
4	was	O
5	raised	O
6	against	O
7	a	O
8	synthetic	O
9	peptide	O
10	corresponding	O
11	to	O
12	a	O
13	hydrophilic	O
14	portion	O
15	of	O
16	the	O
17	translated	O
18	murine	O
19	cDNA	O
20	sequence	O
21	.	O

1	Virol	O
2	.	O

1	To	O
2	study	O
3	the	O
4	structure	O
5	-	O
6	function	O
7	of	O
8	the	O
9	gene	B
10	5	I
11	product	I
12	,	O
13	wild	O
14	-	O
15	type	O
16	and	O
17	mutant	O
18	forms	O
19	of	O
20	NS53	B
21	were	O
22	produced	O
23	by	O
24	using	O
25	a	O
26	recombinant	O
27	baculovirus	O
28	expression	O
29	system	O
30	and	O
31	a	O
32	recombinant	O
33	vaccinia	O
34	virus	O
35	/	O
36	T7	O
37	(	O
38	vTF7	O
39	-	O
40	3	O
41	)	O
42	expression	O
43	system	O
44	.	O

1	With	O
2	exon	O
3	trapping	O
4	,	O
5	we	O
6	could	O
7	isolate	O
8	five	O
9	potential	O
10	exons	O
11	from	O
12	the	O
13	YAC	O
14	946E12	O
15	that	O
16	spans	O
17	the	O
18	region	O
19	,	O
20	four	O
21	of	O
22	which	O
23	could	O
24	be	O
25	placed	O
26	in	O
27	the	O
28	contig	O
29	in	O
30	the	O
31	vicinity	O
32	of	O
33	the	O
34	breakpoints	O
35	.	O

1	If	O
2	NCR	O
3	-	O
4	sensitive	O
5	gene	O
6	expression	O
7	occurs	O
8	exclusively	O
9	by	O
10	this	O
11	pathway	O
12	,	O
13	as	O
14	has	O
15	been	O
16	thought	O
17	to	O
18	be	O
19	the	O
20	case	O
21	,	O
22	then	O
23	the	O
24	NCR	O
25	sensitivity	O
26	of	O
27	a	O
28	gene	O
29	'	O
30	s	O
31	expression	O
32	should	O
33	be	O
34	abolished	O
35	by	O
36	a	O
37	ure2	B
38	delta	I
39	mutation	I
40	.	O

1	However	O
2	,	O
3	when	O
4	,	O
5	where	O
6	and	O
7	how	O
8	the	O
9	DSPP	B
10	is	O
11	cleaved	O
12	into	O
13	DSP	B
14	and	O
15	DPP	B
16	is	O
17	not	O
18	clear	O
19	.	O

1	Furthermore	O
2	,	O
3	beta	B
4	2	I
5	-	I
6	adrenoceptor	I
7	sensitivity	O
8	appears	O
9	to	O
10	be	O
11	unaltered	O
12	in	O
13	BHT	O
14	.	O

1	The	O
2	final	O
3	predicted	O
4	structure	O
5	has	O
6	an	O
7	overall	O
8	backbone	O
9	deviation	O
10	of	O
11	0	O
12	.	O
13	7	O
14	A	O
15	from	O
16	that	O
17	of	O
18	ras	B
19	-	O
20	p21	B
21	.	O

1	This	O
2	loss	O
3	was	O
4	independent	O
5	of	O
6	drug	O
7	concentration	O
8	and	O
9	a	O
10	correction	O
11	factor	O
12	was	O
13	employed	O
14	to	O
15	calculate	O
16	the	O
17	true	O
18	free	O
19	diazepam	O
20	concentration	O
21	.	O

1	Transforming	B
2	growth	I
3	factor	I
4	(	I
5	TGF	I
6	)-	I
7	beta1	I
8	induces	O
9	extracellular	O
10	matrix	O
11	deposition	O
12	and	O
13	proliferation	O
14	of	O
15	mesenchymal	O
16	cells	O
17	.	O

1	NPT	B
2	II	I
3	synthesis	O
4	,	O
5	measured	O
6	by	O
7	agar	O
8	plate	O
9	assays	O
10	of	O
11	kanamycin	O
12	resistance	O
13	and	O
14	by	O
15	immunoprecipitation	O
16	of	O
17	the	O
18	NPT	B
19	II	I
20	protein	I
21	,	O
22	was	O
23	repressed	O
24	in	O
25	the	O
26	presence	O
27	of	O
28	cysteine	O
29	and	O
30	derepressed	O
31	in	O
32	its	O
33	absence	O
34	.	O

1	INTERVENTION	O
2	(	O
3	S	O
4	):	O
5	Twenty	O
6	-	O
7	six	O
8	hemostasis	O
9	parameters	O
10	evaluated	O
11	repeatedly	O
12	in	O
13	patients	O
14	undergoing	O
15	IVF	O
16	-	O
17	ET	O
18	.	O

1	Calcinosis	O
2	cutis	O
3	following	O
4	intravenous	O
5	infusion	O
6	of	O
7	calcium	O
8	gluconate	O
9	.	O

1	Subsets	O
2	of	O
3	patients	O
4	were	O
5	performed	O
6	according	O
7	to	O
8	the	O
9	severity	O
10	of	O
11	trauma	O
12	(	O
13	ISS	O
14	<	O
15	9	O
16	;	O
17	9	O
18	-	O
19	17	O
20	;	O
21	18	O
22	-	O
23	31	O
24	;	O
25	>	O
26	32	O
27	),	O
28	based	O
29	on	O
30	the	O
31	different	O
32	injury	O
33	pattern	O
34	,	O
35	and	O
36	survivors	O
37	versus	O
38	nonsurvivors	O
39	as	O
40	well	O
41	.	O

1	Transient	O
2	tyrosine	O
3	phosphorylation	O
4	of	O
5	Crk	B
6	in	O
7	fibroblast	B
8	growth	I
9	factor	I
10	-	I
11	2	I
12	-	O
13	stimulated	O
14	endothelial	O
15	cells	O
16	was	O
17	dependent	O
18	on	O
19	the	O
20	juxtamembrane	O
21	tyrosine	O
22	residue	O
23	463	O
24	in	O
25	FGFR	B
26	-	I
27	1	I
28	,	O
29	and	O
30	a	O
31	Crk	B
32	SH2	I
33	domain	I
34	precipitated	O
35	FGFR	B
36	-	I
37	1	I
38	via	O
39	phosphorylated	O
40	Tyr	O
41	-	O
42	463	O
43	,	O
44	indicating	O
45	direct	O
46	complex	O
47	formation	O
48	between	O
49	Crk	B
50	and	O
51	FGFR	B
52	-	I
53	1	I
54	.	O

1	IA	O
2	-	O
3	CT	O
4	with	O
5	cisplatin	O
6	50	O
7	mg	O
8	and	O
9	doxorubicin	O
10	30	O
11	mg	O
12	was	O
13	administered	O
14	by	O
15	one	O
16	shot	O
17	method	O
18	in	O
19	bilateral	O
20	internal	O
21	iliac	O
22	arteries	O
23	.	O

1	However	O
2	,	O
3	when	O
4	a	O
5	second	O
6	,	O
7	upstream	B
8	IRE	I
9	-	I
10	like	I
11	sequence	I
12	was	O
13	evaluated	O
14	by	O
15	EMSA	O
16	,	O
17	a	O
18	DNA	O
19	binding	O
20	pattern	O
21	distinct	O
22	from	O
23	that	O
24	seen	O
25	following	O
26	exposure	O
27	to	O
28	IFN	B
29	-	I
30	gamma	I
31	alone	O
32	was	O
33	observed	O
34	after	O
35	prolonged	O
36	stimulation	O
37	with	O
38	both	O
39	IFN	B
40	-	I
41	alpha	I
42	and	O
43	IFN	B
44	-	I
45	gamma	I
46	.	O

1	We	O
2	detected	O
3	mos	B
4	transcripts	I
5	by	O
6	Northern	O
7	(	O
8	RNA	O
9	)	O
10	analyses	O
11	in	O
12	RNA	O
13	prepared	O
14	from	O
15	chicken	O
16	and	O
17	quail	O
18	ovaries	O
19	and	O
20	testes	O
21	.	O

1	The	O
2	circadian	O
3	rhythmicity	O
4	of	O
5	sleep	O
6	was	O
7	pronounced	O
8	.	O

1	Canalith	O
2	repositioning	O
3	is	O
4	the	O
5	mainstay	O
6	of	O
7	treatment	O
8	.	O

1	Tolerance	O
2	test	O
3	of	O
4	HB	O
5	419	O
6	in	O
7	animal	O
8	experiments	O

1	Electromagnetic	O
2	blood	O
3	flow	O
4	(	O
5	BF	O
6	)	O
7	probe	O
8	was	O
9	applied	O
10	on	O
11	the	O
12	left	O
13	anterior	O
14	descending	O
15	artery	O
16	(	O
17	LAD	O
18	).	O

1	This	O
2	region	O
3	of	O
4	hsp90	B
5	mediates	O
6	ATP	O
7	-	O
8	independent	O
9	chaperone	O
10	activity	O
11	,	O
12	overlaps	O
13	the	O
14	hsp90	B
15	dimerization	I
16	domain	I
17	,	O
18	and	O
19	includes	O
20	structural	O
21	elements	O
22	important	O
23	for	O
24	steroid	B
25	receptor	I
26	interaction	O
27	.	O

1	Serum	O
2	ascorbic	O
3	acid	O
4	had	O
5	an	O
6	inverse	O
7	and	O
8	the	O
9	strongest	O
10	association	O
11	with	O
12	systolic	O
13	blood	O
14	pressure	O
15	among	O
16	the	O
17	risk	O
18	factors	O
19	including	O
20	blood	O
21	pressure	O
22	,	O
23	total	O
24	cholesterol	O
25	,	O
26	triglyceride	O
27	,	O
28	gamma	B
29	-	I
30	GTP	I
31	and	O
32	obesity	O
33	.	O

1	Fast	O
2	continuous	O
3	expansion	O
4	.	O

1	Lower	O
2	extremity	O
3	weight	O
4	bearing	O
5	under	O
6	various	O
7	standing	O
8	conditions	O
9	in	O
10	independently	O
11	ambulatory	O
12	patients	O
13	with	O
14	hemiparesis	O
15	.	O

1	The	O
2	frequency	O
3	of	O
4	lactase	B
5	phenotypes	I
6	in	O
7	Aymara	O
8	children	O
9	.	O

1	Functional	O
2	postnatal	O
3	development	O
4	of	O
5	the	O
6	rat	O
7	primary	O
8	visual	O
9	cortex	O
10	and	O
11	the	O
12	role	O
13	of	O
14	visual	O
15	experience	O
16	:	O
17	dark	O
18	rearing	O
19	and	O
20	monocular	O
21	deprivation	O
22	.	O

1	The	O
2	R	B
3	.	I
4	meliloti	I
5	nifH	I
6	promoter	I
7	but	O
8	not	O
9	the	O
10	K	B
11	.	I
12	pneumoniae	I
13	nifH	I
14	promoter	I
15	showed	O
16	sigma	B
17	54	I
18	-	O
19	dependent	O
20	methylation	O
21	protection	O
22	of	O
23	guanine	O
24	residues	O
25	at	O
26	-	O
27	14	O
28	,	O
29	-	O
30	25	O
31	and	O
32	-	O
33	26	O
34	,	O
35	the	O
36	most	O
37	conserved	O
38	nucleotides	O
39	characteristic	O
40	of	O
41	sigma	B
42	54	I
43	-	I
44	dependent	I
45	promoters	I
46	.	O

1	Synthesis	O
2	of	O
3	(+)-	O
4	lysergic	O
5	acid	O
6	diethylamide	O
7	tartrate	O

1	In	O
2	a	O
3	randomised	O
4	double	O
5	-	O
6	blind	O
7	study	O
8	,	O
9	46	O
10	first	O
11	episode	O
12	schizophrenics	O
13	were	O
14	given	O
15	pimozide	O
16	or	O
17	flupenthixol	O
18	for	O
19	up	O
20	to	O
21	5	O
22	weeks	O
23	;	O
24	the	O
25	mean	O
26	daily	O
27	dose	O
28	at	O
29	the	O
30	end	O
31	was	O
32	18	O
33	.	O
34	8	O
35	mg	O
36	pimozide	O
37	and	O
38	20	O
39	mg	O
40	flupenthixol	O
41	.	O

1	The	O
2	ether	O
3	phospholipid	O
4	1	O
5	-	O
6	O	O
7	-	O
8	octadecyl	O
9	-	O
10	2	O
11	-	O
12	O	O
13	-	O
14	methyl	O
15	-	O
16	rac	O
17	-	O
18	glycero	O
19	-	O
20	3	O
21	-	O
22	phosphocholine	O
23	(	O
24	ET	O
25	-	O
26	18	O
27	-	O
28	OCH3	O
29	;	O
30	edelfosine	O
31	)	O
32	is	O
33	a	O
34	potent	O
35	inducer	O
36	of	O
37	apoptosis	O
38	in	O
39	human	O
40	tumor	O
41	cells	O
42	.	O

1	Antipyretic	O
2	therapy	O
3	:	O
4	physiologic	O
5	rationale	O
6	,	O
7	diagnostic	O
8	implications	O
9	,	O
10	and	O
11	clinical	O
12	consequences	O
13	.	O

1	The	O
2	financial	O
3	impact	O
4	of	O
5	childhood	O
6	asthma	O
7	has	O
8	not	O
9	been	O
10	assessed	O
11	since	O
12	Vance	O
13	and	O
14	Taylor	O
15	reported	O
16	their	O
17	data	O
18	in	O
19	Annals	O
20	of	O
21	Allergy	O
22	13	O
23	years	O
24	ago	O
25	.	O

1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	RAD30	I
5	gene	I
6	,	O
7	a	O
8	homologue	B
9	of	I
10	Escherichia	I
11	coli	I
12	dinB	I
13	and	O
14	umuC	B
15	,	O
16	is	O
17	DNA	O
18	damage	O
19	inducible	O
20	and	O
21	functions	O
22	in	O
23	a	O
24	novel	O
25	error	O
26	-	O
27	free	O
28	postreplication	O
29	repair	O
30	mechanism	O
31	.	O

1	To	O
2	test	O
3	promotor	O
4	function	O
5	,	O
6	chimeric	O
7	genes	O
8	were	O
9	constructed	O
10	linking	O
11	fragments	O
12	of	O
13	chicken	O
14	IGF	B
15	-	I
16	I	I
17	5	O
18	'-	O
19	flanking	O
20	DNA	O
21	to	O
22	a	O
23	promoterless	O
24	reporter	O
25	plasmid	O
26	.	O

1	3	O
2	'	O
3	RNA	O
4	boundary	O
5	experiments	O
6	indicate	O
7	that	O
8	the	O
9	5	O
10	'	O
11	structure	O
12	reduces	O
13	the	O
14	number	O
15	of	O
16	(	O
17	G	O
18	/	O
19	U	O
20	)	O
21	AG	O
22	repeats	O
23	required	O
24	for	O
25	stable	O
26	TRAP	B
27	-	O
28	trp	B
29	leader	O
30	RNA	O
31	association	O
32	.	O

1	The	O
2	naltrexone	O
3	/	O
4	lofexidine	O
5	combination	O
6	was	O
7	associated	O
8	with	O
9	a	O
10	more	O
11	rapid	O
12	resolution	O
13	of	O
14	the	O
15	opiate	O
16	withdrawal	O
17	syndrome	O
18	than	O
19	a	O
20	7	O
21	-	O
22	day	O
23	lofexidine	O
24	-	O
25	only	O
26	treatment	O
27	schedule	O
28	,	O
29	without	O
30	substantial	O
31	increases	O
32	in	O
33	withdrawal	O
34	symptoms	O
35	or	O
36	hypotensive	O
37	side	O
38	-	O
39	effects	O
40	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	examined	O
6	hepatic	O
7	stellate	O
8	cell	O
9	regulation	O
10	of	O
11	M6P	B
12	/	O
13	IGFIIR	B
14	expression	O
15	and	O
16	found	O
17	that	O
18	M6P	B
19	/	O
20	IGFIIR	B
21	mRNA	O
22	transcript	O
23	levels	O
24	increased	O
25	in	O
26	stellate	O
27	cells	O
28	from	O
29	rats	O
30	exposed	O
31	to	O
32	carbon	O
33	tetrachloride	O
34	(	O
35	CCl4	O
36	),	O
37	a	O
38	potent	O
39	fibrogenic	O
40	stimulant	O
41	.	O

1	However	O
2	,	O
3	whether	O
4	or	O
5	not	O
6	nonsense	O
7	codon	O
8	recognition	O
9	within	O
10	TPI	B
11	transcripts	I
12	takes	O
13	place	O
14	prior	O
15	to	O
16	or	O
17	after	O
18	splicing	O
19	remained	O
20	unresolved	O
21	.	O

1	Acad	O
2	.	O

1	Conditions	O
2	influencing	O
3	inhibitors	O
4	of	O
5	the	O
6	colony	B
7	-	I
8	stimulating	I
9	factor	I
10	(	O
11	CSF	B
12	).	O

1	For	O
2	the	O
3	5HT5A	B
4	receptor	I
5	the	O
6	addition	O
7	of	O
8	yohimbine	O
9	resulted	O
10	in	O
11	a	O
12	similar	O
13	but	O
14	smaller	O
15	effect	O
16	.	O

1	Rice	B
2	dwarf	I
3	phytoreovirus	I
4	segment	I
5	S12	I
6	transcript	I
7	is	O
8	tricistronic	O
9	in	O
10	vitro	O
11	.	O

1	(	O
2	3	O
3	).	O

1	[	B
2	Ala85	I
3	]	I
4	Dk	I
5	(	I
6	69	I
7	-	I
8	85	I
9	)	I
10	retains	O
11	full	O
12	biological	O
13	activity	O
14	.	O

1	1	O
2	.	O

1	Salazopyrine	O
2	desensitization	O

1	MSSPs	B
2	are	O
3	believed	O
4	to	O
5	regulate	O
6	DNA	O
7	replication	O
8	,	O
9	transcription	O
10	,	O
11	apopotosis	O
12	and	O
13	cell	O
14	cycle	O
15	progression	O
16	by	O
17	interacting	O
18	with	O
19	the	O
20	C	B
21	-	I
22	MYC	I
23	protein	I
24	.	O

1	Interferon	B
2	Regulatory	I
3	Factor	I
4	(	I
5	IRF	I
6	)-	I
7	1	I
8	has	O
9	been	O
10	characterized	O
11	as	O
12	an	O
13	important	O
14	growth	O
15	regulatory	O
16	and	O
17	immunomodulatory	O
18	transcription	O
19	factor	O
20	.	O

1	Cloning	O
2	of	O
3	a	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	CDC2	B
9	-	I
10	related	I
11	kinase	I
12	by	O
13	complementation	O
14	of	O
15	a	O
16	budding	B
17	yeast	I
18	cdc28	I
19	mutation	O
20	.	O

1	The	O
2	mRNAs	O
3	of	O
4	the	O
5	GRF	B
6	genes	I
7	are	O
8	encoded	O
9	by	O
10	six	O
11	exons	O
12	interrupted	O
13	by	O
14	five	O
15	introns	O
16	.	O

1	It	O
2	can	O
3	also	O
4	be	O
5	used	O
6	to	O
7	examine	O
8	various	O
9	laryngeal	O
10	parameters	O
11	obtained	O
12	from	O
13	videotaped	O
14	endoscopic	O
15	and	O
16	stroboscopic	O
17	examinations	O
18	.	O

1	Most	O
2	of	O
3	the	O
4	prepeptide	O
5	portion	O
6	of	O
7	the	O
8	precursor	O
9	polypeptide	O
10	is	O
11	encoded	O
12	by	O
13	the	O
14	next	O
15	three	O
16	exons	O
17	,	O
18	and	O
19	the	O
20	mature	O
21	form	O
22	of	O
23	IL	B
24	-	I
25	1	I
26	alpha	I
27	is	O
28	encoded	O
29	by	O
30	the	O
31	remaining	O
32	three	O
33	exons	O
34	.	O

1	Cystatin	B
2	A	I
3	,	O
4	a	O
5	cysteine	B
6	proteinase	I
7	inhibitor	O
8	,	O
9	is	O
10	one	O
11	of	O
12	the	O
13	precursor	O
14	proteins	O
15	of	O
16	cornified	B
17	cell	I
18	envelope	I
19	of	O
20	keratinocytes	O
21	and	O
22	is	O
23	expressed	O
24	during	O
25	the	O
26	late	O
27	stage	O
28	of	O
29	keratinocyte	O
30	differentiation	O
31	.	O

1	Furthermore	O
2	,	O
3	no	O
4	Shine	O
5	-	O
6	Dalgarno	O
7	sequences	O
8	are	O
9	present	O
10	upstream	O
11	of	O
12	the	O
13	presumed	O
14	translational	O
15	start	O
16	codons	O
17	.	O

1	Fourteen	O
2	different	O
3	species	O
4	(	O
5	eight	O
6	Platyhelmintha	O
7	,	O
8	one	O
9	Nematoda	O
10	and	O
11	five	O
12	Crustacea	O
13	)	O
14	have	O
15	been	O
16	inventorized	O
17	.	O

1	Their	O
2	biosynthesis	O
3	proceeds	O
4	via	O
5	linear	O
6	precursors	O
7	that	O
8	become	O
9	branched	O
10	by	O
11	beta1	B
12	,	I
13	6	I
14	-	I
15	GlcNAc	I
16	transferases	I
17	(	O
18	IGnT6	O
19	,	O
20	GlcNAc	O
21	to	O
22	Gal	O
23	).	O

1	Chem	O
2	.	O

1	Yusuf	O
2	Dawood	O
3	Docrat	O
4	L	O
5	.	O
6	R	O
7	.	O
8	C	O
9	.	O
10	P	O
11	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	destrin	B
8	is	O
9	165	O
10	residues	O
11	long	O
12	and	O
13	is	O
14	very	O
15	similar	O
16	(	O
17	71	O
18	%	O
19	identical	O
20	)	O
21	to	O
22	that	O
23	of	O
24	cofilin	B
25	,	O
26	a	O
27	widely	O
28	distributed	O
29	,	O
30	pH	O
31	-	O
32	sensitive	O
33	actin	B
34	-	O
35	modulating	O
36	protein	O
37	.	O

1	Cyclin	B
2	-	I
3	dependent	I
4	kinase	I
5	-	I
6	2	I
7	(	O
8	Cdk2	B
9	)	O
10	forms	O
11	an	O
12	inactive	O
13	complex	O
14	with	O
15	cyclin	B
16	D1	I
17	since	O
18	Cdk2	B
19	associated	O
20	with	O
21	cyclin	B
22	D1	I
23	is	O
24	not	O
25	phosphorylated	O
26	by	O
27	Cdk7	B
28	-	O
29	cyclin	B
30	-	I
31	H	I
32	.	O

1	Mobility	O
2	and	O
3	supershift	O
4	assays	O
5	demonstrated	O
6	that	O
7	upstream	B
8	stimulatory	I
9	factor	I
10	(	O
11	USF	B
12	)	O
13	and	O
14	Sp1	B
15	bind	O
16	to	O
17	the	O
18	former	O
19	elements	O
20	and	O
21	competition	O
22	experiments	O
23	confirmed	O
24	that	O
25	CREB	B
26	/	O
27	ATF	B
28	and	O
29	AP	B
30	-	I
31	1	I
32	bind	O
33	to	O
34	the	O
35	CRE	O
36	/	O
37	TRE	O
38	element	O
39	.	O

1	During	O
2	skeletal	O
3	muscle	O
4	development	O
5	,	O
6	different	O
7	types	O
8	of	O
9	muscle	O
10	fibers	O
11	are	O
12	generated	O
13	,	O
14	which	O
15	express	O
16	different	O
17	combinations	O
18	of	O
19	muscle	O
20	-	O
21	specific	O
22	gene	O
23	products	O
24	.	O

1	We	O
2	conclude	O
3	that	O
4	common	O
5	upstream	O
6	signals	O
7	cause	O
8	activation	O
9	of	O
10	Ras	B
11	and	O
12	TC21	B
13	,	O
14	but	O
15	activated	O
16	TC21	B
17	controls	O
18	cell	O
19	growth	O
20	via	O
21	distinct	O
22	Raf	B
23	-	O
24	independent	O
25	downstream	O
26	signaling	O
27	pathways	O
28	.	O

1	In	O
2	all	O
3	experimental	O
4	eyes	O
5	,	O
6	there	O
7	was	O
8	a	O
9	marked	O
10	reduction	O
11	,	O
12	but	O
13	never	O
14	a	O
15	complete	O
16	absence	O
17	of	O
18	adrenergic	O
19	nerves	O
20	in	O
21	the	O
22	iris	O
23	.	O

1	A	O
2	TATA	O
3	-	O
4	less	O
5	promoter	O
6	containing	O
7	binding	O
8	sites	O
9	for	O
10	ubiquitous	O
11	transcription	O
12	factors	O
13	mediates	O
14	cell	O
15	type	O
16	-	O
17	specific	O
18	regulation	O
19	of	O
20	the	O
21	gene	O
22	for	O
23	transcription	B
24	enhancer	I
25	factor	I
26	-	I
27	1	I
28	(	O
29	TEF	B
30	-	I
31	1	I
32	).	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	increase	O
7	in	O
8	V	O
9	O2	O
10	may	O
11	have	O
12	been	O
13	a	O
14	consequence	O
15	of	O
16	the	O
17	increase	O
18	in	O
19	Q	O
20	O2	O
21	rather	O
22	than	O
23	a	O
24	response	O
25	to	O
26	the	O
27	procedure	O
28	itself	O
29	.	O

1	This	O
2	region	O
3	contains	O
4	a	O
5	motif	O
6	with	O
7	partial	O
8	identity	O
9	with	O
10	the	O
11	binding	O
12	site	O
13	for	O
14	the	O
15	ubiquitous	O
16	transcription	O
17	factor	O
18	upstream	B
19	stimulatory	I
20	factor	I
21	(	O
22	USF	B
23	),	O
24	which	O
25	binds	O
26	to	O
27	the	O
28	human	B
29	insulin	I
30	promoter	I
31	.	O

1	A	O
2	neonatal	O
3	alloimmune	O
4	thrombocytopenia	O
5	with	O
6	an	O
7	HPA	B
8	-	I
9	3a	I
10	(	O
11	Baka	O
12	)	O
13	incompatibility	O
14	was	O
15	confirmed	O
16	.	O

1	Similar	O
2	to	O
3	Hp140	B
4	,	O
5	isolated	O
6	Hp55	B
7	binds	O
8	DNA	O
9	with	O
10	moderate	O
11	strength	O
12	and	O
13	was	O
14	a	O
15	specificity	O
16	for	O
17	double	O
18	-	O
19	stranded	O
20	primer	O
21	-	O
22	template	O
23	DNA	O
24	.	O

1	The	O
2	incidence	O
3	of	O
4	fetal	O
5	breathing	O
6	movements	O
7	(	O
8	06	O
9	.	O
10	00	O
11	-	O
12	10	O
13	.	O
14	00	O
15	h	O
16	)	O
17	decreased	O
18	with	O
19	increasing	O
20	gestational	O
21	age	O
22	while	O
23	fetal	O
24	arterial	O
25	concentrations	O
26	of	O
27	plasma	O
28	PGE	O
29	increased	O
30	significantly	O
31	over	O
32	the	O
33	same	O
34	period	O
35	of	O
36	gestation	O
37	.	O

1	A	O
2	prospective	O
3	trial	O
4	was	O
5	carried	O
6	out	O
7	in	O
8	156	O
9	unselected	O
10	patients	O
11	(	O
12	41	O
13	men	O
14	,	O
15	mean	O
16	age	O
17	67	O
18	.	O
19	5	O
20	years	O
21	,	O
22	115	O
23	women	O
24	,	O
25	mean	O
26	age	O
27	71	O
28	.	O
29	4	O
30	years	O
31	)	O
32	who	O
33	had	O
34	undergone	O
35	total	O
36	hip	O
37	joint	O
38	replacement	O
39	because	O
40	of	O
41	degenerative	O
42	or	O
43	inflammatory	O
44	arthritis	O
45	or	O
46	fracture	O
47	of	O
48	the	O
49	neck	O
50	of	O
51	the	O
52	femur	O
53	.	O

1	In	O
2	patients	O
3	with	O
4	limited	O
5	disease	O
6	,	O
7	the	O
8	survival	O
9	in	O
10	the	O
11	alternating	O
12	arm	O
13	was	O
14	significantly	O
15	superior	O
16	to	O
17	the	O
18	survival	O
19	in	O
20	the	O
21	CAV	O
22	arm	O
23	(	O
24	P	O
25	=	O
26	.	O
27	014	O
28	)	O
29	or	O
30	the	O
31	survival	O
32	in	O
33	the	O
34	PE	O
35	arm	O
36	(	O
37	P	O
38	=	O
39	.	O
40	023	O
41	).	O

1	The	O
2	interindividual	O
3	variability	O
4	of	O
5	the	O
6	parameters	O
7	is	O
8	taken	O
9	into	O
10	consideration	O
11	by	O
12	interactively	O
13	determining	O
14	the	O
15	threshold	O
16	levels	O
17	.	O

1	Early	O
2	heparin	O
3	therapy	O
4	in	O
5	60	O
6	children	O
7	with	O
8	acute	O
9	meningococcemia	O
10	.	O

1	The	O
2	CT	O
3	characteristics	O
4	are	O
5	discussed	O
6	and	O
7	the	O
8	recent	O
9	literature	O
10	is	O
11	reviewed	O
12	.	O

1	Of	O
2	165	O
3	women	O
4	with	O
5	non	O
6	-	O
7	malignant	O
8	diagnoses	O
9	26	O
10	(	O
11	16	O
12	%)	O
13	had	O
14	CA	B
15	125	I
16	levels	O
17	in	O
18	excess	O
19	of	O
20	35	O
21	U	O
22	/	O
23	ml	O
24	and	O
25	8	O
26	(	O
27	5	O
28	%)	O
29	greater	O
30	than	O
31	65	O
32	U	O
33	/	O
34	ml	O
35	.	O

1	Considering	O
2	these	O
3	sources	O
4	of	O
5	error	O
6	some	O
7	of	O
8	the	O
9	variability	O
10	in	O
11	the	O
12	present	O
13	investigation	O
14	might	O
15	be	O
16	avoided	O
17	by	O
18	systematic	O
19	instructions	O
20	.	O

1	The	O
2	present	O
3	paper	O
4	elucidates	O
5	the	O
6	existing	O
7	discrepancies	O
8	,	O
9	and	O
10	offers	O
11	a	O
12	consistent	O
13	terminology	O
14	incorporating	O
15	also	O
16	such	O
17	terms	O
18	as	O
19	"	O
20	additivity	O
21	",	O
22	"	O
23	potentiation	O
24	",	O
25	and	O
26	"	O
27	simple	O
28	similarity	O
29	".	O

1	In	O
2	gel	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	low	O
8	binding	O
9	activity	O
10	of	O
11	CBF	B
12	to	O
13	the	O
14	wild	B
15	-	I
16	type	I
17	AtpC	I
18	promoter	I
19	sequence	I
20	was	O
21	observed	O
22	with	O
23	nuclear	O
24	extracts	O
25	from	O
26	tissue	O
27	with	O
28	low	O
29	AtpC	B
30	expression	O
31	levels	O
32	,	O
33	i	O
34	.	O
35	e	O
36	.	O
37	extracts	O
38	from	O
39	etiolated	O
40	and	O
41	photobleached	O
42	seedlings	O
43	,	O
44	whereas	O
45	high	O
46	binding	O
47	activity	O
48	was	O
49	detectable	O
50	with	O
51	extracts	O
52	from	O
53	tissues	O
54	with	O
55	high	O
56	AtpC	B
57	expression	O
58	levels	O
59	,	O
60	i	O
61	.	O
62	e	O
63	.	O
64	extracts	O
65	from	O
66	light	O
67	-	O
68	grown	O
69	seedlings	O
70	and	O
71	etiolated	O
72	seedlings	O
73	treated	O
74	with	O
75	cytokinin	B
76	.	O

1	Computer	O
2	software	O
3	assisted	O
4	ordering	O
5	(	O
6	CSAO	O
7	)	O
8	was	O
9	developed	O
10	to	O
11	integrate	O
12	PN	O
13	Ca	O
14	:	O
15	P	O
16	solubility	O
17	with	O
18	clinical	O
19	data	O
20	to	O
21	improve	O
22	parenteral	O
23	Ca	O
24	and	O
25	P	O
26	administration	O
27	.	O

1	However	O
2	the	O
3	sequence	O
4	surrounding	O
5	the	O
6	transcription	O
7	start	O
8	site	O
9	CTCA	O
10	(+	O
11	1	O
12	)	O
13	TTCC	O
14	was	O
15	similar	O
16	to	O
17	the	O
18	consensus	O
19	CTCA	O
20	(+	O
21	1	O
22	)	O
23	NTCT	O
24	(	O
25	N	O
26	is	O
27	any	O
28	nucleoside	O
29	)	O
30	for	O
31	an	O
32	initiator	O
33	element	O
34	found	O
35	in	O
36	terminal	B
37	deoxynucleotidyltransferase	I
38	and	O
39	a	O
40	number	O
41	of	O
42	other	O
43	highly	O
44	regulated	O
45	genes	O
46	.	O

1	The	O
2	pen	O
3	can	O
4	heal	O
5	.	O

1	On	O
2	parents	O

1	CONCLUSIONS	O
2	:	O
3	While	O
4	INR	O
5	correction	O
6	may	O
7	be	O
8	achieved	O
9	by	O
10	all	O
11	the	O
12	above	O
13	methods	O
14	,	O
15	that	O
16	relating	O
17	log	O
18	reference	O
19	INR	O
20	to	O
21	log	O
22	local	O
23	prothrombin	B
24	time	O
25	by	O
26	linear	O
27	regression	O
28	analysis	O
29	is	O
30	the	O
31	simplest	O
32	to	O
33	perform	O
34	.	O

1	(	O
2	1996a	O
3	)	O
4	Biochemistry	O
5	35	O
6	,	O
7	1589	O
8	-	O
9	1598	O
10	].	O

1	Therefore	O
2	,	O
3	the	O
4	results	O
5	indicate	O
6	that	O
7	repeated	O
8	exposure	O
9	to	O
10	amphetamine	O
11	or	O
12	apomorphine	O
13	overcomes	O
14	the	O
15	context	O
16	-	O
17	dependent	O
18	component	O
19	of	O
20	sensitization	O
21	of	O
22	amphetamine	O
23	-	O
24	or	O
25	apomorphine	O
26	-	O
27	induced	O
28	stereotyped	O
29	behavior	O
30	.	O

1	Forty	O
2	patients	O
3	,	O
4	divided	O
5	according	O
6	to	O
7	their	O
8	initial	O
9	total	O
10	gastrointestinal	O
11	transit	O
12	times	O
13	and	O
14	presenting	O
15	symptoms	O
16	,	O
17	were	O
18	treated	O
19	with	O
20	cimetropium	O
21	bromide	O
22	50	O
23	mg	O
24	t	O
25	.	O
26	d	O
27	.	O
28	s	O
29	.	O
30	or	O
31	placebo	O
32	for	O
33	1	O
34	month	O
35	according	O
36	to	O
37	a	O
38	double	O
39	-	O
40	blind	O
41	,	O
42	parallel	O
43	group	O
44	design	O
45	.	O

1	Transcripts	O
2	from	O
3	a	O
4	second	O
5	POU	B
6	-	I
7	domain	I
8	gene	I
9	,	O
10	Oct	B
11	-	I
12	25	I
13	,	O
14	were	O
15	present	O
16	at	O
17	low	O
18	levels	O
19	in	O
20	oocytes	O
21	and	O
22	early	O
23	embryos	O
24	and	O
25	were	O
26	dramatically	O
27	upregulated	O
28	during	O
29	early	O
30	gastrulation	O
31	.	O

1	Piroximone	O
2	is	O
3	a	O
4	new	O
5	phosphodiesterase	B
6	III	I
7	inhibitor	O
8	that	O
9	combines	O
10	inotropic	O
11	and	O
12	vasodilator	O
13	properties	O
14	.	O

1	A	O
2	mutant	O
3	form	O
4	of	O
5	Vps1p	B
6	lacking	O
7	the	O
8	entire	O
9	GTP	O
10	-	O
11	binding	O
12	domain	O
13	interfered	O
14	with	O
15	vacuolar	O
16	protein	O
17	sorting	O
18	in	O
19	wild	O
20	-	O
21	type	O
22	cells	O
23	.	O

1	Using	O
2	gel	O
3	retardation	O
4	assays	O
5	with	O
6	HepG2	O
7	nuclear	O
8	extract	O
9	,	O
10	we	O
11	demonstrated	O
12	the	O
13	presence	O
14	of	O
15	a	O
16	specific	O
17	protein	O
18	which	O
19	bound	O
20	to	O
21	the	O
22	NRE	O
23	fragment	O
24	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	cis	O
6	elements	O
7	positioned	O
8	between	O
9	the	O
10	alpha	B
11	3	I
12	and	O
13	beta	B
14	4	I
15	coding	O
16	regions	O
17	are	O
18	important	O
19	for	O
20	establishing	O
21	part	O
22	of	O
23	the	O
24	restricted	O
25	CNS	O
26	patterns	O
27	of	O
28	beta	B
29	4	I
30	,	O
31	alpha	B
32	3	I
33	,	O
34	and	O
35	alpha	B
36	5	I
37	gene	I
38	transcription	O
39	.	O

1	Enhancer	O
2	and	O
3	promoter	O
4	elements	O
5	directing	O
6	activation	O
7	and	O
8	glucocorticoid	O
9	repression	O
10	of	O
11	the	O
12	alpha	B
13	1	I
14	-	I
15	fetoprotein	I
16	gene	I
17	in	O
18	hepatocytes	O
19	.	O

1	In	O
2	the	O
3	studies	O
4	described	O
5	in	O
6	this	O
7	report	O
8	,	O
9	we	O
10	have	O
11	investigated	O
12	the	O
13	signaling	O
14	pathway	O
15	(	O
16	s	O
17	)	O
18	that	O
19	are	O
20	responsible	O
21	for	O
22	CREB	B
23	activation	O
24	in	O
25	normal	O
26	T	O
27	cells	O
28	.	O

1	On	O
2	d	O
3	112	O
4	,	O
5	progesterone	O
6	was	O
7	higher	O
8	(	O
9	P	O
10	less	O
11	than	O
12	.	O
13	05	O
14	)	O
15	in	O
16	hysterectomized	O
17	heifers	O
18	than	O
19	in	O
20	other	O
21	treatment	O
22	groups	O
23	.	O

1	Dopamine	O
2	SERS	O
3	spectra	O
4	from	O
5	these	O
6	electrodes	O
7	are	O
8	similar	O
9	to	O
10	those	O
11	obtained	O
12	at	O
13	uncoated	O
14	electrodes	O
15	.	O

1	The	O
2	recombinant	O
3	enzymes	O
4	exist	O
5	as	O
6	monomers	O
7	.	O

1	Chronic	O
2	dose	O
3	effects	O
4	of	O
5	methyl	O
6	parathion	O
7	on	O
8	nuthatches	O
9	:	O
10	cholinesterase	B
11	and	O
12	ptilochronology	O
13	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	minimal	O
7	catalytic	O
8	domain	O
9	of	O
10	Nmt1p	B
11	is	O
12	located	O
13	between	O
14	Ile59	O
15	-->	O
16	Phe96	O
17	and	O
18	Gly451	O
19	-->	O
20	Leu455	O
21	.	O

1	The	O
2	factor	O
3	structure	O
4	of	O
5	"	O
6	schizotypal	O
7	'	O
8	traits	O
9	:	O
10	a	O
11	large	O
12	replication	O
13	study	O
14	.	O

1	Structural	O
2	changes	O
3	in	O
4	the	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	Ca2	O
10	+-	O
11	bound	O
12	rat	B
13	S100B	I
14	(	O
15	beta	B
16	beta	I
17	)	O
18	upon	O
19	binding	O
20	to	O
21	a	O
22	peptide	O
23	derived	O
24	from	O
25	the	O
26	C	O
27	-	O
28	terminal	O
29	regulatory	O
30	domain	O
31	of	O
32	p53	B
33	.	O

1	Unusual	O
2	course	O
3	of	O
4	plasmocytosis	O
5	.	O

1	Lymphatics	O
2	in	O
3	the	O
4	aorta	O
5	of	O
6	rats	O
7	treated	O
8	with	O
9	a	O
10	soy	O
11	-	O
12	bean	O
13	oil	O
14	extract	O
15	(	O
16	lipofundin	O
17	).	O

1	A	O
2	portion	O
3	of	O
4	Region	O
5	II	O
6	also	O
7	resembles	O
8	part	O
9	of	O
10	the	O
11	human	O
12	c	B
13	-	I
14	jun	I
15	oncoprotein	O
16	'	O
17	s	O
18	leucine	O
19	zipper	O
20	,	O
21	which	O
22	in	O
23	turn	O
24	,	O
25	has	O
26	been	O
27	demonstrated	O
28	to	O
29	be	O
30	the	O
31	heterodimerization	O
32	site	O
33	between	O
34	the	O
35	jun	B
36	and	O
37	fos	B
38	oncoproteins	I
39	.	O

1	Other	O
2	uncertainties	O
3	in	O
4	the	O
5	dosimetry	O
6	at	O
7	Y	O
8	-	O
9	12	O
10	and	O
11	Vinca	O
12	are	O
13	unaltered	O
14	.	O

1	When	O
2	nifA	B
3	mRNA	I
4	5	O
5	'	O
6	start	O
7	points	O
8	were	O
9	mapped	O
10	by	O
11	primer	O
12	extension	O
13	,	O
14	both	O
15	a	O
16	minor	O
17	upstream	O
18	transcript	O
19	(	O
20	s	O
21	)	O
22	starting	O
23	45	O
24	bp	O
25	distal	O
26	to	O
27	the	O
28	anaerobox	O
29	and	O
30	a	O
31	major	O
32	downstream	O
33	transcript	O
34	starting	O
35	10	O
36	bp	O
37	distal	O
38	to	O
39	the	O
40	sigma	B
41	54	I
42	box	O
43	were	O
44	observed	O
45	.	O

1	Selection	O
2	was	O
3	based	O
4	on	O
5	expression	O
6	of	O
7	an	O
8	integrated	O
9	DNA	O
10	fragment	O
11	containing	O
12	the	O
13	con	B
14	-	I
15	10	I
16	promoter	I
17	-	I
18	regulatory	I
19	region	I
20	followed	O
21	by	O
22	the	O
23	initial	O
24	segment	O
25	of	O
26	the	O
27	con	B
28	-	I
29	10	I
30	open	I
31	reading	I
32	frame	I
33	fused	O
34	in	O
35	frame	O
36	with	O
37	the	O
38	bacterial	B
39	hygromycin	I
40	B	I
41	phosphotransferase	I
42	structural	I
43	gene	I
44	(	O
45	con10	B
46	'-'	I
47	hph	I
48	).	O

1	The	O
2	effect	O
3	of	O
4	anticonvulsants	O
5	on	O
6	sodium	B
7	-	I
8	potassium	I
9	-	I
10	activated	I
11	ATPase	I
12	,	O
13	sodium	O
14	,	O
15	and	O
16	potassim	O
17	in	O
18	cortex	O
19	.	O

1	Heterodimers	O
2	of	O
3	myogenin	B
4	and	O
5	E12	B
6	(	O
7	or	O
8	MyoD	B
9	and	O
10	E12	B
11	)	O
12	specifically	O
13	bound	O
14	a	O
15	restriction	O
16	fragment	O
17	extending	O
18	from	O
19	-	O
20	200	O
21	to	O
22	-	O
23	103	O
24	relative	O
25	to	O
26	the	O
27	start	O
28	of	O
29	cardiac	B
30	alpha	I
31	-	I
32	actin	I
33	transcription	O
34	.	O

1	The	O
2	corticosterone	O
3	synthesis	O
4	inhibitor	O
5	metyrapone	O
6	(	O
7	75	O
8	mg	O
9	/	O
10	kg	O
11	i	O
12	.	O
13	p	O
14	.)	O
15	was	O
16	given	O
17	to	O
18	attenuate	O
19	the	O
20	rise	O
21	of	O
22	corticosterone	O
23	to	O
24	a	O
25	level	O
26	typical	O
27	of	O
28	stressed	O
29	males	O
30	.	O

1	All	O
2	numbers	O
3	refer	O
4	to	O
5	nucleotide	O
6	positions	O
7	on	O
8	the	O
9	wild	O
10	-	O
11	type	O
12	HIV	O
13	-	O
14	1	O
15	transcript	O
16	.	O

1	Human	B
2	immunodeficiency	I
3	virus	I
4	type	I
5	1	I
6	(	I
7	HIV	I
8	-	I
9	1	I
10	)	I
11	IN	I
12	,	O
13	expressed	O
14	in	O
15	Escherichia	O
16	coli	O
17	,	O
18	was	O
19	purified	O
20	to	O
21	near	O
22	homogeneity	O
23	.	O

1	It	O
2	was	O
3	established	O
4	that	O
5	intrathecal	O
6	or	O
7	intraperitoneal	O
8	PTFL	O
9	,	O
10	elevated	O
11	the	O
12	nociceptive	O
13	threshold	O
14	for	O
15	mechanical	O
16	stimuli	O
17	in	O
18	the	O
19	formalin	O
20	test	O
21	in	O
22	rats	O
23	.	O

1	Of	O
2	these	O
3	carriers	O
4	149	O
5	were	O
6	diagnosed	O
7	to	O
8	be	O
9	asymptomatic	O
10	clinically	O
11	,	O
12	biochemically	O
13	and	O
14	echographically	O
15	.	O

1	We	O
2	propose	O
3	that	O
4	two	O
5	pathways	O
6	regulate	O
7	Stat5	B
8	serine	O
9	phosphorylation	O
10	,	O
11	one	O
12	that	O
13	is	O
14	prolactin	B
15	-	O
16	activated	O
17	and	O
18	PD98059	O
19	-	O
20	resistant	O
21	and	O
22	one	O
23	that	O
24	is	O
25	constitutively	O
26	active	O
27	and	O
28	PD98059	O
29	-	O
30	sensitive	O
31	and	O
32	preferentially	O
33	targets	O
34	Stat5a	B
35	.	O

1	SF	B
2	-	I
3	1	I
4	does	O
5	not	O
6	have	O
7	an	O
8	N	O
9	-	O
10	terminal	O
11	AF1	O
12	domain	O
13	.	O

1	Each	O
2	individual	O
3	shot	O
4	25	O
5	bullets	O
6	in	O
7	about	O
8	5	O
9	minutes	O
10	,	O
11	at	O
12	an	O
13	intensity	O
14	level	O
15	calculated	O
16	at	O
17	163	O
18	dB	O
19	.	O

1	The	O
2	effect	O
3	of	O
4	calcitonin	B
5	,	O
6	a	O
7	large	O
8	amount	O
9	of	O
10	calcium	O
11	given	O
12	orally	O
13	,	O
14	pentagastrin	O
15	and	O
16	glucagon	B
17	on	O
18	plasma	O
19	47Ca	O
20	radioactivity	O
21	curves	O
22	in	O
23	subjects	O
24	pretreated	O
25	with	O
26	47Ca	O
27	was	O
28	examined	O
29	.	O

1	A	O
2	sheep	O
3	testicular	O
4	cDNA	O
5	library	O
6	constructed	O
7	in	O
8	pcDNA1	O
9	vector	O
10	was	O
11	screened	O
12	with	O
13	a	O
14	probe	O
15	generated	O
16	by	O
17	polymerase	O
18	chain	O
19	reaction	O
20	(	O
21	PCR	O
22	)	O
23	and	O
24	corresponding	O
25	to	O
26	a	O
27	1	O
28	.	O
29	6	O
30	kb	O
31	fragment	O
32	of	O
33	the	O
34	rat	B
35	luteinizing	I
36	hormone	I
37	receptor	I
38	cDNA	I
39	.	O

1	Although	O
2	it	O
3	has	O
4	been	O
5	shown	O
6	that	O
7	it	O
8	is	O
9	possible	O
10	to	O
11	use	O
12	orally	O
13	administered	O
14	testosterone	O
15	to	O
16	maintain	O
17	se	O
18	-	O
19	T	O
20	levels	O
21	in	O
22	the	O
23	normal	O
24	male	O
25	range	O
26	,	O
27	the	O
28	convenience	O
29	to	O
30	the	O
31	patient	O
32	must	O
33	be	O
34	balanced	O
35	against	O
36	the	O
37	cost	O
38	and	O
39	possible	O
40	side	O
41	effects	O
42	of	O
43	the	O
44	large	O
45	doses	O
46	required	O
47	.	O

1	Merr	O
2	.)	O
3	embryo	O
4	library	O
5	.	O

1	These	O
2	observed	O
3	drug	O
4	interactions	O
5	,	O
6	plus	O
7	the	O
8	known	O
9	effect	O
10	of	O
11	probenecid	O
12	to	O
13	block	O
14	secretion	O
15	of	O
16	PZA	O
17	,	O
18	have	O
19	to	O
20	be	O
21	considered	O
22	in	O
23	evaluating	O
24	the	O
25	effect	O
26	of	O
27	the	O
28	two	O
29	drugs	O
30	given	O
31	together	O
32	,	O
33	compared	O
34	to	O
35	the	O
36	effect	O
37	of	O
38	each	O
39	drug	O
40	given	O
41	separately	O
42	.	O

1	These	O
2	clones	O
3	overlapped	O
4	and	O
5	contained	O
6	the	O
7	structural	O
8	gene	O
9	encoding	O
10	the	O
11	complete	O
12	C5	B
13	alpha	I
14	-	I
15	chain	I
16	and	O
17	90	O
18	%	O
19	of	O
20	the	O
21	beta	O
22	-	O
23	chain	O
24	.	O

1	A	O
2	significant	O
3	direct	O
4	relationship	O
5	was	O
6	observed	O
7	between	O
8	the	O
9	percent	O
10	area	O
11	density	O
12	of	O
13	smooth	O
14	muscle	O
15	and	O
16	the	O
17	percent	O
18	change	O
19	in	O
20	peak	O
21	urinary	O
22	flow	O
23	rate	O
24	.	O

1	Higher	O
2	CYP3A23	B
3	basal	O
4	activity	O
5	appears	O
6	to	O
7	be	O
8	due	O
9	to	O
10	an	O
11	E	O
12	-	O
13	box	O
14	in	O
15	3A23SiteA	B
16	that	O
17	interacts	O
18	with	O
19	USF1	B
20	,	O
21	a	O
22	ubiquitous	O
23	bHLH	B
24	/	I
25	leucine	I
26	zipper	I
27	transcription	I
28	factor	I
29	.	O

1	Candidate	O
2	tumor	O
3	suppressor	O
4	genes	O
5	,	O
6	Mts1	B
7	(	O
8	p16INK4a	B
9	)	O
10	and	O
11	Mts2	B
12	(	O
13	p15INK4b	B
14	),	O
15	have	O
16	been	O
17	mapped	O
18	to	O
19	this	O
20	region	O
21	,	O
22	but	O
23	by	O
24	Southern	O
25	blot	O
26	analysis	O
27	,	O
28	no	O
29	homozygous	O
30	deletions	O
31	were	O
32	detected	O
33	in	O
34	either	O
35	gene	O
36	.	O

1	Transcriptional	O
2	activation	O
3	of	O
4	the	O
5	chicken	B
6	lysozyme	I
7	gene	I
8	by	O
9	NF	B
10	-	I
11	kappa	I
12	Bp65	I
13	(	O
14	RelA	B
15	)	O
16	and	O
17	c	B
18	-	I
19	Rel	I
20	,	O
21	but	O
22	not	O
23	by	O
24	NF	B
25	-	I
26	kappa	I
27	Bp50	I
28	.	O

1	The	O
2	accuracies	O
3	of	O
4	presence	O
5	or	O
6	absence	O
7	of	O
8	neuroblastoma	O
9	were	O
10	compared	O
11	between	O
12	131I	O
13	-	O
14	MIBG	O
15	imaging	O
16	and	O
17	several	O
18	tumor	O
19	markers	O
20	.	O

1	Thyroid	O
2	lymphoma	O
3	and	O
4	its	O
5	management	O
6	.	O

1	Immunolocalization	O
2	of	O
3	Sop1p	B
4	revealed	O
5	a	O
6	cytoplasmic	O
7	distribution	O
8	and	O
9	cell	O
10	fractionation	O
11	studies	O
12	showed	O
13	that	O
14	a	O
15	significant	O
16	fraction	O
17	of	O
18	Sop1p	B
19	was	O
20	recovered	O
21	in	O
22	a	O
23	sedimentable	O
24	fraction	O
25	of	O
26	the	O
27	cytosolic	O
28	material	O
29	.	O

1	Growth	O
2	factors	O
3	induce	O
4	the	O
5	expression	O
6	of	O
7	the	O
8	immediate	B
9	early	I
10	gene	I
11	products	I
12	MAP	I
13	kinase	I
14	phosphatase	I
15	-	I
16	1	I
17	(	O
18	MKP	B
19	-	I
20	1	I
21	),	O
22	c	B
23	-	I
24	Fos	I
25	and	O
26	c	B
27	-	I
28	Jun	I
29	.	O

1	Release	O
2	of	O
3	this	O
4	selective	O
5	pressure	O
6	,	O
7	however	O
8	,	O
9	gave	O
10	way	O
11	to	O
12	homologous	O
13	resolution	O
14	of	O
15	the	O
16	cointegrate	O
17	structures	O
18	.	O

1	The	O
2	solution	O
3	structure	O
4	of	O
5	the	O
6	adduct	O
7	derived	O
8	from	O
9	the	O
10	covalent	O
11	bonding	O
12	of	O
13	the	O
14	fjord	O
15	region	O
16	(+)-(	O
17	11S	O
18	,	O
19	12R	O
20	,	O
21	13R	O
22	,	O
23	14S	O
24	)	O
25	stereoisomer	O
26	of	O
27	anti	O
28	-	O
29	11	O
30	,	O
31	12	O
32	-	O
33	dihydroxy	O
34	-	O
35	13	O
36	,	O
37	14	O
38	-	O
39	epoxy	O
40	-	O
41	11	O
42	,	O
43	12	O
44	,	O
45	13	O
46	,	O
47	14	O
48	-	O
49	tetrahydrobenzo	O
50	[	O
51	g	O
52	]	O
53	chrysene	O
54	,	O
55	(+)-	O
56	anti	O
57	-	O
58	B	O
59	[	O
60	g	O
61	]	O
62	CDE	O
63	,	O
64	to	O
65	the	O
66	exocyclic	O
67	N	O
68	(	O
69	6	O
70	)	O
71	amino	O
72	group	O
73	of	O
74	the	O
75	adenine	O
76	residue	O
77	dA6	O
78	,	O
79	(	O
80	designated	O
81	(+)-	O
82	trans	O
83	-	O
84	anti	O
85	-(	O
86	B	O
87	[	O
88	g	O
89	]	O
90	C	O
91	)	O
92	dA6	O
93	),	O
94	positioned	O
95	opposite	O
96	a	O
97	thymine	O
98	residue	O
99	dT17	O
100	in	O
101	the	O
102	DNA	O
103	sequence	O
104	context	O
105	d	O
106	(	O
107	C1	O
108	-	O
109	T2	O
110	-	O
111	C3	O
112	-	O
113	T4	O
114	-	O
115	C5	O
116	-(	O
117	B	O
118	[	O
119	g	O
120	]	O
121	C	O
122	)	O
123	A6	O
124	-	O
125	C7	O
126	-	O
127	T8	O
128	-	O
129	T9	O
130	-	O
131	C10	O
132	-	O
133	C11	O
134	).	O
135	d	O
136	(	O
137	G12	O
138	-	O
139	G13	O
140	-	O
141	A14	O
142	-	O
143	A15	O
144	-	O
145	G16	O
146	-	O
147	T17	O
148	-	O
149	G18	O
150	-	O
151	A19	O
152	-	O
153	G20	O
154	++	O
155	+-	O
156	A21	O
157	-	O
158	G22	O
159	)	O
160	(	O
161	designated	O
162	(	O
163	B	O
164	[	O
165	g	O
166	]	O
167	C	O
168	)	O
169	dA	O
170	.	O
171	dT	O
172	11	O
173	-	O
174	mer	O
175	duplex	O
176	),	O
177	has	O
178	been	O
179	studied	O
180	using	O
181	structural	O
182	information	O
183	derived	O
184	from	O
185	NMR	O
186	data	O
187	in	O
188	combination	O
189	with	O
190	molecular	O
191	dynamics	O
192	(	O
193	MD	O
194	)	O
195	calculations	O
196	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	the	O
7	traI	B
8	structural	I
9	gene	I
10	and	O
11	application	O
12	of	O
13	purified	O
14	mutant	O
15	TraI	B
16	proteins	I
17	for	O
18	in	O
19	vitro	O
20	assays	O
21	served	O
22	to	O
23	evaluate	O
24	the	O
25	functional	O
26	importance	O
27	of	O
28	conserved	O
29	amino	O
30	acid	O
31	residues	O
32	.	O

1	Members	O
2	of	O
3	the	O
4	MAPK	B
5	family	I
6	include	O
7	the	O
8	extracellular	B
9	response	I
10	kinases	I
11	(	O
12	ERKs	B
13	or	O
14	p42	B
15	/	I
16	44	I
17	(	O
18	MAPK	B
19	)),	O
20	the	O
21	c	B
22	-	I
23	Jun	I
24	amino	I
25	-	I
26	terminal	I
27	kinases	I
28	(	O
29	JNKs	B
30	),	O
31	and	O
32	the	O
33	p38	B
34	/	O
35	Hog	B
36	1	I
37	protein	O
38	kinases	O
39	.	O

1	Some	O
2	of	O
3	the	O
4	mutations	O
5	obtained	O
6	do	O
7	not	O
8	contain	O
9	a	O
10	copy	O
11	of	O
12	the	O
13	Ulysses	B
14	element	I
15	at	O
16	the	O
17	mutant	O
18	locus	O
19	,	O
20	suggesting	O
21	that	O
22	a	O
23	different	O
24	transposable	O
25	element	O
26	may	O
27	be	O
28	responsible	O
29	for	O
30	the	O
31	mutation	O
32	.	O

1	More	O
2	generally	O
3	,	O
4	Ets1	B
5	and	O
6	Ets2	B
7	could	O
8	regulate	O
9	transcription	O
10	of	O
11	cellular	O
12	genes	O
13	.	O

1	This	O
2	survey	O
3	included	O
4	3000	O
5	randomly	O
6	selected	O
7	Norwegians	O
8	above	O
9	18	O
10	years	O
11	of	O
12	age	O
13	who	O
14	received	O
15	the	O
16	European	O
17	Organization	O
18	for	O
19	Research	O
20	and	O
21	Treatment	O
22	of	O
23	Cancer	O
24	Core	O
25	Quality	O
26	of	O
27	Life	O
28	Questionnaire	O
29	(	O
30	EORTC	O
31	QLQ	O
32	-	O
33	C30	O
34	(+	O
35	3	O
36	)	O
37	by	O
38	mail	O
39	.	O

1	Expression	O
2	of	O
3	the	O
4	CYP11A1	B
5	gene	I
6	is	O
7	increased	O
8	by	O
9	hormones	O
10	,	O
11	such	O
12	as	O
13	adrenocorticotropin	B
14	and	O
15	luteinizing	B
16	hormone	I
17	,	O
18	as	O
19	well	O
20	as	O
21	by	O
22	a	O
23	number	O
24	of	O
25	growth	O
26	factors	O
27	,	O
28	suggesting	O
29	that	O
30	its	O
31	promoter	O
32	may	O
33	contain	O
34	regulatory	O
35	elements	O
36	that	O
37	respond	O
38	to	O
39	multiple	O
40	signal	O
41	transduction	O
42	pathways	O
43	.	O

1	The	O
2	BAL	O
3	-	O
4	to	O
5	-	O
6	plasma	O
7	specific	O
8	activity	O
9	of	O
10	urea	O
11	was	O
12	about	O
13	twice	O
14	that	O
15	of	O
16	Na	O
17	+,	O
18	indicating	O
19	that	O
20	urea	O
21	diffused	O
22	into	O
23	the	O
24	ELF	O
25	more	O
26	rapidly	O
27	than	O
28	Na	O
29	+	O
30	during	O
31	the	O
32	70	O
33	s	O
34	that	O
35	elapsed	O
36	between	O
37	the	O
38	time	O
39	the	O
40	radioactive	O
41	urea	O
42	and	O
43	Na	O
44	+	O
45	were	O
46	injected	O
47	into	O
48	the	O
49	circulation	O
50	and	O
51	the	O
52	time	O
53	when	O
54	lavage	O
55	was	O
56	complete	O
57	.	O

1	Such	O
2	an	O
3	increase	O
4	in	O
5	the	O
6	steady	O
7	-	O
8	state	O
9	testicular	B
10	TIMP	I
11	-	I
12	2	I
13	mRNA	I
14	level	O
15	apparently	O
16	is	O
17	not	O
18	the	O
19	result	O
20	of	O
21	an	O
22	up	O
23	-	O
24	regulation	O
25	by	O
26	germ	O
27	cells	O
28	because	O
29	germ	O
30	cells	O
31	cocultured	O
32	with	O
33	Sertoli	O
34	cells	O
35	failed	O
36	to	O
37	elicit	O
38	an	O
39	increase	O
40	in	O
41	the	O
42	Sertoli	O
43	cell	O
44	steady	O
45	-	O
46	state	O
47	TIMP	B
48	-	I
49	2	I
50	mRNA	I
51	level	O
52	.	O

1	Inhibition	O
2	of	O
3	the	O
4	Mek	B
5	/	O
6	Erk	B
7	pathway	O
8	in	O
9	Rat1	O
10	/	O
11	ras	B
12	cells	O
13	,	O
14	using	O
15	the	O
16	Mek	B
17	inhibitor	O
18	,	O
19	PD98059	O
20	,	O
21	resulted	O
22	in	O
23	complete	O
24	cytoskeletal	O
25	recovery	O
26	,	O
27	indistinguishable	O
28	from	O
29	that	O
30	induced	O
31	by	O
32	HR12	O
33	.	O

1	The	O
2	transcriptional	O
3	unit	O
4	spans	O
5	a	O
6	chromosomal	O
7	region	O
8	of	O
9	about	O
10	55	O
11	kilobase	O
12	pairs	O
13	(	O
14	kbp	O
15	).	O

1	A	O
2	36	O
3	-	O
4	kDa	O
5	protein	O
6	that	O
7	was	O
8	localized	O
9	to	O
10	the	O
11	membrane	O
12	fraction	O
13	was	O
14	detected	O
15	in	O
16	minicells	O
17	containing	O
18	plasmids	O
19	with	O
20	the	O
21	ftsN	B
22	gene	I
23	,	O
24	confirming	O
25	that	O
26	FtsN	B
27	was	O
28	a	O
29	membrane	O
30	protein	O
31	.	O

1	From	O
2	250	O
3	g	O
4	of	O
5	cells	O
6	,	O
7	we	O
8	isolated	O
9	1	O
10	mg	O
11	of	O
12	PDH	B
13	complex	I
14	with	O
15	a	O
16	specific	O
17	activity	O
18	of	O
19	12	O
20	.	O
21	6	O
22	U	O
23	/	O
24	mg	O
25	of	O
26	protein	O
27	.	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	structure	O
6	of	O
7	the	O
8	WNT	B
9	-	I
10	2B	I
11	gene	I
12	.	O

1	TH	B
2	-	O
3	SH3	B
4	binding	O
5	in	O
6	vitro	O
7	is	O
8	abolished	O
9	by	O
10	specific	O
11	,	O
12	single	O
13	amino	O
14	acid	O
15	substitutions	O
16	within	O
17	the	O
18	Btk	B
19	TH	I
20	domain	I
21	or	O
22	the	O
23	Fyn	B
24	SH3	I
25	domain	I
26	.	O

1	An	O
2	immunologically	O
3	related	O
4	protein	O
5	was	O
6	detected	O
7	in	O
8	ribosome	O
9	and	O
10	membrane	O
11	fractions	O
12	of	O
13	mitochondria	O
14	from	O
15	Saccharomyces	O
16	cerevisiae	O
17	.	O

1	Alterations	O
2	in	O
3	DNase	B
4	I	I
5	reactivity	O
6	of	O
7	the	O
8	GC	O
9	-	O
10	response	O
11	element	O
12	region	O
13	suggest	O
14	that	O
15	GC	B
16	receptor	I
17	-	I
18	GC	I
19	complexes	I
20	may	O
21	associate	O
22	,	O
23	in	O
24	a	O
25	transient	O
26	manner	O
27	,	O
28	with	O
29	the	O
30	promoter	O
31	in	O
32	the	O
33	actively	O
34	transcribing	O
35	control	O
36	state	O
37	.	O

1	A	O
2	deproteinization	O
3	procedure	O
4	was	O
5	coupled	O
6	with	O
7	a	O
8	reversed	O
9	-	O
10	phase	O
11	HPLC	O
12	separation	O
13	using	O
14	a	O
15	250x4	O
16	.	O
17	6	O
18	mm	O
19	I	O
20	.	O
21	D	O
22	.	O

1	In	O
2	biopsies	O
3	CK	B
4	-	I
5	MB	I
6	fraction	O
7	of	O
8	total	O
9	myocardial	O
10	CPK	B
11	was	O
12	37	O
13	%,	O
14	the	O
15	total	B
16	-	I
17	CPK	I
18	activity	O
19	of	O
20	human	O
21	skeletal	O
22	muscles	O
23	still	O
24	shows	O
25	a	O
26	5	O
27	%	O
28	fraction	O
29	of	O
30	CK	B
31	-	I
32	MB	I
33	.	O

1	This	O
2	is	O
3	the	O
4	first	O
5	description	O
6	,	O
7	to	O
8	our	O
9	knowledge	O
10	,	O
11	of	O
12	regulatory	O
13	elements	O
14	that	O
15	control	O
16	expression	O
17	of	O
18	a	O
19	gene	O
20	encoding	O
21	a	O
22	B7	B
23	costimulatory	I
24	molecule	I
25	.	O

1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	DNA	O
7	binding	O
8	domain	O
9	of	O
10	ILF	B
11	has	O
12	strong	O
13	homology	O
14	to	O
15	the	O
16	recently	O
17	described	O
18	fork	B
19	head	I
20	DNA	I
21	binding	I
22	domain	I
23	found	O
24	in	O
25	the	O
26	Drosophila	B
27	homeotic	I
28	protein	I
29	fork	I
30	head	I
31	and	O
32	a	O
33	family	O
34	of	O
35	hepatocyte	B
36	nuclear	I
37	factors	I
38	,	O
39	HNF	B
40	-	I
41	3	I
42	.	O

1	The	O
2	Community	O
3	Adjustment	O
4	Scale	O
5	provided	O
6	outcome	O
7	data	O
8	related	O
9	to	O
10	the	O
11	subjects	O
12	'	O
13	degree	O
14	of	O
15	productivity	O
16	,	O
17	ability	O
18	to	O
19	maintain	O
20	close	O
21	relationships	O
22	,	O
23	and	O
24	presence	O
25	/	O
26	absence	O
27	of	O
28	symptomatology	O
29	an	O
30	average	O
31	of	O
32	32	O
33	years	O
34	after	O
35	initial	O
36	admission	O
37	.	O

1	A	O
2	soap	O
3	and	O
4	water	O
5	(	O
6	1	O
7	:	O
8	1	O
9	,	O
10	v	O
11	/	O
12	v	O
13	)	O
14	solution	O
15	effectively	O
16	decontaminated	O
17	powdered	O
18	stratum	O
19	corneum	O
20	.	O

1	In	O
2	contrast	O
3	,	O
4	injection	O
5	of	O
6	a	O
7	plasmid	O
8	encoding	O
9	simian	B
10	virus	I
11	40	I
12	small	I
13	t	I
14	antigen	I
15	,	O
16	which	O
17	interacts	O
18	with	O
19	PP2A	B
20	to	O
21	inhibit	O
22	its	O
23	activity	O
24	towards	O
25	several	O
26	phosphoprotein	O
27	substrates	O
28	,	O
29	had	O
30	no	O
31	effect	O
32	on	O
33	the	O
34	phosphorylation	O
35	state	O
36	of	O
37	CREB	B
38	in	O
39	stimulated	O
40	or	O
41	unstimulated	O
42	NIH	O
43	3T3	O
44	cells	O
45	.	O

1	The	O
2	behavior	O
3	of	O
4	different	O
5	types	O
6	of	O
7	polytetrafluoroethylene	O
8	(	O
9	PTFE	O
10	)	O
11	prostheses	O
12	in	O
13	the	O
14	reparative	O
15	scarring	O
16	process	O
17	of	O
18	abdominal	O
19	wall	O
20	defects	O
21	.	O

1	Clinical	O
2	aspects	O
3	and	O
4	therapy	O

1	Guiding	O
2	patients	O
3	in	O
4	the	O
5	decision	O
6	should	O
7	involve	O
8	a	O
9	multidisciplinary	O
10	team	O
11	composed	O
12	of	O
13	a	O
14	surgical	O
15	oncologist	O
16	,	O
17	geneticist	O
18	,	O
19	pathologist	O
20	,	O
21	psychotherapist	O
22	and	O
23	plastic	O
24	surgeon	O
25	.	O

1	Next	O
2	,	O
3	we	O
4	show	O
5	that	O
6	two	O
7	EMS	O
8	-	O
9	induced	O
10	mutations	O
11	,	O
12	previously	O
13	shown	O
14	to	O
15	interact	O
16	genetically	O
17	with	O
18	zipper	O
19	(	O
20	Ebr	B
21	),	O
22	disrupt	O
23	the	O
24	RhoA	B
25	locus	I
26	.	O

1	Acute	O
2	feasibility	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	smoking	O
8	reduction	O
9	strategy	O
10	for	O
11	smokers	O
12	with	O
13	schizophrenia	O
14	.	O

1	Treatment	O
2	is	O
3	instituted	O
4	with	O
5	prednisone	O
6	and	O
7	cyclophosphamide	O
8	.	O

1	It	O
2	is	O
3	now	O
4	well	O
5	accepted	O
6	that	O
7	the	O
8	p53	B
9	C	I
10	-	I
11	terminus	I
12	plays	O
13	a	O
14	central	O
15	role	O
16	in	O
17	controlling	O
18	the	O
19	activity	O
20	of	O
21	the	O
22	wild	O
23	-	O
24	type	O
25	molecule	O
26	.	O

1	Failures	O
2	of	O
3	colorimetric	O
4	additivity	O
5	under	O
6	these	O
7	experimental	O
8	conditions	O
9	are	O
10	discussed	O
11	.	O

1	The	O
2	ratio	O
3	of	O
4	the	O
5	activity	O
6	of	O
7	arogenate	B
8	dehydrogenase	I
9	to	O
10	that	O
11	of	O
12	prephenate	B
13	dehydrogenase	I
14	(	O
15	approximately	O
16	3	O
17	:	O
18	1	O
19	)	O
20	remained	O
21	constant	O
22	throughout	O
23	purification	O
24	,	O
25	and	O
26	the	O
27	two	O
28	activities	O
29	were	O
30	therefore	O
31	inseparable	O
32	.	O

1	Compound	O
2	1	O
3	is	O
4	either	O
5	21	O
6	-	O
7	O	O
8	-	O
9	angeloyl	O
10	,	O
11	22	O
12	-	O
13	O	O
14	-	O
15	tigloyl	O
16	R1	O
17	-	O
18	barrigenol	O
19	,	O
20	or	O
21	21	O
22	-	O
23	O	O
24	-	O
25	tigloyl	O
26	,	O
27	22	O
28	-	O
29	O	O
30	-	O
31	angeloyl	O
32	R1	O
33	-	O
34	barrigenol	O
35	.	O

1	Study	O
2	of	O
3	the	O
4	physico	O
5	-	O
6	chemical	O
7	state	O
8	of	O
9	plutonium	O
10	-	O
11	239	O
12	in	O
13	a	O
14	citrate	O
15	solution	O
16	-	O
17	blood	O
18	system	O

1	Two	O
2	classes	O
3	of	O
4	inactive	O
5	receptors	O
6	were	O
7	identified	O
8	:	O
9	one	O
10	in	O
11	which	O
12	both	O
13	transcriptional	O
14	activation	O
15	and	O
16	dimerization	O
17	were	O
18	compromised	O
19	and	O
20	a	O
21	second	O
22	in	O
23	which	O
24	only	O
25	transcriptional	O
26	activation	O
27	was	O
28	abolished	O
29	.	O

1	At	O
2	43	O
3	%	O
4	blood	O
5	pressure	O
6	reduction	O
7	,	O
8	PCO2	O
9	fell	O
10	by	O
11	0	O
12	.	O
13	53	O
14	kPa	O
15	,	O
16	a	O
17	decrease	O
18	which	O
19	could	O
20	not	O
21	explain	O
22	the	O
23	observed	O
24	CBF	O
25	fall	O
26	of	O
27	27	O
28	%.	O

1	Extracellular	O
2	fibril	O
3	formation	O
4	by	O
5	neuroglial	O
6	cells	O
7	at	O
8	the	O
9	vitreoretinal	O
10	junction	O
11	of	O
12	the	O
13	human	O
14	eye	O
15	.	O

1	Therefore	O
2	,	O
3	analogs	O
4	of	O
5	vitamin	O
6	D3	O
7	have	O
8	been	O
9	investigated	O
10	in	O
11	a	O
12	number	O
13	of	O
14	trials	O
15	showing	O
16	improvement	O
17	of	O
18	psoriasis	O
19	.	O

1	In	O
2	a	O
3	PC12	O
4	cell	O
5	mutant	O
6	that	O
7	is	O
8	deficient	O
9	in	O
10	protein	B
11	kinase	I
12	A	I
13	activity	O
14	(	O
15	AB	O
16	.	O
17	11	O
18	),	O
19	all	O
20	three	O
21	differentiating	O
22	agents	O
23	were	O
24	unable	O
25	to	O
26	down	O
27	-	O
28	regulate	O
29	nrg	B
30	-	I
31	1	I
32	mRNA	I
33	.	O

1	CONCLUSIONS	O
2	:	O
3	Pretreatment	O
4	with	O
5	OCs	O
6	prior	O
7	to	O
8	pituitary	O
9	suppression	O
10	in	O
11	the	O
12	early	O
13	follicular	O
14	phase	O
15	decreases	O
16	ovarian	O
17	cyst	O
18	formation	O
19	,	O
20	without	O
21	an	O
22	apparent	O
23	effect	O
24	on	O
25	subsequent	O
26	follicular	O
27	recruitment	O
28	or	O
29	pregnancy	O
30	rates	O
31	.	O

1	Blood	O
2	eosinophils	O
3	in	O
4	patients	O
5	with	O
6	Taenia	O
7	saginata	O
8	taeniasis	O
9	.	O

1	To	O
2	understand	O
3	the	O
4	regulatory	O
5	mechanism	O
6	controlling	O
7	its	O
8	expression	O
9	at	O
10	low	O
11	temperature	O
12	,	O
13	the	O
14	promoter	O
15	region	O
16	has	O
17	been	O
18	characterized	O
19	.	O

1	Administration	O
2	of	O
3	growth	B
4	hormone	I
5	leads	O
6	to	O
7	faster	O
8	growth	O
9	,	O
10	but	O
11	also	O
12	faster	O
13	bone	O
14	maturation	O
15	.	O

1	The	O
2	domain	O
3	structure	O
4	of	O
5	bovine	B
6	LTBP	I
7	-	I
8	2	I
9	is	O
10	very	O
11	similar	O
12	to	O
13	that	O
14	of	O
15	the	O
16	human	B
17	LTBP	I
18	-	I
19	2	I
20	,	O
21	containing	O
22	20	O
23	examples	O
24	of	O
25	6	O
26	-	O
27	cysteine	O
28	epidermal	B
29	growth	I
30	factor	I
31	-	I
32	like	I
33	repeats	I
34	,	O
35	16	O
36	of	O
37	which	O
38	have	O
39	the	O
40	consensus	O
41	sequence	O
42	for	O
43	calcium	O
44	binding	O
45	,	O
46	together	O
47	with	O
48	4	O
49	examples	O
50	of	O
51	8	O
52	-	O
53	cysteine	O
54	motifs	O
55	characteristic	O
56	of	O
57	fibrillins	B
58	and	O
59	LTBP	B
60	-	I
61	1	I
62	.	O

1	However	O
2	,	O
3	a	O
4	>	O
5	10	O
6	-	O
7	fold	O
8	increase	O
9	in	O
10	ERK3	B
11	activity	O
12	in	O
13	each	O
14	PKC	B
15	beta	I
16	transfectant	O
17	was	O
18	shown	O
19	by	O
20	immunoprecipitation	O
21	with	O
22	anti	B
23	-	I
24	ERK3	I
25	monoclonal	I
26	antibody	I
27	followed	O
28	by	O
29	either	O
30	immune	O
31	complex	O
32	kinase	O
33	assay	O
34	or	O
35	by	O
36	in	O
37	gel	O
38	kinase	O
39	assay	O
40	.	O

1	Positioning	O
2	this	O
3	uORF	O
4	,	O
5	together	O
6	with	O
7	its	O
8	accompanying	O
9	Kozak	O
10	sequences	O
11	,	O
12	between	O
13	a	O
14	heterologous	O
15	promoter	O
16	from	O
17	SV40	O
18	and	O
19	a	O
20	CAT	B
21	reporter	I
22	gene	I
23	resulted	O
24	in	O
25	marked	O
26	inhibition	O
27	of	O
28	CAT	B
29	protein	I
30	production	O
31	without	O
32	a	O
33	decrease	O
34	in	O
35	CAT	B
36	mRNA	I
37	.	O

1	Retrospective	O
2	analyses	O
3	of	O
4	this	O
5	death	O
6	revealed	O
7	a	O
8	significant	O
9	decrease	O
10	of	O
11	the	O
12	left	O
13	ventricular	O
14	(	O
15	LV	O
16	)	O
17	end	O
18	-	O
19	diastolic	O
20	volume	O
21	index	O
22	(	O
23	EDVI	O
24	)	O
25	of	O
26	21	O
27	ml	O
28	/	O
29	m2	O
30	(	O
31	36	O
32	%	O
33	of	O
34	normal	O
35	).	O

1	Truncated	O
2	mammalian	B
3	Notch1	I
4	activates	O
5	CBF1	B
6	/	O
7	RBPJk	B
8	-	O
9	repressed	O
10	genes	O
11	by	O
12	a	O
13	mechanism	O
14	resembling	O
15	that	O
16	of	O
17	Epstein	B
18	-	I
19	Barr	I
20	virus	I
21	EBNA2	I
22	.	O

1	RNA	B
2	polymerase	I
3	II	I
4	inhibition	O
5	increased	O
6	the	O
7	binding	O
8	of	O
9	ARE	O
10	(	O
11	AUBP	O
12	activity	O
13	)	O
14	and	O
15	poly	O
16	(	O
17	U	O
18	)-	O
19	Sepharose	O
20	by	O
21	cytoplasmic	B
22	hnRNP	I
23	A1	I
24	,	O
25	while	O
26	nuclear	B
27	hnRNP	I
28	A1	I
29	binding	O
30	was	O
31	unaffected	O
32	.	O

1	Tolerance	O
2	to	O
3	fenfluramine	O
4	anorexia	O
5	:	O
6	fact	O
7	or	O
8	fiction	O
9	?	O
10	Recent	O
11	findings	O
12	in	O
13	this	O
14	laboratory	O
15	with	O
16	regard	O
17	to	O
18	tolerance	O
19	to	O
20	fenfluramine	O
21	anorexia	O
22	are	O
23	reviewed	O
24	with	O
25	respect	O
26	to	O
27	generality	O
28	of	O
29	the	O
30	behavioural	O
31	phenomenon	O
32	.	O

1	The	O
2	high	O
3	density	O
4	of	O
5	tegumental	O
6	spines	O
7	on	O
8	posterior	O
9	half	O
10	of	O
11	the	O
12	body	O
13	and	O
14	the	O
15	distribution	O
16	of	O
17	type	O
18	II	O
19	papillae	O
20	on	O
21	dorsal	O
22	surface	O
23	are	O
24	considered	O
25	to	O
26	be	O
27	characteristic	O
28	of	O
29	C	O
30	.	O
31	armatus	O
32	.	O

1	One	O
2	cDNA	O
3	clone	O
4	designated	O
5	NCoA	O
6	-	O
7	62	O
8	,	O
9	encoded	O
10	a	O
11	62	O
12	,	O
13	000	O
14	-	O
15	Da	O
16	protein	O
17	that	O
18	is	O
19	highly	O
20	related	O
21	to	O
22	BX42	B
23	,	O
24	a	O
25	Drosophila	O
26	melanogaster	O
27	nuclear	O
28	protein	O
29	involved	O
30	in	O
31	ecdysone	O
32	-	O
33	stimulated	O
34	gene	O
35	expression	O
36	.	O

1	Mutating	O
2	the	O
3	Fcp1p	B
4	-	O
5	binding	O
6	motif	O
7	KEFGK	O
8	in	O
9	the	O
10	RAP74	B
11	(	O
12	Tfg1p	B
13	)	O
14	subunit	O
15	of	O
16	TFIIF	B
17	to	O
18	EEFGE	O
19	led	O
20	to	O
21	both	O
22	synthetic	O
23	phenotypes	O
24	in	O
25	certain	O
26	fcp1	B
27	tfg1	I
28	double	O
29	mutants	O
30	and	O
31	a	O
32	reduced	O
33	ability	O
34	of	O
35	Fcp1p	B
36	to	O
37	activate	O
38	transcription	O
39	when	O
40	it	O
41	is	O
42	artificially	O
43	tethered	O
44	to	O
45	a	O
46	promoter	O
47	.	O

1	Two	O
2	disulphide	O
3	bridges	O
4	,	O
5	which	O
6	are	O
7	conserved	O
8	in	O
9	all	O
10	spermadhesin	O
11	molecules	O
12	and	O
13	many	O
14	CUB	O
15	domains	O
16	,	O
17	crosslink	O
18	loop	O
19	LA	O
20	and	O
21	strand	O
22	beta	O
23	4	O
24	and	O
25	loops	O
26	LE	O
27	and	O
28	LG	O
29	,	O
30	respectively	O
31	,	O
32	at	O
33	opposite	O
34	edges	O
35	of	O
36	the	O
37	same	O
38	face	O
39	of	O
40	the	O
41	domain	O
42	.	O

1	Newcastle	O
2	disease	O
3	virus	O
4	surveillance	O
5	in	O
6	Hong	O
7	Kong	O
8	on	O
9	local	O
10	and	O
11	imported	O
12	poultry	O
13	.	O

1	The	O
2	Epstein	B
3	-	I
4	Barr	I
5	virus	I
6	transactivator	I
7	Zta	I
8	triggers	O
9	lytic	O
10	gene	O
11	expression	O
12	and	O
13	is	O
14	essential	O
15	for	O
16	replication	O
17	of	O
18	the	O
19	lytic	O
20	origin	O
21	,	O
22	oriLyt	O
23	.	O

1	The	O
2	failures	O
3	frequently	O
4	were	O
5	related	O
6	to	O
7	patient	O
8	intolerance	O
9	or	O
10	poor	O
11	mechanical	O
12	fit	O
13	and	O
14	occurred	O
15	in	O
16	the	O
17	first	O
18	few	O
19	days	O
20	or	O
21	first	O
22	few	O
23	months	O
24	after	O
25	insertion	O
26	.	O

1	Certain	O
2	transcript	O
3	patterns	O
4	in	O
5	Epifagus	O
6	plastids	O
7	are	O
8	highly	O
9	complex	O
10	and	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	tobacco	O
16	operons	O
17	.	O

1	The	O
2	EPO	B
3	levels	O
4	were	O
5	distinctly	O
6	increased	O
7	before	O
8	transfusion	O
9	;	O
10	they	O
11	did	O
12	not	O
13	significantly	O
14	change	O
15	just	O
16	after	O
17	transfusion	O
18	,	O
19	but	O
20	subsequently	O
21	decreased	O
22	.	O

1	(	O
2	LH	B
3	P	O
4	<	O
5	0	O
6	.	O
7	05	O
8	,	O
9	LH	B
10	/	O
11	FSH	B
12	P	O
13	<	O
14	0	O
15	.	O
16	01	O
17	).	O

1	The	O
2	epitope	O
3	-	O
4	protected	O
5	lysine	O
6	(	O
7	K	O
8	)	O
9	was	O
10	present	O
11	in	O
12	a	O
13	30	B
14	-	I
15	aa	I
16	TPO	I
17	fragment	I
18	that	O
19	,	O
20	by	O
21	N	O
22	-	O
23	terminal	O
24	sequencing	O
25	,	O
26	was	O
27	found	O
28	to	O
29	be	O
30	K713	O
31	.	O

1	Other	O
2	adverse	O
3	events	O
4	with	O
5	incidences	O
6	significantly	O
7	higher	O
8	than	O
9	with	O
10	placebo	O
11	were	O
12	dizziness	O
13	,	O
14	constipation	O
15	,	O
16	sweating	O
17	,	O
18	nervousness	O
19	,	O
20	and	O
21	abnormal	O
22	ejaculation	O
23	.	O

1	CONCLUSION	O
2	:	O
3	During	O
4	chronic	O
5	treatment	O
6	,	O
7	the	O
8	haemodynamic	O
9	response	O
10	to	O
11	oral	O
12	cilazapril	O
13	was	O
14	attenuated	O
15	,	O
16	indicating	O
17	that	O
18	continued	O
19	clinical	O
20	improvement	O
21	in	O
22	patients	O
23	with	O
24	CHF	O
25	on	O
26	CLZ	O
27	is	O
28	independent	O
29	of	O
30	to	O
31	its	O
32	acute	O
33	haemodynamic	O
34	effects	O
35	.	O

1	Pigmentary	O
2	rhythms	O
3	as	O
4	indicators	O
5	of	O
6	neurosecretion	O
7	.	O

1	BACKGROUND	O
2	:	O
3	Chemicals	O
4	vary	O
5	considerably	O
6	in	O
7	their	O
8	intrinsic	O
9	ability	O
10	to	O
11	cause	O
12	allergic	O
13	contact	O
14	dermatitis	O
15	.	O

1	The	O
2	major	O
3	type	O
4	involves	O
5	activator	O
6	proteins	O
7	that	O
8	bind	O
9	to	O
10	DNA	O
11	adjacent	O
12	to	O
13	where	O
14	the	O
15	RNA	B
16	polymerase	I
17	(	O
18	RNAP	B
19	)	O
20	holoenzyme	O
21	binds	O
22	,	O
23	usually	O
24	assisting	O
25	in	O
26	recruitment	O
27	of	O
28	the	O
29	RNAP	B
30	to	O
31	the	O
32	promoter	O
33	.	O

1	Videonystagmoscopy	O
2	has	O
3	been	O
4	used	O
5	to	O
6	subjectively	O
7	observe	O
8	the	O
9	responses	O
10	of	O
11	the	O
12	vestibular	O
13	system	O
14	in	O
15	a	O
16	population	O
17	of	O
18	patients	O
19	with	O
20	vestibular	O
21	deficits	O
22	.	O

1	Subsequently	O
2	,	O
3	HD	O
4	inhibited	O
5	healing	O
6	because	O
7	it	O
8	significantly	O
9	delayed	O
10	epithelialization	O
11	and	O
12	caused	O
13	protracted	O
14	inflammation	O
15	.	O

1	The	O
2	findings	O
3	suggest	O
4	that	O
5	ERP	O
6	effects	O
7	of	O
8	distinct	O
9	memory	O
10	processes	O
11	are	O
12	differentially	O
13	influenced	O
14	by	O
15	the	O
16	encoding	O
17	instructions	O
18	.	O

1	An	O
2	analysis	O
3	of	O
4	synthetic	O
5	peptides	O
6	revealed	O
7	a	O
8	minimal	O
9	CTD	O
10	sequence	O
11	that	O
12	is	O
13	sufficient	O
14	to	O
15	bind	O
16	to	O
17	the	O
18	second	O
19	Rsp5	B
20	WW	I
21	domain	I
22	(	O
23	Rsp5	B
24	WW2	I
25	)	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	yeast	O
31	two	O
32	-	O
33	hybrid	O
34	assays	O
35	.	O

1	Stimulation	O
2	with	O
3	MCh	O
4	produced	O
5	a	O
6	Ca	O
7	-	O
8	dependent	O
9	transient	O
10	elevation	O
11	of	O
12	cGMP	O
13	level	O
14	from	O
15	10	O
16	to	O
17	80	O
18	fmol	O
19	/	O
20	gland	O
21	,	O
22	peaking	O
23	at	O
24	1	O
25	-	O
26	2	O
27	min	O
28	but	O
29	returning	O
30	to	O
31	the	O
32	basal	O
33	level	O
34	by	O
35	5	O
36	min	O
37	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	contact	O
6	allergy	O
7	to	O
8	K	O
9	-	O
10	CG	O
11	is	O
12	common	O
13	.	O

1	This	O
2	mutant	O
3	was	O
4	identified	O
5	by	O
6	screening	O
7	with	O
8	a	O
9	TGF	B
10	-	I
11	beta	I
12	-	O
13	inducible	O
14	vector	O
15	a	O
16	series	O
17	of	O
18	mink	O
19	lung	O
20	epithelial	O
21	cell	O
22	clones	O
23	that	O
24	have	O
25	normal	O
26	TGF	B
27	-	I
28	beta	I
29	binding	O
30	activity	O
31	but	O
32	have	O
33	lost	O
34	antiproliferative	O
35	and	O
36	transcriptional	O
37	responses	O
38	to	O
39	TGF	B
40	-	I
41	beta	I
42	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	in	O
6	comparison	O
7	to	O
8	reports	O
9	from	O
10	other	O
11	regions	O
12	,	O
13	Scandinavian	O
14	renal	O
15	transplant	O
16	recipients	O
17	are	O
18	at	O
19	high	O
20	risk	O
21	of	O
22	dying	O
23	of	O
24	IHD	O
25	.	O

1	The	O
2	imprinted	O
3	expression	O
4	of	O
5	the	O
6	endogenous	O
7	gene	O
8	can	O
9	be	O
10	recapitulated	O
11	in	O
12	mice	O
13	by	O
14	using	O
15	a	O
16	14	O
17	-	O
18	kb	O
19	transgene	O
20	encompassing	O
21	4	O
22	kb	O
23	of	O
24	5	O
25	'-	O
26	flanking	O
27	sequence	O
28	,	O
29	8	O
30	kb	O
31	of	O
32	3	O
33	'-	O
34	flanking	O
35	sequence	O
36	,	O
37	which	O
38	includes	O
39	the	O
40	two	O
41	endoderm	O
42	-	O
43	specific	O
44	enhancers	O
45	,	O
46	and	O
47	an	O
48	internally	O
49	deleted	O
50	structural	O
51	gene	O
52	.	O

1	The	O
2	9	O
3	;	O
4	22	O
5	chromosomal	O
6	translocation	O
7	characteristic	O
8	of	O
9	CML	O
10	results	O
11	in	O
12	a	O
13	fused	O
14	bcr	B
15	/	O
16	abl	B
17	gene	O
18	and	O
19	an	O
20	abnormal	O
21	fusion	O
22	protein	O
23	,	O
24	p210bcr	B
25	/	O
26	abl	B
27	.	O

1	Limited	O
2	role	O
3	for	O
4	PCR	O
5	-	O
6	based	O
7	diagnosis	O
8	of	O
9	Whipple	O
10	'	O
11	s	O
12	disease	O
13	from	O
14	peripheral	O
15	blood	O
16	mononuclear	O
17	cells	O
18	.	O

1	To	O
2	determine	O
3	which	O
4	sequences	O
5	in	O
6	the	O
7	rat	B
8	P450c17	I
9	promoter	I
10	may	O
11	be	O
12	responsible	O
13	for	O
14	basal	O
15	and	O
16	cAMP	O
17	-	O
18	stimulated	O
19	gene	O
20	transcription	O
21	,	O
22	deletion	O
23	constructs	O
24	containing	O
25	between	O
26	-	O
27	1	O
28	,	O
29	560	O
30	and	O
31	-	O
32	53	O
33	base	O
34	pairs	O
35	of	O
36	5	O
37	'-	O
38	flanking	O
39	DNA	O
40	from	O
41	the	O
42	rat	B
43	P450c17	I
44	gene	I
45	were	O
46	ligated	O
47	to	O
48	plasmids	O
49	expressing	O
50	the	O
51	reporter	O
52	gene	O
53	luciferase	B
54	and	O
55	transfected	O
56	into	O
57	two	O
58	mouse	O
59	cell	O
60	lines	O
61	,	O
62	adrenal	O
63	Y	O
64	-	O
65	1	O
66	cells	O
67	,	O
68	and	O
69	testicular	O
70	Leydig	O
71	MA	O
72	-	O
73	10	O
74	cells	O
75	.	O

1	In	O
2	addition	O
3	,	O
4	both	O
5	the	O
6	exon	O
7	1	O
8	-	O
9	and	O
10	exon	O
11	2	O
12	-	O
13	initiated	O
14	forms	O
15	of	O
16	the	O
17	c	B
18	-	I
19	Myc	I
20	protein	I
21	stimulated	O
22	transcription	O
23	of	O
24	a	O
25	Myc	B
26	/	O
27	Max	B
28	-	O
29	responsive	O
30	reporter	O
31	construct	O
32	to	O
33	a	O
34	similar	O
35	level	O
36	.	O

1	High	O
2	-	O
3	level	O
4	gains	O
5	(	O
6	HLGs	O
7	)	O
8	indicative	O
9	of	O
10	gene	O
11	amplifications	O
12	were	O
13	identified	O
14	at	O
15	11q13	O
16	in	O
17	two	O
18	cases	O
19	,	O
20	and	O
21	in	O
22	one	O
23	case	O
24	each	O
25	at	O
26	2q33	O
27	-	O
28	34	O
29	,	O
30	3q25	O
31	-	O
32	29	O
33	,	O
34	5p15	O
35	.	O
36	1	O
37	-	O
38	15	O
39	.	O
40	2	O
41	,	O
42	7q21	O
43	-	O
44	22	O
45	,	O
46	11p11	O
47	.	O
48	2	O
49	,	O
50	12p11	O
51	.	O
52	2	O
53	-	O
54	12	O
55	,	O
56	and	O
57	13q34	O
58	.	O

1	The	O
2	rad9	B
3	.	I
4	192	I
5	DNA	I
6	repair	I
7	mutant	I
8	from	I
9	the	I
10	fission	I
11	yeast	I
12	,	I
13	Schizosaccharomyces	I
14	pombe	I
15	,	O
16	is	O
17	sensitive	O
18	to	O
19	both	O
20	UV	O
21	and	O
22	ionising	O
23	radiation	O
24	.	O

1	Contributions	O
2	from	O
3	pairs	O
4	of	O
5	source	O
6	and	O
7	target	O
8	volume	O
9	elements	O
10	are	O
11	summed	O
12	for	O
13	the	O
14	S	O
15	values	O
16	between	O
17	the	O
18	tumor	O
19	and	O
20	itself	O
21	,	O
22	between	O
23	the	O
24	remaining	O
25	healthy	O
26	host	O
27	organ	O
28	and	O
29	itself	O
30	,	O
31	and	O
32	between	O
33	the	O
34	tumor	O
35	and	O
36	the	O
37	remaining	O
38	healthy	O
39	host	O
40	organ	O
41	,	O
42	with	O
43	the	O
44	reciprocity	O
45	theorem	O
46	assumed	O
47	for	O
48	the	O
49	last	O
50	.	O

1	The	O
2	amino	O
3	acid	O
4	sequences	O
5	of	O
6	the	O
7	predicted	O
8	RfbA	B
9	and	O
10	RfbB	B
11	homologs	I
12	showed	O
13	identities	O
14	of	O
15	75	O
16	.	O
17	7	O
18	%	O
19	(	O
20	87	O
21	.	O
22	9	O
23	%	O
24	total	O
25	similarity	O
26	)	O
27	and	O
28	78	O
29	.	O
30	0	O
31	%	O
32	(	O
33	86	O
34	.	O
35	5	O
36	%	O
37	total	O
38	similarity	O
39	),	O
40	respectively	O
41	.	O

1	The	O
2	data	O
3	obtained	O
4	up	O
5	to	O
6	now	O
7	only	O
8	suggest	O
9	the	O
10	future	O
11	potentiality	O
12	of	O
13	Bestatin	O
14	treatment	O
15	for	O
16	these	O
17	types	O
18	of	O
19	malignancy	O
20	.	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	myocardial	O
5	uptake	O
6	of	O
7	99mTc	O
8	sestamibi	O
9	in	O
10	normal	O
11	subjects	O
12	and	O
13	patients	O
14	with	O
15	coronary	O
16	artery	O
17	disease	O
18	is	O
19	comparable	O
20	after	O
21	exercise	O
22	,	O
23	dipyridamole	O
24	,	O
25	and	O
26	adenosine	O
27	stress	O
28	.	O

1	Online	O
2	LATCH	O
3	demonstrates	O
4	a	O
5	shift	O
6	in	O
7	identification	O
8	of	O
9	the	O
10	library	O
11	as	O
12	an	O
13	isolated	O
14	unit	O
15	to	O
16	an	O
17	interactive	O
18	resource	O
19	center	O
20	.	O

1	Vaccinia	O
2	virus	O
3	(	O
4	VV	O
5	)	O
6	is	O
7	a	O
8	potent	O
9	immunogen	O
10	,	O
11	but	O
12	the	O
13	nature	O
14	of	O
15	VV	O
16	proteins	O
17	involved	O
18	in	O
19	the	O
20	activation	O
21	of	O
22	the	O
23	immune	O
24	response	O
25	of	O
26	the	O
27	host	O
28	is	O
29	not	O
30	yet	O
31	known	O
32	.	O

1	The	O
2	percutaneous	O
3	absorption	O
4	of	O
5	clindamycin	O
6	was	O
7	studied	O
8	in	O
9	healthy	O
10	male	O
11	volunteers	O
12	,	O
13	comparing	O
14	two	O
15	investigative	O
16	clindamycin	O
17	(%	O
18	w	O
19	/	O
20	v	O
21	)/	O
22	tretinoin	O
23	(	O
24	0	O
25	.	O
26	025	O
27	%	O
28	w	O
29	/	O
30	v	O
31	)	O
32	gels	O
33	,	O
34	containing	O
35	clindamycin	O
36	phosphate	O
37	ester	O
38	and	O
39	clindamycin	O
40	HCl	O
41	,	O
42	respectively	O
43	,	O
44	relative	O
45	to	O
46	a	O
47	clindamycin	O
48	phosphate	O
49	lotion	O
50	(	O
51	1	O
52	%	O
53	clindamycin	O
54	;	O
55	Dalacin	O
56	T	O
57	).	O

1	Bilateral	O
2	Charnley	O
3	arthroplasty	O
4	as	O
5	a	O
6	single	O
7	procedure	O
8	.	O

1	Because	O
2	of	O
3	the	O
4	operon	O
5	structure	O
6	of	O
7	this	O
8	organism	O
9	,	O
10	traditional	O
11	methods	O
12	such	O
13	as	O
14	insertional	O
15	mutagenesis	O
16	run	O
17	the	O
18	risk	O
19	of	O
20	introducing	O
21	polar	O
22	effects	O
23	on	O
24	downstream	O
25	genes	O
26	or	O
27	creating	O
28	secondary	O
29	mutations	O
30	elsewhere	O
31	in	O
32	the	O
33	genome	O
34	.	O

1	Recombinant	B
2	Leishmania	I
3	surface	I
4	glycoprotein	I
5	GP63	I
6	is	O
7	secreted	O
8	in	O
9	the	O
10	baculovirus	O
11	expression	O
12	system	O
13	as	O
14	a	O
15	latent	O
16	metalloproteinase	B
17	.	O

1	Paroxysmal	O
2	fluctuations	O
3	in	O
4	observed	O
5	parasitemia	O
6	in	O
7	Plasmodium	O
8	falciparum	O
9	malaria	O
10	.	O

1	Prostate	B
2	specific	I
3	antigen	I
4	shows	O
5	the	O
6	metastatic	O
7	cases	O
8	better	O
9	[	O
10	correction	O
11	of	O
12	worse	O
13	]	O
14	than	O
15	prostatic	B
16	acid	I
17	phosphatase	I
18	.	O

1	In	O
2	this	O
3	situation	O
4	the	O
5	convlusion	O
6	threshold	O
7	for	O
8	the	O
9	8	O
10	substances	O
11	is	O
12	as	O
13	follows	O
14	:	O
15	pethidine	O
16	20	O
17	mg	O
18	.	O
19	kg	O
20	-	O
21	1	O
22	I	O
23	.	O
24	V	O
25	.,	O
26	piritramide	O
27	30	O
28	,	O
29	morphine	O
30	180	O
31	,	O
32	phenoperidine	O
33	4	O
34	,	O
35	R	O
36	39	O
37	209	O
38	5	O
39	,	O
40	fentanyl	O
41	4	O
42	,	O
43	sufentanil	O
44	4	O
45	and	O
46	R	O
47	34	O
48	995	O
49	10	O
50	mg	O
51	.	O
52	kg	O
53	-	O
54	1	O
55	I	O
56	.	O
57	V	O
58	.	O

1	RESULTS	O
2	:	O
3	Using	O
4	information	O
5	in	O
6	the	O
7	dbEST	O
8	database	O
9	of	O
10	expressed	O
11	sequence	O
12	tags	O
13	,	O
14	we	O
15	isolated	O
16	an	O
17	Arabidopsis	O
18	thaliana	O
19	gene	O
20	(	O
21	GCR1	B
22	)	O
23	that	O
24	encodes	O
25	a	O
26	protein	O
27	with	O
28	seven	O
29	predicted	O
30	membrane	O
31	-	O
32	spanning	O
33	domains	O
34	and	O
35	other	O
36	features	O
37	characteristic	O
38	of	O
39	7TM	B
40	receptors	I
41	.	O

1	In	O
2	particular	O
3	,	O
4	the	O
5	potential	O
6	for	O
7	prostate	O
8	cancer	O
9	chemoprevention	O
10	using	O
11	nonsteroidal	O
12	anti	O
13	-	O
14	inflammatory	O
15	drugs	O
16	(	O
17	cyclo	B
18	-	I
19	oxygenase	I
20	inhibitors	O
21	;	O
22	NSAIDs	O
23	)	O
24	has	O
25	received	O
26	little	O
27	attention	O
28	.	O

1	These	O
2	latter	O
3	results	O
4	showed	O
5	that	O
6	the	O
7	ABFI	B
8	protein	I
9	,	O
10	like	O
11	the	O
12	RAP1	B
13	protein	I
14	,	O
15	bound	O
16	sequences	O
17	required	O
18	for	O
19	positive	O
20	as	O
21	well	O
22	as	O
23	negative	O
24	regulation	O
25	of	O
26	gene	O
27	expression	O
28	.	O

1	Small	B
2	Maf	I
3	proteins	I
4	heterodimerize	O
5	with	O
6	Fos	B
7	and	O
8	may	O
9	act	O
10	as	O
11	competitive	O
12	repressors	O
13	of	O
14	the	O
15	NF	B
16	-	I
17	E2	I
18	transcription	I
19	factor	I
20	.	O

1	Diagnostic	O
2	value	O
3	of	O
4	serum	B
5	myoglobin	I
6	in	O
7	cases	O
8	of	O
9	neuromuscular	O
10	disease	O

1	Bone	O
2	marrow	O
3	abnormalities	O
4	in	O
5	Hodgkin	O
6	'	O
7	s	O
8	disease	O
9	are	O
10	reviewed	O
11	and	O
12	the	O
13	current	O
14	understanding	O
15	of	O
16	the	O
17	pathological	O
18	mechanisms	O
19	leading	O
20	to	O
21	aplastic	O
22	anemia	O
23	is	O
24	discussed	O
25	.	O

1	Time	O
2	delay	O
3	effects	O
4	on	O
5	the	O
6	tensile	O
7	bond	O
8	strength	O
9	developed	O
10	by	O
11	the	O
12	Silicoater	O
13	.	O

1	Retroviral	O
2	replication	O
3	requires	O
4	that	O
5	a	O
6	portion	O
7	of	O
8	the	O
9	primary	O
10	transcripts	O
11	generated	O
12	from	O
13	proviral	O
14	DNA	O
15	be	O
16	spliced	O
17	to	O
18	serve	O
19	as	O
20	mRNA	O
21	for	O
22	the	O
23	envelope	B
24	protein	I
25	and	O
26	in	O
27	Rous	O
28	sarcoma	O
29	virus	O
30	as	O
31	src	B
32	mRNA	I
33	.	O

1	The	O
2	TATA	B
3	box	I
4	-	I
5	binding	I
6	protein	I
7	(	O
8	TBP	B
9	)	O
10	plays	O
11	an	O
12	essential	O
13	role	O
14	in	O
15	transcription	O
16	by	O
17	all	O
18	three	O
19	eukaryotic	O
20	nuclear	B
21	RNA	I
22	polymerases	I
23	,	O
24	polymerases	B
25	(	I
26	Pol	I
27	)	I
28	I	I
29	,	I
30	II	I
31	,	I
32	and	I
33	III	I
34	.	O

1	Tonometry	O
2	of	O
3	blood	O
4	samples	O
5	from	O
6	patients	O
7	may	O
8	also	O
9	be	O
10	used	O
11	in	O
12	the	O
13	determination	O
14	of	O
15	acid	O
16	-	O
17	base	O
18	quantities	O
19	and	O
20	hemoglobin	B
21	-	O
22	oxygen	O
23	affinity	O
24	e	O
25	.	O
26	g	O
27	.	O
28	p50	O
29	.	O

1	Muscle	B
2	GSH	I
3	-	I
4	Px	I
5	activity	O
6	after	O
7	prolonged	O
8	exercise	O
9	,	O
10	training	O
11	,	O
12	and	O
13	selenium	O
14	supplementation	O
15	.	O

1	Expression	O
2	of	O
3	the	O
4	proapoptotic	B
5	protein	I
6	Bax	I
7	under	O
8	the	O
9	control	O
10	of	O
11	a	O
12	GAL10	B
13	promoter	I
14	in	O
15	Saccharomyces	O
16	cerevisiae	O
17	resulted	O
18	in	O
19	galactose	O
20	-	O
21	inducible	O
22	cell	O
23	death	O
24	.	O

1	AGO1	B
2	is	O
3	similar	O
4	to	O
5	QDE	B
6	-	I
7	2	I
8	required	O
9	for	O
10	quelling	O
11	and	O
12	RDE	B
13	-	I
14	1	I
15	required	O
16	for	O
17	RNAi	O
18	.	O

1	She	O
2	also	O
3	had	O
4	slight	O
5	weakness	O
6	of	O
7	the	O
8	upper	O
9	extremities	O
10	.	O

1	Immunodepression	O
2	was	O
3	combined	O
4	with	O
5	the	O
6	increase	O
7	of	O
8	glucocorticoid	O
9	activity	O
10	of	O
11	adrenal	O
12	cortex	O
13	,	O
14	while	O
15	no	O
16	significant	O
17	changes	O
18	in	O
19	thyroid	O
20	hormones	O
21	were	O
22	registered	O
23	.	O

1	SvO2	O
2	can	O
3	be	O
4	determined	O
5	in	O
6	vitro	O
7	and	O
8	in	O
9	vivo	O
10	.	O

1	One	O
2	of	O
3	these	O
4	factors	O
5	,	O
6	HRF	B
7	-	I
8	1	I
9	,	O
10	recognizes	O
11	a	O
12	cis	O
13	element	O
14	consisting	O
15	of	O
16	an	O
17	inverted	O
18	palindromic	O
19	motif	O
20	.	O

1	In	O
2	Schizosaccharomyces	O
3	pombe	O
4	,	O
5	the	O
6	activity	O
7	of	O
8	the	O
9	M	O
10	-	O
11	phase	O
12	-	O
13	inducing	O
14	Cdc2	B
15	/	O
16	Cdc13	B
17	cyclin	O
18	-	O
19	dependent	O
20	kinase	O
21	is	O
22	inhibited	O
23	by	O
24	Wee1	B
25	and	O
26	Mik1	B
27	tyrosine	I
28	kinases	I
29	,	O
30	and	O
31	activated	O
32	by	O
33	Cdc25	B
34	and	O
35	Pyp3	B
36	tyrosine	I
37	phosphatases	I
38	.	O

1	Expansins	B
2	are	O
3	a	O
4	family	O
5	of	O
6	proteins	O
7	that	O
8	catalyse	O
9	long	O
10	-	O
11	term	O
12	extension	O
13	of	O
14	isolated	O
15	plant	O
16	cell	O
17	walls	O
18	due	O
19	to	O
20	an	O
21	as	O
22	yet	O
23	unknown	O
24	biochemical	O
25	mechanism	O
26	.	O

1	These	O
2	cells	O
3	fail	O
4	to	O
5	generate	O
6	the	O
7	signals	O
8	to	O
9	phosphorylate	O
10	CREB	B
11	and	O
12	produce	O
13	significantly	O
14	less	O
15	of	O
16	the	O
17	cytokine	O
18	Interleukin	B
19	-	I
20	2	I
21	(	O
22	IL	B
23	-	I
24	2	I
25	)	O
26	in	O
27	response	O
28	to	O
29	agents	O
30	that	O
31	either	O
32	increase	O
33	intracellular	O
34	Ca2	O
35	+	O
36	and	O
37	/	O
38	or	O
39	activate	O
40	protein	B
41	kinase	I
42	C	I
43	.	O

1	TCR	B
2	alpha	I
3	(	O
4	TCRA	B
5	)	O
6	expression	O
7	was	O
8	examined	O
9	in	O
10	RNA	O
11	samples	O
12	from	O
13	PBMC	O
14	and	O
15	isolated	O
16	populations	O
17	of	O
18	CD4	O
19	+,	O
20	CD8	O
21	+,	O
22	and	O
23	DN	O
24	T	O
25	cells	O
26	from	O
27	15	O
28	healthy	O
29	individuals	O
30	.	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	largest	O
5	value	O
6	of	O
7	the	O
8	joint	O
9	space	O
10	may	O
11	be	O
12	used	O
13	when	O
14	evaluating	O
15	rheumatoid	O
16	AC	O
17	joint	O
18	space	O
19	.	O

1	On	O
2	the	O
3	role	O
4	of	O
5	transferrin	B
6	in	O
7	the	O
8	uptake	O
9	of	O
10	gallium	O
11	by	O
12	tumor	O
13	cells	O
14	.	O

1	The	O
2	role	O
3	of	O
4	daunorubicin	O
5	in	O
6	induction	O
7	therapy	O
8	for	O
9	adult	O
10	acute	O
11	myeloid	O
12	leukemia	O

1	The	O
2	end	O
3	-	O
4	stage	O
5	or	O
6	involutional	O
7	phase	O
8	of	O
9	proliferative	O
10	diabetic	O
11	retinopathy	O
12	may	O
13	result	O
14	in	O
15	stabilization	O
16	of	O
17	vision	O
18	for	O
19	long	O
20	periods	O
21	of	O
22	time	O
23	.	O

1	Hybridization	O
2	of	O
3	plasmid	O
4	-	O
5	transformed	O
6	Escherichia	O
7	coli	O
8	RR1	O
9	colonies	O
10	with	O
11	32P	O
12	-	O
13	labeled	O
14	viral	O
15	genome	O
16	RNAs	O
17	demonstrated	O
18	the	O
19	presence	O
20	of	O
21	DNA	O
22	clones	O
23	representative	O
24	of	O
25	each	O
26	of	O
27	the	O
28	10	O
29	reovirus	O
30	RNAs	O
31	and	O
32	10	O
33	of	O
34	the	O
35	11	O
36	constituent	O
37	segments	O
38	of	O
39	the	O
40	rotavirus	O
41	genome	O
42	.	O

1	A	O
2	transgenic	O
3	complementation	O
4	assay	O
5	was	O
6	used	O
7	to	O
8	test	O
9	whether	O
10	NIa	B
11	supplied	O
12	in	O
13	trans	O
14	could	O
15	rescue	O
16	amplification	O
17	-	O
18	defective	O
19	viral	O
20	genomes	O
21	encoding	O
22	altered	O
23	NIa	B
24	proteins	I
25	.	O

1	The	O
2	other	O
3	two	O
4	clones	O
5	,	O
6	Ash	B
7	-	I
8	m	I
9	and	I
10	-	I
11	s	I
12	,	O
13	had	O
14	nucleotide	O
15	sequences	O
16	identical	O
17	with	O
18	Ash	B
19	-	I
20	l	I
21	cDNA	O
22	in	O
23	the	O
24	amino	O
25	-	O
26	terminal	O
27	region	O
28	.	O

1	The	O
2	partial	O
3	ORF	O
4	was	O
5	found	O
6	to	O
7	be	O
8	identical	O
9	to	O
10	the	O
11	C	O
12	terminus	O
13	of	O
14	HrpJ2	B
15	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	ROS	O
6	production	O
7	by	O
8	viable	O
9	spermatozoa	O
10	is	O
11	highly	O
12	correlated	O
13	with	O
14	the	O
15	concentration	O
16	of	O
17	PMN	B
18	elastase	I
19	and	O
20	the	O
21	number	O
22	of	O
23	both	O
24	peroxidase	B
25	-	O
26	positive	O
27	and	O
28	round	O
29	cells	O
30	.	O

1	SCID	O
2	V	B
3	(	O
4	D	B
5	)	O
6	J	B
7	recombination	O
8	can	O
9	be	O
10	partly	O
11	rescued	O
12	in	O
13	T	O
14	-	O
15	lymphocytes	O
16	by	O
17	either	O
18	DNA	O
19	-	O
20	damaging	O
21	agents	O
22	(	O
23	gamma	O
24	-	O
25	irradiation	O
26	and	O
27	bieomycin	O
28	)	O
29	or	O
30	a	O
31	null	O
32	mutation	O
33	of	O
34	the	O
35	p53	B
36	gene	I
37	,	O
38	possibly	O
39	because	O
40	of	O
41	transiently	O
42	elevated	O
43	DNA	O
44	repair	O
45	activity	O
46	in	O
47	response	O
48	to	O
49	DNA	O
50	damage	O
51	or	O
52	to	O
53	delayed	O
54	apoptosis	O
55	in	O
56	the	O
57	absence	O
58	of	O
59	p53	B
60	.	O

1	Band	O
2	structure	O
3	effects	O
4	of	O
5	transport	O
6	properties	O
7	in	O
8	icosahedral	O
9	quasicrystals	O
10	.	O

1	Baseline	O
2	electrocorticography	O
3	over	O
4	the	O
5	surface	O
6	of	O
7	the	O
8	temporal	O
9	lobe	O
10	and	O
11	depth	O
12	electrode	O
13	recordings	O
14	in	O
15	the	O
16	amygdala	O
17	and	O
18	hippocampus	O
19	were	O
20	obtained	O
21	,	O
22	followed	O
23	by	O
24	10	O
25	min	O
26	of	O
27	recording	O
28	before	O
29	and	O
30	after	O
31	the	O
32	i	O
33	.	O
34	v	O
35	.	O
36	administration	O
37	of	O
38	both	O
39	alfentanil	O
40	50	O
41	microg	O
42	/	O
43	kg	O
44	and	O
45	fentanyl	O
46	10	O
47	microg	O
48	/	O
49	kg	O
50	.	O

1	This	O
2	observation	O
3	suggests	O
4	that	O
5	the	O
6	methyl	O
7	-	O
8	directed	O
9	repair	O
10	system	O
11	utilizes	O
12	the	O
13	proximal	O
14	d	O
15	(	O
16	GATC	O
17	)	O
18	sequence	O
19	to	O
20	direct	O
21	correction	O
22	.	O

1	These	O
2	data	O
3	support	O
4	a	O
5	possible	O
6	biological	O
7	significance	O
8	of	O
9	the	O
10	frameshift	O
11	to	O
12	occur	O
13	at	O
14	this	O
15	position	O
16	of	O
17	the	O
18	large	O
19	overlap	O
20	by	O
21	including	O
22	the	O
23	putative	O
24	RNA	O
25	template	O
26	-	O
27	binding	O
28	site	O
29	of	O
30	the	O
31	PLRV	B
32	replicase	I
33	in	O
34	the	O
35	ORF2a	B
36	/	I
37	ORF2b	I
38	transframe	I
39	protein	I
40	.	O

1	Thus	O
2	,	O
3	hGRbeta	B
4	potentially	O
5	functions	O
6	as	O
7	a	O
8	dominant	O
9	negative	O
10	inhibitor	O
11	of	O
12	hGRalpha	B
13	activity	O
14	.	O

1	Horseradish	B
2	peroxidase	I
3	as	O
4	a	O
5	permeability	O
6	marker	O
7	in	O
8	injured	O
9	rat	O
10	caudal	O
11	and	O
12	iliac	O
13	arteries	O
14	.	O

1	Complete	O
2	sequences	O
3	were	O
4	obtained	O
5	for	O
6	the	O
7	three	O
8	large	O
9	thrombic	O
10	peptides	O
11	,	O
12	and	O
13	these	O
14	were	O
15	aligned	O
16	by	O
17	using	O
18	peptides	O
19	from	O
20	the	O
21	V8	B
22	protease	I
23	digest	O
24	.	O

1	The	O
2	neglect	O
3	of	O
4	Richards	O
5	'	O
6	s	O
7	theory	O
8	demonstrates	O
9	the	O
10	range	O
11	of	O
12	factors	O
13	,	O
14	other	O
15	than	O
16	the	O
17	strictly	O
18	scientific	O
19	,	O
20	which	O
21	can	O
22	be	O
23	important	O
24	in	O
25	determining	O
26	the	O
27	influence	O
28	or	O
29	otherwise	O
30	of	O
31	a	O
32	psychological	O
33	theory	O
34	.	O

1	This	O
2	machinery	O
3	involves	O
4	a	O
5	secondary	O
6	structure	O
7	,	O
8	SECIS	O
9	element	O
10	,	O
11	in	O
12	the	O
13	selenoprotein	B
14	-	O
15	encoding	O
16	mRNA	O
17	,	O
18	directing	O
19	selenocysteine	O
20	insertion	O
21	at	O
22	the	O
23	position	O
24	of	O
25	an	O
26	opal	O
27	(	O
28	UGA	O
29	)	O
30	codon	O
31	,	O
32	normally	O
33	conferring	O
34	termination	O
35	of	O
36	translation	O
37	.	O

1	Transcriptional	O
2	activation	O
3	by	O
4	the	O
5	HIV	B
6	-	I
7	1	I
8	Tat	I
9	protein	I
10	requires	O
11	specific	O
12	residues	O
13	in	O
14	the	O
15	hexanucleotide	O
16	loop	O
17	and	O
18	trinucleotide	O
19	bulge	O
20	of	O
21	the	O
22	TAR	B
23	RNA	O
24	stem	O
25	-	O
26	loop	O
27	structure	O
28	found	O
29	in	O
30	the	O
31	5	O
32	'-	O
33	untranslated	O
34	leader	O
35	of	O
36	all	O
37	viral	O
38	transcripts	O
39	.	O

1	The	O
2	fatigue	O
3	exercise	O
4	showed	O
5	relatively	O
6	high	O
7	blood	O
8	lactate	O
9	concentration	O
10	[	O
11	12	O
12	.	O
13	5	O
14	(	O
15	SD	O
16	2	O
17	.	O
18	6	O
19	)	O
20	mmol	O
21	x	O
22	l	O
23	(-	O
24	1	O
25	)]	O
26	and	O
27	an	O
28	increase	O
29	of	O
30	serum	B
31	creatine	I
32	kinase	I
33	(	O
34	CK	B
35	)	O
36	activity	O
37	delayed	O
38	by	O
39	2	O
40	days	O
41	[	O
42	540	O
43	(	O
44	SD	O
45	407	O
46	)	O
47	U	O
48	x	O
49	l	O
50	(-	O
51	1	O
52	)].	O

1	Further	O
2	,	O
3	the	O
4	reduction	O
5	in	O
6	5	O
7	-	O
8	hydroxytryptophan	O
9	(	O
10	5	O
11	-	O
12	HTP	O
13	)	O
14	accumulation	O
15	by	O
16	LSD	O
17	showed	O
18	regional	O
19	differences	O
20	in	O
21	inhibition	O
22	by	O
23	methiothepin	O
24	(	O
25	hypothalamus	O
26	greater	O
27	than	O
28	cortex	O
29	greater	O
30	than	O
31	striatum	O
32	)	O
33	which	O
34	paralleled	O
35	the	O
36	autoreceptor	O
37	antagonist	O
38	activity	O
39	of	O
40	methiothepin	O
41	in	O
42	vitro	O
43	.(	O
44	ABSTRACT	O
45	TRUNCATED	O
46	AT	O
47	250	O
48	WORDS	O
49	)	O

1	The	O
2	complete	O
3	circular	O
4	TTV	O
5	genome	O
6	contained	O
7	a	O
8	novel	O
9	sequence	O
10	of	O
11	113	O
12	nt	O
13	(	O
14	nt	O
15	3740	O
16	to	O
17	3852	O
18	[=	O
19	0	O
20	])	O
21	in	O
22	between	O
23	the	O
24	known	O
25	3	O
26	'-	O
27	and	O
28	5	O
29	'-	O
30	end	O
31	arms	O
32	,	O
33	forming	O
34	a	O
35	117	O
36	-	O
37	nt	O
38	GC	O
39	-	O
40	rich	O
41	stretch	O
42	(	O
43	GC	O
44	content	O
45	,	O
46	90	O
47	.	O
48	6	O
49	%	O
50	at	O
51	nt	O
52	3736	O
53	to	O
54	3852	O
55	).	O

1	A	O
2	protocol	O
3	is	O
4	elaborated	O
5	for	O
6	the	O
7	preparation	O
8	and	O
9	characterization	O
10	of	O
11	a	O
12	quality	O
13	control	O
14	material	O
15	(	O
16	QCM	O
17	)	O
18	containing	O
19	intrinsic	O
20	concentration	O
21	of	O
22	cadmium	O
23	(	O
24	Cd	O
25	)	O
26	(	O
27	0	O
28	.	O
29	8	O
30	microgram	O
31	/	O
32	L	O
33	)	O
34	and	O
35	lead	O
36	(	O
37	Pb	O
38	)	O
39	(	O
40	13	O
41	.	O
42	4	O
43	micrograms	O
44	/	O
45	dL	O
46	)	O
47	from	O
48	bovine	O
49	blood	O
50	and	O
51	an	O
52	elevated	O
53	QCM	O
54	containing	O
55	Cd	O
56	(	O
57	5	O
58	.	O
59	0	O
60	micrograms	O
61	/	O
62	L	O
63	),	O
64	mercury	O
65	(	O
66	Hg	O
67	)	O
68	(	O
69	11	O
70	.	O
71	2	O
72	micrograms	O
73	/	O
74	L	O
75	),	O
76	and	O
77	Pb	O
78	(	O
79	34	O
80	.	O
81	5	O
82	micrograms	O
83	/	O
84	dL	O
85	)	O
86	from	O
87	bovine	O
88	blood	O
89	spiked	O
90	with	O
91	aqueous	O
92	spiking	O
93	-	O
94	solutions	O
95	prepared	O
96	with	O
97	salts	O
98	of	O
99	Cd	O
100	,	O
101	Hg	O
102	,	O
103	and	O
104	Pb	O
105	.	O

1	The	O
2	patient	O
3	initially	O
4	attained	O
5	complete	O
6	remission	O
7	(	O
8	CR1	O
9	)	O
10	with	O
11	conventional	O
12	chemotherapy	O
13	and	O
14	then	O
15	relapsed	O
16	14	O
17	months	O
18	later	O
19	.	O

1	Twenty	O
2	-	O
3	eight	O
4	(	O
5	7	O
6	.	O
7	0	O
8	%)	O
9	infants	O
10	without	O
11	periventricular	O
12	hemorrhage	O
13	were	O
14	revealed	O
15	as	O
16	having	O
17	spastic	O
18	cerebral	O
19	palsy	O
20	by	O
21	neurodevelopmental	O
22	evaluation	O
23	in	O
24	later	O
25	infancy	O
26	.	O

1	Pneumonia	O
2	in	O
3	children	O

1	It	O
2	was	O
3	found	O
4	that	O
5	the	O
6	primary	O
7	visual	O
8	cortex	O
9	of	O
10	the	O
11	rat	O
12	is	O
13	asymmetrical	O
14	in	O
15	volume	O
16	,	O
17	and	O
18	that	O
19	the	O
20	asymmetry	O
21	reflects	O
22	side	O
23	differences	O
24	in	O
25	the	O
26	number	O
27	of	O
28	neurons	O
29	.	O

1	Our	O
2	results	O
3	confirm	O
4	the	O
5	participation	O
6	of	O
7	intron	O
8	1	O
9	in	O
10	transcriptional	O
11	regulation	O
12	of	O
13	the	O
14	c	B
15	-	I
16	myb	I
17	gene	I
18	(	O
19	in	O
20	mouse	O
21	and	O
22	human	O
23	)	O
24	and	O
25	implicate	O
26	multiple	O
27	and	O
28	complex	O
29	regulatory	O
30	mechanisms	O
31	of	O
32	activation	O
33	during	O
34	myelomonocytic	O
35	differentiation	O
36	and	O
37	leukemic	O
38	cell	O
39	growth	O
40	control	O
41	.	O

1	Expression	O
2	of	O
3	activated	O
4	Cdc42	B
5	results	O
6	in	O
7	the	O
8	translocation	O
9	of	O
10	PKClambda	B
11	from	O
12	the	O
13	nucleus	O
14	into	O
15	the	O
16	cytosol	O
17	,	O
18	and	O
19	Cdc42	B
20	and	O
21	PKClambda	B
22	colocalize	O
23	at	O
24	the	O
25	plasma	O
26	membrane	O
27	and	O
28	in	O
29	the	O
30	cytoplasm	O
31	.	O

1	Both	O
2	verapamil	O
3	and	O
4	propranolol	O
5	can	O
6	exhibit	O
7	additive	O
8	effects	O
9	with	O
10	adenosine	O
11	in	O
12	prolonging	O
13	AV	O
14	nodal	O
15	conduction	O
16	time	O
17	;	O
18	however	O
19	,	O
20	only	O
21	verapamil	O
22	can	O
23	reduce	O
24	the	O
25	dose	O
26	of	O
27	adenosine	O
28	required	O
29	to	O
30	produce	O
31	AV	O
32	nodal	O
33	block	O
34	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequences	O
6	of	O
7	each	O
8	of	O
9	the	O
10	W3A1	B
11	ETF	I
12	subunits	I
13	exhibit	O
14	only	O
15	approximately	O
16	30	O
17	%	O
18	identity	O
19	with	O
20	the	O
21	corresponding	O
22	subunits	O
23	of	O
24	the	O
25	ETF	B
26	from	O
27	human	O
28	,	O
29	rat	O
30	,	O
31	and	O
32	Paracoccus	O
33	denitrificans	O
34	,	O
35	which	O
36	as	O
37	a	O
38	group	O
39	are	O
40	greater	O
41	than	O
42	50	O
43	%	O
44	identical	O
45	.	O

1	The	O
2	SR	B
3	protein	I
4	family	I
5	is	O
6	involved	O
7	in	O
8	constitutive	O
9	and	O
10	regulated	O
11	pre	O
12	-	O
13	mRNA	O
14	splicing	O
15	and	O
16	has	O
17	been	O
18	found	O
19	to	O
20	be	O
21	evolutionarily	O
22	conserved	O
23	in	O
24	metazoan	O
25	organisms	O
26	.	O

1	A	O
2	reciprocal	O
3	binding	O
4	assay	O
5	using	O
6	IM	O
7	-	O
8	9	O
9	cells	O
10	as	O
11	a	O
12	source	O
13	of	O
14	SHP	B
15	-	I
16	1	I
17	and	O
18	SHP	B
19	-	I
20	2	I
21	revealed	O
22	specific	O
23	association	O
24	of	O
25	SHP	B
26	-	I
27	2	I
28	(	O
29	but	O
30	not	O
31	SHP	B
32	-	I
33	1	I
34	)	O
35	with	O
36	a	O
37	glutathione	B
38	S	I
39	-	I
40	transferase	I
41	fusion	I
42	incorporating	O
43	GHR	B
44	cytoplasmic	I
45	domain	I
46	residues	I
47	485	I
48	-	I
49	620	I
50	,	O
51	but	O
52	only	O
53	if	O
54	the	O
55	fusion	O
56	was	O
57	first	O
58	rendered	O
59	tyrosine	O
60	-	O
61	phosphorylated	O
62	.	O

1	Leukemia	B
2	-	I
3	inhibitory	I
4	factor	I
5	(	O
6	LIF	B
7	)	O
8	is	O
9	a	O
10	neuropoietin	B
11	able	O
12	to	O
13	regulate	O
14	the	O
15	differentiation	O
16	and	O
17	the	O
18	survival	O
19	of	O
20	many	O
21	cell	O
22	types	O
23	,	O
24	which	O
25	include	O
26	some	O
27	neuronal	O
28	populations	O
29	.	O

1	The	O
2	state	O
3	of	O
4	the	O
5	liver	O
6	in	O
7	generalized	O
8	forms	O
9	of	O
10	meningococcal	O
11	infection	O

1	These	O
2	genetic	O
3	alterations	O
4	do	O
5	not	O
6	affect	O
7	synthesis	O
8	of	O
9	the	O
10	major	O
11	c	B
12	-	I
13	myc	I
14	protein	I
15	,	O
16	p64	B
17	,	O
18	which	O
19	is	O
20	initiated	O
21	from	O
22	the	O
23	first	O
24	AUG	O
25	codon	O
26	in	O
27	exon	O
28	2	O
29	.	O

1	In	O
2	wild	O
3	-	O
4	type	O
5	cells	O
6	,	O
7	SSM1b	B
8	transcripts	I
9	accumulate	O
10	to	O
11	twice	O
12	the	O
13	level	O
14	of	O
15	SSM1a	B
16	transcripts	I
17	,	O
18	suggesting	O
19	that	O
20	SSM1b	B
21	is	O
22	responsible	O
23	for	O
24	the	O
25	majority	O
26	of	O
27	the	O
28	Ssm1p	B
29	pool	O
30	.	O

1	METHODS	O
2	--	O
3	16	O
4	volunteered	O
5	for	O
6	spirometry	O
7	with	O
8	methacholine	O
9	provocation	O
10	test	O
11	including	O
12	a	O
13	test	O
14	for	O
15	small	O
16	airways	O
17	function	O
18	by	O
19	volume	O
20	of	O
21	trapped	O
22	gas	O
23	(	O
24	VTG	O
25	).	O

1	RESULTS	O
2	:	O
3	Patients	O
4	in	O
5	Group	O
6	A	O
7	had	O
8	a	O
9	higher	O
10	incidence	O
11	of	O
12	posterolateral	O
13	wall	O
14	motion	O
15	abnormalities	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	001	O
22	)	O
23	on	O
24	radionuclide	O
25	ventriculography	O
26	,	O
27	a	O
28	larger	O
29	infarct	O
30	area	O
31	(	O
32	as	O
33	evidenced	O
34	by	O
35	higher	O
36	peak	O
37	creatine	B
38	kinase	I
39	levels	O
40	)	O
41	(	O
42	p	O
43	<	O
44	0	O
45	.	O
46	02	O
47	)	O
48	and	O
49	a	O
50	lower	O
51	left	O
52	ventricular	O
53	ejection	O
54	fraction	O
55	(	O
56	LVEF	O
57	)	O
58	at	O
59	hospital	O
60	discharge	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	008	O
67	)	O
68	than	O
69	those	O
70	in	O
71	Group	O
72	B	O
73	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	cysteine	B
6	synthase	I
7	cDNA	I
8	from	O
9	Citrullus	O
10	vulgaris	O
11	(	O
12	watermelon	O
13	)	O
14	by	O
15	genetic	O
16	complementation	O
17	in	O
18	an	O
19	Escherichia	O
20	coli	O
21	Cys	O
22	-	O
23	auxotroph	O
24	.	O

1	Bullous	O
2	keratopathy	O
3	was	O
4	usually	O
5	aphakic	O
6	in	O
7	origin	O
8	in	O
9	1982	O
10	,	O
11	but	O
12	after	O
13	1983	O
14	pseudophakic	O
15	bullous	O
16	keratopathy	O
17	(	O
18	PBK	O
19	)	O
20	was	O
21	the	O
22	most	O
23	common	O
24	cause	O
25	of	O
26	bullous	O
27	keratopathy	O
28	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	increase	O
6	in	O
7	the	O
8	RH	O
9	level	O
10	boosts	O
11	the	O
12	current	O
13	values	O
14	by	O
15	2	O
16	-	O
17	3	O
18	orders	O
19	of	O
20	magnitude	O
21	;	O
22	contrariwise	O
23	,	O
24	the	O
25	voltage	O
26	values	O
27	rise	O
28	by	O
29	about	O
30	three	O
31	times	O
32	with	O
33	drop	O
34	in	O
35	the	O
36	RH	O
37	.	O

1	Deformities	O
2	of	O
3	the	O
4	tip	O
5	of	O
6	the	O
7	olecranon	O
8	and	O
9	of	O
10	the	O
11	coronoid	O
12	process	O
13	are	O
14	also	O
15	described	O
16	(	O
17	De	O
18	Palma	O
19	1956	O
20	,	O
21	Jordan	O
22	1958	O
23	,	O
24	Ahlberg	O
25	1965	O
26	,	O
27	Weseloh	O
28	1973	O
29	).	O

1	A	O
2	two	O
3	phase	O
4	slug	O
5	flow	O
6	tubular	O
7	heat	O
8	exchanger	O
9	was	O
10	used	O
11	for	O
12	the	O
13	thermal	O
14	inactivation	O
15	of	O
16	Listeria	O
17	monocytogenes	O
18	in	O
19	natural	O
20	infected	O
21	milk	O
22	from	O
23	seven	O
24	cows	O
25	.	O

1	1	O
2	-(	O
3	m	O
4	-	O
5	Chlorophenyl	O
6	)	O
7	piperazine	O
8	(	O
9	mCPP	O
10	,	O
11	0	O
12	.	O
13	1	O
14	-	O
15	3	O
16	.	O
17	0	O
18	mg	O
19	/	O
20	kg	O
21	)	O
22	and	O
23	1	O
24	-(	O
25	m	O
26	-	O
27	trifluoromethylphenyl	O
28	)	O
29	piperazine	O
30	(	O
31	TFMPP	O
32	,	O
33	0	O
34	.	O
35	1	O
36	-	O
37	3	O
38	.	O
39	0	O
40	mg	O
41	/	O
42	kg	O
43	),	O
44	both	O
45	thought	O
46	to	O
47	act	O
48	primarily	O
49	at	O
50	5	B
51	-	I
52	HT1	I
53	sites	I
54	,	O
55	also	O
56	decreased	O
57	responding	O
58	and	O
59	this	O
60	effect	O
61	was	O
62	blocked	O
63	by	O
64	methysergide	O
65	and	O
66	by	O
67	1	O
68	-	O
69	NP	O
70	,	O
71	but	O
72	not	O
73	by	O
74	ketanserin	O
75	.	O

1	Next	O
2	,	O
3	we	O
4	stably	O
5	overexpressed	O
6	wild	B
7	-	I
8	type	I
9	Shc	I
10	or	O
11	Y317F	B
12	mutant	I
13	Shc	I
14	into	O
15	HIRc	O
16	cells	O
17	.	O

1	Objective	O
2	:	O
3	To	O
4	evaluate	O
5	endometrial	O
6	thickness	O
7	and	O
8	the	O
9	incidence	O
10	of	O
11	uterine	O
12	bleeding	O
13	in	O
14	postmenopausal	O
15	women	O
16	using	O
17	either	O
18	tibolone	O
19	2	O
20	.	O
21	5	O
22	mg	O
23	or	O
24	continuous	O
25	combined	O
26	2	O
27	mg	O
28	estradiol	O
29	and	O
30	1	O
31	mg	O
32	norethisterone	O
33	acetate	O
34	(	O
35	E	O
36	+	O
37	NETA	O
38	)	O
39	daily	O
40	as	O
41	hormone	O
42	replacement	O
43	therapy	O
44	.	O

1	Human	B
2	PDK1	I
3	is	O
4	homologous	O
5	to	O
6	the	O
7	Drosophila	B
8	protein	I
9	kinase	I
10	DSTPK61	I
11	,	O
12	which	O
13	has	O
14	been	O
15	implicated	O
16	in	O
17	the	O
18	regulation	O
19	of	O
20	sex	O
21	differentiation	O
22	,	O
23	oogenesis	O
24	and	O
25	spermatogenesis	O
26	.	O

1	In	O
2	order	O
3	to	O
4	determine	O
5	which	O
6	sequences	O
7	in	O
8	the	O
9	GATA	B
10	-	I
11	1	I
12	promoter	I
13	are	O
14	crucial	O
15	for	O
16	activation	O
17	by	O
18	the	O
19	ME26	B
20	viral	I
21	protein	I
22	,	O
23	we	O
24	made	O
25	deletions	O
26	of	O
27	the	O
28	promoter	O
29	,	O
30	cloned	O
31	them	O
32	into	O
33	a	O
34	luciferase	B
35	expression	O
36	vector	O
37	and	O
38	tested	O
39	their	O
40	activity	O
41	in	O
42	mouse	O
43	fibroblasts	O
44	,	O
45	which	O
46	do	O
47	not	O
48	express	O
49	GATA	B
50	-	I
51	1	I
52	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	of	O
5	LeMT	B
6	(	I
7	A	I
8	)	I
9	and	O
10	LeMT	B
11	(	I
12	B	I
13	)	I
14	showed	O
15	that	O
16	transcripts	O
17	of	O
18	both	O
19	MT	B
20	-	I
21	like	I
22	genes	I
23	were	O
24	more	O
25	abundant	O
26	in	O
27	leaves	O
28	than	O
29	roots	O
30	in	O
31	tomato	O
32	plants	O
33	grown	O
34	without	O
35	addition	O
36	of	O
37	extra	O
38	metal	O
39	ions	O
40	,	O
41	a	O
42	characteristic	O
43	of	O
44	type	B
45	II	I
46	MTs	I
47	.	O

1	Interestingly	O
2	,	O
3	in	O
4	the	O
5	adult	O
6	,	O
7	transgene	O
8	expression	O
9	patterns	O
10	within	O
11	the	O
12	cerebellum	O
13	in	O
14	two	O
15	lines	O
16	appeared	O
17	to	O
18	mark	O
19	distinct	O
20	anterior	O
21	-	O
22	posterior	O
23	compartments	O
24	.	O

1	Hypotension	O
2	was	O
3	produced	O
4	by	O
5	head	O
6	up	O
7	tilt	O
8	.	O

1	Plasma	O
2	lecithin	B
3	/	I
4	cholesterol	I
5	acyltransferase	I
6	(	O
7	LCAT	B
8	)	O
9	activity	O
10	in	O
11	multiple	O
12	-	O
13	organ	O
14	donors	O
15	:	O
16	a	O
17	predictor	O
18	of	O
19	allograft	O
20	viability	O
21	in	O
22	clinical	O
23	liver	O
24	transplantation	O
25	.	O

1	In	O
2	contrast	O
3	,	O
4	c	B
5	-	I
6	Src	I
7	activated	O
8	by	O
9	isoproterenol	O
10	led	O
11	to	O
12	tyrosine	O
13	phosphorylation	O
14	of	O
15	Shc	B
16	and	O
17	subsequent	O
18	Erk	B
19	activation	O
20	,	O
21	but	O
22	not	O
23	tyrosine	O
24	phosphorylation	O
25	of	O
26	cortactin	B
27	or	O
28	Stat3	B
29	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	CCCC	O
6	module	O
7	is	O
8	structurally	O
9	related	O
10	to	O
11	the	O
12	DNA	O
13	-	O
14	binding	O
15	domain	O
16	of	O
17	the	O
18	erythroid	B
19	transcription	I
20	factor	I
21	GATA	I
22	-	I
23	1	I
24	.	O

1	The	O
2	rats	O
3	were	O
4	used	O
5	for	O
6	the	O
7	study	O
8	of	O
9	the	O
10	effects	O
11	of	O
12	sepsis	O
13	on	O
14	the	O
15	utilization	O
16	of	O
17	exogenous	O
18	fat	O
19	emulsion	O
20	.	O

1	Effect	O
2	of	O
3	aging	O
4	on	O
5	respiratory	O
6	skeletal	O
7	muscles	O
8	.	O

1	Fenfluramine	O
2	(	O
3	in	O
4	doses	O
5	ranging	O
6	from	O
7	0	O
8	.	O
9	0625	O
10	-	O
11	4	O
12	.	O
13	0	O
14	mg	O
15	/	O
16	kg	O
17	/	O
18	infusion	O
19	)	O
20	did	O
21	not	O
22	maintain	O
23	self	O
24	-	O
25	administration	O
26	behavior	O
27	at	O
28	or	O
29	above	O
30	the	O
31	minimum	O
32	requirement	O
33	(	O
34	FR	O
35	30	O
36	).	O

1	In	O
2	vitro	O
3	protein	O
4	retention	O
5	experiments	O
6	in	O
7	which	O
8	Hsp90	B
9	heterocomplexes	I
10	were	O
11	precipitated	O
12	resulted	O
13	in	O
14	coprecipitation	O
15	of	O
16	Cns1	B
17	.	O

1	The	O
2	SUP44	B
3	suppressor	I
4	mutation	I
5	occurs	O
6	near	O
7	a	O
8	region	O
9	of	O
10	the	O
11	protein	O
12	that	O
13	corresponds	O
14	to	O
15	the	O
16	known	O
17	positions	O
18	of	O
19	alterations	O
20	in	O
21	E	B
22	.	I
23	coli	I
24	S5	I
25	ram	I
26	mutations	I
27	.	O

1	Characterization	O
2	of	O
3	the	O
4	3	O
5	'	O
6	ends	O
7	of	O
8	the	O
9	plus	O
10	-	O
11	strand	O
12	DNA	O
13	fragments	O
14	reveals	O
15	(	O
16	1	O
17	)	O
18	that	O
19	the	O
20	upstream	O
21	fragment	O
22	is	O
23	elongated	O
24	beyond	O
25	PPT2	B
26	creating	O
27	a	O
28	plus	O
29	-	O
30	strand	O
31	overlap	O
32	and	O
33	(	O
34	2	O
35	)	O
36	that	O
37	the	O
38	majority	O
39	of	O
40	plus	O
41	-	O
42	strand	O
43	strong	O
44	-	O
45	stop	O
46	DNA	O
47	fragments	O
48	bear	O
49	a	O
50	copy	O
51	of	O
52	the	O
53	minus	O
54	-	O
55	strand	O
56	primer	O
57	binding	O
58	site	O
59	in	O
60	agreement	O
61	with	O
62	the	O
63	accepted	O
64	model	O
65	of	O
66	retroviral	O
67	genomic	O
68	RNA	O
69	reverse	O
70	transcription	O
71	.	O

1	Hydropathy	O
2	analysis	O
3	of	O
4	KCC1	B
5	indicates	O
6	structural	O
7	homology	O
8	to	O
9	NKCC	B
10	,	O
11	including	O
12	12	O
13	transmembrane	O
14	domains	O
15	,	O
16	a	O
17	large	O
18	extracellular	O
19	loop	O
20	with	O
21	potential	O
22	N	O
23	-	O
24	linked	O
25	glycosylation	O
26	sites	O
27	,	O
28	and	O
29	cytoplasmic	O
30	N	O
31	-	O
32	and	O
33	C	O
34	-	O
35	terminal	O
36	regions	O
37	.	O

1	In	O
2	sorted	O
3	bone	O
4	marrow	O
5	cells	O
6	expression	O
7	of	O
8	both	O
9	VpreB	B
10	genes	I
11	was	O
12	detected	O
13	in	O
14	pro	O
15	-	O
16	B	O
17	/	O
18	pre	O
19	-	O
20	BI	O
21	and	O
22	large	O
23	pre	O
24	-	O
25	BII	O
26	cells	O
27	,	O
28	while	O
29	the	O
30	RNA	O
31	steady	O
32	state	O
33	levels	O
34	were	O
35	at	O
36	least	O
37	100	O
38	-	O
39	fold	O
40	lower	O
41	in	O
42	small	O
43	pre	O
44	-	O
45	BII	O
46	and	O
47	immature	O
48	/	O
49	mature	O
50	B	O
51	cells	O
52	.	O

1	In	O
2	one	O
3	patient	O
4	with	O
5	severe	O
6	diarrhea	O
7	the	O
8	estriol	O
9	concentration	O
10	in	O
11	serum	O
12	was	O
13	low	O
14	until	O
15	the	O
16	intestinal	O
17	function	O
18	normalised	O
19	and	O
20	the	O
21	estriol	O
22	concentration	O
23	went	O
24	up	O
25	exactly	O
26	when	O
27	the	O
28	diarrhea	O
29	stopped	O
30	.	O

1	The	O
2	structure	O
3	of	O
4	the	O
5	free	O
6	SH2	B
7	domain	I
8	has	O
9	been	O
10	compared	O
11	to	O
12	that	O
13	of	O
14	the	O
15	SH2	B
16	complexed	O
17	with	O
18	a	O
19	doubly	O
20	phosphorylated	O
21	peptide	O
22	derived	O
23	from	O
24	polyomavirus	B
25	middle	I
26	T	I
27	antigen	I
28	(	O
29	MT	B
30	).	O

1	Almost	O
2	complete	O
3	sequence	O
4	identity	O
5	was	O
6	found	O
7	between	O
8	the	O
9	3	O
10	'	O
11	end	O
12	of	O
13	the	O
14	DXS6673E	B
15	gene	I
16	and	O
17	two	O
18	expressed	O
19	sequence	O
20	tags	O
21	(	O
22	ESTs	O
23	)	O
24	and	O
25	between	O
26	the	O
27	5	O
28	'	O
29	end	O
30	of	O
31	the	O
32	DXS6673E	B
33	gene	I
34	and	O
35	a	O
36	third	O
37	EST	O
38	.	O

1	Among	O
2	booked	O
3	patients	O
4	the	O
5	maternal	O
6	mortality	O
7	rate	O
8	was	O
9	0	O
10	.	O
11	32	O
12	and	O
13	among	O
14	unbooked	O
15	patients	O
16	11	O
17	.	O
18	13	O
19	per	O
20	1000	O
21	deliveries	O
22	.	O

1	Further	O
2	research	O
3	is	O
4	required	O
5	to	O
6	better	O
7	measure	O
8	treatment	O
9	effects	O
10	,	O
11	modification	O
12	of	O
13	MS	O
14	natural	O
15	history	O
16	,	O
17	and	O
18	net	O
19	societal	O
20	costs	O
21	of	O
22	IFN	B
23	beta	I
24	-	I
25	1b	I
26	in	O
27	RRMS	O
28	.	O

1	The	O
2	binding	O
3	of	O
4	PH	B
5	domains	I
6	to	O
7	Gbetagamma	B
8	was	O
9	inhibited	O
10	by	O
11	preincubation	O
12	of	O
13	Gbetagamma	B
14	with	O
15	the	O
16	GDP	O
17	-	O
18	bound	O
19	but	O
20	not	O
21	the	O
22	GTP	O
23	-	O
24	bound	O
25	form	O
26	of	O
27	Gialpha	B
28	.	O

1	The	O
2	same	O
3	response	O
4	occurs	O
5	whether	O
6	acrylamide	O
7	is	O
8	given	O
9	immediately	O
10	after	O
11	nerve	O
12	ligation	O
13	or	O
14	1	O
15	week	O
16	later	O
17	.	O

1	The	O
2	neurohypophysial	O
3	vasopressin	B
4	and	O
5	oxytocin	B
6	content	O
7	was	O
8	bioassayed	O
9	by	O
10	pressor	O
11	effect	O
12	following	O
13	Dekanski	O
14	or	O
15	milk	O
16	-	O
17	ejection	O
18	activity	O
19	in	O
20	vitro	O
21	following	O
22	van	O
23	Dongen	O
24	and	O
25	Hays	O
26	,	O
27	respectively	O
28	.	O

1	One	O
2	linker	O
3	-	O
4	peptide	O
5	insertion	O
6	in	O
7	the	O
8	RsaA	B
9	C	I
10	terminus	I
11	(	I
12	amino	I
13	acid	I
14	784	I
15	)	I
16	had	O
17	no	O
18	effect	O
19	on	O
20	S	O
21	-	O
22	layer	O
23	biogenesis	O
24	,	O
25	while	O
26	another	O
27	(	O
28	amino	O
29	acid	O
30	907	O
31	)	O
32	disrupted	O
33	secretion	O
34	of	O
35	the	O
36	protein	O
37	,	O
38	suggesting	O
39	that	O
40	RsaA	B
41	possesses	O
42	a	O
43	secretion	O
44	signal	O
45	lying	O
46	C	O
47	terminal	O
48	to	O
49	amino	O
50	acid	O
51	784	O
52	,	O
53	near	O
54	or	O
55	including	O
56	amino	O
57	acid	O
58	907	O
59	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	nucleotide	O
6	sequence	O
7	of	O
8	the	O
9	p54	B
10	gene	I
11	carried	O
12	by	O
13	two	O
14	virulent	O
15	ASFV	O
16	strains	O
17	(	O
18	E70	O
19	and	O
20	E75	O
21	)	O
22	with	O
23	that	O
24	obtained	O
25	from	O
26	virus	O
27	Ba71V	O
28	showed	O
29	100	O
30	%	O
31	similarity	O
32	.	O

1	Hydrocortisone	O
2	seems	O
3	to	O
4	be	O
5	unable	O
6	to	O
7	hinder	O
8	the	O
9	postdenervation	O
10	changes	O
11	in	O
12	the	O
13	muscle	O
14	membrane	O
15	whereas	O
16	high	O
17	doses	O
18	of	O
19	the	O
20	hormone	O
21	are	O
22	able	O
23	to	O
24	induce	O
25	changes	O
26	in	O
27	the	O
28	muscle	O
29	membrane	O
30	.	O

1	Issues	O
2	of	O
3	distribution	O
4	of	O
5	kinetic	O
6	energy	O
7	of	O
8	traumatizing	O
9	object	O
10	in	O
11	direct	O
12	contact	O
13	interaction	O
14	with	O
15	head	O
16	during	O
17	impact	O
18	are	O
19	discussed	O
20	from	O
21	position	O
22	of	O
23	biomechanics	O
24	.	O

1	(	O
2	Emeritus	O
3	)	O
4	John	O
5	Henri	O
6	Roosegaarde	O
7	Bisschop	O

1	Optical	O
2	-	O
3	absorption	O
4	spectra	O
5	,	O
6	crystal	O
7	-	O
8	field	O
9	energy	O
10	levels	O
11	,	O
12	and	O
13	transition	O
14	line	O
15	strengths	O
16	of	O
17	holmium	O
18	in	O
19	trigonal	O
20	Na3	O

1	After	O
2	surgery	O
3	,	O
4	patients	O
5	self	O
6	administered	O
7	one	O
8	of	O
9	three	O
10	possible	O
11	postsurgical	O
12	medications	O
13	,	O
14	which	O
15	included	O
16	placebo	O
17	,	O
18	codeine	O
19	60	O
20	mg	O
21	,	O
22	and	O
23	ibuprofen	O
24	400	O
25	mg	O
26	,	O
27	when	O
28	their	O
29	pain	O
30	reached	O
31	a	O
32	moderate	O
33	or	O
34	severe	O
35	intensity	O
36	.	O

1	All	O
2	of	O
3	the	O
4	newly	O
5	acquired	O
6	proviruses	O
7	identified	O
8	in	O
9	mosaic	O
10	founder	O
11	SWR	O
12	/	O
13	J	O
14	-	O
15	RF	O
16	/	O
17	J	O
18	mice	O
19	that	O
20	could	O
21	be	O
22	transmitted	O
23	through	O
24	the	O
25	germ	O
26	line	O
27	were	O
28	also	O
29	present	O
30	in	O
31	somatic	O
32	tissues	O
33	,	O
34	demonstrating	O
35	that	O
36	viral	O
37	integration	O
38	occurred	O
39	before	O
40	the	O
41	germ	O
42	line	O
43	was	O
44	set	O
45	aside	O
46	from	O
47	the	O
48	somatic	O
49	lineages	O
50	.	O

1	The	O
2	P	B
3	-	I
4	wr	I
5	and	O
6	P	B
7	-	I
8	rr	I
9	cDNA	I
10	sequences	I
11	are	O
12	very	O
13	similar	O
14	in	O
15	their	O
16	5	O
17	'	O
18	regions	O
19	.	O

1	The	O
2	results	O
3	imply	O
4	that	O
5	kindling	O
6	does	O
7	not	O
8	produce	O
9	its	O
10	facilitating	O
11	effect	O
12	on	O
13	acquisition	O
14	of	O
15	HPC	O
16	SS	O
17	by	O
18	removing	O
19	a	O
20	disruptive	O
21	effect	O
22	of	O
23	the	O
24	stimulation	O
25	.	O

1	Serological	O
2	studies	O
3	of	O
4	antibodies	O
5	to	O
6	Epstein	O
7	-	O
8	Barr	O
9	virus	O
10	in	O
11	infectious	O
12	mononucleosis	O

1	This	O
2	report	O
3	describes	O
4	the	O
5	identification	O
6	of	O
7	a	O
8	gene	O
9	of	O
10	related	O
11	function	O
12	,	O
13	SMD1	B
14	,	O
15	located	O
16	immediately	O
17	3	O
18	'	O
19	to	O
20	PRP38	B
21	.	O

1	To	O
2	investigate	O
3	the	O
4	potential	O
5	role	O
6	of	O
7	SP1	B
8	,	O
9	we	O
10	examined	O
11	nuclear	O
12	extracts	O
13	from	O
14	HCMV	O
15	-	O
16	infected	O
17	cells	O
18	.	O

1	The	O
2	purpose	O
3	of	O
4	this	O
5	investigation	O
6	was	O
7	to	O
8	describe	O
9	a	O
10	new	O
11	formulation	O
12	of	O
13	silver	O
14	sulfadiazine	O
15	in	O
16	a	O
17	water	O
18	soluble	O
19	gel	O
20	,	O
21	poloxamer	O
22	188	O
23	.	O

1	Upon	O
2	analysis	O
3	of	O
4	various	O
5	deletion	O
6	and	O
7	point	O
8	-	O
9	mutated	O
10	variants	O
11	of	O
12	the	O
13	human	B
14	IL	I
15	-	I
16	6	I
17	gene	I
18	promoter	I
19	coupled	O
20	to	O
21	a	O
22	reporter	O
23	gene	O
24	,	O
25	we	O
26	screened	O
27	for	O
28	possible	O
29	cooperating	O
30	transcription	O
31	factors	O
32	.	O

1	Mastocytosis	O
2	.	O

1	Individual	O
2	mutations	O
3	in	O
4	motifs	O
5	III	O
6	,	O
7	IV	O
8	,	O
9	and	O
10	V	O
11	had	O
12	distinctive	O
13	effects	O
14	on	O
15	the	O
16	affinity	O
17	of	O
18	enzyme	O
19	for	O
20	GTP	O
21	,	O
22	the	O
23	rate	O
24	of	O
25	covalent	O
26	catalysis	O
27	(	O
28	EpG	O
29	formation	O
30	),	O
31	or	O
32	the	O
33	transfer	O
34	of	O
35	GMP	O
36	from	O
37	enzyme	O
38	to	O
39	RNA	O
40	.	O

1	63	O
2	.	O
3	3	O
4	micromol	O
5	/	O
6	1	O
7	,	O
8	p	O
9	<	O
10	0	O
11	.	O
12	01	O
13	)	O
14	and	O
15	area	O
16	under	O
17	the	O
18	plasma	O
19	concentration	O
20	-	O
21	time	O
22	curve	O
23	extrapolated	O
24	to	O
25	infinity	O
26	AUC	O
27	9	O
28	(	O
29	0	O
30	-	O
31	infinity	O
32	)(	O
33	518	O
34	.	O
35	7	O
36	vs	O
37	.	O

1	Overall	O
2	,	O
3	lesions	O
4	infiltrating	O
5	the	O
6	deep	O
7	lamina	O
8	propria	O
9	do	O
10	not	O
11	exhibit	O
12	a	O
13	reduced	O
14	frequency	O
15	of	O
16	occurrence	O
17	compared	O
18	to	O
19	lesions	O
20	infiltrating	O
21	the	O
22	skeletal	O
23	muscle	O
24	;	O
25	however	O
26	,	O
27	carcinomas	O
28	affecting	O
29	other	O
30	oral	O
31	sites	O
32	showed	O
33	a	O
34	reduced	O
35	frequency	O
36	of	O
37	deeply	O
38	infiltrating	O
39	lesions	O
40	in	O
41	comparison	O
42	to	O
43	more	O
44	superficial	O
45	lesions	O
46	.	O

1	The	O
2	effect	O
3	of	O
4	feeding	O
5	patterns	O
6	on	O
7	fat	O
8	deposition	O
9	in	O
10	mice	O
11	.	O

1	DESIGN	O
2	:	O
3	A	O
4	cross	O
5	-	O
6	sectional	O
7	study	O
8	.	O

1	Sterols	O
2	in	O
3	pollen	O
4	.	O

1	To	O
2	assess	O
3	the	O
4	effects	O
5	of	O
6	alveolar	O
7	hypoxia	O
8	and	O
9	angiotensin	B
10	II	I
11	infusion	O
12	on	O
13	distribution	O
14	of	O
15	blood	O
16	flow	O
17	to	O
18	the	O
19	lung	O
20	we	O
21	performed	O
22	perfusion	O
23	lung	O
24	scans	O
25	on	O
26	anesthetized	O
27	mechanically	O
28	ventilated	O
29	lambs	O
30	.	O

1	The	O
2	N3	O
3	wave	O
4	of	O
5	the	O
6	SSEP	O
7	'	O
8	s	O
9	,	O
10	which	O
11	has	O
12	been	O
13	found	O
14	to	O
15	correlate	O
16	best	O
17	with	O
18	neurological	O
19	recovery	O
20	,	O
21	returned	O
22	to	O
23	65	O
24	%	O
25	+/-	O
26	48	O
27	%	O
28	of	O
29	the	O
30	preischemia	O
31	amplitude	O
32	in	O
33	the	O
34	insulin	B
35	-	O
36	treated	O
37	animals	O
38	,	O
39	compared	O
40	to	O
41	40	O
42	%	O
43	+/-	O
44	34	O
45	%	O
46	in	O
47	the	O
48	fasted	O
49	group	O
50	and	O
51	26	O
52	%	O
53	+/-	O
54	24	O
55	%	O
56	in	O
57	the	O
58	control	O
59	animals	O
60	.	O

1	To	O
2	study	O
3	the	O
4	retinal	O
5	surface	O
6	in	O
7	the	O
8	human	O
9	eye	O
10	in	O
11	normal	O
12	and	O
13	diseased	O
14	states	O
15	we	O
16	used	O
17	laser	O
18	scanning	O
19	tomography	O
20	.	O

1	Since	O
2	general	B
3	regulatory	I
4	factor	I
5	I	I
6	(	O
7	GRFI	B
8	)/	O
9	repressor	B
10	/	I
11	activator	I
12	site	I
13	binding	I
14	protein	I
15	1	I
16	(	O
17	RAP1	B
18	)/	O
19	translation	B
20	upstream	I
21	factor	I
22	(	O
23	TUF	B
24	)	O
25	is	O
26	believed	O
27	to	O
28	be	O
29	an	O
30	activator	O
31	of	O
32	MAT	B
33	alpha	I
34	expression	O
35	,	O
36	we	O
37	examined	O
38	whether	O
39	PYK1	B
40	,	O
41	which	O
42	is	O
43	known	O
44	to	O
45	be	O
46	regulated	O
47	by	O
48	GRFI	B
49	/	O
50	RAP1	B
51	/	O
52	TUF	B
53	,	O
54	is	O
55	also	O
56	affected	O
57	by	O
58	the	O
59	gal11	B
60	mutation	I
61	.	O

1	Levels	O
2	of	O
3	TSG	B
4	-	I
5	14	I
6	protein	I
7	(	O
8	also	O
9	termed	O
10	PTX	B
11	-	I
12	3	I
13	)	O
14	become	O
15	elevated	O
16	in	O
17	the	O
18	serum	O
19	of	O
20	mice	O
21	and	O
22	humans	O
23	after	O
24	injection	O
25	with	O
26	bacterial	O
27	lipopolysaccharide	O
28	,	O
29	but	O
30	in	O
31	contrast	O
32	to	O
33	conventional	O
34	acute	O
35	phase	O
36	proteins	O
37	,	O
38	the	O
39	bulk	O
40	of	O
41	TSG	B
42	-	I
43	14	I
44	synthesis	O
45	in	O
46	the	O
47	intact	O
48	organism	O
49	occurs	O
50	outside	O
51	the	O
52	liver	O
53	.	O

1	Since	O
2	very	O
3	recent	O
4	scanning	O
5	-	O
6	deletion	O
7	analysis	O
8	indicates	O
9	that	O
10	there	O
11	is	O
12	a	O
13	critical	O
14	region	O
15	for	O
16	activity	O
17	near	O
18	Cys	O
19	-	O
20	118	O
21	and	O
22	that	O
23	Cys	O
24	-	O
25	118	O
26	is	O
27	necessary	O
28	for	O
29	maximal	O
30	activity	O
31	,	O
32	we	O
33	conclude	O
34	that	O
35	the	O
36	Cys	O
37	-	O
38	118	O
39	residue	O
40	is	O
41	necessary	O
42	for	O
43	proper	O
44	glycosylation	O
45	and	O
46	maximal	O
47	biologic	O
48	activity	O
49	of	O
50	GM	B
51	-	I
52	CSF	I
53	.	O

1	Although	O
2	no	O
3	differences	O
4	were	O
5	noted	O
6	in	O
7	the	O
8	decrease	O
9	in	O
10	platelet	O
11	counts	O
12	between	O
13	the	O
14	two	O
15	groups	O
16	,	O
17	fibrinogen	B
18	levels	O
19	and	O
20	alpha	B
21	2	I
22	-	I
23	antiplasmin	I
24	levels	O
25	declined	O
26	less	O
27	drastically	O
28	in	O
29	the	O
30	antithrombin	B
31	-	O
32	treated	O
33	group	O
34	.	O

1	Through	O
2	a	O
3	stretch	O
4	of	O
5	56	O
6	amino	O
7	acids	O
8	,	O
9	constituting	O
10	the	O
11	MADS	B
12	domain	I
13	,	O
14	the	O
15	two	O
16	proteins	O
17	are	O
18	identical	O
19	except	O
20	for	O
21	two	O
22	conservative	O
23	amino	O
24	acid	O
25	substitutions	O
26	.	O

1	Of	O
2	these	O
3	patients	O
4	,	O
5	46	O
6	,	O
7	164	O
8	were	O
9	placed	O
10	on	O
11	a	O
12	waiting	O
13	list	O
14	for	O
15	transplantation	O
16	,	O
17	23	O
18	,	O
19	275	O
20	of	O
21	whom	O
22	received	O
23	a	O
24	first	O
25	cadaveric	O
26	transplant	O
27	between	O
28	1991	O
29	and	O
30	1997	O
31	.	O

1	Furthermore	O
2	,	O
3	the	O
4	insertion	O
5	of	O
6	the	O
7	ColE1	B
8	cer	I
9	site	I
10	into	O
11	the	O
12	RK2	O
13	plasmid	O
14	deleted	O
15	for	O
16	the	O
17	par	O
18	region	O
19	failed	O
20	to	O
21	stabilize	O
22	the	O
23	plasmid	O
24	in	O
25	the	O
26	MC1061K	O
27	strain	O
28	,	O
29	indicating	O
30	that	O
31	the	O
32	multimer	O
33	resolution	O
34	activity	O
35	encoded	O
36	by	O
37	parCBA	B
38	is	O
39	not	O
40	by	O
41	itself	O
42	responsible	O
43	for	O
44	the	O
45	stabilization	O
46	activity	O
47	observed	O
48	for	O
49	this	O
50	operon	O
51	.	O

1	An	O
2	examination	O
3	was	O
4	performed	O
5	in	O
6	15	O
7	patients	O
8	who	O
9	had	O
10	developed	O
11	pronounced	O
12	osteomalacia	O
13	following	O
14	gastric	O
15	resection	O
16	.	O

1	Relationship	O
2	between	O
3	gross	O
4	lesions	O
5	and	O
6	Escherichia	O
7	coli	O
8	serotypes	O
9	in	O
10	chronic	O
11	respiratory	O
12	disease	O
13	(	O
14	CRD	O
15	)	O
16	of	O
17	poultry	O
18	.	O

1	The	O
2	experiments	O
3	show	O
4	that	O
5	it	O
6	is	O
7	the	O
8	micromilieu	O
9	of	O
10	the	O
11	alveoli	O
12	and	O
13	the	O
14	condition	O
15	of	O
16	the	O
17	AM	O
18	(	O
19	certain	O
20	physiological	O
21	activation	O
22	states	O
23	,	O
24	such	O
25	as	O
26	phagocytic	O
27	activity	O
28	)	O
29	that	O
30	essentially	O
31	determine	O
32	the	O
33	degree	O
34	of	O
35	recovery	O
36	.	O

1	The	O
2	persistence	O
3	of	O
4	members	O
5	of	O
6	the	O
7	prostigmatid	O
8	families	O
9	Tydeidae	O
10	,	O
11	Nanorchestidae	O
12	and	O
13	Tarsonemidae	O
14	in	O
15	the	O
16	moisture	O
17	-	O
18	deficient	O
19	90	O
20	%-	O
21	concentration	O
22	treatments	O
23	supports	O
24	previous	O
25	evidence	O
26	of	O
27	adaptations	O
28	to	O
29	low	O
30	-	O
31	water	O
32	-	O
33	content	O
34	habitats	O
35	.	O

1	Fentanyl	O
2	,	O
3	a	O
4	prototypic	O
5	mu	B
6	-	I
7	opiate	I
8	receptor	I
9	agonist	O
10	,	O
11	has	O
12	been	O
13	previously	O
14	shown	O
15	to	O
16	produce	O
17	a	O
18	syndrome	O
19	characterized	O
20	by	O
21	marked	O
22	analgesia	O
23	and	O
24	locomotor	O
25	stimulation	O
26	as	O
27	well	O
28	as	O
29	tachycardia	O
30	,	O
31	tachypnoea	O
32	and	O
33	behavioural	O
34	arousal	O
35	.	O

1	Among	O
2	the	O
3	v	B
4	-	I
5	myc	I
6	codons	O
7	,	O
8	the	O
9	first	O
10	5	O
11	are	O
12	derived	O
13	from	O
14	the	O
15	noncoding	O
16	5	O
17	'	O
18	terminus	O
19	of	O
20	the	O
21	second	O
22	c	B
23	-	I
24	myc	I
25	exon	O
26	,	O
27	and	O
28	412	O
29	codons	O
30	correspond	O
31	to	O
32	the	O
33	c	B
34	-	I
35	myc	I
36	coding	O
37	region	O
38	.	O

1	Simultaneous	O
2	,	O
3	bilateral	O
4	and	O
5	permanent	O
6	ventilation	O
7	with	O
8	a	O
9	diaphragm	O
10	pacing	O
11	in	O
12	childhood	O
13	:	O
14	the	O
15	implantation	O
16	technique	O
17	and	O
18	indications	O

1	Its	O
2	C	O
3	-	O
4	terminal	O
5	catalytic	O
6	domain	O
7	was	O
8	found	O
9	to	O
10	be	O
11	highly	O
12	conserved	O
13	in	O
14	the	O
15	homologues	O
16	p140	B
17	(	O
18	ras	B
19	-	O
20	GRF	B
21	)	O
22	and	O
23	Sos	B
24	.	O

1	The	O
2	5	O
3	'	O
4	end	O
5	of	O
6	the	O
7	genomic	O
8	RNA	O
9	of	O
10	rubella	O
11	virus	O
12	(	O
13	RUB	O
14	)	O
15	contains	O
16	a	O
17	14	O
18	-	O
19	nucleotide	O
20	(	O
21	nt	O
22	)	O
23	single	O
24	-	O
25	stranded	O
26	leader	O
27	(	O
28	ss	O
29	-	O
30	leader	O
31	)	O
32	followed	O
33	by	O
34	a	O
35	stem	O
36	-	O
37	and	O
38	-	O
39	loop	O
40	structure	O
41	[	O
42	5	O
43	'(+)	O
44	SL	O
45	]	O
46	(	O
47	nt	O
48	15	O
49	to	O
50	65	O
51	),	O
52	the	O
53	complement	O
54	of	O
55	which	O
56	at	O
57	the	O
58	3	O
59	'	O
60	end	O
61	of	O
62	the	O
63	minus	O
64	-	O
65	strand	O
66	RNA	O
67	[	O
68	3	O
69	'(-)	O
70	SL	O
71	]	O
72	has	O
73	been	O
74	proposed	O
75	to	O
76	function	O
77	as	O
78	a	O
79	promoter	O
80	for	O
81	synthesis	O
82	of	O
83	genomic	O
84	plus	O
85	strands	O
86	.	O

1	All	O
2	patients	O
3	with	O
4	deterioriation	O
5	in	O
6	mental	O
7	status	O
8	showed	O
9	a	O
10	marked	O
11	increase	O
12	in	O
13	liver	O
14	enzymes	O
15	(	O
16	aspartate	B
17	and	I
18	alanine	I
19	aminotransaminases	I
20	)	O
21	and	O
22	severe	O
23	coagulopathy	O
24	.	O

1	RESULTS	O
2	:	O
3	Neither	O
4	basal	O
5	FSH	B
6	level	O
7	nor	O
8	stimulated	O
9	FSH	B
10	level	O
11	alone	O
12	were	O
13	statistically	O
14	significant	O
15	predictors	O
16	of	O
17	IVF	O
18	success	O
19	;	O
20	however	O
21	,	O
22	no	O
23	patient	O
24	with	O
25	a	O
26	day	O
27	3	O
28	FSH	B
29	level	O
30	>	O
31	11	O
32	.	O
33	1	O
34	mIU	O
35	/	O
36	ml	O
37	or	O
38	a	O
39	stimulated	O
40	day	O
41	10	O
42	FSH	B
43	level	O
44	>	O
45	13	O
46	.	O
47	5	O
48	mIU	O
49	/	O
50	ml	O
51	conceived	O
52	and	O
53	carried	O
54	a	O
55	pregnancy	O
56	.	O

1	Instead	O
2	,	O
3	they	O
4	contained	O
5	dendritic	O
6	cells	O
7	that	O
8	express	O
9	melanogenic	O
10	marker	O
11	proteins	O
12	such	O
13	as	O
14	tyrosinase	B
15	and	O
16	tyrosinase	B
17	-	I
18	related	I
19	protein	I
20	1	I
21	.	O

1	This	O
2	region	O
3	binds	O
4	two	O
5	ubiquitous	O
6	nuclear	O
7	factors	O
8	,	O
9	USF	B
10	/	O
11	MLTF	B
12	and	O
13	the	O
14	CAAT	B
15	-	I
16	binding	I
17	transcription	I
18	factor	I
19	/	O
20	nuclear	B
21	factor	I
22	1	I
23	(	O
24	CTF	B
25	/	O
26	NF1	B
27	).	O

1	Effects	O
2	of	O
3	perceptual	O
4	salience	O
5	on	O
6	the	O
7	matrix	O
8	task	O
9	performance	O
10	of	O
11	four	O
12	-	O
13	and	O
14	six	O
15	-	O
16	year	O
17	-	O
18	old	O
19	children	O
20	.	O

1	The	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	ThlA	B
8	is	O
9	involved	O
10	in	O
11	the	O
12	metabolism	O
13	of	O
14	both	O
15	acid	O
16	and	O
17	solvent	O
18	formation	O
19	,	O
20	whereas	O
21	the	O
22	physiological	O
23	function	O
24	of	O
25	ThlB	B
26	has	O
27	yet	O
28	to	O
29	be	O
30	elucidated	O
31	.	O

1	The	O
2	Oct	B
3	-	I
4	2	I
5	glutamine	O
6	-	O
7	rich	O
8	and	O
9	proline	O
10	-	O
11	rich	O
12	activation	O
13	domains	O
14	can	O
15	synergize	O
16	with	O
17	each	O
18	other	O
19	or	O
20	duplicates	O
21	of	O
22	themselves	O
23	to	O
24	activate	O
25	transcription	O
26	.	O

1	In	O
2	the	O
3	Oct	B
4	-	I
5	1	I
6	crystal	O
7	,	O
8	the	O
9	POU	B
10	-	I
11	specific	I
12	domain	I
13	recognizes	O
14	a	O
15	GCAT	O
16	half	O
17	-	O
18	site	O
19	,	O
20	while	O
21	the	O
22	corresponding	O
23	sequence	O
24	recognized	O
25	by	O
26	the	O
27	Pit	B
28	-	I
29	1	I
30	POU	I
31	-	O
32	specific	O
33	domain	O
34	,	O
35	GTAT	O
36	,	O
37	is	O
38	on	O
39	the	O
40	opposing	O
41	strand	O
42	.	O

1	Lack	O
2	of	O
3	effect	O
4	of	O
5	the	O
6	appetite	O
7	stimulant	O
8	pizotifen	O
9	(	O
10	BC	O
11	105	O
12	)	O
13	on	O
14	the	O
15	absorption	O
16	of	O
17	isonicotinylhydrazine	O
18	.	O

1	As	O
2	well	O
3	,	O
4	further	O
5	deletion	O
6	of	O
7	the	O
8	promoter	O
9	region	O
10	to	O
11	nucleotide	O
12	-	O
13	110	O
14	,	O
15	which	O
16	contains	O
17	only	O
18	one	O
19	SF	B
20	-	I
21	1	I
22	binding	I
23	site	I
24	,	O
25	still	O
26	retained	O
27	the	O
28	ability	O
29	to	O
30	respond	O
31	to	O
32	exogenous	O
33	SF	B
34	-	I
35	1	I
36	.	O

1	Duch	O
2	,	O
3	and	O
4	F	O
5	.	O

1	A	O
2	G22V	B
3	mutant	I
4	of	O
5	M	B
6	-	I
7	Ras	I
8	was	O
9	constitutively	O
10	active	O
11	and	O
12	its	O
13	expression	O
14	in	O
15	an	O
16	interleukin	B
17	-	I
18	3	I
19	(	O
20	IL	B
21	-	I
22	3	I
23	)-	O
24	dependent	O
25	mast	O
26	cell	O
27	/	O
28	megakaryocyte	O
29	cell	O
30	line	O
31	resulted	O
32	in	O
33	increased	O
34	survival	O
35	in	O
36	the	O
37	absence	O
38	of	O
39	IL	B
40	-	I
41	3	I
42	,	O
43	increased	O
44	growth	O
45	in	O
46	IL	B
47	-	I
48	4	I
49	,	O
50	and	O
51	,	O
52	at	O
53	high	O
54	expression	O
55	levels	O
56	,	O
57	in	O
58	factor	O
59	-	O
60	independent	O
61	growth	O
62	.	O

1	Regulators	O
2	responsible	O
3	for	O
4	the	O
5	pervasive	O
6	,	O
7	nonsex	O
8	-	O
9	specific	O
10	alternative	O
11	pre	O
12	-	O
13	mRNA	O
14	splicing	O
15	characteristic	O
16	of	O
17	metazoans	O
18	are	O
19	almost	O
20	entirely	O
21	unknown	O
22	or	O
23	uncertain	O
24	.	O

1	In	O
2	yeast	O
3	,	O
4	the	O
5	products	O
6	of	O
7	the	O
8	UPF1	B
9	and	O
10	UPF3	B
11	genes	I
12	are	O
13	required	O
14	for	O
15	this	O
16	decay	O
17	pathway	O
18	,	O
19	and	O
20	in	O
21	this	O
22	report	O
23	we	O
24	focus	O
25	on	O
26	the	O
27	identification	O
28	and	O
29	characterization	O
30	of	O
31	additional	O
32	factors	O
33	required	O
34	for	O
35	rapid	O
36	decay	O
37	of	O
38	nonsense	O
39	-	O
40	containing	O
41	mRNAs	O
42	.	O

1	Propagation	O
2	and	O
3	hormone	O
4	production	O
5	by	O
6	human	O
7	normal	O
8	and	O
9	malignant	O
10	trophoblast	O
11	in	O
12	rats	O
13	.	O

1	A	O
2	decrease	O
3	in	O
4	insulin	B
5	-	O
6	induced	O
7	receptor	O
8	kinase	O
9	activity	O
10	was	O
11	observed	O
12	for	O
13	solubilized	O
14	chimeric	O
15	receptors	O
16	.	O

1	Sp1	B
2	and	O
3	two	O
4	Sp3	B
5	isoforms	I
6	were	O
7	detected	O
8	as	O
9	the	O
10	primary	O
11	cellular	O
12	constituents	O
13	of	O
14	DNA	O
15	-	O
16	protein	O
17	complexes	O
18	formed	O
19	with	O
20	the	O
21	NF	B
22	-	I
23	kappaB	I
24	-	I
25	proximal	I
26	site	I
27	.	O

1	METHODS	O
2	:	O
3	rHb1	B
4	.	I
5	1	I
6	or	O
7	human	B
8	serum	I
9	albumin	I
10	was	O
11	administered	O
12	intravenously	O
13	to	O
14	fasting	O
15	male	O
16	volunteers	O
17	.	O

1	Interspecific	O
2	backcross	O
3	analysis	O
4	using	O
5	progeny	O
6	derived	O
7	from	O
8	matings	O
9	of	O
10	(	O
11	C57BL	O
12	/	O
13	6J	O
14	x	O
15	Mus	O
16	spretus	O
17	)	O
18	F1	O
19	x	O
20	C57BL	O
21	/	O
22	6J	O
23	mice	O
24	indicates	O
25	that	O
26	the	O
27	thrombospondin	B
28	gene	I
29	is	O
30	tightly	O
31	linked	O
32	to	O
33	the	O
34	Fshb	B
35	,	O
36	Actcl	B
37	,	O
38	Ltk	B
39	,	O
40	and	O
41	B2M	B
42	loci	I
43	on	O
44	murine	O
45	chromosome	O
46	2	O
47	.	O

1	The	O
2	alpha	O
3	7A	O
4	form	O
5	RNA	O
6	contains	O
7	an	O
8	additional	O
9	113	O
10	nucleotides	O
11	compared	O
12	to	O
13	the	O
14	B	O
15	form	O
16	,	O
17	and	O
18	a	O
19	common	O
20	coding	O
21	region	O
22	in	O
23	the	O
24	A	O
25	and	O
26	B	O
27	form	O
28	RNAs	O
29	is	O
30	used	O
31	in	O
32	alternate	O
33	reading	O
34	frames	O
35	.	O

1	Ang	B
2	II	I
3	-	O
4	induced	O
5	fibronectin	B
6	mRNA	O
7	was	O
8	not	O
9	affected	O
10	by	O
11	PKC	B
12	inhibitors	O
13	or	O
14	PKC	B
15	depletion	O
16	,	O
17	whereas	O
18	specific	O
19	inhibition	O
20	of	O
21	EGF	B
22	-	I
23	R	I
24	function	O
25	by	O
26	a	O
27	dominant	B
28	negative	I
29	EGF	I
30	-	I
31	R	I
32	mutant	I
33	and	O
34	tyrphostin	O
35	AG1478	O
36	abolished	O
37	induction	O
38	of	O
39	fibronectin	B
40	mRNA	I
41	.	O

1	Following	O
2	2	O
3	.	O
4	5	O
5	Gy	O
6	,	O
7	HbO2	B
8	changes	O
9	were	O
10	minimal	O
11	.	O

1	Thrombolysis	O
2	was	O
3	followed	O
4	by	O
5	a	O
6	similar	O
7	increase	O
8	of	O
9	platelet	O
10	activity	O
11	with	O
12	maximal	O
13	values	O
14	reached	O
15	at	O
16	the	O
17	3rd	O
18	hour	O
19	in	O
20	both	O
21	groups	O
22	(	O
23	196	O
24	+/-	O
25	43	O
26	IU	O
27	/	O
28	ml	O
29	in	O
30	Group	O
31	1	O
32	and	O
33	192	O
34	+/-	O
35	39	O
36	in	O
37	Group	O
38	2	O
39	:	O
40	p	O
41	&	O
42	lt	O
43	;	O
44	001versus	O
45	baseline	O
46	and	O
47	p	O
48	NS	O
49	between	O
50	the	O
51	groups	O
52	).	O

1	Hematopoietic	O
2	system	O
3	in	O
4	streptococcal	O
5	allergy	O
6	.	O

1	Thus	O
2	,	O
3	Fis	B
4	acts	O
5	as	O
6	an	O
7	accessory	O
8	transcriptional	O
9	activator	O
10	at	O
11	the	O
12	mar	B
13	promoter	I
14	.	O

1	Their	O
2	conduction	O
3	velocity	O
4	ranged	O
5	from	O
6	0	O
7	.	O
8	23	O
9	to	O
10	0	O
11	.	O
12	98	O
13	m	O
14	/	O
15	sec	O
16	(	O
17	group	O
18	C	O
19	).	O

1	Petko	O
2	,	O
3	and	O
4	S	O
5	.	O

1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	the	O
8	expression	O
9	of	O
10	c	B
11	-	I
12	Jun	I
13	plus	O
14	c	B
15	-	I
16	Fos	I
17	enhanced	O
18	the	O
19	transactivation	O
20	of	O
21	oIFNtau	B
22	-	O
23	CAT	B
24	but	O
25	the	O
26	expression	O
27	of	O
28	GATA	B
29	-	I
30	1	I
31	,	O
32	GATA	B
33	-	I
34	2	I
35	or	O
36	GATA	B
37	-	I
38	3	I
39	did	O
40	not	O
41	.	O

1	As	O
2	hypothesized	O
3	,	O
4	believers	O
5	showed	O
6	relatively	O
7	higher	O
8	right	O
9	hemispheric	O
10	activation	O
11	and	O
12	reduced	O
13	hemispheric	O
14	asymmetry	O
15	of	O
16	functional	O
17	complexity	O
18	.	O

1	Altogether	O
2	these	O
3	results	O
4	suggest	O
5	that	O
6	,	O
7	in	O
8	KG1a	O
9	cells	O
10	,	O
11	TNFalpha	B
12	can	O
13	stimulate	O
14	in	O
15	parallel	O
16	PC	B
17	-	I
18	PLC	I
19	and	O
20	PLD	B
21	,	O
22	whose	O
23	lipid	O
24	products	O
25	activate	O
26	in	O
27	turn	O
28	mitogen	B
29	-	I
30	activated	I
31	protein	I
32	kinase	I
33	(	O
34	MAP	B
35	kinase	I
36	)	O
37	and	O
38	NF	B
39	-	I
40	kappaB	I
41	signalling	O
42	respectively	O
43	.	O

1	These	O
2	well	O
3	-	O
4	characterized	O
5	brain	O
6	regions	O
7	may	O
8	provide	O
9	a	O
10	basis	O
11	for	O
12	future	O
13	studies	O
14	of	O
15	RPTP	B
16	-	I
17	kappa	I
18	function	O
19	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	DNA	O
6	methylation	O
7	,	O
8	chromatin	O
9	structure	O
10	,	O
11	and	O
12	transactivation	O
13	at	O
14	an	O
15	Sp1	B
16	site	I
17	contribute	O
18	to	O
19	the	O
20	highly	O
21	restricted	O
22	expression	O
23	of	O
24	this	O
25	myelomonocytic	O
26	lineage	O
27	specific	O
28	gene	O
29	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	although	O
6	218leu	O
7	retains	O
8	normal	O
9	transactivation	O
10	activity	O
11	on	O
12	a	O
13	p53	B
14	promoter	I
15	in	O
16	yeast	O
17	at	O
18	physiological	O
19	temperatures	O
20	,	O
21	it	O
22	is	O
23	not	O
24	capable	O
25	of	O
26	normal	O
27	p53	B
28	function	O
29	in	O
30	the	O
31	presence	O
32	of	O
33	a	O
34	248trp	B
35	allele	I
36	in	O
37	SNU	O
38	-	O
39	C5	O
40	cells	O
41	.	O

1	Tctex	B
2	-	I
3	1	I
4	binding	O
5	required	O
6	the	O
7	first	O
8	19	O
9	amino	O
10	acids	O
11	of	O
12	Fyn	B
13	and	O
14	integrity	O
15	of	O
16	two	O
17	lysine	O
18	residues	O
19	within	O
20	this	O
21	sequence	O
22	that	O
23	were	O
24	previously	O
25	shown	O
26	to	O
27	be	O
28	important	O
29	for	O
30	Fyn	B
31	interactions	O
32	with	O
33	the	O
34	immunoreceptor	O
35	tyrosine	O
36	-	O
37	based	O
38	activation	O
39	motifs	O
40	(	O
41	ITAMs	O
42	)	O
43	of	O
44	lymphocyte	B
45	Ag	I
46	receptors	I
47	.	O

1	Two	O
2	splice	O
3	variants	O
4	of	O
5	ALF1	B
6	cDNA	I
7	have	O
8	been	O
9	found	O
10	,	O
11	differing	O
12	by	O
13	a	O
14	72	O
15	-	O
16	bp	O
17	insertion	O
18	,	O
19	coding	O
20	for	O
21	putative	O
22	proteins	O
23	of	O
24	682	O
25	and	O
26	706	O
27	amino	O
28	acids	O
29	.	O

1	Therefore	O
2	,	O
3	in	O
4	order	O
5	to	O
6	search	O
7	for	O
8	the	O
9	latent	O
10	genes	O
11	,	O
12	we	O
13	used	O
14	allotype	O
15	-	O
16	specific	O
17	oligonucleotides	O
18	for	O
19	b5	O
20	,	O
21	b6	O
22	and	O
23	b9	O
24	to	O
25	probe	O
26	DNAs	O
27	from	O
28	both	O
29	normal	O
30	and	O
31	T	O
32	.	O
33	brucei	O
34	-	O
35	infected	O
36	rabbits	O
37	by	O
38	Southern	O
39	blotting	O
40	.	O

1	The	O
2	interaction	O
3	between	O
4	DDB	B
5	and	O
6	E2F1	B
7	can	O
8	also	O
9	be	O
10	detected	O
11	by	O
12	coimmunoprecipitation	O
13	experiments	O
14	.	O

1	The	O
2	ESEM	O
3	differs	O
4	from	O
5	conventional	O
6	SEM	O
7	in	O
8	that	O
9	no	O
10	sample	O
11	preparation	O
12	is	O
13	needed	O
14	,	O
15	eliminating	O
16	artifactual	O
17	changes	O
18	.	O

1	MR	O
2	imaging	O
3	of	O
4	traumatic	O
5	head	O
6	injuries	O
7	using	O
8	FLAIR	O
9	technique	O

1	By	O
2	analyzing	O
3	the	O
4	RanGAP	B
5	activity	O
6	of	O
7	a	O
8	series	O
9	of	O
10	recombinantly	O
11	expressed	O
12	rna1p	B
13	mutant	I
14	derivatives	O
15	,	O
16	we	O
17	show	O
18	that	O
19	the	O
20	highly	O
21	acidic	O
22	sequence	O
23	in	O
24	the	O
25	C	O
26	-	O
27	terminal	O
28	domain	O
29	of	O
30	both	O
31	yeast	O
32	proteins	O
33	is	O
34	indispensable	O
35	for	O
36	activating	O
37	Ran	B
38	-	O
39	mediated	O
40	GTP	O
41	hydrolysis	O
42	.	O

1	In	O
2	case	O
3	of	O
4	a	O
5	pathologically	O
6	convoluted	O
7	internal	O
8	carotid	O
9	the	O
10	common	O
11	carotid	O
12	artery	O
13	was	O
14	resected	O
15	with	O
16	an	O
17	end	O
18	-	O
19	to	O
20	-	O
21	end	O
22	anastomosis	O
23	.	O

1	Sterol	O
2	-	O
3	mediated	O
4	suppression	O
5	of	O
6	cleavage	O
7	of	O
8	SREBP	B
9	-	I
10	1	I
11	was	O
12	found	O
13	to	O
14	be	O
15	dependent	O
16	on	O
17	the	O
18	extreme	O
19	COOH	O
20	-	O
21	terminal	O
22	region	O
23	(	O
24	residue	O
25	1034	O
26	to	O
27	the	O
28	COOH	O
29	terminus	O
30	),	O
31	which	O
32	exists	O
33	in	O
34	two	O
35	forms	O
36	as	O
37	a	O
38	result	O
39	of	O
40	alternative	O
41	splicing	O
42	.	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	a	O
6	raised	O
7	hydroxykynurenine	O
8	/	O
9	hydroxyanthranilic	O
10	acid	O
11	ratio	O
12	does	O
13	not	O
14	necessarily	O
15	indicate	O
16	vitamin	O
17	B6	O
18	deficiency	O
19	but	O
20	may	O
21	represent	O
22	a	O
23	nonspecific	O
24	response	O
25	of	O
26	tryptophan	O
27	metabolism	O
28	to	O
29	stress	O
30	.	O

1	In	O
2	some	O
3	early	O
4	B	O
5	cells	O
6	and	O
7	Abelson	O
8	murine	O
9	leukemia	O
10	virus	O
11	-	O
12	transformed	O
13	pre	O
14	-	O
15	B	O
16	-	O
17	cell	O
18	lines	O
19	,	O
20	LT	B
21	mRNA	I
22	is	O
23	constitutively	O
24	expressed	O
25	.	O

1	Oleate	O
2	induced	O
3	steady	O
4	-	O
5	state	O
6	levels	O
7	of	O
8	M	B
9	-	I
10	CPT	I
11	I	I
12	mRNA	I
13	4	O
14	.	O
15	5	O
16	-	O
17	fold	O
18	.	O

1	In	O
2	concept	O
3	II	O
4	62	O
5	patients	O
6	were	O
7	treated	O
8	with	O
9	selective	O
10	vagotomy	O
11	and	O
12	pyloroplasty	O
13	.	O

1	Low	O
2	-	O
3	grade	O
4	glioma	O
5	.	O

1	Comparison	O
2	of	O
3	patients	O
4	receiving	O
5	phenytoin	O
6	and	O
7	those	O
8	who	O
9	were	O
10	not	O
11	showed	O
12	significantly	O
13	lower	O
14	serum	O
15	folate	O
16	in	O
17	the	O
18	sub	O
19	-	O
20	group	O
21	receiving	O
22	phenytoin	O
23	,	O
24	but	O
25	there	O
26	was	O
27	no	O
28	significant	O
29	difference	O
30	between	O
31	the	O
32	sub	O
33	-	O
34	groups	O
35	with	O
36	respect	O
37	to	O
38	vitamin	O
39	B12	O
40	or	O
41	behaviour	O
42	problem	O
43	rating	O
44	.	O

1	One	O
2	hundred	O
3	and	O
4	four	O
5	(	O
6	14	O
7	per	O
8	cent	O
9	)	O
10	second	O
11	primary	O
12	tumours	O
13	were	O
14	reported	O
15	.	O

1	Much	O
2	evidence	O
3	indicates	O
4	that	O
5	p38	B
6	is	O
7	an	O
8	activator	O
9	of	O
10	MyoD	B
11	:	O
12	(	O
13	i	O
14	)	O
15	p38	B
16	kinase	I
17	activity	O
18	is	O
19	required	O
20	for	O
21	the	O
22	expression	O
23	of	O
24	MyoD	B
25	-	O
26	responsive	O
27	genes	O
28	,	O
29	(	O
30	ii	O
31	)	O
32	enforced	O
33	induction	O
34	of	O
35	p38	B
36	stimulates	O
37	the	O
38	transcriptional	O
39	activity	O
40	of	O
41	a	O
42	Gal4	B
43	-	O
44	MyoD	B
45	fusion	O
46	protein	O
47	and	O
48	allows	O
49	efficient	O
50	activation	O
51	of	O
52	chromatin	O
53	-	O
54	integrated	O
55	reporters	O
56	by	O
57	MyoD	B
58	,	O
59	and	O
60	(	O
61	iii	O
62	)	O
63	MyoD	B
64	-	O
65	dependent	O
66	myogenic	O
67	conversion	O
68	is	O
69	reduced	O
70	in	O
71	mouse	O
72	embryonic	O
73	fibroblasts	O
74	derived	O
75	from	O
76	p38alpha	B
77	(-/-)	I
78	embryos	O
79	.	O

1	Treatment	O
2	and	O
3	care	O
4	of	O
5	adult	O
6	diabetes	O
7	mellitus	O
8	without	O
9	coma	O

1	The	O
2	various	O
3	available	O
4	data	O
5	strongly	O
6	suggesting	O
7	an	O
8	environmental	O
9	toxic	O
10	origin	O
11	for	O
12	the	O
13	"	O
14	sperm	O
15	fall	O
16	"	O
17	will	O
18	be	O
19	presented	O
20	as	O
21	well	O
22	as	O
23	the	O
24	most	O
25	frequently	O
26	suspected	O
27	class	O
28	of	O
29	substances	O
30	,	O
31	the	O
32	xenoestrogens	O
33	.	O

1	Nonreplicating	O
2	vaccinia	O
3	vector	O
4	efficiently	O
5	expresses	O
6	recombinant	O
7	genes	O
8	.	O

1	A	O
2	possible	O
3	role	O
4	for	O
5	the	O
6	mixed	O
7	function	O
8	oxidase	B
9	enzyme	O
10	system	O
11	in	O
12	the	O
13	requirement	O
14	for	O
15	selenium	O
16	in	O
17	the	O
18	rat	O
19	.	O

1	Remarkably	O
2	,	O
3	U21	B
4	contains	O
5	a	O
6	long	O
7	stretch	O
8	(	O
9	13	O
10	nt	O
11	.)	O
12	of	O
13	complementarity	O
14	to	O
15	a	O
16	highly	O
17	conserved	O
18	sequence	O
19	in	O
20	28S	B
21	rRNA	I
22	.	O

1	In	O
2	group	O
3	I	O
4	adults	O
5	both	O
6	of	O
7	these	O
8	variables	O
9	increased	O
10	.	O

1	An	O
2	approximately	O
3	37	O
4	-	O
5	kDa	O
6	cytoplasmic	O
7	protein	O
8	is	O
9	rapidly	O
10	tyrosine	O
11	-	O
12	phosphorylated	O
13	in	O
14	the	O
15	response	O
16	of	O
17	mouse	O
18	BAC1	O
19	.	O
20	2F5	O
21	macrophages	O
22	to	O
23	colony	B
24	stimulating	I
25	factor	I
26	-	I
27	1	I
28	(	O
29	CSF	B
30	-	I
31	1	I
32	).	O
33	pp37	B
34	was	O
35	purified	O
36	from	O
37	the	O
38	cytosolic	O
39	fraction	O
40	by	O
41	anti	B
42	-	I
43	Tyr	I
44	(	I
45	P	I
46	)	I
47	affinity	O
48	chromatography	O
49	,	O
50	size	O
51	exclusion	O
52	chromatography	O
53	,	O
54	and	O
55	C4	O
56	reverse	O
57	phase	O
58	high	O
59	pressure	O
60	liquid	O
61	chromatography	O
62	.	O

1	Several	O
2	artifacts	O
3	occurred	O
4	that	O
5	interfered	O
6	with	O
7	visualization	O
8	of	O
9	the	O
10	diaphragm	O
11	.	O

1	Co	O
2	-	O
3	transfection	O
4	of	O
5	expression	O
6	vectors	O
7	for	O
8	CCAAT	B
9	/	I
10	enhancer	I
11	binding	I
12	protein	I
13	(	I
14	C	I
15	/	I
16	EBP	I
17	)	I
18	alpha	I
19	and	O
20	C	B
21	/	I
22	EBP	I
23	beta	I
24	trans	O
25	-	O
26	activated	O
27	the	O
28	rat	B
29	uncoupling	I
30	protein	I
31	gene	I
32	promoter	I
33	due	O
34	to	O
35	sequences	O
36	in	O
37	the	O
38	5	O
39	'	O
40	proximal	O
41	region	O
42	.	O

1	Amino	O
2	acid	O
3	sequence	O
4	comparisons	O
5	of	O
6	the	O
7	E74A	B
8	protein	I
9	reveal	O
10	a	O
11	highly	O
12	conserved	O
13	C	O
14	-	O
15	terminal	O
16	region	O
17	that	O
18	is	O
19	rich	O
20	in	O
21	basic	O
22	amino	O
23	acid	O
24	residues	O
25	and	O
26	which	O
27	has	O
28	been	O
29	proposed	O
30	to	O
31	possess	O
32	sequence	O
33	-	O
34	specific	O
35	DNA	O
36	binding	O
37	activity	O
38	.	O

1	The	O
2	central	O
3	globular	O
4	domain	O
5	is	O
6	highly	O
7	similar	O
8	to	O
9	those	O
10	regions	O
11	from	O
12	other	O
13	H1	B
14	molecules	I
15	,	O
16	and	O
17	the	O
18	carboxyl	O
19	-	O
20	terminal	O
21	domain	O
22	contains	O
23	a	O
24	repeating	O
25	hexapeptide	O
26	motif	O
27	,	O
28	variants	O
29	of	O
30	which	O
31	are	O
32	conserved	O
33	among	O
34	H1	B
35	molecules	I
36	.	O

1	This	O
2	study	O
3	demonstrates	O
4	secretion	O
5	of	O
6	bicarbonate	O
7	by	O
8	the	O
9	human	O
10	stomach	O
11	in	O
12	vivo	O
13	at	O
14	a	O
15	rate	O
16	equivalent	O
17	to	O
18	10	O
19	--	O
20	20	O
21	%	O
22	of	O
23	basal	O
24	acid	O
25	secretion	O
26	.	O

1	Intravenous	O
2	antibiotic	O
3	therapy	O
4	in	O
5	cystic	O
6	fibrosis	O
7	:	O
8	in	O
9	hospital	O
10	or	O
11	at	O
12	home	O
13	?	O

1	Thus	O
2	,	O
3	an	O
4	increase	O
5	in	O
6	plasma	B
7	TBG	I
8	and	O
9	a	O
10	shift	O
11	from	O
12	adrenal	O
13	androgen	O
14	and	O
15	mineralocorticoid	O
16	steroid	O
17	secretion	O
18	towards	O
19	cortisol	O
20	secretion	O
21	may	O
22	be	O
23	endocrine	O
24	markers	O
25	for	O
26	progression	O
27	of	O
28	the	O
29	disease	O
30	in	O
31	patients	O
32	with	O
33	HIV	O
34	-	O
35	infection	O
36	.	O

1	Activated	O
2	areas	O
3	have	O
4	been	O
5	identified	O
6	by	O
7	means	O
8	of	O
9	cross	O
10	-	O
11	correlation	O
12	analysis	O
13	.	O

1	The	O
2	proposed	O
3	algorithm	O
4	consists	O
5	of	O
6	several	O
7	steps	O
8	.	O

1	We	O
2	use	O
3	the	O
4	term	O
5	corticosteroid	O
6	-	O
7	dependent	O
8	IA	O
9	to	O
10	refer	O
11	to	O
12	the	O
13	serious	O
14	problem	O
15	of	O
16	chronic	O
17	IA	O
18	requiring	O
19	maintenance	O
20	prednisone	O
21	therapy	O
22	.	O

1	The	O
2	three	O
3	isoforms	O
4	purified	O
5	with	O
6	anti	B
7	-	I
8	FLAG	I
9	antibody	I
10	affinity	O
11	column	O
12	transferred	O
13	sulfate	O
14	to	O
15	heparan	O
16	sulfate	O
17	and	O
18	heparin	O
19	but	O
20	not	O
21	to	O
22	other	O
23	glycosaminoglycans	O
24	.	O

1	METHODS	O
2	:	O
3	The	O
4	responses	O
5	of	O
6	a	O
7	31	O
8	-	O
9	year	O
10	-	O
11	old	O
12	woman	O
13	with	O
14	complex	O
15	regional	O
16	pain	O
17	syndrome	O
18	type	O
19	I	O
20	(	O
21	reflex	O
22	sympathetic	O
23	dystrophy	O
24	)	O
25	to	O
26	a	O
27	thermal	O
28	grill	O
29	were	O
30	evaluated	O
31	before	O
32	and	O
33	after	O
34	stellate	O
35	ganglion	O
36	block	O
37	.	O

1	Genetic	O
2	and	O
3	molecular	O
4	complexity	O
5	of	O
6	the	O
7	position	O
8	effect	O
9	variegation	O
10	modifier	O
11	mod	B
12	(	O
13	mdg4	B
14	)	O
15	in	O
16	Drosophila	O
17	.	O
18	mod	B
19	(	O
20	mdg4	B
21	),	O
22	also	O
23	known	O
24	as	O
25	E	B
26	(	I
27	var	I
28	)	I
29	3	I
30	-	I
31	93D	I
32	,	O
33	is	O
34	involved	O
35	in	O
36	a	O
37	variety	O
38	of	O
39	processes	O
40	,	O
41	such	O
42	as	O
43	gene	O
44	silencing	O
45	in	O
46	position	O
47	effect	O
48	variegation	O
49	(	O
50	PEV	O
51	),	O
52	the	O
53	control	O
54	of	O
55	gypsy	B
56	insulator	I
57	sequences	I
58	,	O
59	regulation	O
60	of	O
61	homeotic	B
62	gene	I
63	expression	O
64	,	O
65	and	O
66	programmed	O
67	cell	O
68	death	O
69	.	O

1	Twenty	O
2	-	O
3	five	O
4	patients	O
5	(	O
6	80	O
7	,	O
8	6	O
9	%)	O
10	with	O
11	mixed	O
12	neoplasms	O
13	were	O
14	operated	O
15	on	O
16	by	O
17	total	O
18	conservative	O
19	parotidectomy	O
20	(	O
21	T	O
22	.	O
23	C	O
24	.	O
25	P	O
26	.),	O
27	3	O
28	(	O
29	9	O
30	,	O
31	7	O
32	%)	O
33	by	O
34	S	O
35	.	O
36	P	O
37	.	O
38	and	O
39	3	O
40	(	O
41	9	O
42	,	O
43	7	O
44	%)	O
45	by	O
46	En	O
47	.	O

1	Reconstitution	O
2	of	O
3	Raf	B
4	-	I
5	1	I
6	activity	O
7	was	O
8	observed	O
9	only	O
10	with	O
11	kinase	O
12	active	O
13	Jak1	B
14	in	O
15	both	O
16	cell	O
17	lines	O
18	.	O

1	We	O
2	show	O
3	that	O
4	c	B
5	-	I
6	Fos	I
7	(	O
8	the	O
9	c	B
10	-	I
11	fos	I
12	protooncogene	I
13	product	I
14	),	O
15	which	O
16	is	O
17	an	O
18	intrinsically	O
19	unstable	O
20	nuclear	O
21	protein	O
22	,	O
23	is	O
24	metabolically	O
25	highly	O
26	stabilized	O
27	,	O
28	and	O
29	greatly	O
30	enhances	O
31	the	O
32	transforming	O
33	efficiency	O
34	of	O
35	NIH	O
36	3T3	O
37	cells	O
38	,	O
39	by	O
40	Mos	B
41	.	O

1	VIII	O
2	in	O
3	doses	O
4	2	O
5	-	O
6	3	O
7	times	O
8	higher	O
9	than	O
10	usually	O
11	used	O
12	in	O
13	haemophiliacs	O
14	without	O
15	inhibitor	O
16	were	O
17	successful	O
18	.	O

1	A	O
2	rate	O
3	-	O
4	decreasing	O
5	dose	O
6	of	O
7	physostigmine	O
8	,	O
9	an	O
10	acetylcholinesterase	B
11	inhibitor	O
12	,	O
13	was	O
14	studied	O
15	in	O
16	combination	O
17	with	O
18	the	O
19	range	O
20	of	O
21	atropine	O
22	doses	O
23	.	O

1	Toxicity	O
2	was	O
3	very	O
4	mild	O
5	with	O
6	both	O
7	regimens	O
8	,	O
9	although	O
10	sedation	O
11	was	O
12	significantly	O
13	higher	O
14	in	O
15	arm	O
16	B	O
17	(	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	001	O
24	).	O

1	POU	B
2	-	I
3	domain	I
4	proteins	I
5	,	O
6	such	O
7	as	O
8	the	O
9	pituitary	B
10	-	I
11	specific	I
12	factor	I
13	Pit	I
14	-	I
15	1	I
16	,	O
17	are	O
18	members	O
19	of	O
20	the	O
21	homeodomain	B
22	family	I
23	of	O
24	proteins	O
25	which	O
26	are	O
27	important	O
28	in	O
29	development	O
30	and	O
31	homeostasis	O
32	,	O
33	acting	O
34	constitutively	O
35	or	O
36	in	O
37	response	O
38	to	O
39	signal	O
40	-	O
41	transduction	O
42	pathways	O
43	to	O
44	either	O
45	repress	O
46	or	O
47	activate	O
48	the	O
49	expression	O
50	of	O
51	specific	O
52	genes	O
53	.	O

1	In	O
2	contrast	O
3	,	O
4	tobacco	B
5	GS	I
6	-	I
7	2	I
8	is	O
9	composed	O
10	of	O
11	subunits	O
12	of	O
13	identical	O
14	size	O
15	in	O
16	all	O
17	organs	O
18	examined	O
19	.	O

1	The	O
2	PSD2	B
3	gene	I
4	was	O
5	heterologously	O
6	expressed	O
7	by	O
8	infection	O
9	of	O
10	Sf	O
11	-	O
12	9	O
13	insect	O
14	cells	O
15	with	O
16	recombinant	O
17	baculovirus	O
18	,	O
19	resulting	O
20	in	O
21	a	O
22	10	O
23	-	O
24	fold	O
25	increase	O
26	in	O
27	PSD	B
28	activity	O
29	.	O

1	The	O
2	perioperative	O
3	mortality	O
4	of	O
5	all	O
6	patients	O
7	was	O
8	1	O
9	.	O
10	9	O
11	%,	O
12	the	O
13	mortality	O
14	of	O
15	patients	O
16	older	O
17	than	O
18	70	O
19	years	O
20	was	O
21	4	O
22	.	O
23	3	O
24	%.	O

1	Resistance	O
2	training	O
3	shifts	O
4	the	O
5	power	O
6	curve	O
7	in	O
8	a	O
9	positive	O
10	direction	O
11	when	O
12	the	O
13	measurements	O
14	are	O
15	determined	O
16	with	O
17	absolute	O
18	loads	O
19	,	O
20	but	O
21	the	O
22	increased	O
23	power	O
24	may	O
25	not	O
26	be	O
27	transferred	O
28	to	O
29	an	O
30	absolute	O
31	performance	O
32	task	O
33	like	O
34	the	O
35	SSP	O
36	.	O

1	Antithrombin	B
2	III	I
3	deficiency	O
4	:	O
5	when	O
6	substitute	O
7	,	O
8	when	O
9	heparin	O
10	?	O
11	Thrombosis	O
12	ABC	O
13	,	O
14	3	O
15	:	O
16	The	O
17	role	O
18	of	O
19	antithrombin	B
20	III	I

1	The	O
2	data	O
3	suggest	O
4	that	O
5	ICP10	B
6	constitutively	O
7	increases	O
8	ras	B
9	activity	O
10	,	O
11	and	O
12	its	O
13	TM	O
14	segment	O
15	plays	O
16	a	O
17	critical	O
18	role	O
19	in	O
20	transformation	O
21	-	O
22	related	O
23	signaling	O
24	pathways	O
25	.	O

1	After	O
2	4	O
3	h	O
4	,	O
5	lesions	O
6	in	O
7	the	O
8	secretory	O
9	part	O
10	of	O
11	the	O
12	stomach	O
13	were	O
14	scored	O
15	and	O
16	mucosal	O
17	prostaglandin	O
18	E2	O
19	synthesis	O
20	was	O
21	determined	O
22	by	O
23	the	O
24	ex	O
25	vivo	O
26	prostaglandin	O
27	generation	O
28	technique	O
29	.	O

1	Mutations	O
2	in	O
3	a	O
4	region	O
5	located	O
6	15	O
7	to	O
8	30	O
9	bp	O
10	downstream	O
11	from	O
12	the	O
13	major	O
14	transcription	O
15	start	O
16	site	O
17	that	O
18	shows	O
19	good	O
20	homology	O
21	to	O
22	a	O
23	sequence	O
24	in	O
25	the	O
26	first	O
27	exon	O
28	of	O
29	c	B
30	-	I
31	fos	I
32	implicated	O
33	as	O
34	a	O
35	negative	O
36	regulatory	O
37	element	O
38	resulted	O
39	in	O
40	a	O
41	significant	O
42	increase	O
43	in	O
44	basal	O
45	gene	O
46	expression	O
47	but	O
48	did	O
49	not	O
50	affect	O
51	regulation	O
52	.	O

1	Endocrine	O
2	cells	O
3	were	O
4	studied	O
5	by	O
6	means	O
7	of	O
8	Grimelius	O
9	'	O
10	silver	O
11	staining	O
12	and	O
13	immunostaining	O
14	for	O
15	chromogranin	B
16	,	O
17	a	O
18	general	O
19	marker	O
20	of	O
21	endocrine	O
22	cells	O
23	.	O

1	C	O
2	.	O
3	D2	O
4	-	O
5	Chr	O
6	4	O
7	congenic	O
8	strains	O
9	harboring	O
10	DBA	O
11	/	O
12	2	O
13	alleles	O
14	associated	O
15	with	O
16	the	O
17	Pctr1	B
18	locus	I
19	contained	O
20	DBA	O
21	/	O
22	2	O
23	"	O
24	resistant	O
25	"	O
26	alleles	O
27	of	O
28	the	O
29	CDK4	B
30	/	O
31	CDK6	B
32	inhibitors	O
33	p16	B
34	and	O
35	p15	B
36	.	O

1	They	O
2	were	O
3	then	O
4	subjected	O
5	to	O
6	whole	O
7	-	O
8	body	O
9	heat	O
10	stress	O
11	(	O
12	water	O
13	-	O
14	perfused	O
15	suits	O
16	),	O
17	and	O
18	the	O
19	3	O
20	minutes	O
21	of	O
22	LBNP	O
23	was	O
24	repeated	O
25	.	O

1	Structural	O
2	characteristics	O
3	of	O
4	the	O
5	erythrocyte	O
6	membrane	O
7	,	O
8	peroxidation	O
9	processes	O
10	and	O
11	antioxidant	O
12	function	O
13	in	O
14	children	O
15	with	O
16	diffuse	O
17	glomerulonephritis	O

1	Analysis	O
2	of	O
3	the	O
4	sequence	O
5	upstream	O
6	of	O
7	this	O
8	initiation	O
9	codon	O
10	reveals	O
11	the	O
12	presence	O
13	of	O
14	a	O
15	promotor	O
16	sequence	O
17	.	O

1	Actins	B
2	show	O
3	two	O
4	different	O
5	forms	O
6	of	O
7	N	O
8	-	O
9	terminal	O
10	processing	O
11	dependent	O
12	on	O
13	their	O
14	N	O
15	-	O
16	terminal	O
17	sequence	O
18	.	O

1	Cells	O
2	differentiate	O
3	in	O
4	response	O
5	to	O
6	various	O
7	extracellular	O
8	stimuli	O
9	.	O

1	Sites	O
2	1	O
3	and	O
4	4	O
5	in	O
6	lumican	B
7	and	O
8	keratocan	B
9	are	O
10	in	O
11	a	O
12	homologous	O
13	location	O
14	.	O

1	Indoor	O
2	concentrations	O
3	were	O
4	only	O
5	weakly	O
6	correlated	O
7	with	O
8	outdoor	O
9	concentrations	O
10	,	O
11	however	O
12	,	O
13	and	O
14	personal	O
15	exposures	O
16	were	O
17	even	O
18	more	O
19	poorly	O
20	correlated	O
21	with	O
22	outdoor	O
23	concentrations	O
24	.	O

1	Nevertheless	O
2	,	O
3	they	O
4	are	O
5	functionally	O
6	distinct	O
7	in	O
8	that	O
9	FcalphaRI	B
10	binds	O
11	human	B
12	IgA	I
13	(	O
14	hIgA	B
15	)	O
16	but	O
17	not	O
18	bovine	B
19	IgG2	I
20	(	O
21	bIgG2	B
22	),	O
23	whereas	O
24	bFcgamma2R	B
25	binds	O
26	bIgG2	B
27	but	O
28	not	O
29	hIgA	B
30	.	O

1	The	O
2	partial	O
3	sequence	O
4	of	O
5	the	O
6	62	B
7	-	I
8	kDa	I
9	nuclear	I
10	pore	I
11	glycoprotein	I
12	shows	O
13	little	O
14	similarity	O
15	to	O
16	other	O
17	characterized	O
18	proteins	O
19	and	O
20	elucidates	O
21	structural	O
22	features	O
23	of	O
24	a	O
25	member	O
26	of	O
27	the	O
28	family	O
29	of	O
30	nuclear	B
31	pore	I
32	glycoproteins	I
33	.	O

1	Role	O
2	of	O
3	superoxide	B
4	dismutase	I
5	in	O
6	cellular	O
7	oxidative	O
8	processes	O
9	and	O
10	method	O
11	of	O
12	its	O
13	determination	O
14	in	O
15	biological	O
16	materials	O

1	We	O
2	recently	O
3	found	O
4	that	O
5	17	O
6	beta	O
7	-	O
8	estradiol	O
9	(	O
10	E2	O
11	)	O
12	not	O
13	only	O
14	suppresses	O
15	bone	O
16	resorption	O
17	but	O
18	also	O
19	stimulates	O
20	bone	O
21	formation	O
22	in	O
23	the	O
24	cancellous	O
25	bone	O
26	of	O
27	female	O
28	rats	O
29	.	O

1	Although	O
2	stone	O
3	-	O
4	formers	O
5	were	O
6	not	O
7	found	O
8	to	O
9	display	O
10	any	O
11	features	O
12	of	O
13	magnesium	O
14	metabolism	O
15	that	O
16	were	O
17	different	O
18	from	O
19	those	O
20	in	O
21	the	O
22	control	O
23	group	O
24	,	O
25	their	O
26	lower	O
27	urinary	O
28	excretion	O
29	of	O
30	magnesium	O
31	in	O
32	relation	O
33	to	O
34	calcium	O
35	may	O
36	be	O
37	a	O
38	factor	O
39	in	O
40	their	O
41	increased	O
42	stone	O
43	-	O
44	forming	O
45	propensity	O
46	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	action	O
6	of	O
7	GLP	B
8	-	I
9	1	I
10	at	O
11	the	O
12	CRE	O
13	was	O
14	not	O
15	blocked	O
16	by	O
17	cotransfection	O
18	with	O
19	M1	B
20	-	I
21	CREB	I
22	,	O
23	an	O
24	isoform	O
25	that	O
26	lacks	O
27	a	O
28	consensus	O
29	serine	O
30	residue	O
31	serving	O
32	as	O
33	substrate	O
34	for	O
35	PKA	B
36	-	O
37	mediated	O
38	phosphorylation	O
39	.	O

1	Immunologic	O
2	mechanisms	O
3	in	O
4	chronic	O
5	brucellosis	O
6	in	O
7	humans	O
8	.	O

1	Eight	O
2	induced	O
3	cDNA	O
4	sequences	O
5	were	O
6	identified	O
7	and	O
8	designated	O
9	message	B
10	up	I
11	-	I
12	regulated	I
13	during	I
14	death	I
15	(	I
16	mud	I
17	)-	I
18	1	I
19	-	I
20	8	I
21	.	O

1	Positive	O
2	CRP	B
3	test	O
4	were	O
5	seen	O
6	.	O

1	All	O
2	nuclear	O
3	receptors	O
4	have	O
5	several	O
6	well	O
7	-	O
8	characterized	O
9	structural	O
10	domains	O
11	,	O
12	including	O
13	a	O
14	conserved	O
15	DNA	O
16	-	O
17	binding	O
18	domain	O
19	,	O
20	and	O
21	a	O
22	ligand	O
23	binding	O
24	domain	O
25	at	O
26	the	O
27	carboxyl	O
28	terminus	O
29	of	O
30	the	O
31	receptor	O
32	.	O

1	Plastic	O
2	solution	O
3	of	O
4	elbow	O
5	joint	O
6	ankylosis	O
7	with	O
8	a	O
9	decorticated	O
10	cylindrical	O
11	flap	O

1	A	O
2	suspected	O
3	new	O
4	storage	O
5	disease	O
6	in	O
7	cattle	O
8	.	O

1	Identification	O
2	of	O
3	the	O
4	region	O
5	in	O
6	actin	B
7	-	I
8	binding	I
9	protein	I
10	that	O
11	binds	O
12	to	O
13	the	O
14	cytoplasmic	O
15	domain	O
16	of	O
17	glycoprotein	B
18	IBalpha	I
19	.	O

1	An	O
2	analytic	O
3	method	O
4	for	O
5	comparative	O
6	parameter	O
7	weighting	O
8	in	O
9	magnetic	O
10	resonance	O
11	(	O
12	MR	O
13	)	O
14	imaging	O
15	has	O
16	been	O
17	developed	O
18	using	O
19	the	O
20	concept	O
21	of	O
22	"	O
23	fractional	O
24	sensitivity	O
25	."	O
26	This	O
27	new	O
28	approach	O
29	results	O
30	in	O
31	easily	O
32	calculated	O
33	indexes	O
34	for	O
35	T1	O
36	,	O
37	T2	O
38	,	O
39	and	O
40	hydrogen	O
41	weighting	O
42	.	O

1	In	O
2	the	O
3	chicken	O
4	liver	O
5	,	O
6	levels	O
7	of	O
8	chicken	B
9	MT	I
10	mRNA	I
11	were	O
12	rapidly	O
13	induced	O
14	by	O
15	metals	O
16	(	O
17	Cd2	O
18	+,	O
19	Zn2	O
20	+,	O
21	Cu2	O
22	+),	O
23	glucocorticoids	O
24	and	O
25	lipopolysaccharide	O
26	.	O

1	Pneumoscrotum	O
2	is	O
3	a	O
4	rare	O
5	condition	O
6	that	O
7	receives	O
8	little	O
9	discussion	O
10	in	O
11	standard	O
12	texts	O
13	of	O
14	urology	O
15	.	O

1	Angiotensin	B
2	converting	I
3	enzyme	I
4	inhibitors	O
5	enhance	O
6	the	O
7	antihypertensive	O
8	efficacy	O
9	of	O
10	diuretics	O
11	and	O
12	blunt	O
13	or	O
14	prevent	O
15	adverse	O
16	metabolic	O
17	effects	O
18	.	O

1	The	O
2	MMA	B
3	,	I
4	DMA	I
5	,	I
6	and	I
7	TMA	I
8	methyltransferases	I
9	are	O
10	not	O
11	homologs	O
12	;	O
13	however	O
14	,	O
15	like	O
16	the	O
17	MMA	B
18	methyltransferase	I
19	gene	I
20	,	O
21	the	O
22	genes	O
23	encoding	O
24	the	O
25	DMA	B
26	and	I
27	TMA	I
28	methyltransferases	I
29	each	O
30	contain	O
31	a	O
32	single	O
33	in	O
34	-	O
35	frame	O
36	amber	O
37	codon	O
38	.	O

1	Regulation	O
2	at	O
3	37	O
4	degrees	O
5	C	O
6	,	O
7	therefore	O
8	,	O
9	involves	O
10	the	O
11	action	O
12	of	O
13	three	O
14	protein	O
15	kinase	O
16	cascades	O
17	that	O
18	repress	O
19	HSF1	B
20	through	O
21	phosphorylation	O
22	of	O
23	serine	O
24	residues	O
25	303	O
26	,	O
27	307	O
28	,	O
29	and	O
30	363	O
31	and	O
32	may	O
33	promote	O
34	growth	O
35	by	O
36	suppressing	O
37	the	O
38	heat	O
39	shock	O
40	response	O
41	.	O

1	The	O
2	efficacy	O
3	of	O
4	quantitative	O
5	and	O
6	qualitative	O
7	chloride	O
8	titrators	O
9	in	O
10	the	O
11	estimation	O
12	of	O
13	human	O
14	salt	O
15	intake	O
16	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	B
5	-	I
6	negative	I
7	ras	I
8	gene	I
9	also	O
10	blocks	O
11	TIS10	B
12	/	O
13	PGS2	B
14	induction	O
15	by	O
16	v	B
17	-	I
18	src	I
19	.	O

1	In	O
2	serum	O
3	-	O
4	free	O
5	media	O
6	,	O
7	p50E4F	B
8	accelerated	O
9	E1A	B
10	-	O
11	induced	O
12	apoptosis	O
13	.	O

1	Four	O
2	putative	O
3	positive	O
4	cDNA	O
5	clones	O
6	were	O
7	isolated	O
8	,	O
9	and	O
10	the	O
11	largest	O
12	insert	O
13	(	O
14	pASB	B
15	-	I
16	1	I
17	)	O
18	was	O
19	sequenced	O
20	in	O
21	both	O
22	orientations	O
23	.	O

1	Insertional	O
2	inactivation	O
3	of	O
4	sms	B
5	led	O
6	to	O
7	increased	O
8	sensitivity	O
9	to	O
10	the	O
11	alkylating	O
12	agent	O
13	methylmethane	O
14	sulfonate	O
15	,	O
16	but	O
17	not	O
18	to	O
19	a	O
20	requirement	O
21	for	O
22	serine	O
23	or	O
24	other	O
25	metabolites	O
26	.	O

1	Review	O
2	:	O
3	deterioration	O
4	of	O
5	glucose	O
6	tolerance	O
7	with	O
8	age	O
9	:	O
10	the	O
11	role	O
12	of	O
13	insulin	B
14	resistance	O
15	.	O

1	Acupuncture	O
2	effect	O
3	on	O
4	deep	O
5	receptors	O
6	was	O
7	not	O
8	limited	O
9	to	O
10	one	O
11	point	O
12	but	O
13	within	O
14	a	O
15	certain	O
16	area	O
17	,	O
18	namely	O
19	distant	O
20	effect	O
21	existed	O
22	.	O

1	These	O
2	equilibrium	O
3	solutions	O
4	are	O
5	then	O
6	shown	O
7	to	O
8	arise	O
9	from	O
10	the	O
11	vertices	O
12	of	O
13	a	O
14	particular	O
15	convex	O
16	polyhedron	O
17	.	O

1	UDP	B
2	-	I
3	GlcNAc	I
4	:	O
5	alpha	B
6	-	I
7	6	I
8	-	I
9	D	I
10	-	I
11	mannoside	I
12	beta	I
13	-	I
14	1	I
15	,	I
16	2	I
17	-	I
18	N	I
19	-	I
20	acetylglucosaminyltransferase	I
21	II	I
22	(	O
23	GnT	B
24	II	I
25	;	O
26	EC	B
27	2	I
28	.	I
29	4	I
30	.	I
31	1	I
32	.	I
33	143	I
34	)	O
35	is	O
36	essential	O
37	for	O
38	the	O
39	normal	O
40	assembly	O
41	of	O
42	complex	O
43	Asn	O
44	-	O
45	linked	O
46	glycans	O
47	.	O

1	Also	O
2	,	O
3	the	O
4	BALB	B
5	/	I
6	c	I
7	gene	I
8	contains	O
9	a	O
10	single	O
11	substitution	O
12	in	O
13	a	O
14	conserved	O
15	octamer	O
16	sequence	O
17	approximately	O
18	equal	O
19	to	O
20	100	O
21	nucleotides	O
22	upstream	O
23	of	O
24	the	O
25	coding	O
26	region	O
27	,	O
28	which	O
29	could	O
30	affect	O
31	its	O
32	expression	O
33	.	O

1	In	O
2	study	O
3	2	O
4	,	O
5	the	O
6	correlation	O
7	coefficients	O
8	between	O
9	the	O
10	ISO2	O
11	measurements	O
12	obtained	O
13	at	O
14	the	O
15	ulcer	O
16	margin	O
17	and	O
18	at	O
19	the	O
20	adjacent	O
21	normal	O
22	mucosa	O
23	,	O
24	and	O
25	delta	O
26	ISO2	O
27	obtained	O
28	by	O
29	the	O
30	experienced	O
31	observer	O
32	and	O
33	one	O
34	of	O
35	the	O
36	three	O
37	learners	O
38	were	O
39	0	O
40	.	O
41	94	O
42	,	O
43	0	O
44	.	O
45	97	O
46	,	O
47	and	O
48	0	O
49	.	O
50	94	O
51	,	O
52	respectively	O
53	.	O

1	Duration	O
2	of	O
3	remission	O
4	in	O
5	advanced	O
6	gastric	O
7	cancer	O
8	patients	O
9	responding	O
10	to	O
11	sequential	O
12	dose	O
13	of	O
14	MTX	O
15	and	O
16	5	O
17	-	O
18	FU	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	P	B
6	-	I
7	type	I
8	ATPase	I
9	gene	I
10	from	O
11	the	O
12	cyanobacterium	O
13	Synechocystis	O
14	sp	O
15	.	O

1	Collectively	O
2	,	O
3	these	O
4	results	O
5	suggest	O
6	that	O
7	components	O
8	of	O
9	the	O
10	protein	B
11	kinase	I
12	A	I
13	signaling	O
14	pathway	O
15	are	O
16	recruited	O
17	by	O
18	mIg	B
19	to	O
20	induce	O
21	junB	B
22	transcription	O
23	.	O

1	Coexpression	O
2	of	O
3	mouse	O
4	PKR	B
5	(	I
6	1	I
7	-	I
8	515	I
9	)	I
10	WT	I
11	as	O
12	a	O
13	Gal4	B
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	fusion	O
19	with	O
20	either	O
21	the	O
22	catalytic	O
23	-	O
24	deficient	O
25	human	O
26	PKR	B
27	(	I
28	1	I
29	-	I
30	551	I
31	)	I
32	K296R	O
33	mutant	O
34	,	O
35	the	O
36	RNA	O
37	-	O
38	binding	O
39	-	O
40	deficient	O
41	human	O
42	PKR	B
43	(	I
44	1	I
45	-	I
46	551	I
47	)	I
48	K64E	I
49	/	I
50	K296R	I
51	double	O
52	mutant	O
53	,	O
54	or	O
55	wild	O
56	-	O
57	type	O
58	mouse	O
59	PKR	B
60	(	I
61	1	I
62	-	I
63	515	I
64	)	I
65	WT	I
66	as	O
67	full	O
68	-	O
69	length	O
70	PKR	B
71	-	O
72	Gal4	B
73	activation	O
74	domain	O
75	fusions	O
76	resulted	O
77	in	O
78	activation	O
79	of	O
80	the	O
81	HIS3	B
82	and	O
83	lacZ	B
84	reporters	O
85	.	O

1	DNase	B
2	I	I
3	footprinting	O
4	of	O
5	the	O
6	proximal	O
7	promoter	O
8	revealed	O
9	four	O
10	regions	O
11	of	O
12	protection	O
13	.	O

1	Stromelysin	B
2	-	I
3	1	I
4	,	O
5	matrix	B
6	metalloproteinase	I
7	-	I
8	3	I
9	(	O
10	MMP	B
11	-	I
12	3	I
13	),	O
14	is	O
15	an	O
16	important	O
17	endopeptidase	O
18	selectively	O
19	expressed	O
20	by	O
21	somatic	O
22	cells	O
23	in	O
24	organ	O
25	tissues	O
26	.	O

1	Rabbit	O
2	eyes	O
3	were	O
4	removed	O
5	and	O
6	held	O
7	in	O
8	temperature	O
9	-	O
10	regulated	O
11	chambers	O
12	and	O
13	irrigated	O
14	with	O
15	saline	O
16	.	O

1	This	O
2	combined	O
3	intravenous	O
4	anaesthetic	O
5	regimen	O
6	gave	O
7	good	O
8	anaesthesia	O
9	and	O
10	analgesia	O
11	to	O
12	pigs	O
13	for	O
14	up	O
15	to	O
16	2	O
17	h	O
18	as	O
19	monitored	O
20	by	O
21	clinical	O
22	signs	O
23	.	O

1	The	O
2	MVV	O
3	-	O
4	value	O
5	is	O
6	under	O
7	the	O
8	predicted	O
9	level	O
10	in	O
11	the	O
12	case	O
13	of	O
14	67	O
15	-	O
16	76	O
17	percent	O
18	.	O

1	The	O
2	60A	B
3	transcripts	I
4	and	O
5	protein	O
6	are	O
7	first	O
8	detected	O
9	at	O
10	the	O
11	onset	O
12	of	O
13	gastrulation	O
14	,	O
15	primarily	O
16	in	O
17	the	O
18	mesoderm	O
19	of	O
20	the	O
21	extending	O
22	germ	O
23	band	O
24	.	O

1	Monitoring	O
2	patients	O
3	with	O
4	acute	O
5	leukemia	O
6	for	O
7	IL	B
8	-	I
9	1	I
10	and	O
11	TNF	B
12	levels	O
13	throughout	O
14	the	O
15	clinical	O
16	course	O
17	of	O
18	disease	O
19	may	O
20	help	O
21	clarify	O
22	the	O
23	causes	O
24	of	O
25	febrile	O
26	episodes	O
27	.	O

1	These	O
2	data	O
3	demonstrate	O
4	that	O
5	DMVA	O
6	does	O
7	not	O
8	cause	O
9	more	O
10	myocardial	O
11	trauma	O
12	than	O
13	CPB	O
14	when	O
15	used	O
16	to	O
17	provide	O
18	resuscitative	O
19	circulatory	O
20	support	O
21	.	O

1	In	O
2	contrast	O
3	,	O
4	recent	O
5	evidence	O
6	suggests	O
7	that	O
8	children	O
9	with	O
10	sickle	B
11	-	I
12	hemoglobin	I
13	C	I
14	disease	O
15	do	O
16	not	O
17	develop	O
18	functional	O
19	asplenia	O
20	before	O
21	3	O
22	to	O
23	4	O
24	years	O
25	of	O
26	age	O
27	and	O
28	thus	O
29	may	O
30	not	O
31	benefit	O
32	from	O
33	penicillin	O
34	prophylaxis	O
35	.	O

1	However	O
2	,	O
3	the	O
4	increase	O
5	in	O
6	biliary	O
7	excretion	O
8	did	O
9	not	O
10	compensate	O
11	for	O
12	the	O
13	reduced	O
14	elimination	O
15	of	O
16	bretylium	O
17	and	O
18	hexylsalicylic	O
19	acid	O
20	via	O
21	the	O
22	kidney	O
23	.	O

1	Compensatory	O
2	renal	O
3	hypertrophy	O
4	in	O
5	parabiotic	O
6	rats	O
7	.	O

1	RESULTS	O
2	:	O
3	No	O
4	significant	O
5	deformation	O
6	in	O
7	vertebral	O
8	artery	O
9	flow	O
10	was	O
11	noted	O
12	in	O
13	the	O
14	flexion	O
15	-	O
16	distraction	O
17	Stage	O
18	I	O
19	injuries	O
20	within	O
21	the	O
22	physiologic	O
23	range	O
24	of	O
25	cervical	O
26	flexion	O
27	.	O

1	The	O
2	immunophilin	B
3	,	O
4	which	O
5	can	O
6	be	O
7	of	O
8	the	O
9	FK506	O
10	-	O
11	or	O
12	cyclosporin	O
13	A	O
14	-	O
15	binding	O
16	class	O
17	,	O
18	binds	O
19	to	O
20	hsp90	B
21	via	O
22	its	O
23	tetratricopeptide	O
24	repeat	O
25	(	O
26	TPR	O
27	)	O
28	domain	O
29	,	O
30	and	O
31	different	O
32	receptor	O
33	heterocomplexes	O
34	exist	O
35	depending	O
36	upon	O
37	which	O
38	immunophilin	B
39	occupies	O
40	the	O
41	TPR	O
42	-	O
43	binding	O
44	region	O
45	of	O
46	hsp90	B
47	.	O

1	In	O
2	view	O
3	of	O
4	the	O
5	short	O
6	t1	O
7	/	O
8	2	O
9	,	O
10	we	O
11	used	O
12	three	O
13	doses	O
14	/	O
15	day	O
16	.	O

1	W	O
2	.	O
3	G	O
4	.	O

1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	13	O
7	latest	O
8	BPVs	O
9	,	O
10	age	O
11	ranged	O
12	from	O
13	three	O
14	days	O
15	to	O
16	13	O
17	.	O
18	1	O
19	years	O
20	(	O
21	mean	O
22	5	O
23	.	O
24	7	O
25	+/-	O
26	SD	O
27	4	O
28	.	O
29	8	O
30	years	O
31	).	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	demonstrate	O
6	that	O
7	the	O
8	production	O
9	of	O
10	active	B
11	recombinant	I
12	telomerase	I
13	requires	O
14	a	O
15	factor	O
16	in	O
17	rabbit	O
18	reticulocyte	O
19	lysate	O
20	that	O
21	promotes	O
22	ribonucleoprotein	O
23	assembly	O
24	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	and	O
6	competition	O
7	experiments	O
8	showed	O
9	that	O
10	site	O
11	A	O
12	is	O
13	recognized	O
14	by	O
15	an	O
16	NF1	B
17	protein	I
18	.	O

1	Pacing	O
2	the	O
3	Roux	O
4	limb	O
5	abolished	O
6	the	O
7	ectopic	O
8	pacemakers	O
9	,	O
10	restored	O
11	the	O
12	slow	O
13	emptying	O
14	of	O
15	liquids	O
16	to	O
17	the	O
18	more	O
19	rapid	O
20	rate	O
21	found	O
22	in	O
23	the	O
24	Billroth	O
25	dogs	O
26	(	O
27	t1	O
28	/	O
29	2	O
30	:	O
31	paced	O
32	Roux	O
33	,	O
34	72	O
35	+/-	O
36	15	O
37	minutes	O
38	;	O
39	Billroth	O
40	,	O
41	43	O
42	+/-	O
43	9	O
44	minutes	O
45	;	O
46	p	O
47	greater	O
48	than	O
49	0	O
50	.	O
51	05	O
52	)	O
53	and	O
54	did	O
55	not	O
56	change	O
57	emptying	O
58	of	O
59	solids	O
60	.	O

1	The	O
2	TAF	O
3	factor	O
4	appears	O
5	to	O
6	be	O
7	particularly	O
8	significant	O
9	in	O
10	OCD	O
11	.	O

1	An	O
2	experiment	O
3	on	O
4	the	O
5	return	O
6	-	O
7	of	O
8	-	O
9	fear	O
10	(	O
11	ROF	O
12	)	O
13	was	O
14	carried	O
15	out	O
16	on	O
17	40	O
18	snake	O
19	-	O
20	or	O
21	spider	O
22	-	O
23	phobic	O
24	subjects	O
25	in	O
26	order	O
27	to	O
28	determine	O
29	whether	O
30	an	O
31	arousing	O
32	event	O
33	that	O
34	occurs	O
35	shortly	O
36	before	O
37	retest	O
38	influences	O
39	the	O
40	magnitude	O
41	of	O
42	the	O
43	ROF	O
44	.	O

1	In	O
2	broken	O
3	L	O
4	-	O
5	cell	O
6	membranes	O
7	expressing	O
8	wild	O
9	type	O
10	or	O
11	mutant	B
12	M6P	I
13	/	I
14	IGF	I
15	II	I
16	receptors	I
17	,	O
18	30	O
19	nM	O
20	IGF	B
21	II	I
22	also	O
23	failed	O
24	to	O
25	affect	O
26	the	O
27	pertussis	B
28	toxin	I
29	substrate	O
30	activity	O
31	.	O

1	EEG	O
2	theta	O
3	waves	O
4	and	O
5	psychological	O
6	phenomena	O
7	:	O
8	a	O
9	review	O
10	and	O
11	analysis	O
12	.	O

1	Mutagenesis	O
2	of	O
3	each	O
4	NRF	B
5	-	I
6	1	I
7	motif	I
8	in	O
9	the	O
10	ALAS	B
11	promoter	I
12	gave	O
13	substantially	O
14	lowered	O
15	levels	O
16	of	O
17	chloramphenicol	B
18	acetyltransferase	I
19	expression	O
20	,	O
21	whereas	O
22	mutagenesis	O
23	of	O
24	both	O
25	NRF	B
26	-	I
27	1	I
28	motifs	I
29	resulted	O
30	in	O
31	the	O
32	almost	O
33	complete	O
34	loss	O
35	of	O
36	expression	O
37	.	O

1	HDL	B
2	-	I
3	cholesterol	I
4	(+	O
5	6	O
6	%,	O
7	P	O
8	less	O
9	than	O
10	.	O
11	01	O
12	)	O
13	and	O
14	apolipoprotein	B
15	A	I
16	-	I
17	I	I
18	(+	O
19	6	O
20	%,	O
21	P	O
22	less	O
23	than	O
24	.	O
25	01	O
26	)	O
27	concentrations	O
28	increased	O
29	significantly	O
30	only	O
31	in	O
32	the	O
33	young	O
34	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	overall	O
7	performance	O
8	of	O
9	a	O
10	new	O
11	oscillometric	O
12	wrist	O
13	blood	O
14	pressure	O
15	monitor	O
16	(	O
17	Braun	O
18	PrecisionSensor	O
19	,	O
20	Braun	O
21	GmbH	O
22	,	O
23	Kronberg	O
24	,	O
25	Germany	O
26	)	O
27	as	O
28	defined	O
29	by	O
30	the	O
31	ANSI	O
32	/	O
33	AAMI	O
34	SP10	O
35	-	O
36	1992	O
37	guidelines	O
38	,	O
39	and	O
40	to	O
41	analyze	O
42	the	O
43	data	O
44	for	O
45	the	O
46	optimized	O
47	selection	O
48	of	O
49	the	O
50	algorithm	O
51	that	O
52	derives	O
53	the	O
54	blood	O
55	pressure	O
56	values	O
57	from	O
58	the	O
59	oscillometric	O
60	blood	O
61	pressure	O
62	curves	O
63	.	O

1	Two	O
2	separate	O
3	NF1	B
4	-	I
5	binding	I
6	loci	I
7	were	O
8	also	O
9	found	O
10	in	O
11	the	O
12	equivalent	O
13	IE68	B
14	gene	I
15	of	O
16	HCMV	O
17	(	O
18	Towne	O
19	)	O
20	DNA	O
21	,	O
22	but	O
23	in	O
24	this	O
25	case	O
26	the	O
27	DNA	O
28	sequence	O
29	and	O
30	competition	O
31	filter	O
32	binding	O
33	experiments	O
34	indicated	O
35	a	O
36	maximum	O
37	of	O
38	only	O
39	four	O
40	to	O
41	five	O
42	consensus	O
43	binding	O
44	sites	O
45	encompassing	O
46	the	O
47	promoter	O
48	-	O
49	enhancer	O
50	region	O
51	.	O

1	Most	O
2	of	O
3	the	O
4	patients	O
5	had	O
6	locally	O
7	advanced	O
8	lesions	O
9	(	O
10	63	O
11	T3	O
12	-	O
13	4	O
14	:	O
15	91	O
16	.	O
17	5	O
18	%)	O
19	according	O
20	to	O
21	the	O
22	adopted	O
23	TNM	O
24	system	O
25	(	O
26	Lederman	O
27	-	O
28	Gadeberg	O
29	,	O
30	Sisson	O
31	-	O
32	Jesse	O
33	).	O

1	Catch	O
2	-	O
3	up	O
4	growth	O
5	and	O
6	craniofacial	O
7	dimensions	O
8	following	O
9	administration	O
10	of	O
11	the	O
12	antineoplastic	O
13	agent	O
14	vincristine	O
15	to	O
16	young	O
17	rats	O
18	.	O

1	A	O
2	-	O
3	69	O
4	-	O
5	year	O
6	-	O
7	old	O
8	patient	O
9	with	O
10	postoperative	O
11	small	O
12	-	O
13	bowel	O
14	obstruction	O
15	underwent	O
16	laparotomy	O
17	three	O
18	times	O
19	.	O

1	Using	O
2	this	O
3	reporter	O
4	gene	O
5	system	O
6	,	O
7	we	O
8	previously	O
9	showed	O
10	that	O
11	EPO	B
12	-	O
13	induced	O
14	activation	O
15	of	O
16	the	O
17	c	B
18	-	I
19	fos	I
20	promoter	I
21	can	O
22	be	O
23	detected	O
24	rapidly	O
25	and	O
26	sensitively	O
27	as	O
28	an	O
29	elevation	O
30	of	O
31	cellular	B
32	luciferase	I
33	activity	O
34	.	O

1	It	O
2	is	O
3	shown	O
4	that	O
5	the	O
6	(	O
7	G	O
8	+	O
9	C	O
10	)-	O
11	rich	O
12	element	O
13	of	O
14	the	O
15	aldolase	B
16	C	I
17	promoter	I
18	directs	O
19	transcription	O
20	in	O
21	neuronal	O
22	as	O
23	well	O
24	as	O
25	in	O
26	nonneuronal	O
27	cells	O
28	.	O

